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90% of people living with HIV (PLWH) in the UK are now on treatment in the form of antiretroviral 
therapy (ART) and 87% of these PLWH are virally supressed. Due to the success of ART, PLWH are 
now living longer, and the mean age of PLWH in the UK is now 48 years (Public Health England, 
2019).  
Despite successful ART, which has seen an increase in the quality of life for PLWH, some PLWH are 
living with an excess of frailty and reduction in physical function, as well as an increased 
susceptibility to acquiring age-related comorbidities (Guaraldi et al., 2011; Kooij et al., 2016; 
Desquilbet et al., 2007; Desquilbet et al., 2009; Brothers et al., 2017). This phenomenon is 
understood to be highly heterogeneic, but while many of the risk factors are known, the exact 
pathological basis remains poorly understood. This could be due to the fact that there has been a 
lack of studies investigating the cellular and molecular causes in functionally relevant tissues such as 
skeletal muscle.   
Mitochondrial dysfunction is one of the nine cellular and molecular hallmarks of ageing 
characterised by Lopez-Otin (Lopez-Otin et al., 2013). Mitochondrial defects are increased in HIV 
infection, despite viremia control as a result of ART (Payne et al., 2011), and PLWH have a high 
prevalence of mitochondrial-associated toxicities such as myopathy and peripheral neuropathy 
(Selvaraj et al., 2014; Cupler et al., 1995). These toxicities are strongly associated with nucleoside 
reverse-transcriptase inhibitors (NRTIs) such as zidovudine (AZT), zalcitabine (ddC), stavudine (d4T) 
and didanosine (ddI) (Dalakas et al., 1990; Arnaudo et al., 1991; Lim & Copeland, 2001; Lewis, 2003). 
However, mitochondrial dysfunction has also been demonstrated in individuals treated with newer 
antiretrovirals with a safter profile and low mitochondrial polymerase binding affinity, such as 
tenofovir disoproxil fumarate (TDF) (Samuels et al., 2017). 
Given the close association between mitochondrial dysfunction and ageing (Lopez-Otin et al., 2013), 
and mitochondrial dysfunction in HIV infection (Erlandson et al., 2013; Payne et al., 2011; Chou et 
al., 2013), it is more than plausible to suggest that mitochondrial dysfunction plays a significant role 
in the accelerated ageing seen in PLWH. Due to the fact that there is a lack of concise studies which 
have investigated the role of mitochondrial dysfunction in ageing PLWH, I employed a wide range of 
cellular and molecular techniques to study mitochondrial dysfunction and other age-related 
pathology in skeletal muscle of older PLWH. This was correlated with clinical and treatment data, as 
well as physical function and body composition. 
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In addition, techniques established for the study of mitochondrial dysfunction in skeletal muscle 
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Chapter 1 – Introduction 
1.1 Human immunodeficiency virus 
1.1.1 Background and history 
The human immunodeficiency virus (HIV) is a lentivirus within the Retroviridae family (Luciw, 1996) 
that is classified into HIV type I (HIV-1) and HIV type 2 (HIV-2). Due to the fact that HIV-1 is much 
more prevalent and significant for this work it will hereby be referred to as HIV in this thesis for 
brevity.   
According to epidemiological and phylogenetic studies, HIV was first introduced into humans 
sometime between 1920-1940. HIV-1 evolved from non-human primate immunodeficiency viruses 
from the Central African chimpanzees (SIVcpz), most likely in Kinshasa in the Democratic Republic of 
Congo. In contrast, HIV-2 was introduced by the West African sooty mangabeys (SIVsm) (Gao et al., 
1999; Sharp & Hahn, 2011; Faria et al., 2014).  
HIV was first reported to be the causative agent of Acquired Immune Deficiency Syndrome (AIDS) in 
1983, two years after AIDS was recognised as a new disease (CDC, 1981; Barre-Sinoussi et al., 1983; 
Popovic et al., 1984). This means that HIV spread for around 50 to 70 years before it was recognised.  
1.1.2 Epidemiology 
By the end of 2019, an estimated 38 million (range 31.6-44.5 million) people are thought to be HIV 
positive (HIV+), with ~690,000 HIV-related deaths occurring throughout that year. Approximately 
three quarters of HIV+ individuals reside in Sub-Saharan Africa, and approximately two-thirds of 
newly diagnosed cases occur in this region. Since the beginning of the HIV/AIDS epidemic roughly 78 
million individuals have contracted HIV, with about 33 million individuals dying as a result (WHO, 
2020). Importantly, the prevalence of HIV-related mortalities has declined since 1999, largely due to 
the advent of effective antiretroviral therapy (ART) (GDB 2017 HIV collaborators, 2019). 
In 2018, there were 96,142 individuals who were HIV+ and receiving care in the UK, with 4453 newly 
diagnosed PLWH. The median age of PLWH in the UK is currently 48 years, and this number is 
increasing (Public Health England, 2019). 
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1.1.3 Genetics  
The HIV genome consists of two identical single-stranded viral RNA molecules enclosed within a viral 
capsid core (Figure 1.1b). Once inside of the target cell, the viral RNA is reverse transcribed into 
double-stranded proviral DNA (HIV provirus) where it integrates into the human genome.  
The HIV genome is flanked on either side by long terminal repeat (LTR) sequences, in which the 5’ 
LTR acts as the promoter for viral gene transcription (Figure 1.1a). Following down the reading frame 
in a 5’ to 3’ fashion, the first gene is the gag gene, which is responsible for encoding outer core 
membrane protein (MA/p17), capsid protein (CA/p24), nucleocapsid protein (NC/p7), and a nuclear 
acid stabilising protein (p6). The next gene on the reading frame is the pol gene, which encodes the 
protease (PR/p12), reverse transcriptase (RT/p51), RNAase H (p15) and integrase (IN/p31). Next, the 
env gene encodes the two envelope glycoproteins gp120 (SU) and gp41 (TM). In addition to these 
genes, the viral genome encodes various regulatory proteins. These include Tat and Rev, which are 
required for the initiation of replication, as well as Nef, Vif, Vpr and Vpu, which are required for viral 
replication, budding and pathogenesis respectively (Levy, 2007; Sauter et al., 2012). 
 
 
Figure 1.1 - HIV genome and particle. (A) The HIV genome is encoded on a single strand of RNA. The gag gene encodes 
viral capsid proteins; pol encodes the viral reverse transcriptase (HIV-RT); env encodes the HIV envelope-associated 





1.1.4 HIV pathogenesis  
HIV is transmitted as a cell-free or cell-associated virus, most commonly in semen or at mucosal 
surfaces. Transmission can also occur via injection drug use, through the placenta to the foetus, or 
exposure to infected blood products (Moir et al., 2011).  
Initially, HIV-1 particles interact with the CD4 receptor and either the CXCR4 co-receptor on the 
plasma membrane of T cells, or the CCR5 co-receptor on macrophages and some T lymphocytes  
(Naif, 2013) (Figure 1.2). Once within the cytoplasm, the viral RNA-encoded genome is reverse-
transcribed into linear proviral DNA by HIV-1 reverse transcriptase (HIV-RT). The proviral DNA is then 
integrated into the host nuclear DNA by the viral integrase, which catalyses 3’ end processing and 
viral DNA strand transfer (Sato et al., 2006). Proviral mRNA species are then transcribed following 
the integration of proviral DNA into the host cell’s nuclear DNA. mRNA destined to encode 
regulatory proteins are spliced in the nucleus, while mRNA encoding structural proteins are 
transported into the cytoplasm where they are translated and packaged into new HIV particles along 
with unspliced proviral mRNA.  
If there are no pre-existing immune pressures, the HIV virus will disseminate rapidly following 
transmission and will exponentially increase viremia (viral RNA) by infecting resting CD4+ T cells. At 
this stage (1-2 days post infection) the virus can be detected in regional lymphatic tissue (Maher et 
al., 2005). 
Shortly afterwards (5-6 days post infection), activated CD4+ T cells are infected and the HIV virus 
rapidly migrates to gut-associated lymphoid tissue (GALT) via draining lymph nodes, where it induces 
the depletion of memory CD4+ T cells (particularly the CD4+, CCR5+ subset) and acts as the major site 
for HIV replication (Guadalupe et al., 2003). After 3-6 weeks post infection the humoral response is 
activated, initiating the onset of clinical symptoms such as fever, malaise, fatigue, rash, acute 
neuropathy and gastrointestinal abnormalities (Levy, 2007; Burin des Roziers et al., 1995). This 
symptomatic phase then lasts roughly 2-6 weeks before the onset of an asymptomatic phase, where 
the viral load can drop from 105-1010 copies/ml down to as low as 102 copies/ml. 
If left untreated, the pathogenesis of HIV infection progresses and CD4 count becomes gradually 
depleted until eventually a critical CD4 count threshold of 200 copies/l is reached. At this point, the 
individual’s immune system is severely weakened, and the individual has a significantly increased 
susceptibility to acquiring opportunistic infections and neoplasms. Here, the individual has 
progressed to AIDS. The progression from initial HIV infection to the development of AIDS is highly 




Figure 1.2 – Replicative life cycle of HIV infection. Schematic depicting the various stages of the HIV infection lifecycle alongside the point of action of various antiretroviral classes. 
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1.2 Antiretroviral therapy 
At present, there is no available treatment that completely eradicates the HIV virus in an infected 
individual. As such, the most effective option for reducing morbidity and mortality in people living 
with HIV (PLWH) is through long-lasting viral suppression, which is achieved through ART.  
1.2.1 History of ART 
In 1987 the first antiretroviral (ARV) to be approved was zidovudine (AZT), which was prescribed as a 
monotherapy (FDA, 1987). Since then, more than 30 individual ARVs of various classes have been 
approved and rolled out for treatment, and one dual combination ARV has been approved for the 
prevention of HIV infection (Gulick, 2018; Clayden, 2018) (Figure 1.3). In addition, fixed-dose 
combination (FDC) tablets with a long half-life have reduced the burden of ART to once or twice daily 
dosing.  
The early ARVs of the first half of the 90s were prescribed as mono- or dual-therapies. Many were 
overtly toxic whilst not being particularly potent. In response, highly active and better tolerated 
ARVs were developed and began to be prescribed as triple drug regimens, often with FDCs. Triple 
combination ART where ARVs from at least two different classes are used is termed ‘combination 
antiretroviral therapy’ (cART) or ‘highly active antiretroviral therapy’ (HAART) (WHO, 2016).  
By the end of 2019, the global number of PLWH who are on ART is approximately 25.4 million, which 
is ~67% of the HIV+ population (WHO, 2020). The vast majority of untreated PLWH reside in less 
developed countries. Importantly, in the UK, 97% of diagnosed PLWH were on ART by the end of 








1.2.2 Classes of ART and method of action 
There are six main classes of ART drugs, each targeting different stages of the HIV-1 life cycle. These 
are: nucleoside reverse transcriptase inhibitors (NRTIs); protease inhibitors (PIs); non-nucleoside 
reverse transcriptase inhibitors (NNRTIs); integrase inhibitors (INIs); CCR5 antagonists, and fusion 
inhibitors (FIIs) (Arts & Hazuda, 2012). 
NRTIs are prodrugs that exert their suppressive effects by inhibiting transcription of viral RNA via 
chain termination. Chain termination can occur during either RNA-dependant viral DNA synthesis or 
DNA-dependant viral DNA synthesis (Richman, 2011). In developed countries, abacavir (ABC), 
emtricitabine (FTC) and lamivudine (3TC) are the most commonly used NRTIs. Didanosine (ddI), 
stavudine (d4T), zalcitabine (ddC) and zidovudine (AZT) are older NRTIs that are no longer in use in 
developed countries due to their associated toxicity, although some are still in use in less developed 
countries and regions such as sub-Saharan Africa. Tenofovir disoproxil fumarate (TDF) and tenofovir 
alafenamide (TAF) are a nucleotide analogue rather than nucleosides, due to the phosphate group 
being located on the nitrous base. They are therefore sometimes referred to as NtRTIs, and both are 
in common use globally.  
NNRTIs are another class of ARV that exert their suppressive effects by inhibiting HIV-RT. As opposed 
to NRTIs which inhibit polymerase activity by forming a hydrophobic pocket over the active site, 
NNRTIs are allosteric inhibitors and so induce the formation of a hydrophobic pocket proximal to the 
active site – indirectly reducing polymerase activity (Kohlstaedt et al., 1992; Tantillo et al., 1994). 
Currently used NNRTIs include efavirenz (EFV), etravirine (ETR), nevirapine (NVP), doravirine (DOR) 
and rilpivirine (RPV). 
PIs are responsible for inhibiting the viral protease enzyme. The HIV-1 protease cleaves viral gag and 
gag-pol polyprotein precursors following transcription and during viral maturation (Park & Morrow, 
1993). Therefore, inhibition of protease will result in a decrease in the formation of new HIV virus 
particles. Atazanavir (ATV) and darunavir (DRV) are the most commonly used PIs, but other PIs which 
were more commonly used in the past include amprenavir (APV), fosamprenavir (FPV), indinavir 
(IDV), lopinavir (LPV), nelfinavir (NFV), ritonavir (RTV), saquinavir (SQV) and tipranavir (TPV). 
Integrase inhibitors are the newest and most mechanistically complex class of ARVs. They act by 
sequestering and inhibiting the viral integrase active site magnesiums, whilst simultaneously forming 
a hydrophobic group to block the proviral DNA binding to integrase (Grobler et al., 2002). 
Dolutegravir (DTG), elvitegravir (EVG), bictegravir (BIC) and raltegravir (RAL) are currently 
administered integrase inhibitors. 
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Enfuviritide (T20) is the only FII currently available. Fusion inhibitors block the fusion of HIV-1 
particles with target cells by inhibiting the interaction between the two homologous domains of the 
viral gp41 protein, which are essential for HIV pathogenesis (Kahle et al., 2009). Unfortunately, T20 
has a low antiviral activity and easily induces resistance. It can only be administered by 
subcutaneous injection.  
CCR5 antagonists work by binding and inducing the stabilisation of a CCR5 receptor conformation 
that is not recognised by either HIV-1 CCR5 agonists. They do this by binding to hydrophobic pockets 
present in the transmembrane helices of CCR5 (Dragic et al., 2000; Tsamis et al., 2003). Maraviroc 
(MVC) and ibalizumab (IBZ) are the only currently licenced CCR5 antagonists. 
1.2.3 Future perspectives of ART research 
Since 2010 there have been three international conferences on ARV drug optimisation – CADO-1 in 
2010, CADO-2 in 2013 and CADO-3 in 2017. At the most recent, CADO-3 conference, the goal was to 
better define the research necessary to optimise second- and third-line therapy (WHO, 2016). Whilst 
the general success of ART makes identifying improvements difficult, the top short (1-2 years) and 
medium term (2-5 years) priorities for the future of ART was identified as being the improvement 
and increased usage of TAF and DTG ARVs in cART globally. These are seen as being the current ARVs 
with the greatest potency and the lowest toxicity. The long term (>5 years) priorities were identified 
as being the improvement of long-acting formulations of new compounds, as well as the 
development of capsid and maturation inhibitors (Vitoria et al., 2018; WHO, 2016). 
As of the beginning of 2019 there were six new ARVs in phase III studies. These include four entry 




1.3 Biology of ageing  
Ageing is characterised by the progressive accumulation of molecular and cellular damage leading to 
a deterioration in replicative and regenerative processes in tissue, and an increased susceptibility to 
acquiring age-associated diseases such as cancer and diabetes (Kirkwood, 2005). 
1.3.1 Evolutionary theories of ageing: 
The mutation accumulation theory (Medwar, 1952) postulates that ageing is the result of random 
mutations which accumulate in the genome with increasing age, contributing to physical 
deterioration. 
The antagonistic pleiotropy theory (Williams, 1957) suggests that organismal ageing is caused by 
pleiotrophic genes (genes with multiple phenotypic effects). These pleiotrophic genes provide a 
favourable advantage for reproduction early in life but become harmful and increase the rate of 
ageing later in life. 
Thomas Kirkwood’s Disposable Soma theory (Kirkwood, 1977), posits that ageing is caused by the 
physiological stand-off between somatic maintenance and investment in biological functions such as 
reproduction, with over commitment of resources to one resulting in decline of the other. 
1.3.2 Molecular ageing and the mitochondrial theory of ageing 
During the natural course of ageing, somatic (acquired) mutations accumulate in the mitochondrial 
genome. However, it is unknown whether these mutations are a consequence of the ageing process 
itself or a causative driver of ageing. 
The mitochondrial free radical theory of ageing (MFRTA) (Harman, 1965) states that an increase in 
the production of reactive oxygen species (ROS) due to age-related mitochondrial dysfunction 
causes further mitochondrial deterioration and global cellular damage. At low levels, ROS are 
essential for intracellular signalling, but become toxic at increased levels as they damage many 
lipids, proteins and nucleic acids - increasing the rate of mutagenesis (Koopman et al., 2010). 
According to the MFRTA, as organisms age, the accumulation of mitochondrial DNA (mtDNA) 
mutations increases, leading to respiratory chain abnormalities and an increase in ROS leakage. This 
in turn further increases the accumulation of mtDNA mutations, and so on in a ‘vicious cycle’ 
(Harman, 1972). However, if this were the case the propagation of mtDNA mutations would be 
exponential, which has been dismissed by more recent extensive studies (Tengan et al., 1997; Mott 
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et al., 2001; Kennedy et al., 2013; Itsara et al., 2014). In addition, in vivo and in vitro studies have 
demonstrated that manipulation of ROS has no effects on ageing or maximal lifespan (Ristow, 2011).  
In 2004 Trifunovic and colleagues developed a knock-in mouse model deficient in the proof-reading 
domain of the mitochondrial polymerase ꝩ. Subsequently, mice with this genotype experience an 
accumulation of age-related mtDNA point mutations and deletions, leading to the onset of a 
premature ageing phenotype. These mice exhibit a reduced lifespan, weight loss, osteoporosis, 
anaemia, reduced fertility, alopecia, loss of subcutaneous fat, kyphosis, and heart enlargement 
(Trifunovic et al., 2004). Taken together, the development of this mouse model has strengthened the 
causal link between mtDNA mutations, mitochondrial dysfunction and ageing, and has helped 
further understanding in this field.  
More recently, López-Otín et al. (2013) characterised ageing into 9 cellular and molecular hallmarks: 
loss of proteolysis, telomere attrition, genomic instability, epigenetic alterations, altered intercellular 
communication, stem cell exhaustion, cellular senescence, deregulated nutrient signalling and 
mitochondrial dysfunction – further solidifying the significant role mitochondrial dysfunction plays in 
the multifactorial process of ageing (López-Otín et al., 2013). This thesis primarily focuses on the 




1.4 Mitochondrial biology  
1.4.1 Origins of mitochondria 
Mitochondria are dynamic double-membraned organelles present in nearly every nucleated 
eukaryotic cell, and are significantly involved in a wide range of cellular processes such as energy 
production, haem synthesis, regulation of apoptosis and calcium handling, among others.  
It is thought that mitochondria were once a prokaryotic species that become engulfed in eukaryotic 
cells as the result of an endosymbiotic relationship (Sagan, 1967). Whilst the exact mechanism 
behind this theory remains unknown, there are two prevalent mechanisms which have been 
proposed.  
The first hypothesis is based on the small subunit ribosomal RNA (rRNA) phylogenetic tree and posits 
that a nucleated archezoa host phagocytosed an α-protobacterial endosymbiont, which was 
subsequently transformed into a mitochondrion (Yang et al., 1985; Cavalier-Smith et al., 1987). This 
hypothesis is commonly referred to as the ‘archezoan hypothesis’. The second hypothesis, termed 
the ‘symbiogenesis hypothesis’ suggests that the endosymbiotic event entailing a physical and 
metabolic fusion occurred before the diversion of eukaryotes from prokaryotes, and this event then 
generated the ancestor of the eukaryotic cell. This was then followed by another divergence and 
development of a nucleus to form a eukaryotic cell (Martin & Muller, 1998).  
Both hypotheses have plausible aspects, although it is the archezoan hypothesis which is considered  
the more plausible, due to the rRNA phylogenetic tree evidence (Roger et al., 2017).  
1.4.2 Mitochondrial structure  
As mentioned above, mitochondria are double-membrane structures that lie in the cytoplasm of 
most eukaryotic cells. The outer mitochondrial membrane (OMM) surrounds the inner 
mitochondrial membrane (IMM), which in turn encloses the mitochondrial matrix. The space 
between the OMM and IMM is termed the intermembrane space (IMS) (Figure 1.4).  
The structure of the mitochondrion was first described by Palade (1953) through the utilisation of 
electron microscopy (EM). In this study, Palade noted the characteristic pattern of convoluted and 
pleomorphic IMM invaginations repeated in mitochondria in what was termed the ‘baffle’ model of 
cristae structure (Palade, 1953). The advancement of microscopy in later years has since disproved 
this theory by providing evidence that cristae are in fact connected to the IMS by tubular cristae 






Figure 1.4 – Mitochondrial ultrastructure. (A) Schematic depicting the OMM and IMM, as well as the IMS, cristae, matrix, 







The double membrane of the mitochondrion is critical for the regulated transport of ions and 
metabolites into and out of the mitochondria. Here, due to the smooth porous structure of the 
OMM, ions and small uncharged molecules (up to ~5,000 Da) can diffuse into the IMS. Larger 
molecules such as proteins as well as hydrophilic molecules are able to pass into the IMS through 
protein channels such as the voltage-dependant anion channel (VDAC) or translocase of the outer 
mitochondrial membrane (TOMM) (Ponnalagu et al., 2016). In addition to its role in molecule 
transport, the OMM is a platform for cell signalling convergence as well as being responsible for 
forming the interface with other subcellular organelles and compartments such as the endoplasmic 
reticulum (ER) and lysosomes.  
In the immediate interior, the IMM encloses the matrix space, and can be divided into two distinct 
domains connected by cristae junctions – the inner boundary membrane (IMB) and the cristae 
membrane (CM). Importantly, the IMM houses the five complexes required for oxidative 
phosphorylation (OXPHOS) and so is the site of OXPHOS and protein synthesis (Vogel et al., 2006). 
Cristae organisation is modulated in order to maximise conditions for bioenergetic processes. This 
includes tightening of junctions prior to respiration (Demongeot et al., 2007; Hackenbrock et al., 
1966; Mannella et al., 2001). In addition, during cell death cristae undergo morphological changes 
termed cristae remodelling, which promotes the redistribution and release of cytochrome c 
(Scorrano et al., 2002). Compared to the OMM, the IMM is far less permeable and so transport in 
and out of the IMM requires more stringent regulation. To highlight the difference in membrane 
permeability, even small solutes such as ions cannot pass through the IMM without the assistance of 
inner mitochondrial membrane translocases (TIMM) (Kulawiak et al., 2013).  
The mitochondrial matrix is the site where many important biochemical processes such as the 
tricarboxylic acid cycle (TCA) and iron-sulphur (Fe-S) cluster formation occurs. In addition, the 
mitochondrial matrix contains many copies of the mitochondrial genome (mtDNA), which are 
packaged in the form of circular nucleoids, as well as the transcription and translation machinery 





1.4.3 Mitochondrial dynamics 
The multifaceted and heterogenic involvement of mitochondria in a wide range of cellular processes 
is underscored by the vast morphological variability of the organelle. It has long been recognised 
that mitochondrial shape, size, length and organisation can vary between cells and in response to 
certain metabolic and cellular signals (Giacomello et al., 2020). In addition, mitochondria are known 
to constantly undergo fission and fusion processes in order to adapt to cellular and tissue demands 
(Bereiter-Hahn & Voth, 1994). The frequency of these fission and fusion processes is tightly 
regulated, as metabolic and cellular demands are constantly shifting. Mitochondrial fission is 
involved in the selective removal of damaged mitochondria (mitophagy), as well as distribution of 
the organelle, whereas fusion is essential for the stabilisation of mtDNA (Chen et al., 2010), 
adenosine triphosphate (ATP) production (Yao et al., 2019) and exchange of matrix components to 
mitigate mitochondrial stress (Legros et al., 2002). 
Collectively, the processes that allow the alterations to mitochondria are known as mitochondrial 
dynamics. Disruptions of mitochondrial dynamics can lead to several human pathologies such as 
optic atrophy (Alexander et al., 2000; Delettre et al., 2000), Parkinson’s Disease (Van Laar & Berman, 
2009) and Charcot-Marie-Tooth disease (Palau et al., 2009). 
1.4.3.1 Fusion  
Mitochondrial fusion is the process whereby two mitochondria fuse together to form a single 
mitochondrion. This process is a controlled, double membrane fusion event governed by several 
proteins of the dynamin-related (DRP) family of large GTPases. OMM fusion is performed by 
mitofusins 1 and 2 (MFN1 and MFN2) (Zuchner et al., 2004), whilst IMM fusion is undertaken by 
optic atrophy 1 (Opa1) (Meeusen et al., 2006) (Figure 1.5). 
MFN1 and MFN2 have a high degree of structural homology, with both containing two 4,3 
hydrophobic heptad repeats (HR1 and HR2) (Koshiba et al., 2004), and both being able to form 
homo- or heterodimers (Chen et al., 2005). However, genetic and biochemical studies have 
demonstrated that the two mitofusins have different functions and both are required for 
mitochondrial fusion. Whilst MFN1 is the core component of the fusion process together with Opa1, 
the exact role of MFN2 is unknown, although it has been shown to be associated with interactions 
with other organelles such as the endoplasmic reticulum (ER) (Cipolat et al., 2004; Ishihara et al., 
2004; de Brito et al., 2008). During OMM fusion, MFN1 acts as a tether between the two fusing 
mitochondria, where adjacent HR2 domains dimerise in a GTP-dependant fashion to induce 
membrane clustering (Qi et al., 2016).  
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As mentioned above, Opa1 is the driver of IMM fission. Opa1 resides in the IMM as well as the IMS,  
and exists as one of two isoforms – L-Opa1, which is a membrane-bound protein that protrudes into 
the IMS in order to promote tethering to the IMM from the adjacent fusing mitochondria, and S-
Opa1, which is thought to regulate cristae structure during fission (Mishra et al., 2014; DeVay et al., 




Figure 1.5 – Mitochondrial fusion. Initially, the HR2 domain of MFN1/2 (green circle) docks to an adjacent HR2 domain of 
another MFN1/2, inducing a conformational change which drives the GTP-dependant hydrolysis of MFN1/2, leading to the 






Mitochondrial fission is the process by which a mitochondrion divides into two mitochondria. Fission 
is primarily carried out by the cytosolic Drp1 (Smirnova et al., 2001), which translocates to the 
mitochondria where it binds to OMM receptors: mitochondrial fission factor (MFF), mitochondrial 
fission protein 1 (FIS1) and mitochondrial dynamics protein of 49 kDa (MID49) (Otera et al., 2010; 
James et al., 2003; Loson et al., 2013). Next, GTP-mediated binding induces a conformational change 
and formation of linear polymers on the OMM. Through GTP hydrolysis, these polymers shorten to 
cause constriction of the mitochondrial membranes, ultimately leading to membrane scission (Mears 
et al., 2011; Kalia et al., 2018) (Figure 1.6). 
In addition to the important role of the receptor proteins FIS1, MID49 and MFF, the ER has been 
shown to play an essential role in membrane constriction. Here, ER wraps around a mitochondrion 
to form mitochondria-ER tethers, initiating pre-recruitment mitochondrial constriction (Friedman & 
Nunnari, 2014). This ER-mediated constriction reduces the diameter of membranes to 30-70nm, 
which is not sufficient for membrane scission, and so Drp1 recruitment is required (Bohuszewicz & 




Figure 1.6 – Mitochondrial fission. Upon Drp1 dephosphorylation by calcineurin, it is translocated to the mitochondria 




1.4.4 Mitochondrial stress response  
1.4.4.1 Biogenesis  
Mitochondrial biogenesis is a tightly regulated mechanism whereby mitochondria increase their 
mass and mtDNA copy number in order to adapt to cell-specific bioenergetic requirements. The 
major regulator of mitochondrial biogenesis is the peroxisome proliferator-activated receptor- 
(PPAR) coactivator-1 (PGC-1). PGC1 is a co-transcriptional regulation factor that activates 
various transcription factors such as nuclear respiratory factor 1 and 2 (NRF-1/2), oestrogen related 
receptor  (ERR), glucocorticoid, and PPAR. These transcription factors ultimately promote the 
expression of the mitochondrial transcription factor A (TFAM) (Wu et al., 1999), which is responsible 
for promoting the transcription and replication of mtDNA (Virbasius & Scarpulla, 1994). 
As depicted in Figure 1.7, PGC-1 is activated by AMP-activated protein kinase (AMPK), which is the 
master regulator of intracellular bioenergetics in response to acute crises in energy requirement 
(Hardie, 2007). Here, an increased AMP:ATP and NAD+:NADH ratio is detected by AMPK and Sirtuin 1 
(SIRT1), which subsequently leads to PGC-1 phosphorylation and activation (Canto et al., 2009).  
In addition to AMPK, nitric oxide (NO) (Nisoli et al., 2003), calcium-dependant protein kinase IV 
(CaMKIV) (Wu et al., 2000; Wu et al., 2002), Calcineurin (Chin et al., 1998; Ryder et al., 2003), and 
p38 mitogen-activated protein kinase (MAPK) (Boppart et al., 2000) have also been shown to be 
regulators of mitochondrial biogenesis in humans.  
 
Figure 1.7 – Mitochondrial biogenesis signalling pathway. PGC-1  is the master regulator of mitochondrial biogenesis by 
promoting the transcription of various nuclear transcription factors such as NRF-1/2, PPAR and ERR. In the event of 
increased Ca2+ levels, CaMKIV is activated and then subsequently promotes the activation of PGC-1.. In the event of energy 
deprivation (e.g. after exercise) AMP:ATP and NAD+:NADH ratios are increased and detected by AMPK and SIRT1 




The selective degradation of irreparably damaged mitochondria, termed mitophagy, is an essential 
cellular quality control mechanism required to maintain bioenergetics. Impairment of mitophagy is 
associated with mitochondrial dysfunction, with consequences of cellular and tissue damage, and 
eventual manifestation of pathology. In particular, abnormalities in mitophagy are commonly age-
related and so are associated with geriatric conditions such as Parkinson’s Disease, cardiovascular 
problems, metabolic disorders and cancer (Palikaras et al., 2018). 
Mitophagy is stimulated by several factors and can be classified as being either ‘basal mitophagy’, 
which is the continued process of mitophagy required for removal of old and damaged mitochondria 
(Palikaras et al., 2018), ‘stress-induced mitophagy’, which is induced by factors such as hypoxia or 
starvation (Liu et al., 2012; Kanki et al., 2009), or ‘programmed mitophagy’, which is required for 
development in several cell types (Sandoval et al., 2008; Schweers et al., 2007; Novak et al., 2010) or 
preventing paternal inheritance of mtDNA (Al Rawi et al., 2011; Rojansky et al., 2016). 
There are several mechanisms of mitophagy that are utilised in different tissues, and the factors that 
regulate mitophagy can be classified as either ‘ubiquitin-dependant’ or ‘ubiquitin-independent’ 
(Khaminets et al., 2016). 
Ubiquitin-dependant mitophagy progresses down the Parkin-PINK1 (phosphatase and tensin 
homologue (PTEN)-induced putative kinase 1) pathway (Pickles et al., 2018) (Figure 1.8). In basal 
conditions, PINK1 is imported into the IMS and rapidly cleaved and degraded by several proteases 
such as presenilin-associated rhomboid-like protein (PARL) (Jin et al., 2010). In the event of 
mitochondrial stress, membrane dissipation prevents the IMS translocation of truncated PINK1, and 
it is instead stabilised on the OMM where it is autophosphorylated (Harper et al., 2018; Sekine & 
Youle, 2018). PINK1 phosphorylation then initiates the recruitment of the E3 ubiquitin ligase Parkin, 
where it is subsequently phosphorylated and activated by PINK1 (Lazarou et al., 2012). In addition to 
phosphorylating Parkin, PINK1 also phosphorylates ubiquitin (Ub) and poly-Ub chains on several 
proteins on the OMM of mitochondria, thereby targeting them for degradation by the 
autophagosome (Chan et al., 2011; Sarraf et al, 2013). Additionally, PINK1 indirectly activates Drp1 
activity to promote mitochondrial fission and enhance autophagic degradation of the mitochondria 
(Pryde et al., 2016), as well as targeting MFNs for proteasomal degradation, thus preventing 
mitochondrial fusion (Tanaka et al., 2010). 
Aside from Parkin-mediated mitophagy, several other molecules can regulate ubiquitin-dependant 
mitophagy, such as Gp78, MUL1 and SMURF1 (Orvedahl et al., 2011). These molecules induce the 
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ubiquitination of OMM proteins in a similar way to Parkin ubiquitination, thereby anchoring the 
autophagosome to damaged mitochondria via their autophagosomal light chain (LC3). 
In contrast to ubiquitin-dependant mitophagy, mitochondrial proteins themselves can induce 
mitophagy by acting as mitophagy receptors. Again, these molecules can attract and bind the 
autophagosome through LC3-interacting region (LIF) motifs (Gatica et al., 2018). Examples of these 
mitophagy-inducing OMM proteins include NIP3-like protein X (NIX) and BCL2 interacting protein 3 
(BNIP3) (Quinsay et al., 2010; Zhang et al., 2016). 
 
 
Figure 1.8 – PINK1-Parkin mitophagy pathway. Damaged mitochondria have low membrane potential and are separated 
from the mitochondrial network. Under normal conditions, truncated PINK1 is cleaved and degradated by PARL and other 
proteases. During mitophagy, PARL protease activity is inhibited and truncated PINK1 localises on the OMM where it 
recruits and stabilises Parkin. Next, Parkin mediates the ubiquitination of OMM proteins, which subsequently initiates the 




1.4.4.3 Mitochondrial protein homeostasis 
Mitochondria contain their own genome, which encodes 37 essential genes (detailed further in 
Section 1.4.7) important for mitochondrial homeostasis. The other essential proteins and molecules 
required to maintain mitochondrial function, are encoded by the nucleus (nDNA), and are 
translocated into the mitochondria. The majority of these proteins arrive in a post-translational 
manner through TOM complexes on the OMM, and TIM complexes in the IMM. They then require 
post-transcriptional modifications and guidance to the right mitochondrial sub-compartment, which 
is commonly performed by Hsp70 (Sickmann et al., 2003; Young et al., 2003) (Figure 1.9).  
The next step after nDNA-encoded protein importation and sorting is maturation, which is required 
for the assembly of the proteins into functional complexes. For the majority of these proteins the 
first step is proteolytic removal of the pre-sequence (Mossmann et al., 2012). This action is 
performed by the mitochondrial membrane protease (MPP), which cleaves the N-terminal pre-
sequence, followed by additional cleavage by Icp55 and Oct1 (Vogtle et al., 2011). Another 
important processing event is undertaken on one of the subunits of the mitochondrial ribosome, 
MrpL32, performed by the m-AAA protease, which is part of the AAA+ family of proteases (Bonn et 
al., 2011).  
Following maturation, the mitochondrial proteins require assembly into functional multimeric 
complexes. This process is performed by a range of chaperones and co-chaperones that reside in the 
mitochondrial matrix such as mtHsp70 and its co-chaperones, mtHsp60 and mtHsp10 (Lill et al., 
2012). Whilst the exact process of protein assembly is unknown, it is suspected that protein folding 
requires disulphide bond formation (Banci et al., 2009; Weckbecker et al., 2012). 
 
Figure 1.9 – Mitochondrial protein import and assembly. Nuclear-encoded unfolded proteins are translocated to the 
mitochondria where they are imported via TOM and TIM complexes into the mitochondrial matrix. Once imported, the 
mitochondrial chaperone mtHsp70 mediates the assembly and folding of the proteins into functional complexes.  
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1.4.4.4 Mitochondrial protein degradation and stress response 
As with regular cellular homeostasis, misfolded, damaged, or non-assembled proteins in the 
mitochondria pose a serious threat to mitochondrial homeostasis and have been implicated in 
various pathologies such as Parkinson’s and Alzheimer’s disease (Kong et al., 2018). Protein damage 
can be induced by stressors such as reactive oxygen species (ROS), or alternatively by deleterious 
mtDNA mutations (Corral-Debrinski et al., 1991; Ahlqvist et al., 2012; Ross et al., 2013). 
The mitochondrial proteome has an extremely high turnover rate, with an estimated 6-12% of the 
whole proteome being degraded during each generation (Augustin et al., 2005). As a result, 
mitochondria contain several quality control mechanisms in order to deal with the threat of 
proteotoxicity. The first of these processes is a highly conserved cross-membrane proteolytic system 
which removes and destroys abnormal proteins. Here, LonP and ClpX/P proteases reside in the 
matrix, whilst the m-AAA protease is localised on the IMM facing the matrix and the i-AAA protease 
resides on the IMM facing the IMS (Figure 1.10). The two AAA proteases are responsible for 
degradation of membrane proteins, but also contribute to cleavage of matrix proteins (Benedetti et 
al., 2006; Matsuda et al., 2010). Of these membrane proteins, the most significant proteins that are 
degradated by the AAA proteases belong to OXPHOS complexes, which are extremely susceptible to 
damage due to the amount of ROS produced during electron transfer.  
 
 
Figure 1.10 – Intramitochondrial proteolysis. Mitochondria contain a highly conserved proteolytic system consisting of i-
AAA proteases in the IMM facing the IMS, m-AAA proteases in the IMM facing the matrix, and LonP and ClpX/P proteases 
residing in the mitochondrial matrix. This system of proteases is responsible for proteolytically cleaving imported proteins as 
well as degradation of internal mitochondrial proteins such as OXPHOS complexes.  
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The other conserved system of mitochondrial protein homeostasis is called the mitochondrial 
unfolded protein response (mtUPR). In the mtUPR, proteotoxic stress within the mitochondria is 
detected and triggers the activation of a nDNA-encoded gene expression program aimed at the 
proteolytic removal of the stress (Figure 1.11). An additional function of the mtUPR is to divert 
metabolism away from oxidative phosphorylation towards anaerobic cytoplasmic glycolysis in order 
to alleviate mitochondrial stress (Nargund et al., 2015).  
Whilst the mechanisms by which misfolded or damaged proteins are recognised by the mtUPR are 
not fully understood, it is known that the mtUPR becomes activated in response to various stimuli, 
including: mtDNA depletion (Martinus et al., 1996); oxidative stress (Fiorese & Haynes, 2017); 
inhibition of mtDNA translation (Houtkooper et al., 2013); OXPHOS dysfunction (Duriex et al., 2011); 
or damage to mitochondrial chaperones (Haynes et al., 2007). To date, the strongest hypothesis is 
that oligopeptides generated in the matrix by ClpP proteases are detected by AFTS-1, which 
subsequently activates the mtUPR (Houtkooper et al., 2013). Here, ATFS-1 accumulates in the 
cytoplasm in response to declining membrane potential as a result of proteotoxicity, where its C-
terminal nuclear localisation sequence has access to nuclear import machinery. Once in the nucleus, 
ATFS-1 promotes the activation of a range of genes involved in mitochondrial homeostasis, including 
genes involved in antioxidation, glycolytic factors, genes involved in regulating mitochondrial 




Figure 1.11 – The mtUPR. Schematic depicting the mtUPR signalling pathway. Here, stressors are detected by the 
transcription factor ATFS-1 which becomes activated and subsequently translocated to the nucleus where it promotes the 




The final mechanism of mitochondrial protein homeostasis is the isolation and transportation of 
proteins for degradation away from the mitochondria. The most prominent mechanisms of this 
process are performed by mitochondria-derived vesicles (MDVs) and mitochondrial-derived 
compartments (MDCs) (Moehle et al., 2018).  
MDVs have been shown to be strongly implicated in the early response to oxidative stress, preceding 
membrane depolarisation (Soubannier et al., 2012), by transporting oxidised proteins to the 
lysosome for degradation, as well as other mitochondrial proteins such as MAPL for degradation in 
the peroxisomes. Although MDV formation can occur independently of mitophagy, MDV trafficking 
relies on both PINK1 and Parkin (McLelland et al., 2014).  
In contrast to MDV formation and trafficking, MDCs rely directly on mitochondrial fission and 





1.4.5 Mitochondrial electron transport chain  
One of the key functions of mitochondria is to regulate oxidative metabolism and provide cellular 
energy in the form of ATP. There are three respiratory pathways in which mitochondria produce ATP 
– anaerobic glycolysis, the tricarboxylic acid (TCA) cycle, and OXPHOS via the mitochondrial electron 
transport chain (ETC). In normal conditions, the generation of ATP is a multistep process that begins 
with glycolysis and leads to the TCA cycle in the mitochondrial matrix and finally OXPHOS.  
1.4.5.1 Glycolysis and the TCA cycle 
Glycolysis is an anaerobic process that occurs in the cell cytoplasm and produces two molecules of 
pyruvate and the net production of two molecules of ATP (Equation 1.1). The glycolysis pathway is 
composed of two stages: (1) initially, glucose is converted into fructose-1, 6-bisphosphate. Fructose-
1, 6-bisphosphate is then further cleaved into three carbon fragments. (2) In the second stage, NAD+ 
is converted to NADH through reduction reactions. NAD+ levels are then regenerated back to 
baseline levels through the reduction of pyruvate into lactate (Berg et al., 2015a). 
 
𝐺𝑙𝑢𝑐𝑜𝑠𝑒 + 2(𝑃𝑖) + 2(𝐴𝐷𝑃) + 2(𝑁𝐴𝐷
+)
→ 2 𝑝𝑦𝑟𝑢𝑣𝑎𝑡𝑒 + 2(𝐻+) + 2(𝐴𝑇𝑃) + 2(𝑁𝐴𝐷𝐻) + 2(𝐻2𝑂) 
Equation 1.1 – Glycolysis reaction (Berg et al., 2015a). 
 
The next stage of respiration is the TCA (or Kreb’s) cycle, which occurs in the mitochondrial matrix. 
The TCA cycle functions to harvest electrons for use in the ETC as well as aerobically processing 
glucose. The first stage is the generation of acetyl coenzyme A (acetyl CoA) from pyruvate, which is 
catalysed by pyruvate decarboxylase (Equation 1.2). This acetyl-CoA then feeds into the TCA cycle. 
Here, a series of oxidation and reduction reactions generate a single molecule of ATP, two molecules 
of CO2, three NADH, and two FADH2 electron carriers (Equation 1.3), all of which are required for 
oxidative phosphorylation via the ETC (Berg et al., 2015b).  
𝑃𝑦𝑟𝑢𝑣𝑎𝑡𝑒 + 𝐶𝑜𝐴 + 𝑁𝐴𝐷+ → 𝐴𝑐𝑒𝑡𝑦𝑙 𝐶𝑜𝐴 + 𝑁𝐴𝐷𝐻 + 𝐻+ + 𝐶𝑂2 
Equation 1.2 Pyruvate decarboxylation reaction. This reaction is catalysed by pyruvate dehydrogenase (Berg et al., 2015b). 
 
𝐴𝑐𝑒𝑡𝑦𝑙 𝐶𝑜𝐴 + 3[𝑁𝐴𝐷+ + 𝐹𝐴𝐷 + 𝐴𝐷𝑃 + 𝑃𝑖 + 2(𝐻2𝑂)]
→ 𝐶𝑜𝐴 + 3(𝑁𝐴𝐷𝐻) + 2(𝐻+) + 𝐹𝐴𝐷𝐻2 + 𝐴𝑇𝑃 + 2(𝐶𝑂2) 
Equation 1.3 Net reaction of the TCA cycle (Berg et al., 2015b). 
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1.4.5.2 Oxidative phosphorylation  
The final stage of respiration is OXPHOS, which comprises the mitochondrial respiratory chain 
complexes I-IV as well as ATP synthase/complex V, all of which are embedded into the IMM (Figure 
1.12). Here, the transport of electrons along complexes I-IV, in combination with the translocation of 
protons across the IMM, produces a chemiosmotic gradient. This chemiosmotic gradient is then 
harnessed by complex V (CV) to allow the flow of electrons through the catalytic domain of ATP 
synthase, thus generating the energy required to drive ATP production.  
 
 
Figure 1.12 – Oxidative phosphorylation. Electron transport chain complexes I-IV are embedded into the IMM. Electrons   
(e-) enter the electron transport chain at complexes I and II and are then shuttled to complex IV via Cytochrome c (Cyt c). 
This transfer of electrons generates the energy needed to translocate protons (H+) across the IMM into the IMS. Finally, 




1.4.5.3 Oxidative phosphorylation complexes  
As mentioned above, there are four complexes embedded into the IMM which make up the 
mitochondrial ETC, in addition to ATP synthase. Four of the five complexes have subunits encoded 
by mtDNA (CI, CIII, CIV and CV), whilst CII is the only complex that is entirely composed of nuclear-
encoded subunits. In addition, it is the only complex that does not contribute to the electrochemical 
gradient (Chaban et al., 2014).  
Complex I (NADH dehydrogenase), is the largest of the ETC complexes, with a molecular mass of 
~1000kDa. It is composed of 45 subunits, seven of which are encoded by mtDNA whilst the other 38 
are nDNA-encoded (Carrol et al., 2006). CI has a characteristic L shape that is mainly embedded into 
the IMM lipid bilayer, with a small shoulder protruding into the matrix (Baradaran et al., 2013). The 
complex is made up of three functional modules: the P-module, Q-module and N-module. 
CI binds NADH at the distal end of the N-module (in the matrix) and then transfers two electrons 
from NADH down seven Fe-S clusters to ubiquinone via flavin mononucleotide (FMN). Reduction of 
ubiquinone then induces a conformational change that triggers the translocation of four protons (H+) 
into the IMS (Baradaran et al., 2013) (Equation 1.4). 
 
𝑁𝐴𝐷𝐻 + 𝑄 + 5(𝐻+)𝑚𝑎𝑡𝑟𝑖𝑥 → 𝑁𝐴𝐷
+ + 𝑄𝐻2 + 4(𝐻
+)𝑐𝑦𝑡𝑜𝑝𝑙𝑎𝑠𝑚 
Equation 1.4 – Complex I reaction (Berg et al., 2015b). 
 
Complex II (succinate dehydrogenase) is the smallest complex of the ETC, being ~123kDa, and is 
composed of four nDNA-encoded subunits. In addition to its role in oxidising succinate, CII is 
responsible for the transfer of three electrons to ubiquinone via three Fe-S clusters, as described in 
Equation 1.5 (Cecchine, 2003). 
 
𝑆𝑢𝑐𝑐𝑖𝑛𝑎𝑡𝑒 + 𝐹𝐴𝐷 + 2(𝐻+) + 𝑄 → 𝐹𝑢𝑚𝑢𝑟𝑎𝑡𝑒 + 𝐹𝐴𝐷𝐻2 + 𝑄 → 𝐹𝑢𝑚𝑒𝑟𝑎𝑡𝑒 + 𝐹𝐴𝐷 + 𝑄𝐻2 
Equation 1.5 – Complex II reaction (Berg et al, 2015b). 
 
Complex III (cytochrome c oxioreductase) exists in the IMM as a dimer. It is composed of 11 
subunits, of which only one is encoded by mtDNA (cytochrome b) (Benit et al., 2009). The first role of 
CIII is to oxidise ubiquinone into ubiquinol, which facilitates the translocation of two protons from 
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the matrix across the IMM into the IMS. Next, the electrons released from the newly formed 
ubiquinol are transferred to cytochrome c via cytochrome b (Equation 1.6) (Chaban et al., 2014).  
2(𝑄𝐻2) + 𝑄 + 2(𝐶𝑦𝑡 𝑐)𝑜𝑥 + 2(𝐻
+)𝑚𝑎𝑡𝑟𝑖𝑥 → 2(𝑄) + 𝑄𝐻2 + 2(𝐶𝑦𝑡 𝑐)𝑟𝑒𝑑 + (4𝐻
+)𝑐𝑦𝑡𝑜𝑝𝑙𝑎𝑠𝑚 
Equation 1.6 – Complex III reaction (Berg et al., 2015b). 
 
Complex IV (cytochrome c oxidase (COX)) is the third largest of the ETC complexes, being composed 
of 13 subunits, of which three are mtDNA-encoded. CIV accepts electrons from reduced cytochrome 
c and transfers it to molecular oxygen, forming two molecules of water (H2O). This facilitates the 
pumping of four protons from the matrix into the IMS, thus contributing to the electrochemical 
gradient in the IMS (Equation 1.7) (Diaz et al., 2010).  
 
4(𝐶𝑦𝑡 𝑐)𝑟𝑒𝑑 + 𝑂2 + 8(𝐻
+)𝑚𝑎𝑡𝑟𝑖𝑥 → 4(𝐶𝑦𝑡 𝑐)𝑜𝑥 + 2(𝐻2𝑂) + 4(𝐻
+)𝑐𝑦𝑡𝑜𝑝𝑙𝑎𝑠𝑚 
Equation 1.7 – Complex IV reaction (Berg et al., 2015). 
 
Complex V (ATP synthase) is the final complex of the OXPHOS system and is the site of ATP 
production. It is the second largest of the complexes, being composed of 15-18 subunits and 
weighing ~600kDa (Stock et al., 2000). The complex is composed of F0 and F1 domains. The F0 
domain resides in the IMM and contains subunits a, b, c, d, A6L, e, f, g, and OSCP, which form a ring-
shaped barrel, whilst the F1 domain is composed of subunits , , , and , which collectively form a 
central and peripheral stalk structure (Devenish et al., 2008; Jonckheere et al., 2012). 
As alluded to above, the role of CV is to generate ATP from ADP. Here, the proton motive force 
generated by the electrochemical gradient is harnessed in order to drive the F0 motor. This results in 
a conformational change in the catalytic F1 domain that allows the phosphorylation of ADP and 
release of ATP (Chaban et al., 2014). 
1.4.5.4 Supercomplexes 
Several studies utilising the blue-native polyacrylamide gel electrophoresis (BN-PAGE) assay have 
demonstrated that ETC complexes are able to assemble into larger structures termed 
‘supercomplexes’ (Schagger & Pfeiffer, 2000). These supercomplexes can be divided into four main 
groups. Here, complexes I, III2 and IV were found to assemble into I + III2, III2 + IV1-2, or I + III2 + IV1-4 
supercomplexes. In addition, CV is able to form dimers which resemble oligomeric cristae chains 
(Chaban et al., 2014). The abundance of these supercomplexes varies between species, and it has 
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been shown that in mammals the predominant supercomplex is the I + III2 + IV1-4 complex (Schagger 
& Pfeiffer, 2000).  
Whilst the structures of the supercomplexes has been elucidated, it is still unclear what the exact 
function of these macromolecules are. The overriding hypothesis of the function of supercomplexes 
is that they aid in maximising the flow of electrons across the ETC, thereby speeding up and 
increasing the efficiency of OXPHOS (Schagger & Pfeiffer, 2000). In addition, it is thought that the 
formation of supercomplexes reduces the leakage of electrons, and thus, the formation of ROS 




1.4.6 Other functions of mitochondria  
1.4.6.1 Apoptosis signalling 
Apoptosis is the coordinated process of controlled cell death required in multi-cellular organisms to 
maintain homeostatic balance between newly formed cells and irreparably damaged cells. In 
addition, apoptosis is necessary for the development of anatomical structures such as fingers and 
toes (Zakeri & Ahuja, 1997). Originally described by Kerr et al. (1972), apoptosis is regulated by a vast 
array of regulatory genes and proteins, and the event of apoptosis dysregulation can lead to 
uncontrolled cellular growth and cancer, as well as the accumulation of damaged cells and proteins 
which can cause diseases such as Alzheimer’s Disease (D’Arcy, 2019). 
Apoptosis can be divided into two major pathways: the intrinsic pathway (otherwise known as the 
mitochondrial pathway), where intracellular signals are detected by sensors in response to cellular 
damage such as hypoxia or DNA damage (Igney & Krammer, 2002); or the extrinsic pathway 
(otherwise known as the death receptor pathway), where a damaged cell is detected by the immune 
system and apoptosis is initiated by activation of receptors of the tumour necrosis factor (TNF) 
receptor family. The initiation of both pathways is dependent on the activation of a variety of 
cysteine-aspartic proteases termed caspases (Elmore, 2007). 
As alluded to above, mitochondria play an essential role in the initiation of the intrinsic pathway 
(Figure 1.13). In response to factors such as DNA damage or the absence of cytokines or hormones, 
the mitochondrial permeability transition pore (MPTP) opens in conjunction with the loss of 
membrane potential. The opening of the MPTP facilitates the export of several pro-apoptotic 
molecules such as cytochrome c, Smac/Diablo, and HtrA2/Omi into the cytoplasm in order to initiate 
the apoptosis signalling cascade. Here, the initiator caspase, caspase-9, binds to the caspase 
recruitment (CARD) domain of the adapter protein apoptotic protease activating factor 1 (APAF1) to 
form the ‘apoptosome’, which then cleaves and activates caspases-3 and 7 to initiate apoptosis. 
(Cain et al., 2002). A second group of pro-apoptotic proteins are released from the mitochondria as a 
late stage event of apoptosis after the cell has already committed to die. These proteins include AIF, 
endonuclease G, and CAD, and they function in a caspase-independent manner to promote DNA and 
nuclear fragmentation (Joza et al., 2001). 
Control and regulation of the intrinsic pathway of apoptosis is performed by members of the Bcl-2 
family of proteins. There have been more than 25 members of the Bcl-2 family identified, of which 
some are pro-apoptotic, such as Bax, Bak, Bid, and Bad, and some are anti-apoptotic, including Bcl-2, 








1.4.6.2 Calcium handling 
Calcium (Ca2+) regulated signalling is a highly conserved mechanism that plays a vital role in several 
cellular and physiological processes such as muscle contraction, energy production and regulation of 
apoptosis.   
Whilst ER are known to be the main site of calcium storage, various other organelles are involved in 
Ca2+ signalling such as lysosomes (Rodriguez e al., 1997), endosomes (Gerasimenko et al., 1998), 
Golgi apparatus (Pinton et al., 1998) and significantly, mitochondria (Contreras et al., 2010). Due to 
the vital role played by both the ER and mitochondria in regulating cellular Ca2+, these organelles are 
commonly localised in close association with each other (Filippin et al., 2003). 
With regards to the role of Ca2+ in mitochondrial biology, Ca2+ entry into the mitochondrial matrix is 
facilitated by the IMM mitochondrial Ca2+ uniporter (mCU), which is regulated by membrane 
potential (Kirichok et al., 2004). The function of several matrix proteins such as matrix 
dehydrogenases are regulated by Ca2+ levels (Denton, 2009). In addition, cytosolic Ca2+ has been 
shown to modulate several IMM enzymatic processes such as the malate-aspartate shuffle involved 
in respiration, or glutamate/malate respiration (Gellerich et al., 2009). Most importantly, increased 
import and overexpression of Ca2+ in mitochondria has been shown to induce mitochondrial 
membrane depolarisation and opening of the MPTP, leading to the initiation of the intrinsic pathway 
of apoptosis (Kroemer et al., 2007).  
As mentioned above, regulation of intracellular Ca2+ levels is crucial for physiological processes such 
as muscle contraction. Here, action potentials arriving at the neuromuscular junction (NMJ) triggers 
the opening of Ca2+ channels, leading to the influx of extracellular Ca2+ into the neuron. This then 
triggers the release of acetylcholine (ACh) into the synaptic cleft, where it induces the opening of 
sodium (Na+) and potassium (K+) channels and subsequently depolarisation of the sarcolemal 
membrane. Depolarisation and opening of the sarcolemal membrane leads to Ca2+ release into the 
cytosol via L-type Ca2+ channels on the sarcoplasmic reticulum (SR). The cytosolic Ca2+ then binds to 
the actin filament regulatory protein troponin, which induces a conformational change in order to 
allow the formation of actin-myosin cross bridging and finally muscle contraction (Leiber, 2010). 
Muscle relaxation additionally requires the reuptake of Ca2+ by the SR via ATP-dependant Ca2+ 




1.4.6.3 Iron sulphur cluster formation 
Individually, iron (Fe) and sulphur (S) are indispensable ubiquitous molecules in cells, but when 
overloaded induce cellular toxicity. To prevent this cellular toxicity, iron and sulphur elements are 
assembled into Fe-S clusters (Lill, 2009). These Fe-S clusters are essential co-factors for various 
proteins involved in cellular functions such as DNA replication and repair, gene expression regulation 
via tRNA modifications and importantly, OXPHOS (Lill et al., 2012). 
In a regular eukaryotic cell, Fe-S cluster assembly machinery is found in both the cytosol and 
mitochondria. With regard to the mitochondrial Fe-S cluster assembly machinery, there are 18 
proteins so far that have been identified in yeast, whilst 11 cytosolic proteins involved in Fe-S cluster 
formation have been identified (Braymer & Lill, 2017).  
The process of Fe-S cluster formation can be divided into four stages: (1) de novo 2Fe-2S synthesis 
on Isu1 scaffolding proteins; (2) mtHsp70-mediated trafficking and export of 2Fe-2S clusters into the 
cytosol as well as insertion into mitochondrial apo-proteins; (3) conversion of 2Fe-2S clusters into 
4Fe-4S clusters; (4) trafficking and import of the newly formed 4Fe-4S clusters back into the 
mitochondria (Rouault, 2012) (Figure 1.14).  
As mentioned above, Fe-S clusters are essential in order for the TCA cycle and OXPHOS to function. 
They are found within complexes I-IV where they facilitate the transfer of electrons through 
continuous redox reactions (Beinert et al., 1997). 
 
Figure 1.14 – Fe-S cluster formation and functions. The formation and assembly of various Fe-S clusters is essential for 
several functions in eukaryotic cells. 
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1.4.6.4 Reactive oxygen species (ROS) production 
Reactive oxygen (ROS) and reactive nitrogen species (RNS) are a range of chemically active species 
that are involved in various intracellular signalling pathways, but can cause damage to various 
biomolecules such as proteins and DNA when levels are not controlled (Cui et al., 2012).  
ROS are endogenously formed after the incomplete reduction of oxygen. The most commonly 
produced ROS is superoxide (O2-), which is formed after electrons leak from the mitochondrial 
respiratory chain and are accepted by molecular oxygen (Turrens, 2003). O2- can then be stabilised 
by superoxide dismutase to form hydrogen peroxide (H2O2), which is highly toxic and inflicts 
significant damage to macromolecules. H2O2 can subsequently be broken down into water and 
molecular oxygen through the actions of catalase (Ray et al., 2012). The other common ROS is the 
hydroxyl radical (HO•) (Ray et al., 2012).  
As well as being the site of ROS production, mitochondria also contain a highly conserved defensive 
mechanism termed the antioxidant system. Oxidative stress is the physiological phenomenon caused 
by dysregulation of the antioxidant system, or when ROS levels themselves become too high and 
overwhelm the system. Oxidative stress results in the direct or indirect damage of macromolecules 
such as nucleic acids, proteins and lipids, and has been associated with the onset or progression of 
several pathologies (Sies, 2015) such as diabetes, atherosclerosis (Paravicini et al., 2006), 
neurodegeneration (Shukla et al., 2011; Kim et al., 2015), and cancer (Trachootham  et al., 2009; 
Hayes et al., 2020). 
Due to the close proximity of mitochondrial proteins and mtDNA nucleoids to the ROS-producing 
ETC, as well as the fact that these macromolecules have no protective histones or sufficient DNA 
repair machinery, they are highly susceptible to damage from these ROS (Turrens, 2003). 
In contrast to the deleterious effects of ROS and RNS, these molecules play an essential role in a 
variety of intracellular signalling pathways such as autophagy (Scherz-Shouval et al., 2007), immunity 
(West et al., 2011), hypoxia (Chandel et al., 1998), mitochondrial dynamics (Bartz et al., 2015), and 
apoptosis (Pierce et al., 1991).   
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1.4.7 Mitochondrial genetics  
1.4.7.1 mtDNA genome 
Mitochondria are unique organelles in that they are the only organelle with its own genome. The 
mitochondrial genome is a circular double-stranded molecule roughly 16.6kb large (Figure 1.15). It 
encodes 37 genes: 13 OXPHOS complex subunits, as well as 22 transfer RNAs (tRNA), and two 
ribosomal RNAs (rRNA) required for the transcription and translation of the OXPHOS subunits 
(Anderson et al., 1981). The two strands of mtDNA differ in their composition with regard to guanine 
saturation, and so can be separated into heavy (H) and light (L) strands. 
mtDNA is a very compact molecule and does not contain any non-coding introns. Instead, mtDNA 
possess a noncoding region (NCR) where the displacement loop (D-loop) is located. The NCR 
contains promoters of polycistronic transcription for both the H and L strands, appropriately termed 
the heavy strand promoter (HSP) and light strand promoter (LSP). Importantly, the NCR also 
harbours the origin for H strand replication (OH) (Shadel & Clayton, 1997). The origin for light strand 
replication (OL) is located in a tRNA cluster roughly 11,000bp downstream of the OH (Falkenberg, 
2018). 
The mitochondrial genome exists in numerous copies per cell and can be found in the mitochondrial 
matrix in the form of circular nucleoids, localised within a close proximity to the IMM and OXPHOS 
complexes (Satoh & Kuroiwa, 1991). The number of mtDNA nucleoids per cell depends on the cell 
type and its energy requirement. For example, there are roughly 100,000 copies in mature oocytes, 
which require vast amounts of energy supply, whilst there are roughly 3600 copies in skeletal muscle 




Figure 1.15 – Mitochondrial genome. The mtDNA genome contains a noncoding region (D-Loop) and 37 genes – 13 
OXPHOS subunits (CI = blue, CIII = purple, CIV = red and CV = dark grey), 22 tRNAs (black lines) and 2 rRNAs (yellow). In 




1.4.7.2 mtDNA replication 
mtDNA replication occurs independently of the cell cycle and so is termed ‘relaxed replication’. As a 
result, mtDNA replication requires its own distinct set of replication machinery. This machinery 
consists of: a mitochondrial polymerase, polymerase gamma (POLG); a helicase, Twinkle; a 
mitochondrial RNA polymerase (POLRMT); single-stranded binding protein (mtSSB); RNA ligase 
(RNaseH1), and topoisomerases (Milenkovic et al., 2013).  
POLG is a heterotrimer that is composed of a catalytic subunit (POLGA) and two accessory subunits 
(POLGB), which are involved in replication fidelity (Gray & Wong, 1992; Fan et al., 2006). Whilst 
there are other known mtDNA polymerases, they are not essential for mtDNA replication (Sykora et 
al., 2017; Wisnovsky et al., 2016). The mtDNA helicase Twinkle is responsible for unwinding of 
mtDNA prior to transcription, whilst the function of mtSSB is to stabilise the unwound, single-
stranded mtDNA. The POLRMT is responsible for initiating the synthesis of RNA stands, and finally, 
the topoisomerases are responsible for unwinding the mtDNA as it progresses through the 
replication fork (Young & Copeland, 2016). 
There is still no consensus as to how mtDNA replication occurs in mammals, although extensive 
research over the last 20 years has demonstrated the presence of two distinct classes of mtDNA 
replication – ‘synchronous’ and ‘asynchronous’ (Figure 1.16). 
In the ‘synchronous’ (or ‘strand-coupled’) model of mtDNA replication, initiation of the H and L 
strand occurs simultaneously at OH in response to priming by oligonucleotide Okazaki fragments, and 
proceeds bidirectionally (Holt et al., 2000). This model of replication was first proposed by 
Robberson et al. (1972) and later developed by Holt et al. (2000), who discovered double-stranded 
replication intermediates through work using two-dimensional agarose gel electrophoresis (2D-
AGE). Further progress to this model was demonstrated through the discovery of long stretches of 
DNA/RNA hybrids, in which whilst the leading H strand replicates as usual from OH, the lagging 
strand replicates as short segments of RNA which subsequently hybridise with the leading strand to 
form mature DNA (Yang et al., 2002; Holt & Reyes, 2012). This model was called the RNA 
incorporation throughout the lagging strand (RITOLS) model of mtDNA replication.  
In contrast to the two synchronous models of mtDNA replication, the asynchronous or ‘stand-
displacement model’ (SDM) of replication suggests that replication of the H strand occurs within the 
D-loop at OH and proceeds unidirectionally in a clockwise manner. After replication has progressed 
around two thirds of the H strand it reaches and exposes the OL. This exposing of the OL then 
initiates replication of the L strand, which proceeds in an anti-clockwise direction, lagging behind the 
H strand (the leading strand) (Brown et al., 2005; McKinney & Oliveria, 2013). The SDM of replication 
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was first proposed by Kasamatsu & Vinograd (1973), who observed the arrangement of replicating 
stands through electron microscopy work. This model was later refined by Clayton (1982). 
 
 
Figure 1.16 – Models of mtDNA replication. The strand-displacement theory of mtDNA replication is an asynchronous 
model of replication, whilst the strand-coupled and RITOLS models propose a synchronous method of mtDNA replication.  





Transcription of mtDNA is a conserved process whereby genetic information encoded by mtDNA is 
copied onto messenger RNA (mRNA), which is then followed by its translation. Due to the fact that 
the mtDNA genome lacks non-coding introns, transcripts are generated as polycistronic mRNA that 
require cleavage. This cleavage occurs at the tRNA coding regions by RNA processing enzymes 
(MRPP1, 2 and 3), which is facilitated by folding of the mRNA (Ojala et al., 1981).  
Transcription of both the H and L strands of mtDNA is initiated at the D-Loop of the mtDNA genome. 
In particular, H strand transcription is initiated at the HSP at two specific sites (HSP1 and HSP2). 
Here, initiation at HSP1 generates a transcript for the two mtDNA-encoded rRNAs, whilst initiation at 
HSP2 generates the transcript encoding the majority of the other mtDNA genes (Chang & Clayton, 
1984; Zollo et al., 2012). Transcription of the L strand is initiated at the LSP. Importantly, 
transcription is a bidirectional process.  
As with mtDNA replication, a range of nDNA-encoded regulatory proteins are required in order to 
undertake mtDNA transcription. The POLRMT is responsible for the actual transcription of mtDNA, 
but it cannot interact with the promoter DNA and initiate transcription without the assistance of 
mitochondrial transcription factor A (TFAM) and the mitochondrial transcription factor B2 (TFB2M) 
(Falkenberg et al., 2002; Barshad et al., 2018). Here, TFAM binds to a region 10-15bp upstream of 
the HSP and LSP, inducing a conformation change in the promoter region. This then allows the 
recruitment of POLMRT to the promoter region. Next, POLRMT binds to TFAM and then recruits 
TFB2M, forming the transcription competent initiation complex (Morozov et al., 2015) (Figure 1.17).  
The next stage of transcription is the elongation process, before finally, the termination process. The 
termination stage is mediated by mitochondrial termination factor (mTERF), which induces the 
unwinding and base flipping of the DNA molecule by binding to the tRNAleu(UUR) gene (Yakubovskaya 
et al., 2010). 
 
 
Figure 1.17 – Transcription initiation. (1) TFAM binds to a region upstream of the HSP and LSP, (2) facilitating the binding 
of POLRMT and promoting its conformational change. (3) TFB2M binds to TFAM and POLRMT to form the transcription 




Translation of mitochondrial transcripts is a three-stage process that requires a range of nDNA-
encoded regulatory proteins (Figure 1.18). The first stage of transcription is the initiation phase. 
Here, mt-mRNA is recruited to the mitochondrial small subunit (mtSSU) with the aid of the initiation 
factor 3 (IF3), which prevents the premature association with the large subunit (mtLSU) by 
competitively inhibiting its initiation codons (Bhargava & Spremulli, 2005). Next, initiation factor 2 
(IF2) promotes the association of the P-binding site of mt-mRNA and tRNAfmet in a GTP-mediated 
fashion to form the ‘mitochondrial monosome’, which promotes the initiation of the elongation 
stage of translation (Ma & Spremulli, 1996; Kummer et al., 2018). 
As mentioned above, the next step of mtDNA translation is the elongation stage, which requires the 
presence of three mitochondrial elongation factors (mtEF-Tu, mtEF-G1 and mtEF-Ts) (Di Notia et al., 
2017). Firstly, the mt-mRNA, together with mtEF-Tu, charged mt-tRNA, and GTP, form a tertiary 
complex called the ‘mitoribosome’. Following GTP hydrolysis, a mtEF-Tu/GDP complex is released for 
recycling by mtEF-T, allowing the tRNA to associate with the peptidyl (P) site of the mitoribosome, 
which promotes the formation of a peptide bond in the peptidyl transferase centre of mt-LSU (Cai et 
al., 2000). This results in the mitoribosome complex containing a deacetylated mt-tRNA and a de-
peptidyl-tRNA at the A-site. Finally, the association of mtEF-G1 induces a conformational change in 
the mitoribosome that initiates the movement of the tRNA to the exit (E)-site and the di-peptidyl-
tRNA to the A-site (Katunin et al., 2002). After rounds of cycling, the newly synthesised polypeptide 
is translocated into the mitochondrial matrix where it is folded via protein folding mechanisms 
described in Section 1.4.4.3.  
The final stage of mtDNA translation is the termination step. Termination is initiated when the STOP 
codon enters the A-site of the mitoribosome, and several mitochondrial release factors (mtRFs) are 
associated with translation termination (Richter et al., 2010). Firstly, mtRF1a promotes the 
hydrolysis of the ester bond between the mt-tRNA at the P-site and the polypeptide chain, which is 
followed by the disassociation of the mitoribosome and release of mRNA and tRNA to be used in 
future translation. These steps are performed by the mitoribosome recycling factors mtRRF-1 and 







Figure 1.18 – Mitochondrial translation. The process of mtDNA translation can be divided into the three phases of 




1.4.7.5 Heteroplasmy and the threshold effect 
As mtDNA exists in a highly polyploid state within cells it is possible for both wild-type and mutated 
mtDNA nucleoids to exist side-by-side in the same cell. This phenomenon is termed ‘heteroplasmy’, 
and if all the nucleoids in a cell are genetically identical it is said that the cell is homoplasmic.  
Heteroplasmy is measured as a percentage of total mtDNA copy number and can vary greatly 
throughout adjacent cells of the same tissue. If the proportion of mutated mtDNA exceeds a certain 
threshold it can result in the phenotypic manifestation of the pathogenic mutational defect in what 
is known as the ‘threshold effect’ (Rossignol et al., 2003) (Figure 1.19). The threshold effect varies 
between the type of mtDNA mutation and the cell type themselves. For example, point mutations 
have been shown to have a threshold of around 90% heteroplasmy (Moslemi et al., 1999), whilst the 
threshold of mtDNA deletions is thought to range between 50-90% (Porteous et al., 1998; Sciacco et 
al., 1994). The large reported variation in threshold for deletions is thought to arise from the 
variation in size and location on the mtDNA genome (Rocha et al., 2018).  
 
 
Figure 1.19 – mtDNA heteroplasmy and the threshold effect. As heteroplasmy increases due to the increased proportion of 
mutant mtDNA compared to wild-type mtDNA, the function of OXPHOS (black line) decreases until a certain threshold is 




1.4.7.6 Maternal inheritance and the bottleneck theory 
A unique aspect of mtDNA is that it is exclusively inherited down the maternal line (Giles et al., 1980; 
Wallace, 2007). Whilst the mechanism behind this phenomenon is still not completely understood, it 
is thought to be the result of a combination of factors, one being that sperm contain ~1000 times 
less mtDNA than oocytes, in addition to the presence of a selective mechanism targeting sperm 
mtDNA for degradation (Sutovsky et al., 2000). The result of this exclusive maternal inheritance 
means that clinically asymptomatic women with low levels of mutated mtDNA may pass down their 
mutated mtDNA to their offspring. However, the proportion of mutated mtDNA variants can be 
highly variable between individual offspring, a phenomenon termed the ‘mitochondrial bottleneck’  
(Howell et al., 2000; Taylor & Turnbull, 2005) (Figure 1.20). The cause of this phenomenon can be 
attributed to the initial reduction in compartmentalised mtDNA nucleoids followed by rapid 
replication of the remaining mtDNA following fertilisation (Cree et al., 2008; Brown et al., 2001). 
If the level of heteroplasmy exceeds the threshold, an individual may present with biochemical 
deficiency and clinical mitochondrial disease. For example, if the Leigh syndrome causing m.8993T > 
G mutation exceeds 30% then the child will likely present with clinical symptoms. The level of 
severity is increased in proportion to the level of heteroplasmy (White et al., 1999).  
Interestingly, a recent study has questioned the theory of exclusively maternal mtDNA inheritance 
(Luo et al., 2018), although more work needs to be done in order to confirm this theory. 
 
 
Figure 1.20 – Mitochondrial bottleneck. Schematic depicting the inheritance of wild-type and mutated mtDNA variants and 
their amplification, which results in cells with varying levels of heteroplasmy. 
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1.4.8 mtDNA mutations 
mtDNA mutations can either be inherited or acquired throughout life as de novo mutations. 
Compared to nDNA, the mitochondrial genome is hyper-mutable, with a mutation rate roughly 10 
times higher than that of nDNA (Brown et al., 1979). The hyper-mutable nature of mtDNA is caused 
by several factors. Firstly, mtDNA is damaged by high levels of ROS due to the fact that mtDNA 
nucleoids are localised in close proximity to the electron transport chain, where ROS is produced 
(Miquel et al., 1980). Secondly, as mtDNA is packaged as nucleoids and not as densely-packaged 
chromatin like nDNA, they are highly susceptible to damage from ROS and other factors. 
Importantly, the proof-reading exonuclease domain of the mtDNA polymerase POLG has a low 
fidelity, which in combination with the fact that the rate of mtDNA replication is very high, results in 
the increased susceptibility for mutation formation (Kunkel & Loeb, 1981; Bogenhagen & Clayton, 
1977). In addition, mtDNA DNA repair machinery is not as comprehensive as that for nDNA, and so 
mutations are often not fully resolved (Fukui & Moraes, 2009).  
The first mtDNA mutations were identified in 1989 (Holt et al., 1989; Wallace, 1989) and intense 
work in the field has since identified numerous other mtDNA mutations, with the estimated 
prevalence of mtDNA mutations in the North East of England being 20 for every 100,000 people 
(Gorman et al., 2015). The clinical pathology induced by mtDNA mutations, as well as the timing of 
onset, is extremely heterogeneous, with some mutations affecting isolated tissues and other causing 
multi-system pathologies (Campbell et al., 2014; Taylor et al., 2003).  
1.4.8.1 Point mutations 
mtDNA point mutations are a single base pair substitution. Point mutations are present in roughly 1 
in 5000 of the adult population, and commonly occur in the 22 tRNA genes on the mtDNA genome 
(Gorman et al., 2015).  
Point mutations are often caused by ROS-induced DNA damage, the most common of which are 
thymine glycol and 7,8-dihydro-8-oxo-2’-deoxyguanosine (8-oxo-dG) base lesions, of which 8-oxo-dG 
lesions are highly mutagenic (Bohr, 2002). For example, 8-oxo-dG lesions result in G:C to T:A 
transversions as a result of POLG mis-incorporating an A base opposite the oxidised G base. 
The most common and well characterised mtDNA point mutations are the m.3243A>G and 
m.8344A>G mutations, which occur in the MT-TL1 and MT-TK tRNA genes, respectively (Gorman et 
al., 2015). There is large variability in the phenotypic spectrum caused by the m.3243A>G mutation, 
with 80% of patients presenting with the mitochondrial encephalopathy, lactic acidosis and stroke-
like episodes (MELAS) phenotype. In contrast, some patients present with chronic progressive 
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external ophthalmoplegia (CPEO) or maternally-inherited diabetes and deafness (MIDD) (Nesbitt & 
McFarland, 2011; Nesbitt et al., 2013; Pickett et al., 2018; Urata et al., 2004). Similarly to the 
m.3242A>G mutation, the m8344A>G mutation has been reported to present as a wide range of 
phenotypes. First reported from patients with myoclonic epilepsy and ragged red fibres (MERRF) 
(Shoffner et al., 1989), the m.8344A>G mutation also presents as ataxia, diabetes mellitus, 
dementia, optic atrophy and hearing loss (Mancuso et al., 2013).  
1.4.8.2 Single, large-scale deletions 
mtDNA deletions are thought to arise sporadically during embryogenesis as the result of errors in 
mtDNA replication or repair of double-stranded breaks (DSBs) (Shoffner et al., 1989; Krishnan et al., 
2008; Fukui & Moraes, 2009). Deletions can be characterised as either class I, II or III deletions 
depending on the mechanism of formation. Class I deletions have direct repeats, class II deletions 
have indirect repeats, whilst class III deletions have no repeats (Reeve et al., 2008).  
Several models of mtDNA deletion formation have been proposed, the first of which assumes the 
asynchronous (or SDM) model of mtDNA replication. Here, during replication the L strand misaligns, 
resulting in the 3’ repeat annealing to the 5’ end of the H strand. This generates a single-strand loop 
that is susceptible to breakage and degeneration (Shoffner et al., 1989). Another model of deletion 
formation suggests that deletions are the result of DSB repair, where the homologous repeats 
generated from POLG exonuclease activity anneal together (Reeve et al., 2008, Krishnan et al., 
2008). More recent work using mouse models has further supported the idea of deletion formation 
during the repair of DSBs. Here, micro-homology-mediated end joining or non-homologous end 
joining of DSBs resulted in class I deletions in neurons (Fukui & Moraes, 2009; Tadi et al., 2009; 
Lieber, 2010). The final model hypothesises that deletions are formed by copy-choice recombination 
during the mtDNA L-strand synthesis step of replication. Here, PolG can dissociate from a newly-
synthesised DNA end following template H-stand replication. Next, the nascent L-stand unpairs from 
the DNA template and reanneals with a downstream repeat sequence. This model is attractive as it 
can account for class I, II and III deletions in vitro, as demonstrated following the recapitulation of 
deletions caused by nDNA-encoded maintenance genes (Persson et al., 2019, Nissanka et al., 2019).   
Whilst there have been several reported mtDNA deletions of varying size, the most commonly 
reported deletion is the 4,977bp deletion between nucleotides 8482 and 13460. This mutation 
accounts for roughly 16% of adult mtDNA mutations and 12% of mitochondrial disease patients, and 
its prevalence has been shown to increase with age (Schon et al., 1989; Gorman et al., 2015; 
Williams et al., 2013). As with mtDNA point mutations, mtDNA deletions induce a range of clinical 
phenotypes. The three most common of these are Pearson syndrome, CPEO and Kearns-Sayre 
46 
 
syndrome (KSS) (Magner et al., 2015). In addition, deletions have been shown to induce non-
syndromic disease symptoms such as ptosis, muscle weakness, and ophthalmoparesis (Mancuso et 
al., 2015). 
In contrast to earlier reports, recent studies have demonstrated a relationship between mtDNA 
genotype and clinical phenotype. In addition, these factors have also been shown to be associated 
with the age of onset of clinical manifestation (Yamashita et al., 2008; Lopez-Gallardo et al., 2009; 
Grady et al., 2014). Interestingly, the pattern of OXPHOS biochemical deficiency was shown to be 
associated with the size and location of mtDNA deletion in skeletal muscle fibres (Rocha et al., 2018). 
In addition, fibres with greater levels of energy requirement harboured higher levels of mutation. 
1.4.8.3 Clonal expansion of mtDNA mutations 
‘Clonal expansion’ of mtDNA mutations is the dynamics process whereby a mutated mtDNA species 
accumulate in a cell and can eventually lead to onset and progression of several inherited and 
somatic mitochondrial diseases (Lawless et al., 2020).  
There are several alternative theories which explain the mechanism of clonal expansion, including 
‘random genetic drift’ (Chinnery & Samuels, 1999; Elson et al., 2001), ‘survival of the sickest’ (de 
Grey, 1997; Yoneda et al., 1992), ‘survival of the smallest’ (Wallace, 1989), the ‘negative feedback 
loop’ theory (Kowald & Kirkwood, 2014; Kowald & Kirkwood, 2018) and the ‘perinuclear niche’ 
theory (Vincent et al., 2018) (Figure 1.21). Different theories appear to better explain the clonal 
expansion of certain forms of mtDNA mutations over the other. For example, the random genetic 
drift theory seems to explain the clonal expansion of point mutations, whilst not being appropriate 
to explain the clonal expansion of deletions.   
The first theory mentioned is the random genetic drift theory. Unlike many of the other models, this 
theory proposes that there is no selective advantage for the replication of mutated mtDNA, and so 
commonly forms the null hypothesis for modelling clonal expansion. In this model, the clonal 
expansion and accumulation of mutated mtDNA occurs by chance due to the relaxed replication of 
mtDNA (Chinnery & Samuels, 1999; Elson et al., 2001; Kimura, 1968). This theory is supported by in 
silico models reported in Elson et al. (2001), which suggested that 4% of post-mitotic cells will 
present with biochemical COX deficiency by the age of 80 years. 
The survival of the smallest theory was first proposed by Wallace (1989) and was the first theory to 
suggest a selection advantage for mutated mtDNA species. This theory suggests that due to the fact 
that mutated mtDNA species are smaller, they would be replicated quicker than wild-type mtDNA 
(Russell et al., 2018). Whilst this theory would seem to fit with the clonal expansion of deleted 
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mtDNA, it would not work for point mutations. Importantly, it was later demonstrated that smaller 
mtDNA species do not have a replication advantage in skeletal muscle fibres (Campbell et al., 2014).  
Another alternative theory based on the selection advantage principle is the negative feedback 
theory. In this theory, mtDNA species which encompass deletions in genes encoding OXPHOS 
subunits have reduced respiratory function and subsequently reduced ROS production. As a result, 
replication of these species is upregulated in an attempt to compensate for biochemical reduction 
(de Grey, 1997; Kowald & Kirkwood, 2014). MT-ND4, MT-ND5 and MT-ND6 have been proposed as 
candidate genes in this hypothesis, as they lie on the major arc of the mtDNA genome and so are 
regularly deleted (Kowald & Kirkwood, 2018). 
The most recent model of clonal expansion is the perinuclear niche theory proposed by Vincent et al. 
(2018). Through the investigation of how single mtDNA mutations expand over post-mitotic skeletal 
muscle fibres, this study demonstrated that genetic rearrangements can originate in a 
subsarcolemmal proliferative perinuclear niche and progressively expand. This theory suggests a 
selective advantage for mutated mtDNA species which results in the localised compensatory 
upregulation of mitochondrial biogenies. Importantly, this theory has only been examined in post-
mitotic skeletal muscle tissue, and so its relevance to other tissues is unknown.  
 
 
Figure 1.21 – Models of clonal expansion. Several mechanisms have been proposed for the model of clonal expansion of 
mutated mtDNA species. Of these, the perinuclear niche, survival of the sickest, and survival of the smallest revolve around 
the idea of a selection advantage for mutated mtDNA, whilst the random genetic drift theory proposed that clonal 
expansion occurs by chance over a lifetime. The perinuclear niche figure was supplied by Lawless et al. (2020).  
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1.4.8.4 Somatic mtDNA mutations and ageing  
With support from various observational and experimental evidence, the accumulation and clonal 
expansion of acquired (somatic) mtDNA mutations with age has been implicated in several age-
related diseases. The driving mechanism behind this pathology is widely hypothesised to be mtDNA-
induced mitochondrial dysfunction (Trifunovic et al., 2008; Krishnan et al., 2007).     
Aged humans present with increased levels of somatic mtDNA mutations compared to younger 
individuals. In contrast to germline inherited mtDNA mutations, somatic mtDNA mutations can be 
present in some cells but not in adjacent ones in tissues such as heart or skeletal muscle (Kang et al., 
2016). This phenomenon subsequently presents as a mosaic pattern of respiratory chain deficiency.  
In order to better understand the role of somatic mtDNA mutations in ageing, mouse models with 
various phenotypes have been developed and studied. In particular, the PolG mutator mouse, which 
carries a nDNA defect within the proofreading domain (D275A) of PolG and so induces increased 
mtDNA mutagenesis, has been extensively studied (Trifunovic et al., 2004; Kujoth et al., 2005). Due 
to this increased mutagenesis, the PolG mouse accumulates a high frequency of somatic mtDNA 
mutations during development and presents with premature ageing phenotypes such as anaemia, 
kyphosis, hearing loss and greying of the hair. Whilst both homozygous and heterozygous PolG mice 
develop mtDNA mutations, only the homozygous mouse presents with premature ageing 
phenotypes, suggesting that the accumulation of somatic mtDNA mutations is not solely responsible 
for the phenotypes. This is supported by a recent observation that increases in heteroplasmy levels 
of both germline and somatic mtDNA mutations was associated with the development of age-




 1.5 Frailty in PLWH and the general population  
Due to the virus-supressing effects of cART, PLWH are living longer. As a result, the average age and 
life expectancy of the roughly 36 million worldwide HIV-infected population is increasing. In addition 
to the fact that 20% of new seroconverts are older than 50, the mean age of PLWH is now 50 years  
or older, with an estimated 73% of PLWH expected to be over 50 years old by 2030 (Centers for 
Disease Control and Prevention, 2013; Smit et al., 2015). In the HIV ageing literature there has 
previously been a tendency to describe PLWH aged over 50 as ‘old’. In the general population 
however, people aged over 65 years are considered ‘old’, whilst individuals aged 50-65 years are 
considered ‘middle-aged’. It is now best practice to use the definitions for HIV+ individuals (Kooij et 
al., 2016). Hence, in this thesis both HIV+ and HIV- individuals between the ages of 50-65 are termed 
‘middle-aged’, over 65 years are termed ‘old’, and collectively anyone over 50 years is considered 
‘older’.  
Whilst cART has been effective in reducing the mortality rate and prevalence of HIV-associated 
comorbidities in PLWH, the increased age of these PLWH has resulted in an elevated burden of age-
associated co-morbidities including neurodegenerative and cardiovascular diseases (Chow et al., 
2012; Nightingale et al., 2014; Nou et al., 2016). 
One of the most significant concerns arising from the rising age of the HIV-infected population is the 
increased prevalence of frailty (Leng & Margolick, 2015). Frailty is an age-related clinical syndrome 
characterised by a diminished physiological reserve alongside an increased susceptibility for 
comorbidities and mortality (Fried et al., 2001).  
Frailty is known to be a multisystem condition involving the metabolic, musculoskeletal, 
neuroendocrine, immune, and cognitive systems (Clegg et al., 2013; Fried et al., 2001). Although the 
exact pathophysiological mechanisms underpinning frailty have yet to be fully elucidated, factors 
such as chronic inflammation (Franceschi et al., 2000; Roubenoff et al., 2003; Soysal et al., 2016; 
Leng et al., 2007), immunosenescence (Dihn et al., 2019), cell senescence (Lehman et al., 2018; Xu et 
al., 2018), decreased stem cell availability (Sousa-Victor et al., 2014; Sousa-Victor et al., 2016; Gonen 
& Toledana, 2014; Larrick & Mendelson, 2017), sarcopenia (Dodds & Sayer, 2015; Thompson & 
Dodds, 2020), insulin resistance (Chow et al., 2020; Perkisas & Vandewounde, 2016), neurocognitive 
decline (Puts et al., 2005; Boyle et al., 2010; Sugimoto et al., 2018), oxidative stress (Soysal et al., 
2017; Vina et al., 2018; Liu et al., 2016; Namioka et al., 2017; Wu et al., 2009; Ingles et al., 2014; 
Serviddio et al., 2009; Ble et al., 2006), and mitochondrial dysfunction (Ferrucci & Zampino, 2020; 
Ashar et al., 2015; Andreux et al., 2018) have been implicated as causative factors (Ashar et al., 
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2015; Andreux et al., 2018). In addition, declines in mitochondrial function are known to contribute 
to the pathogenesis and pathophysiology of each respective factor (Ferruci & Zampino, 2020). 
Whilst there are several validated methods for determining frailty in the clinical setting, the most 
commonly used is the Fried’s frailty phenotype (FFP), developed by Fried and colleagues (Fried et al., 
2001).  
1.5.1 Frieds frailty phenotype and alternative assessments of frailty 
Developed and validated in 2001 using a cohort of men and woman over 65 in the Cardiovascular 
Health Study (CHS), the FFP is the most commonly used assessment method for characterising frailty 
in the clinical and research setting (Buta et al., 2015). FFP is based on the assumption that frailty is a 
clinical syndrome in which a cycle of age-related factors interplay with each other and that age-
associated declines in lean body mass, balance, strength, endurance, walking performance and 
activity level collectively create a cycle of declining energetics and reserve (Fried et al., 2001) (Figure 
1.22).  
Importantly, the frailty phenotype can be used clinically to assess immune function decline and as a 
pre-operative evaluator for whether older individuals who undergo surgery are at risk of 
postoperative complications (Makary et al., 2010). In addition, the frailty phenotype can be used to 
independently predict several adverse health outcomes in older individuals such as cognitive decline, 
falls, disability, dependency, acute illness, and hospitalisation (Fried et al., 2001). 
By using a set of five pre-defined criteria: self-reported weight loss, self-reported physical 
exhaustion, self-reported inactivity, slow gait speed and poor handgrip strength – the FFP can define 
individuals as frail, pre-frail or robust (non-frail) (Table 1.1).  
 
FFP category Eligibility 
Robust 0 criteria 
Pre-frail 1-2 criteria 
Frail 3-5 criteria 
 





Figure 1.22 – Proposed cycle of frailty dynamics. Adapted from Fried et al. (2001).
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The clinical validity of the prefrail category is not universally recognised, although a recent study 
demonstrated a reduction in oxidative capacity as well as protein levels of ETC complexes in skeletal 
muscle from prefrail individuals (defined through a modified three criteria FFP score) compared to 
age-matched individuals who had been classified as ‘active’ according to metabolic expenditure 
(MET) score, gait speed, skeletal muscle mass, and skeletal muscle strength results. These indicators 
of mitochondrial dysfunction at the cellular level were corroborated by the fact that gene sets 
related to mitochondrial function were also significantly downregulated in the old (> 61 years) 
prefrail individuals compared to ‘active’ individuals (Andreux et al., 2018). The fact that roughly half 
of the elderly population displays early signs of muscle decline indicates that the inclusion of the 
prefrail category is important for detecting potentially subtle differences between prefrail and frail 
individuals, which could aid in improving understanding of the pathogenesis of frailty and optimal 
opportunities for the potential intervention (Fernandez-Garrido et al., 2014). 
The second most commonly used measure of frailty is the cumulative deficit model, or frailty index 
(FI). Based on the idea that frailty is an at-risk state caused by the age-related accumulation of 
deficits (Mitnitski et al., 2001), a frailty index can be developed from existing health data, as well as 
from information derived from a comprehensive geriatric assessment (FI-CGA) (Searle et al., 2008; 
Jones et al., 2004; Jones et al., 2005; Rockwood et al, 2010). Each deficit is translated into a binary 
tally and then expressed as the ratio of deficits considered, thus allowing for consistency across 
different studies (Rockwood & Mitnitski, 2011). The hypothesis behind the FI is that frailty is a multi-
factorial state in which the quantity of deficits is more informative than the quality of deficits an 
individual has accumulated over the course of their adult life. Both the FI and FFP have been 
associated with the increased risk of an individual developing age-related comorbidities, albeit 
through alternate pathophysiological mechanisms (Clegg et al., 2013). An advantage of FI over the 
FFP is that the rate of deficit accumulation can be calculated and used to give an estimation of how 
quickly frailty will progress in an individual. Whilst the FI and FFP propose different 
pathophysiological mechanisms for frailty, both measurements appear to similarly predict frailty 
outcomes. Here, the convergent validity between outcome measures of both the FFP and FI were 
tested through both parametric and non-parametric correlation analyses (as described in Rockwood 
et al., 2007), and determined to be 0.65 in a study which utilised both. This indicates that there is 
considerable, but not complete, convergency between the assessments (Rockwood et al., 2007). 
Aside from the FFP and FI, there are other alternative validated methods for measuring frailty. 
Briefly, these include the Study of Osteoporotic Fracture (SOF) Index, which assesses frailty using 
three characteristics in which only two need to be met for an individual to be classified as frail 
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(Ensrud et al., 2007); Edmonton Frailty Scale (EFS), which is commonly used in the hospital setting 
(Rolfson et al., 2006); Clinical Frailty Scale (CFS) which scores frailty on a scale of 1-7 based on clinical 
judgement of known markers of frailty (Rockwood et al., 2005a), and PRISMA-7, which is composed 
of seven self-reported characteristics (Raiche et al., 2008).  
Importantly, in response to the development of various frailty assessments, a consensus between 
leading international frailty delegates agreed that criteria for successfully defining frailty includes 
having content validity (i.e. has multiple determinants and can be applied to numerous situations), 
criterion validity (i.e. can predict adverse outcomes), and construct validity (i.e. consistently predicts 
frailty in certain setting, such as in woman and in advanced age) (Rockwood et al., 2005b; Morley et 
al., 2013) 
The geriatric field is currently looking to move towards more specific instruments and methods for 
assessing frailty in specific populations and settings. Two examples are the electronic Frailty Index 
(eFI) and the Hospital Frailty Risk Score (HFRS). These two methods of assessment can measure 
frailty through deficits solely using electronic heath records, and have both been validated to predict 
adverse health outcomes (Clegg et al., 2016; Ambagtsheer et al., 2019; Gilbert et al., 2018). 
Although these different measurements of frailty are based on alternative pathophysiological 
hypotheses of frailty, there is a consensus that individuals with an increased accumulation of deficits 
are more vulnerable and so likely to be frail. There is also a consistency in the relationship between 
frailty and age, as well as frailty and female gender, within each alternative form of frailty 




1.5.2 Frailty in the general population 
In the general population the process of ageing and complications which arise from adverse ageing 
are highly heterogeneous, with individuals of the same age experiencing vastly different health 
levels. As such, frailty was introduced as a universal term to describe this variability. Frailty is 
associated with age in the HIV-uninfected population (Althoff et al., 2014; Hoogendijk et al., 2018), 
although the severity of frailty can be modified over time (Womack et al., 2013). In addition, the 
presence of frailty (as determined through the original FFP assessment) predicts outcomes such as 
falls, comorbidity, loss of independence and mortality in the general population (Fried et al., 2001; 
Fairhall et al., 2014; Li et al., 2014; Barbosa et al., 2017).  
Due to the variability in study populations and methods of assessment, accurate figures on the 
epidemiology of frailty in the general population have proven difficult. A systematic review by 
Collard and colleagues pooled together results from over 61,000 community-dwelling residents of 
high-income countries aged 65 and over and assessed frailty using the FFP method. They 
demonstrated the weighted prevalence of frailty to be 11%, although there was vast variation in the 
prevalence of frailty between the different studies (4-59%) (Collard et al., 2012). A more recent 
systematic review and meta-analysis using data from more than 120,000 older individuals 
demonstrated that the incidence of frailty (as measured by various assessment criteria) was 43.4 
new cases every 1000 person-years, and the incidence of prefrailty was 150.6 new cases every 1000 
person-years (Ofori-Asenso et al., 2019). Other systematic reviews have demonstrated that the 
prevalence of frailty, as determined by the original FFP, among long-term care residents is 53% 
(Kojima, 2015), 37% in individuals with end-stage renal disease (Kojima, 2017), and 42% in patients 
with haematological malignancies, although in this study frailty was determined by a variety of 
validated methods (Handforth et al., 2015).  
There is still debate regarding the best method for assessing frailty in the clinical and hospital 
setting, mostly due to the large heterogeneity in pathogenesis and presentation of frailty in different 
individuals. Notably, a survey of 62 geriatricians conducted by Fried and Watson reported the 
characteristics that represent frailty. These included: malnourishment, functional dependence, 
pressure sores, prolonged bed rest, gait abnormalities, general muscle weakness, weight loss, being 
over 90 years old, fear of falling, anorexia, dementia, hip fractures, delirium, polypharmacy, and 
confusion (Fried & Watson, 1998). 
Due to the large heterogeneity of frailty and lack of consensus that still exists, frailty is often used as 
an umbrella term for a syndrome that contains a vast array of symptoms, including loss of reserve 
and disability. Disability is related to frailty but is a distinct condition. A disability is defined as the 
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loss of functional ability and capacity to carry out tasks as an individual (Yoo et al., 2018). Disabilities 
may inversely affect an individual’s quality of life (QOL) and cause an increased burden on health 
services, with QOL being inversely associated with frailty in community-dwelling adults (Kojima et 
al., 2016, Crocker et al., 2019). According to the WHO, 15% of people worldwide live with disabilities 
(United Nations, 2015), and up until 1996, the prevalence of disability among community-dwelling 
individuals above 70 years old was between 20-30%, and this number was forecast to keep 
increasing (Adams et al., 1995). A more recent estimation put the prevalence of disability in this 
population at 66% (Virues-Ortega et al., 2011). As mentioned above, disabilities and frailty are 
distinct entities but can frequently coexist. Several studies have demonstrated that five criteria 
frailty phenotype characterised community-dwelling frail or prefrail individuals are more likely to 
develop disability (Makizako et al., 2015; Aguilar-Navarro et al., 2015).  
An analysis of the SHARE study, which included data from more than 35,000 individuals over 50 
years old, demonstrated that frailty, as measured by the FI, was lower in high-income countries 
compared to low-income countries. In addition, the mean FI score was inversely correlated with 
gross domestic product and health expenditure (Theou et al., 2013). Another study investigating the 
association of frailty with racial differences demonstrated that African-American men and woman 
had an adjusted higher prevalence of frailty compared to Caucasian men and women, and that 
African-American men were four times as likely to develop frailty compared to Caucasian men 
(Hirsch et al., 2006). 
As the average age of the general population increases so too does the prevalence of frailty (defined 
by any validated assessment), and this increased prevalence is expected to pose significant problems 
with care of the elderly (Rodrigues-Laso et al., 2018). Indeed, data from various studies have 
indicated a pattern of increased healthcare costs in several sectors where there is an increased 
prevalence of frailty (Ensrud et al., 2018; Kim et al., 2019). Contextualising this issue, studies using 
the original FFP assessment of frailty have shown that greater than 60% of frail individuals are 
admitted to hospital within 3 years, placing strain on healthcare services (Fried et al., 2001; Chang et 
al., 2018). Importantly, as of 2017 England’s National Health Service general practice contract states 
that identification of frailty is now a requirement (National Health Service England, 2017).  
1.5.3 Progression to frailty  
Frailty is a dynamic state in which individuals can progress through the different stages of robust, 
prefrail, and frail in both directions (Trevisan et al., 2017). There have been three distinct stages 
identified in the developmental process of frailty, starting from robustness and progressing to 
prefrailty, where reductions in physiological reserve lead to slight decreases in an individual’s 
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capacity to respond to stressors and injury. Notably, exhaustion tends to be the first physical 
component of the FFP assessment that manifests in individuals developing frailty (Stenholm et al., 
2019). The individual will then progress from prefrailty to frailty, where physiological reserves have 
fallen below the functional threshold and the individual can therefore no longer fully respond to 
stressors and/or injury, resulting in impaired or incomplete recovery (Lang et al., 2009). Finally, the 
individual will progress from frailty to the frail complications stage, where dramatic functional 
declines lead to disabilities, chronic and acute infections, as well as polypharmacy, increased 
hospitalisation, and mortality (Rodrigues-Laso et al., 2019; Ahmed et al., 2007) (Figure 1.23).  
Longitudinal studies have suggested that frailty is reversible up to the frailty complications stage, 
where physiological reserves are exhausted. Indeed, up to 37% of individuals enrolled in longitudinal 
studies experience at least one transition between frailty states within 1-5 years of follow-up. This 
indicates the importance in developing a better understanding of intervention strategies aiming to 
slow or reverse the progression of frailty (Gill et al., 2006; Trevisan et al., 2017; Pollack et al., 2017). 
The Survey of Health, Aging and Retirement in Europe (SHARE) study assessed the frailty status using 
the original FFP criteria, as well as several other factors of over 85,000 individuals aged 65 or older. It 
revealed that while 8.8% of the study population were classified as frail, 39.1% were prefrail. A two-
year follow-up showed that without any intervention, 22.1% worsened, 61.8% did not change status 









1.5.4 Risk factors of frailty  
Over the past couple of decades studies have demonstrated a variety of risk factors directly 
implicated in the development and progression of frailty in the general population. These include old 
age, malnutrition, physical inactivity, cognitive decline, social isolation and being female (Fried et al., 
2001; Nosraty et al., 2012; Luger et al., 2016; Feng et al., 2017; Martone et al., 2013) (Figure 1.24).  
Of the risk factors noted above, physical inactivity appears to play one of the most significant roles. 
Physical inactivity can lead to loss of muscle mass and function, termed sarcopenia (Cruz-Jentoft et 
al., 2019). Sarcopenia will yield a reduced metabolic rate, a slower gait speed and reduced grip 
strength (Bortz, 2002; Walston, 2012; Cruz-Jentoft et al., 2019). Notably, these two factors are two 
of the five factors used in the FFP method of frailty assessment, indicating the significant role 
physical inactivity plays in the development of frailty (Fried et al., 2001). In support of this, a recent 
cohort study demonstrated an increased prevalence of frailty (as determined by a modified FFP 
criteria) in 60+ year old individuals with low physical activity levels and excessive time spent in a 
sitting position (da Silva et al., 2019). Highlighting the heterogeneic and multisystem nature of 
frailty, previous studies have suggested that comorbidities and injury can contribute to the 
development of frailty through the forced inhibition of physical activity (Blaum et al., 2005).  
Malnourishment has a similar contribution to the progression of frailty as does physical inactivity, 
and the two factors can often be interlinked, as hypothesised in the Fried definition of frailty (Fried 
et al., 2001). Nutritional deficiencies, particularly in protein and vitamin D and C intake, will result in 
unintentional weight loss and declines in bone mineral density (BMD), leading to an increased 
susceptibility to developing injuries (Fried et al., 2001; Lorenzo-Lopez et al., 2017). In support of this, 
it was shown that individuals with a low daily energy intake (< 21kcal/kg) have a 24% increased risk 
of developing frailty, as defined by the original FFP (Bartali et al., 2006). Additionally, low calorie 
intake will adversely impact an individual’s energy producing capabilities, and therefore impact the 
individual’s ability to perform daily tasks (Volkert et al., 2019; Landi et al., 2016; Martone et al., 
2013). On the flip side, malnourishment in the form of excessive intake can lead to obesity, and 
obesity and excessive energy intake has been shown to significantly contribute to the pathogenesis 
of frailty (Volkert et al., 2019; Blaum et al., 2005), in particular, inter- and intra-muscular fat 
infiltration as a result of obesity is known to decrease muscle quality (Delmonico et al., 2009). 
Interestingly, a recent study has shown that the Mediterranean diet is linked to a decreased 
prevalence of frailty, defined by the frailty index (Kojima et al., 2018). 
Multimorbidity is a known risk factor for frailty, and the prevalence of comorbid conditions is greater 
in frail individuals, defined through various frailty measurements, when compared to the normal 
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population (Vertano et al., 2019). A recent meta-analysis which included over 14,000 community-
dwelling older individuals enrolled over nine studies demonstrated that 18% of individuals with 
multimorbidity (defined as having two or more comorbid diseases) were frail (regardless of frailty 
assessment) (Vertano et al., 2019), and this was further supported by a large UK study using a 
modified FFP assessment in 37-73 year olds which demonstrated that frailty was associated with 
multimorbidity (Hanlon et al., 2018). Importantly, the National Institute for Health and Care 
Excellence (NICE) in England now advise that the identification of frailty should be attempted in all 
encounters with elderly patients with multimorbidity (National Institute for Health and Care 
Excellence, 2016).  
Another factor contributing to the pathogenesis of frailty is cognitive decline. Declines in cognitive 
function are often attributed to age-related diseases such as Alzheimer’s Disease or other forms of 
dementia, as they can significantly impact an individual’s ability to perform daily activities. In 
addition, cognitive decline can enhance physical function declines (Klein et al., 2005; Panza et al., 
2018). 
Social isolation is more prevalent in frail individuals compared to the general population (Gale et al., 
2018). Consequently, social isolation can lead to a reduction in physical activity as well as weight loss 
(Schrempft et al., 2019). Together, these factors lead to a reduction in QOL and are directly 
associated with increased morbidity levels.   
As mentioned previously, frailty, as defined by five criteria assessments, is more prevalent in females 
compared to age-matched males (Fried et al., 2001; Collard et al., 2012). Although not completely 
understood, this increased prevalence of frailty in females is suspected to be due to lower lean body 
mass and muscle function compared to males.  
As mentioned above, the NICE now advise that frailty should be assessed in older individuals with 
the risk factor of multimorbidity (National Institute for Health and Care Excellence, 2016). Indeed, a 
recent report from the British Geriatrics Society has recommended that all older people who 
encounter health and social care should be assessed for frailty (through the PRISMA-7 questionnaire 
and assessments of gait speed and timed-up-and-go). As frailty is often not recognised in an older 
individual until they experience an adverse outcome such as a fall or delirium, the importance of 
better understanding the risk factors underpinning the pathogenesis of frailty are significant (Morely 
et al., 2013). Identifying frailty earlier through well-designed integrated pathways such as the 
Comprehensive Geriatric Assessment may therefore reduce the burden of frailty-related 
hospitalisations (British Geriatric Society, 2017). Indeed, the NHS is the first health system to 
60 
 
systematically identify individuals ≥65 years using a population-based stratification approach – the 




  Figure 1.24 – Risk factors associated with the onset and progression of frailty
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1.5.5 Pathophysiology of frailty  
Frailty is known as a multisystem disorder (Fried et al., 2001; Thillainadesan et al., 2020; Dent et al., 
2019; Fried et al., 2009), with involvements in the musculoskeletal system (Fried et al., 2001), 
neuroendocrine system (Clegg & Smith, 2018), inflammatory system (Kane et al., 2019), and 
haematological system (Alvarez-Rios et al., 2015), in which there is a nonlinear association between 
the number of abnormally functioning systems and frailty, as well as the number of comorbid 
diseases and frailty (Fried et al., 2009) (Figure 1.25). As such, increasing focus has been given to 
proposed subtypes of frailty, such as cognitive frailty, social frailty, and nutritional frailty (Panza et 
al., 2015).  
1.5.5.1 Potential role of mitochondrial dysfunction in the pathophysiology of frailty  
Although not confirmed, it is heavily suspected that dysregulated energetics may significantly 
underpin the pathogenesis and pathophysiology of frailty (Fried et al., 2001). It is well known that 
mitochondrial function and content declines with age, manifesting clinically as a reduction in 
OXPHOS and energy producing capacities (Short et al., 2005; Chistiakov et al. 2014). This reduction in 
energy production with age subsequently adversely affects the function of high energy-demanding 
tissues such as skeletal muscle and the brain, as discussed later. In support of this, it was recently 
demonstrated that frail animal models have a reduced mitochondrial content as well as increased 
lactate levels and abnormal cristae (Sayed et al., 2018). Further, mitochondrial function is also 
heavily implicated in the pathophysiology of frailty by affecting individual aspects of the frailty 
syndrome. For example, declining skeletal muscle oxidative capacity (as measured by phosphorus 
magnetic resonance spectroscopy, 31P-MRS) is significantly associated with lower gait speed (Choi et 
al., 2016). Using novel immunofluorescence assays and 31P-MRS to investigate OXPHOS complex 
activity was hence utilised in this study to investigate skeletal muscle oxidative capacity in ageing 
PLWH.  
 Aside from decreases in energy producing capacity, age-related mitochondrial dysfunction has 
several other adverse pathophysiological implications which can increase the risk of developing 
frailty. Briefly, these include: the dysregulation of redox signalling and an increase in ROS and 
therefore oxidative stress, which can damage important molecules such as DNA (Wu et al., 2009; 
Peterson et al., 2012). In support of this, studies have demonstrated elevated levels of circulating 
oxidative markers such as serum 8-hydroxy-2’-deoxyguanosine (8-OHdG) (Serviddio et al., 2009); 
inducing an increase in the release of inflammatory markers (Coen et al., 2013) and activation of the 
NLR family pyrin domain containing 3 (NLRP3) inflammasome, which both subsequently lead to 
inflammation in various tissues (Sayed et al., 2018; Volt et al., 2016); impairing calcium regulation, 
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which contributes to dysfunctional neurological system (Powers et al., 2011); and altering 
myofilament structure and function, which can progressively lead to declines in muscle quality and 
strength (Powers et al., 2011). In addition, several studies have implicated a role of mitochondrial 
genetics in frailty. For example, mtDNA copy number has been shown to be associated with frailty 
syndrome severity (Ashar et al., 2015), and there is evidence of mitochondrial haplogroup variation 
causing increased susceptibility to developing frailty (Moore et al., 2010). 
1.5.5.2 Musculoskeletal and neuroendocrine decline in frailty pathophysiology  
Several studies have demonstrated the significance of the musculoskeletal system in the onset and 
development of frailty. On average, sarcopenia begins in individuals around 40 years old and can 
lead to a 30-50% reduction in muscle mass and function by age 80 (Bortz, 2002; Cruz-Jentoft et al., 
2019). Sarcopenia ultimately impairs strength and endurance and can adversely affect balance and 
gait, leaving the individual more susceptible to developing comorbidities and a reduction in QOL 
(Cruz-Jentoft et al., 2019). The pathogenesis and pathophysiology of sarcopenia is explained in more 
detail in Section 1.6.4. With regard to the multisystem nature of the pathophysiology of frailty, both 
hormonal deficiency and cytokine excess are involved in the pathogenesis of frailty (Morely et al., 
2005; Fabbri et al., 2015; Swiecicka et al., 2018; Hanlon et al., 2018; Soysal et al., 2016), and both 
insulin resistance (IR) and diabetes are associated with excessive loss of lean body mass and muscle 
strength (Park et al., 2009), hence why I investigated body composition and intramyocellular lipid 
accumulation in this study. Furthermore, loss of lower leg muscle mass and strength is associated 
with elevated inflammation (Guralnik et al., 1994). 
With regards to the impact of neuroendocrine decline in frailty, hormonal abnormalities, IR and 
increased level of inflammatory markers have been shown to contribute to the progression of frailty, 
irrespective of frailty assessment (Cappola et al., 2003; Swiecicka et al., 2018; Perez-Tasigchana et 
al., 2017; Ruan et al., 2017; Clegg et al., 2018). Underscoring the multisystem aspect of frailty, 
hormonal declines that result in an imbalance between catabolic and anabolic processes can 
adversely impact muscle mass and function and thus lead to sarcopenia (Bortz, 2002; Morley et al., 
2013). The main driver of neuroendocrine decline in frail individuals has been attributed to impaired 
function of the hypothalamic-pituitary-gonadal/adrenal and growth hormone axis, which ultimately 
presents as declines in circulating oestrogen and androgen levels (Swiecicka et al., 2018). Declines in 
oestrogen and androgen levels subsequently increase the release of bone cytoclastic cytokines, 
which in turn lead to a reduction in BMD (Bortz, 2002). As mentioned above, a contributing factor to 
neuroendocrine decline in frail individuals is insulin resistance. It has been demonstrated that IR, as 
measured by the insulin resistance-homeostatic model assessment (IR-HOMA), is associated with 
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frailty prevalence frailty in women and men (determined by five criteria FFP) (Blaum et al., 2005) and 
a four times increased incidence of frailty (determined by five criteria FFP) (Kalyani et al., 2012). 
1.5.5.3 Immunosenescence and inflammation in frailty pathophysiology  
Ageing of the immune system eventually leads to a chronic low-grade systemic inflammatory state 
termed ‘Inflamm-Aging’, which is characterised by elevated levels of inflammatory molecules and an 
increased susceptibility to morbidity and mortality (De Martins et al., 2006; Piggott et al., 2015). 
Numerous studies have also demonstrated the elevated levels of inflammatory markers such as 
cortisol, interleukin-6 (IL-6), C reactive protein (CRP) and TNF-α, as well as declines in IGF-1, 
testosterone and growth hormone concentrations in frail individuals compared to the general 
population (Abbatecola & Paolisso, 2008; Soysal et al., 2016; Walston et al., 2002; Hubbard et al., 
2009). As such, frailty is commonly recognised as a chronic inflammatory state (Vina et al., 2016). 
One aspect of the adverse pathophysiological effects of inflammation is the specific impact on 
muscle strength, as studies have demonstrated an association between increased TNF-α levels and 
declines in muscle strength and mass over a 5-year period, as well as mortality (Bruunsgaard et al., 
2003). This is in part due to the TNF-α induced upregulation of NF-κB-dependant muscle catabolism 
and necrosis processes, which leads to a downregulation in regenerative processes (Concepcion-
Huertas et al., 2013; Li et al., 2008). In addition, studies in both mice and humans have 
demonstrated the significant association between increased IL-6 levels with muscle atrophy and 
frailty (Baltgalvis et al., 2008; Ma et al., 2018; Marcos-Perez et al., 2018). There is also an indirect 
association between frailty and inflammation, as frailty determined by five criteria FFP in the 
Woman’s Health and Aging studies is associated with an increasing number of inflammatory diseases 
(Chang et al., 2012). Interestingly, the degree to which inflammation contributes to the 
pathophysiology of frailty appears to be more significant in women compared to men. For example, 
higher baseline concentrations of CRP and fibrinogen were independently associated with frailty in 
woman but not men (Gale et al., 2013). In addition, elevated CRP levels were shown to be negatively 
associated with cognitive and skeletal muscle performance in women but not men (Canon & 
Crimmins, 2011).  
Elevated inflammation may also be a consequence of diet. With regards to this, a recent study 
investigated the role of higher dietary inflammatory index (DII) in frailty and found that both male 
and female subjects (mean age 63) with a high DII score had an 37% increased risk of frailty, defined 
by SOF index (Shivappa et al., 2018). In support of the significant role which inflammation plays into 
the pathophysiology of frailty, molecular evidence from monocytes derived from frail individuals 
demonstrated an upregulation in the ex vivo expression of inflammatory pathways (Jia et al., 2001).  
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To compound the damaging effects of inflammation and ageing, with time, more cells develop the 
secretory phenotype associated with senescence (SASP). These cells are senescent and excrete 
additional inflammatory markers such as IL-1 and IL-6 (Coppe et al., 2008). Age-related immune 
system alterations which contribute to Inflamm-Aging are known to accelerate the loss of muscle 
mass and strength, as well as decreasing physical function capabilities (Dihn et al., 2019; Walston et 
al., 2006; Schlegal et al., 2006; Ferrucci et al., 2002; Visser et al., 2002; Cesari et al., 2004; Santos-
Eggimann et al., 2009). In support of this, a recent study demonstrated a decreased CD4+/CD8+ T cell 
ratio (in favour of CD8+ cells), and reduced proportion of CD19+ B cells in frail individuals compared 
to robust individuals (Marcos-Perez et al., 2018). Frail individuals also appear to have higher 
proportions of CD8+CD28-, CCR5+CD8+ and CCR5+CD45- T cells compared to robust individuals, 
indicating a diminished immune capability in these frail individuals (both men and very old women 
defined by original five criteria FFP) (De Fanis et al., 2008; Semba et al., 2005). In addition, it has also 
been shown that frailty score is inversely correlated to white blood cell (WBC) count (Fernandez-
Garrdio et al., 2018). These age-related declines in immune function are likely to be somewhat 
caused by homeostatic pressure, which diminishes bone marrow production of B cells and limits 
their subsequent migration (Marttila et al., 2014). 
Importantly, immune system changes are often compounded by increased inflammation in the form 
of a vicious cycle. For example, it has been shown that WBC count, in combination with IL-6 levels, 
were independently associated with frailty (Leng et al., 2007). An acute and dramatic increase in 
WBC count is recognised as an indicator of systemic inflammation, and this increase is associated 
with cardiovascular abnormalities and cancer mortality, as well as with all-cause mortality (Leng et 
al., 2005; Ruggiero et al., 2007). 
1.5.5.4 Oxidative stress and molecular alterations in the pathophysiology of frailty 
Studies have also demonstrated the involvement of oxidative damage and epigenetic modifications 
such as DNA methylation and telomere attrition in the pathophysiology of frailty (Breitling et al, 
2016; Soysal et al., 2017; Vina et al., 2018; Liu et al., 2016; Namioka et al., 2017; Wu et al., 2009; 
Ingles et al., 2014; Serviddio et al., 2009; Ble et al., 2006). Several studies in the past decade have 
demonstrated that elevated levels of plasma markers of oxidative damage were related to frailty 
(defined through various methods), as opposed to the chronological age of the subject (Baptista et 
al., 2012; Liu et al., 2016; Saum et al., 2015; Wu et al., 2009), while additional studies have 
demonstrated the association between frailty and increased methylation of promoter CpG islands 
(Collerton et al., 2014). Of note, markers of oxidative stress such as malondialdehyde, oxidised 
glutathione, 4-hydroxy-2,3-nonenal, and protein carbonylation are elevated in frail individuals 
compared to robust individuals (Soysal et al., 2017; Ingles et al., 2014). In particular, several studies 
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have also shown that oxidative stress is associated with declines in grip strength and walking speed 
(Marcos-Perez et al. 2019; Soysal et al., 2017).  
Oxidative damage is thought to contribute to frailty by upregulating inflammation through the 
activation of the NF-κB pathway, as well as directly impacting muscle quality and function (Baumann 
et al., 2016). Studies have also investigated the role of abhorrent genetic processes in the 
pathogenesis of frailty. As such, in a study investigating 620 single nucleotide polymorphisms (SNPs) 
involved in inflammation and hormone pathways, five were found to be associated with the Fried’s 
frailty classification in men and women over 50 years (Mekli et al., 2015). In addition, variable 
number of tandem repeats (VNTR) polymorphisms in the genes for IL-1RN and IL-4 have been shown 
to be associated with higher FFP scores (Perez-Suarez et al., 2016).  
Although the pathophysiology of frailty is extremely multifactorial, novel biomarkers remain highly 
desirable. MicroRNA (miRNA) are small RNA molecules involved in processing mRNA and are thus 
essential in the regulation of various intracellular signalling cascades and processes such as 
inflammation, response to muscle damage and mitochondrial function. The presence or absence of 
some circulating miRNA such as miR-21 can therefore be indicative of a pathophysiological process 
that is occurring, such as sarcopenia (Ameling et al., 2015; Fan et al., 2016; Weilner et al., 2015). A 
recent report showed that eight miRNAs were enriched in frail individuals (defined by the original 
FFP criteria) compared to young and age-matched robust individuals. These included miR-10a-3p, 
miR-92a-3p, miR-185-3p, miR-194-5p, miR-532-5p, MiR-326, miR-576-5p and miR-760 (Ipson et al., 
2018), which are involved in insulin signalling as well as FoxO and AMPK signalling pathways (Martins 
et al., 2016). Additionally, there are several miRNAs that are involved in regulating mitochondrial 
functions and have been implicated in ageing. For example, miR-21 and miR-126a-3p promote the 
activation of Bcl-2 family members which regulate fission/fusion events as well as induce the 




Figure 1.25 – Factors involved in the pathophysiology of frailty
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1.5.6 Frailty in the HIV-infected population 
Despite effective viral suppression and immune recovery in response to cART, PLWH experience an 
increased prevalence of age-related conditions compared to HIV- individuals of a similar age 
(Guaraldi et al., 2011; Smit et al., 2015; Chow et al., 2012; Althoff et al., 2014; Drummond et al., 
2014; Kirk et al., 2013; Nou et al., 2016; Shiels et al., 2009; Sico et al., 2015; Desquilbet et al., 2007; 
Silverberg et al., 2015). These conditions include sensory dysfunction, falls, cardiovascular disease, 
kidney disease, lung disease, liver disease, cognitive decline, cancers, polypharmacy, and 
importantly, frailty (Greene et al., 2015; Chow et al., 2015; Drummond et al., 2014; Nou e al., 2016; 
Shiels et al., 2009; Sico et al., 2015; Silverberg et al., 2015).  
As mentioned previously, studies utilising the original FFP criteria have shown that the prevalence of 
frailty in community-dwelling men and women over the age of 65 in the United States is between 7-
12% (Fried et al., 2004). Whilst no studies have examined frailty in PLWH over 65s exclusively, the 
prevalence of frailty (as assessed by the original or modified five criteria frailty phenotype) in all ages 
of the HIV-infected population ranged between 9-19% (Altoff et al., 2014; Onen et al., 2009; Piggott 
et al., 2013; Pathai et al., 2012). However, when using a range of assessments, the prevalence of 
frailty in PLWH was found to range between 5-28.6% (Levett et al., 2016). 
Although the underlying pathophysiologies of frailty are still not completely understood, similarities 
between ageing and HIV infection were observed prior to the extensive studies of the late 2000s 
which assessed frailty in the HIV-infected population. These pathologies included sarcopenia, 
lipodystrophy, anaemia, chronic renal disorders, immunosenescence, hepatic disorders, some 
cancers, and an increased susceptibility to acquired infections (Guaraldi et al., 2011; Deeks, 2011; 
Guaraldi et al., 2019a; Tate et al., 2013; Althoff et al., 2014). In addition, there are several shared 
etiologic factors of both frailty and HIV infection, such as oxidative stress, dysregulation of apoptosis 
and other mitochondrial functions, DNA alterations, telomere attrition, neuroendocrine decline and 
chronic inflammation (Bruunsgaard & Pedersen, 2003; Leng et al., 2007; Huang et al., 2005; Chavez 
et al., 2003; Erlandson et al., 2013; Margolick et al., 2017; Erlandson et al., 2017a; Zhang et al., 2015; 
Li et al., 2017; Guaraldi et al., 2019a; Branas et al., 2017). These observations suggest a potential 
overlap in the pathogenesis of frailty and HIV infection and indicate that PLWH are increasingly 
vulnerable to developing frailty and other age-related comorbidities (Margolick et al., 1992).  
The most significant of these shared aetiologies would appear to be chronic inflammation and 
immune decline (Deeks, 2011; Margolick et al., 2017). Both of these factors have been shown to be 
strongly associated with the development of age-related diseases as well as geriatric syndromes 
such as frailty in the general population (Leng et al., 2007; Walston et al., 2002; Soysal et al., 2016). 
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Chronic inflammation and immune senescence are known play a significant role in multisystem 
physiological declines even in virally supressed PLWH (Deeks, 2011). In the HIV-infected population, 
increased levels of inflammation and immune activation were shown to be associated with poor 
Short Physical Performance Battery (SPPB) scores (Erlandson et al., 2014). 
Although there are clearly links between HIV-infection and ageing phenotypes, controversy remains 
as to whether PLWH exhibit an accelerated ageing phenotype, whereby PLWH display an increased 
rate of age-related complications earlier than age-matched HIV- individuals, or instead experience 
accentuated ageing, whereby PLWH exhibit an enhanced frequency of age-related comorbidities in 
comparison to age-matched HIV- individuals (Pathai et al., 2014).  
1.5.6.1 History of frailty research in the HIV setting 
The first study to investigate frailty in the HIV-infected population was performed by Desquilbet and 
colleagues, who demonstrated that HIV infection was strongly associated with a frailty-related 
phenotype in men recruited to the Multicentre AIDS Cohort Study (MACS). Strikingly, this study 
indicated that a 55-year-old HIV+ man on cART was as likely to develop frailty as an ethnicity- and 
education-matched 65-year-old HIV- individual (Desquilbet et al., 2007). A follow-up study from the 
same group further demonstrated the link between frailty and HIV infection by demonstrating that 
CD4 count is an independent predictor of frailty in PLWH (Desquilbet et al., 2009), although future 
studies contradicted this observation (Onen et al., 2009, Althoff et al., 2014). Importantly, the latter 
study by Desquilbet and colleagues also indicated that the susceptibility of PLWH to developing 
frailty is decreased through cART, albeit not significantly.  
In another study – the AIDS Linked to the IntraVenous Experience (ALIVE) study – a similar frailty 
phenotype as was used in the MACS study demonstrated that being HIV+ was associated with a 
three times increased risk of mortality, and being HIV+ as well as frail was associated with a seven 
times increased risk of mortality (Piggot et al., 2013).  
Studies have also investigated the risks of frailty on adverse geriatric outcomes in PLWH using the 
original or modified FFP. Results from these studies include the increased risk of falls with increasing 
FFP score (Erlandson et al., 2012b), as well the increased prevalence of polypharmacy, 
multimorbidity and hospitalisation (Erlandson et al., 2012a) with frailty in PLWH. These studies also 
demonstrated that abnormalities in immune profiles are associated with declines in physical 
function and frailty. For example, individuals with lower physical function (as measured by the SPPB) 
had lower CD4/CD8 ratios, as well as higher proportions of CD38+HLA-DR+ T cells (a marker of T cell 
activation) compared to individuals with high physical function (Erlandson et al., 2012a). Further, 
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frailty was associated with higher levels of immune senescence and activation in PLWH (Erlandson et 
al., 2017a). 
1.5.6.2 Assessments of frailty in PLWH 
Early investigations into frailty in the HIV-infected population using individuals recruited into the 
MACS cohort utilised a frailty-related phenotype, similar to the original five criteria FFP (Fried et al., 
2001; Desquilbet et al., 2007; Desquilbet et al., 2009). 
The Veterans Aging Cohort Study (VACS) index is a FI-type prognostic tool specifically designed to 
measure frailty as a multisystem deterioration state in PLWH. Operationalised using HIV-infected 
men from the VACS study cohort, the VACS index is composed of deficits such as eGFR, hepatitis c 
co-infection, liver fibrosis and HIV-related factors such as CD4 count and viral load (Womack et al., 
2013). Several cross-sectional studies have utilised the VACS index to measure frailty in PLWH and 
have demonstrated that inflammatory markers such as IL-6 and soluble CD14 are strongly correlated 
with VACS index score (Justice et al., 2014). Additionally, VACS index score was also significantly 
associated with cognitive impairment, physical function status and mortality (Justice et al., 2014).  
The FI has also been adapted for the measurement of frailty in PLWH using PLWH in the Modena HIV 
Metabolic Clinic (MHMC). Here, Guaraldi and colleagues operationalised a 37-deficit index and found 
that the prevalence of frailty in virally supressed PLWH was 28% in 2015, and alarmingly, they 
predicted that in 2030, 50% of HIV+ patients will be frail at the age of 75 (Guaraldi et al., 2019b). 
Importantly, this deficit index did not include HIV-related factors (Akgun et al., 2014). The FI used in 
the MHMC study has been shown to more accurately predict 2-year mortality compared to the VACS 
index (Guaraldi et al., 2015). In addition, another study also demonstrated that the FI has a more 
significant association with age, co-morbidities, falls, and disability than the frailty phenotype 
measure used in the MACS studies (Guaraldi et al., 2017). 
1.5.6.3 Risk factors for frailty development in PLWH 
As demonstrated in Table 1.2 there have been several cross-sectional studies involving ART-treated 
PLWH in which multiple factors have been shown to be associated with frailty in older PLWH (as 
assessed through a variety of validated frailty diagnostic methods in both men and women). These 
include age (Onen et al., 2009; Guaraldi et al., 2015) current CD4 count (Guaraldi et al., 2019a; 
Brothers et al., 2017; Branas et al., 2017; Ianas et al., 2013; Althoff et al., 2014; Pathai et al., 2012; 
Piggott et al., 2013; Terzian et al., 2009); nadir CD4 count (Onen et al., 2014; Guaraldi et al., 2017; 
Brothers et al., 2017; Erlandson et al., 2012a); detectable viral load (Althoff et al., 2014; Brothers et 
al., 2017; Piggott et al., 2013; Desquilbet et al., 2009); increased duration since HIV diagnosis (Onen 
et al., 2014; Brothers et al., 2017); use of PI-boosted regimens (Onen et al., 2009); BMI (Onen et al., 
71 
 
2014; Pathai et al., 2012; Shah et al., 2012); hepatitis C co-infection (Ianas et al., 2013; Onen et al., 
2014; Brothers et al., 2017); lipodystrophy (Shah et al., 2012); injection drug use (Brothers et al., 
2017), and unemployment (Onen et al., 2014), amongst others. It is worth noting that the 
heterogeneity in study populations and frailty scales used, as well as the cross-sectional nature of 
many of these studies, undermine the clinical validity of some observations.   
An important facet of frailty is its dynamic and plastic nature in both the general population and HIV-
infected population (Althoff et al., 2014; Gill et al., 2006). In a longitudinal study of the MACS cohort,  
younger age was associated with a reversion from frailty to robust, whilst history of AIDS was 
associated with progression to frailty (defined by the original FFP criteria) (Althoff et al., 2014). In 
addition, a longer duration of HIV infection, smoking history and being female independently 
predicted advancement to frailty in the MHMC cohort (Erlandson et al., 2017a; Brothers et al., 
2017). 
As well as the beneficial effects on viral suppression and immune recovery, the advent of cART 
appeared to decrease the prevalence of frailty in PLWH (Desquilbet et al., 2009). HIV-infected men in 
the MACS study were found to be nine times more likely to be frail than HIV- individuals. Frailty was 
also positively associated with increasing age and increased duration of HIV infection, as well as CD4 
count, viral load, and presence of AIDS (Desquilbet et al., 2007). Interestingly, the prevalence of 
frailty between 1994-1995, when cART usage was <0.1%, was 8%. This had decreased to 5% 
between 2000-2005, when the prevalence of cART usage was >70% (Desquilbet et al., 2009). 
Additionally, an FI based model has predicted that the prevalence of frailty in PLWH over 50 will 
decrease from 26% in 2015 to 7% in 2030, in part thanks to advances in cART effectiveness and 




Table 1.2 – Factors associated with frailty among PLWH.  
 Factors related to frailty in PLWH References 
General factors Age 
Onen et al., 2009; Althoff et al., 2014; Desquilbet et al., 2007; 
Piggott et al., 2013; Ianas et al., 2012; Pathai et al., 2012; 
Guaraldi et al., 2015 
 
 Female gender 
Zeballos et al., 2019; Bandeen-Roche et al., 2015; Womack et 




Onen et al., 2014; Erlandson et al., 2017a; Brothers et al., 2017 
  
Co-morbidities Hepatitis C 
Ianas et al., 2013;  Brothers et al., 2017; Onen et al., 2014 
 BMI Onen et al., 2009; Pathai et al., 2012; Shah et al., 2012 
 Diabetes Kelly et al., 2019; Piggott et al., 2013 
 Hepatotoxicities Piggott et al., 2013 
 Lipodystrophy Shah et al., 2012 
 Inflammation 
Justice et al., 2012; Erlandson et al., 2013; Leng et al., 2011; 
Margolick et al., 2013; Onen et al., 2014 
 Cognitive decline Onen et al., 2009; Marquine et al., 2014 
 Low CD4:CD8 ratio Guaraldi et al., 2019a; Erlandson et al., 2012a 
 Fractures Womack et al., 2013 
HIV-related factors Low CD4 count 
Guaraldi et al., 2019a; Branas et al., 2017; Onen et al., 2014; 
Piggott et al., 2013; Althoff et al., 2014; Adeyemi et al., 2013;  
Brothers et al., 2017 
 
Nadir CD4 count 
Guaraldi et al., 2017; Onen et al., 2014; Erlandson et al., 
2012a;  Brothers et al., 2017 
 Viral load 
Desquilbet et al., 2009; Piggott et al., 2013; Althoff et al., 2014;  
Brothers et al., 2017 
 History of AIDS 
Desquilbet et al., 2009 
 Time since diagnosis 
Onen et al., 2014;  Brothers et al., 2017 
 Duration of cART 
Brothers et al., 2017; Althoff et al., 2014 
 PI-containing ART regimen 
Onen et al., 2014 
 NNRTI-containing ART regimen 
Erlandson et al., 2017a 
Socio-economic factors Unemployment 
Onen et al., 2009; Erlandson et al., 2012a; Onen et al., 2014 
 Poorer education 
Erlandson et al., 2017a; Onen et al., 2009; Althoff et al., 2014; 
Piggott et al. 2013 
 Low income 
Onen et al., 2009 
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1.5.6.4 Comparisons to frailty in type 2 diabetes mellitus patients 
Type 2 diabetes mellitus (T2DM) is chronic age-related disease, and similarly as in the context of HIV, 
T2DM patients appear to be more at risk of developing adverse ageing phenotypes such as frailty 
(Ottenbacher et al., 2009; Cacciatore et al., 2013; Hubbard et al., 2010). For example, frailty (as 
determined by the original five criteria FFP) was demonstrated to be 3-5 times higher in diabetic 
individuals over 65 compared to the age-matched general population (Saum et al., 2014). In 
addition, as in the HIV setting, the population of older T2DM patients is increasing, subsequently 
increasing the potential burden to the healthcare system (Won et al., 2018).  
Of note, a recent systematic review demonstrated that the prevalence of frailty (as defined by 
several frailty measurements in a cohort of men and women with a mean age of 68) was 
approximately 24% in diabetics (Ida et al., 2019). This is slightly above the prevalence of frailty (as 
assessed by the original or modified five criteria frailty phenotype) estimated in all ages of the HIV-
infected population, which ranged between 9-19% (Altoff et al., 2014; Onen et al., 2009; Piggott et 
al., 2013; Pathai et al., 2012). In addition, both are higher than the estimated prevalence of frailty 
(through various frailty assessments) in over 65s in the general population (Fried et al., 2004; Collard 
et al., 2012). 
The underlying pathophysiological mechanisms of frailty in diabetic individuals is similar to that 
proposed in older PLWH, with long-term diabetic pathology accelerating the loss of skeletal muscle 
mass and function (Kalyani et al., 2014), as well as mitochondrial dysfunction as the result of insulin 
resistance (Krentz et al., 2013). Additionally, hyperglycaemia in T2DM is associated with increased 
chronic inflammation and oxidative stress (Morley et al., 2014). Importantly, frailty in older diabetic 
individuals is a multisystem disorder, as is the case in frailty in PLWH (Lee et al., 2017). 
Whilst the risk factors and pathophysiology of frailty in T2DM individuals and older PLWH differ in 
some areas, there are important overlapping mechanisms. Hence, investigations into the 
mechanisms behind adverse ageing phenotypes such as frailty in older diabetic individuals may also 
help better understand frailty in older PLWH, and vice versa.  
1.5.7 Frailty prevention and interventions  
As mentioned above, frailty is a dynamic state and so ‘treatment’ for frailty can either be in the form 
of preventing prefrail individuals from progressing into frailty, or using interventions in order to 
reverse this progression.   
In the case of frailty prevention, the success of care depends on how well-progressed frailty is in the 
individual. Primary care therefore provides the most significant opportunity for prevention. Here, 
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primary care providers who screen older individuals can identify the most at risk individuals, 
including middle-aged individuals with comorbidities such as diabetes and multiple sclerosis. In 
these individuals, frailty can be potentially prevented by first identifying specific factors that make 
that individual susceptible to developing frailty and then attempting to alter lifestyle factors which 
may be beneficial, such as dietary changes or increasing physical activity. As such, primary care 
interventions that promote physical activity have been shown to potentially limit the progression 
from prefrailty to frailty (Serra-Prat et al., 2017; Romera-Liebana et al., 2018). In further support, 
targeted primary care delivery through implementation of the Comprehensive Geriatric Assessment 
(CGA) has been shown to improve physical function, although it did not significantly affect 
emergency department readmission (Preston et al., 2018). In addition, studies have shown that 
interventions which address emergency department staffing and physical infrastructure reduce the 
amount of time a patient is in hospital, as well as the quality of care (Preston et al., 2018). 
Due to the fact that the exact causes and outcomes of frailty in PLWH are yet to be fully determined, 
as well as the fact that there is no consensus in the best method of measuring frailty in PLWH, the 
optimal method of management of frail HIV-infected individuals remains controversial and as of yet, 
no effective pharmacological therapies are available (Calvani et al., 2013). In the general population, 
the gold standard approach to managing frailty is through specific intervention recommendations, 
such as, exercise, nutritional advice, pharmacological interventions, or cognitive therapy. In 
particular, exercise interventions seem the most effective (Walston et al., 2018; Cameron et al., 
2013; Cesari et al., 2015). Whilst studies in the general population have tested clinical interventions 
for individual components of the FFP, no studies have assessed interventions for frailty as a 
syndrome in the HIV+ population. A recently proposed method would be to routinely assess PLWH 
through a HIV-geriatric assessment (Erlandson et al., 2019). This would allow clinicians to 
comprehensively assess a patient’s condition and evaluate the impact of potential interventions. 
Additionally, it is widely accepted that earlier diagnosis of HIV and subsequent earlier initiation of 
cART is beneficial (Molina et al., 2018). 
Targeted clinical trials are evidently an important step in better understanding effective 
interventions for frailty in elderly individuals. However, clinical trials with elderly individuals are 
problematic as recruitment is complex and screening and assessments may be too invasive, 
especially in frail individuals. Other issues include the lack of focus on cost-effectiveness and on 
being patient centric as opposed to generic interventions.  
Dent and colleagues recently published a review of the management of frailty in which they describe 
steps that need to be taken in order to improve the clinical care of frailty. Steps include the better 
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understanding of the pathophysiology of frailty; improving the methodology of clinical trials; 
identifying the best instruments and methods of frailty assessments; expanding knowledge on how 
to prevent the development of frailty; assess and improve screening tools for frailty; and developing 
pathologically-defined and targeted intervention guidelines (Dent et al., 2019). Hence, in this thesis I 
attempt to better understand the pathophysiology of frailty in older PLWH, with a special interest in 
the role mitochondrial dysfunction plays.  
Importantly, frailty based screening services for PLWH are now ongoing, such as the Silver Clinic - a 
CGA based service - at Brighton and Sussex University Hospitals Trust, UK (Levett et al., 2020).  
1.5.7.1 Physical activity as a potential intervention 
With regards to interventions targeting physical function and sarcopenia, although there are several 
ongoing studies with promise, it is hoped that the ongoing Sarcopenia and Physical fRailty In older 
people multi-componenT Treatment strategies (SPRINTT) project will significantly increase our 
understanding of interventional benefits (Hopman et al., 2016). The SPRINTT project is a multi-
centre project involving researchers and participants from 11 European countries and aims to 
specifically test the effect of multicomponent interventions in individuals with early stage frailty and 
sarcopenia.  
Of the most up to date information derived from recent studies, the most promising interventions 
appear to be single-mode physical activity programmes (either resistance, aerobic or balance and 
coordination training programmes) which improve gait speed, mobility, muscle strength and 
ultimately physical function in older frail individuals (Landi et al., 2014; Zubala et al., 2017). 
Additionally, multicomponent activity programmes also improve muscle strength and balance (de 
Labra et al., 2015; Gine-Garriga et al., 2014; Cadore et al., 2013). Furthermore, physical activity 
interventions have been shown to contribute to the reversal of the adverse effects of chronic 
diseases and help maintain functional independence (Paulo et al., 2016; Virtuoso et al., 2012). 
Unfortunately, the effectiveness of the results from these studies are questionable, as they do not 
seem to re-test for frailty post-intervention (Gwyther et al., 2018). And so more work needs to be 
undertaken in order to better understand the optimal programme type for different severities of 
frailty.  
Increasing physical activity has also been shown to have beneficial impacts on mitochondrial 
function in skeletal muscle. In particular, regular exercise in adulthood has been demonstrated to 
maintain the ultrastructure of mitochondria and other organelles involved in calcium handling, 
oxidative phosphorylation, and protein homeostasis (Zampieri et al., 2015). In addition, aerobic 
exercise has been shown to improve the energy producing capabilities of mitochondria by promoting 
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mitochondrial biogenesis through the activation of calcium-mediated signalling pathways, such as 
AMP-activated protein kinase (AMPK) and sirtuins (SIRT) (Marzetti et al., 2008; Rowe et al., 2014). 
Exercise induced ROS signalling also serve as beneficial signal mediators, by activating the PCG-1α 
and NF-κB pathways, which are responsible for regulating several mitochondrial functions such as 
biogenesis and autophagy (Marzetti et al., 2008). In contrast to the metabolic improvements seen in 
response to aerobic exercise, resistance exercise primarily improves muscle mass and strength 
(Suetta et al., 2008; Binder et al., 2005; Campbell et al., 2002; Benito et al., 2020). Mechanisms 
behind this phenomenon are underlined by improvements in endocrine signalling and subsequent 
insulin sensitivity, improved glucose utilisation and enhanced protein homeostasis (Kang & Krauss, 
2010). Another beneficial mechanism of increased physical activity is the improvement in muscle 
stem cell regulation. Both endurance and strength training induce ultra-structural damage to 
skeletal muscle in combination with the release of growth factors such as IGF-1 and fibroblast 
growth factor (FGF), which ultimately results in the differentiation and proliferation of quiescent 
satellite cells (Kang & Krauss, 2010). 
Finally, in PLWH, resistance exercise was also linked to increased CD4+ and CD8+ T cell counts 
(Zanetti et al., 2016; de Brito-Neto et al., 2019) and a decrease in levels of circulating pro-
inflammatory cytokines (Zanetti et al., 2016) in two recent trials.  
1.5.7.2 Dietary and hormonal interventions  
Whilst various studies and clinical trials have attempted to elucidate the beneficial effects of 
hormone therapy, telehealth monitoring, or cognitive training, there is insufficient evidence to 
suggest these are effective therapy strategies (Frost et al., 2017; Apostolo et al., 2018). In particular, 
trials of monotherapies such as oestrogen or testosterone replacement in the late 90’s and 00’s 
improved muscle function but came with significant side effects (Snyder et al., 1999; Taaffe et al., 
2005; Kenny et al., 2010). In contrast, a study by Friedlander and colleagues demonstrated that IGF-1 
therapy improved BMD, muscle strength and ultimately physical function in elderly women who 
presented with no clinical IGF-1 deficiency (Friedlander et al., 2001). 
Dietary changes have also been proposed as potential therapies for frailty and sarcopenia. For 
example, a consensus declared that protein intakes should be between 1.2-1.5 g/kg-bw/day in order 
to impede the loss of muscle mass and strength (Houston et al., 2008). In addition, previous studies 
have also shown that omega 3-fatty acid supplementation may enhance muscle protein synthesis 
and counteract muscle loss (Di Girolamo et al., 2014; Smith et al., 2011). Adherence to the 
Mediterranean diet, which is high in omega 3-fatty acids and antioxidants, has been shown to be 
associated with reduced odds for frailty (Ntanasi et al., 2018). Another study demonstrated that 
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magnesium levels are on average 6% lower in frail individuals compared to robust individuals, and a 
12-week magnesium supplementation improved frail individual’s performance in the chair stand, 
SPPB and 4m walk components of the FFP (Veronese et al., 2014). Finally, vitamin deficiency has also 




1.6 Sarcopenia  
In 2010 the European Working Group on Sarcopenia in Older People (EWGSOP) came to a consensus 
in defining sarcopenia as an age-related syndrome characterised by the progressive and generalised 
loss of skeletal muscle mass and strength, with adverse outcomes in physical function capabilities, 
disability, poor QOL and mortality (Cruz-Jentoft et al., 2010). Over the last decade considerable 
research into sarcopenia has been undertaken and sarcopenia is now recognised as a muscle disease 
with an ICD-10-MC Diagnosis Code (Vellas et al., 2018).  
Improving the understanding of the causes of sarcopenia and optimal methods of care is essential 
due to the high social, personal and economic burden of the condition. As such, sarcopenia increases 
the risk of hospitalisation (Cawthon et al., 2017) and the cost of healthcare itself (Steffl et al., 2017). 
In addition, sarcopenia increases the risk of developing respiratory (Bone et al., 2017), cardiovascular 
(Bahat & Ilhan, 2016), and cognitive disease (Chang et al., 2016), the susceptibility for falls and 
fractures (Bischoff-Ferrari et al., 2015; Schaap et al., 2018), and mortality (De Buyser et al., 2016). 
Systematic reviews using the EWGSOP definition have shown that the prevalence of sarcopenia is 1-
29% in the community-dwelling population and 14-33% in long-term care populations (Cruz-Jentoft 
et al., 2014). Another, more recent meta-analysis demonstrated that PLWH have a 6.1 times higher 
odds ratio for developing sarcopenia compared to age, ethnicity, BMI and sex matched HIV- 
individuals (Oliveira et al., 2020) 
In addition to defining sarcopenia, the EWGSOP made a distinction between primary sarcopenia 
(age-associated) and secondary sarcopenia (disease-associated) (Cruz-Jentoft et al., 2019). It is 
however often difficult to discriminate between the two as many individuals with sarcopenia are 
elderly and 90-95% also have a chronic morbidity (Hung et al., 2011). Other definitions that are used 
to describe adverse changes in muscle mass and function include dynapenia, which defines 
decreased contractility and loss of strength (Manini & Clark, 2012), disuse atrophy, which describes 
muscle loss due to inactivity (Biolo et al., 2005), and cachexia, which describes weakness and 
wasting due to chronic illness (Vanhoutte et al., 2016). 
Both the loss of skeletal mass and strength has been associated with adverse health outcomes such 
as cognitive impairment, loss of physical independence, and an increased risk for hospitalisation and 
developing comorbidities. These include cardiac and respiratory disease, as well as mortality (Tolea 
& Galvin, 2015; Fielding et al., 2011; Morley et al., 2014).  
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Both sarcopenia and frailty are both acknowledged to be adverse age-related complications and 
have been shown to be interlinked with each other, although are not necessarily causative of each 
other (Studenski et al., 2014; Cruz-Jentoft et al., 2019). Underscoring the highly heterogenous and 
complex nature of age-related syndromes, it has been shown that declines in muscle mass and 
strength both contribute to poor health outcomes with age (Mitchell et al., 2012), and that obesity 
combined with loss of muscle strength but not muscle mass is predictive of the risk of falls (Scott et 
al., 2014). In addition, a more recent study demonstrated that the loss of muscle strength is more 
predictive of adverse age-related outcomes such as loss of independence rather than loss of muscle 
mass (dos Santos et al., 2017). 
Muscle strength and muscle mass are associated with each other, although declines in either 
measure does not always equate to decline in the other. It has been demonstrated that the loss of 
muscle strength occurs at a rate five times higher than the loss of skeletal muscle mass in older 
adults, indicating that the loss of muscle strength is more significant to the pathophysiology of 
sarcopenia (Mitchell et al., 2012; Goodpaster et al., 2006; Venturelli et al., 2015). Loss of muscle 
strength is also now widely acknowledged as a better predictor of adverse health outcomes than the 
loss of muscle mass (Schaap et al., 2018, Ibrahim et al., 2016; Schaap et al., 2013). Finally, studies 
conducted within the Baltimore Longitudinal Study of Aging revealed that cognitive performance, 
visceral obesity and velocity of nerve conduction are the strongest predictors of muscle quality 
(Moore et al., 2014). 
1.6.1 Skeletal muscle structure  
Skeletal muscle is organised in a hierarchical formation whereby myofibres are bundled together 
into ‘fascicles’, which are held together by the perimysium. Myofibres contain repeating contractile 
units termed sarcomeres. Sarcomeres are in turn composed of thin and thick contractile 









1.6.2 Skeletal muscle mitochondria  
Skeletal muscle mitochondria can either be intermyofibrillar (IMF) mitochondria or subsarcolemmal 
(SS) mitochondria, which are morphologically and biochemically distinct from each other (Glancy et 
al., 2015). Roughly 80% of skeletal muscle mitochondria are IMF, and they lie between myofibrils to 
form a rigid lattice like structure. SS mitochondria comprise the other ~20% of skeletal muscle 
mitochondria and have been shown to reside in small perinuclear clusters in the immediate interior 
of the sarcolemma (Cogswell et al., 1993).  
As mentioned above, IMF and SS mitochondria have distinct morphology and biochemical functions. 
In particular, IMF mitochondria have a higher IMM and matrix enzyme activity, which is consistent 
with the fact that they provide energy required for muscle contraction (Ferreira et al., 2010). In 
comparison, SS mitochondria are thought to provide energy for the membrane and nucleus (Hood, 
2001). 
1.6.3 Skeletal muscle through the life course 
Two of the parameters of sarcopenia – muscle mass and strength – are dynamic factors, and can 
vary significantly over the life course (Cruz-Jentoft et al., 2019).  
In general, muscle mass and strength are higher in males compared to females, and maximal levels 
of both factors occur in young adulthood (≤ ~40 years) (Dodds et al., 2014). Subsequently, both 
muscle mass and strength decline beyond the age of 50, and the rate of loss also appears to 
accelerate with advancing age. Significantly, muscle mass in men and women is decreased by 
approximately 4.7% and 3.7% respectively in the seventh decade compared to the maximal, and the 
rate of muscle mass decrease accelerates to 0.64-0.7% and 0.8-0.9% each year in woman and men 
over 75 years old (Mitchell et al., 2012). Of note, loss of muscle mass predominantly occurs in the 
lower limbs (Narici & Maffulli, 2010). 
Although the age-related declines in muscle mass and strength are multifactorial, it is acknowledged 
that genetic and lifestyle factors play a significant role (Bloom et al., 2018). In addition, the age-
related decline in mitochondrial function is suspected to accelerate the decline in muscle mass and 
strength, primarily through declines in energy production. This was previously discussed in more 
detail in Section 1.5.5.1. 
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1.6.4 Identification and diagnosis of sarcopenia  
According to the updated consensus of the EWGSOP(2), diagnosis of sarcopenia begins with 
identifying patients at risk of sarcopenia or with sarcopenia symptoms and then progressing the 
patients to further sarcopenia testing (Cruz-Jentoft et al., 2019). Here, individual sarcopenia 
parameters are tested (Table 1.3). Muscle strength is assessed through measurements of grip 
strength via a hand dynameter, as grip strength correlates with muscle strength in other parts of the 
body, and is a strong predictor of adverse patient outcomes (Ibrahim et al., 2016; Leong et al., 2015). 
The chair rise test can also be used to measure muscle strength in the legs. Importantly, the recent 
consensus is that grip strength as measured through a Jamar dynamometer is the best method of 
determining muscle strength (Cruz-Jentoft et al., 2019). 
Muscle mass is also measured as part of the diagnosis of sarcopenia. Muscle mass can be quantified 
by several methods with adjustments for height or BMI (as described in Cruz-Jentoft et al., 2019). 
However, magnetic resonance imaging (MRI) and computed tomography (CT) are considered the 
gold standard for assessing muscle mass (Beaudart et al., 2016). 
The final parameter tested is physical performance, which is defined as an objectively measured 
whole-body function related to locomotion, as it involves both the nervous system as well as the 
musculoskeletal system (Beaudart et al., 2018). A commonly used surrogate for physical 
performance is gait speed, which predicts adverse outcomes such as disability, falls, hospitalisation, 
and mortality (Studenski et al., 2011). Other commonly used surrogates include the SPPB and the 
Timed-Up and Go test (TUG), which also predict adverse health outcomes (Pavasini et al., 2016). 
Although several of the various methods are easily applied in the clinical setting, the most recent 
consensus recommends the use of gait speed to assess physical performance. This is primarily due to 
the convenience of undertaking the test (Cruz-Jentoft et al., 2019). 
Several new methods for measuring sarcopenia at both the clinical and research level are currently 
being assessed. The majority of these tests aim to improve the measurement of muscle mass and 
quality, although some require expensive machinery. Some of these new methods include computed 
tomography (aimed at lumbar 3rd vertebra and psoas muscle) (Mourtzakis et al., 2008;  Rutten et al., 
2017), ultrasound assessment of muscle; d3 creatine A dilution tests (Shankaran et al., 2018), and 
specific biomarkers of sarcopenia. Of these, the d3 creatine A dilution tests appear to be the most 
promising, as higher levels are associated with DXA-derived lean body mass, physical performance 




Characterisation ↓ Muscle mass ↓ Muscle strength ↓ Physical performance  
Robust - - - 
Pre-sarcopenia X - - 
Sarcopenia X X - 
Severe sarcopenia  X X X 
Table 1.3 – Factors required for the diagnosis of sarcopenia (Cruz-Jentoft et aI., 2010). 
 
1.6.5 Pathophysiology of sarcopenia  
Skeletal muscle is the largest organ is the human body, accounting for roughly 40-50% of body mass 
(Tieland et al., 2018). Skeletal muscle is involved in numerous physiological mechanisms including 
heat regulation, energy homeostasis, amino acid metabolism, and insulin sensitivity. With regards to 
the role skeletal muscle plays in insulin sensitivity and other neuroendocrine functions such as the 
release of myokines and anabolic and catabolic peptides, immune function and inflammation, 
skeletal muscle is now considered an endocrine organ (Aversa et al., 2012; Bonetto et al., 2013). 
The most significant factors involved in the pathogenesis of sarcopenia include inflammation (Curcio 
et al., 2016, Cruz-Jentoft et al., 2019), physical inactivity (Mijnarends et al., 2016), malnourishment 
(Muscaritoli et al., 2010; Cederholm et al., 2017; Cederholm et al., 2019), and other age-related 
factors, as described in Figure 1.27.  
1.6.5.1 Chronic inflammation in the pathophysiology of sarcopenia 
As described in previous sections, systemic inflammation plays a hugely significant role in the 
pathophysiology of several adverse age-related pathologies, including frailty. Individuals with 
sarcopenia have higher levels of circulating IL-6, and levels of inflammatory markers such as TNF-α, 
CRP and IL-6 are inversely correlated with skeletal muscle protein synthesis rates (Standley et al., 
2013). These observations suggest that chronic inflammation impedes skeletal muscle anabolic 
functions (Toth et al., 2005; Mayot et al., 2007). Additionally, in skeletal muscle, systemic 
inflammation, in particular increased TNF-α levels, can upregulate mTOR-associated protein 
degradation pathways such as the ubiquitin-proteasome pathway, which can lead to increased 
skeletal muscle autophagy and simultaneously inhibit the production of peptides essential for 
muscle growth (Xia et al., 2017). In addition, TNF-α destabilises MyoD and myogenin to subsequently 
impair skeletal muscle regenerative capacity (Langen et al., 2004). Eventually, these factors can lead 
to increased skeletal muscle senescence and apoptosis, which ultimately results in decreased muscle 
mass and function (Brocca et al., 2012). To highlight the multifactorial nature of sarcopenia, previous 
studies have revealed that the protein intake sufficiently needed to maintain muscle mass and 
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quality is dramatically increased in the presence of high levels of IL-6 (Bartali et al., 2013). The use of 
alcohol and tobacco is also associated with a higher risk of developing sarcopenia (Maddalozzo et al., 
2009; Lee et al., 2007). 
1.6.5.2 Neuroendocrine function and sarcopenia  
Skeletal muscle is responsible for a range of various endocrine functions including the insulin-
stimulated uptake of glucose from blood, fatty acid metabolism, and glycogen synthesis (Otto-
Buckzkowska, 2003). In addition, skeletal muscle derived myokines are involved in regulating 
functions in several tissues including the liver, bone, and adipose tissue (Schnyder & Handschin, 
2015). In resting conditions, skeletal muscle metabolism accounts for roughly 20% of whole-body 
metabolic activities (Muller et al., 2013). Declines in oestrogen in post-menopausal women and 
testosterone in men are responsible for declines in muscle mass and muscle strength, and circulating 
levels of IGF-1, cortisol and vitamin D are lower in frail individuals compared to robust individuals 
(Puts et al., 2005; Leng et al., 2009; Beaudart et al., 2014; Muir et al., 2011). As mentioned 
previously, these observations indicate that dysregulation in the GH-IGF-1 somatotropic axis as well 
as the hypothalamic-pituitary-adrenal axis are implicated in the pathogenesis and pathophysiology 
of sarcopenia and frailty. Dysregulated endocrine signalling has also been implicated in the 
disruption of protein homeostasis through anabolic insensitivity, contributing to loss of muscle mass 
and strength (Koopman & van Loon, 2009). In addition, as circulating IGF-1 is involved in protein 
synthesis via activation of the Akt-mTOR pathway (Glass, 2010), the reduced levels of IGF-1 with age 
will adversely contribute to protein homeostasis.   
The reduction in muscle insulin sensitivity occurs rapidly after physical inactivity and has been shown 
to directly contribute to an increased susceptibility of developing cardiovascular abnormalities, 
through the induction of dyslipidaemia (Mazzucco et al., 2010).  
1.6.5.3 Physical inactivity and sarcopenia 
Numerous studies have demonstrated the age-related decline in skeletal muscle perfusion 
capabilities. This age-related decrease in maximal oxidative capacity is known to adversely impact 
muscle mass and strength by promoting a more oxidative and pro-inflammatory microenvironment, 
in which autophagy and protein homeostasis becomes dysregulated, leading to the upregulation of 
apoptosis and cell senescence (Choi et al., 2016; Zane et al., 2017; Adelnia et al., 2019). Aside from 
age-related mitochondrial decline, the reduction in perfusion capabilities is thought to be explained 
in part by muscle ultrastructure abnormalities such as reduction in capillary number (Bigler et al., 
2016) and impairment of endothelial and other arterial functions (Das et al., 2018; Ward et al., 
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2018). In support of this, Prior and colleagues previously demonstrated the significant association 
between VO2 max and muscle capillary-to-fibre ratio (Prior et al., 2016). 
The loss of muscle mass with age occurs exponentially, and is dictated by the level of physical 
activity. Extended bed rest itself can lead to a 3-5% decline in lean body mass in healthy volunteers, 
and this impact can be accentuated when combined with other risk factors such as chronic disease 
(Genton et al., 2011). In further support, a 6-week bed rest study demonstrated that muscle atrophy 
was associated with a 6% decrease in resting energy expenditure (Ritz et al., 1998). 
Pathophysiologically, physical inactivity is associated with an increased rate of fat deposition (Olsen 
et al., 2008), which can propagate the increase in systemic inflammation and reduced insulin 
sensitivity (Guillet et al., 2012; Masgrau et al., 2012). Altogether, these factors accentuate muscle 
catabolic functions and so lead to reduced muscle mass and strength. This biological phenomenon is 
commonly seen in cancer patients and in other chronic diseases associated with a sedentary lifestyle 
(Manini, 2010). Physical inactivity is also associated with decreased antioxidant activity. With regard 
to this, increased exercise training results in the elevated activities of glutathione peroxidase, and 
physical inactivity leads to redox imbalance (Agostini et al., 2010). 
Reduced levels of lean body mass in combination with excess adiposity is a condition termed 
sarcopenic obesity, and is common in older individuals (Johnson Stoklossa et al., 2017). The 
increased adiposity exacerbates the adverse pathophysiological functions present in sarcopenia by 
increasing the fatty infiltration into muscle, which further increases inflammation, and adversely 
impacts the individual’s physical performance capabilities (Kalinkovich & Livshits, 2017; Barbat-
Artigas et al., 2014). 
Dynapenia has been shown to be associated with fatigue, disability and falls, as well as reduced bone 
stimulation leading to osteoporosis (Manini & Clark, 2012; Binkley et al., 2013). Dynapenia is 









1.6.6 Epidemiology of sarcopenia in PLWH 
In a recent study of 1720 majority male, virally-supressed PLWH (median age 52), the prevalence of 
sarcopenia was determined to be 25.7%. However, the majority of sarcopenic PLWH were female, 
and only 8.8% of men over 50 were classified as sarcopenic (Echeverria et al., 2018). In addition, 
results from this study also demonstrated a close association between sarcopenia and 
presarcopenia. 
The prevalence of sarcopenia in this cohort was similar to previous studies in similarly age, gender, 
and BMI matched PLWH (Pinto Neto et al., 2016; Wasserman et al., 2014; Oliveira et al., 2020). As 
was the association of presarcopenia with sarcopenia (Pinto Neto et al., 2016). Importantly, these 
studies demonstrate that sarcopenia appears to be more prevalent in PLWH compared to matched 
HIV-uninfected individuals. However, differences in the method used to classify sarcopenia appears 
to affect the prevalence of sarcopenia (Echeverria et al., 2018).  
Notably, results from these studies demonstrated that risk factors for sarcopenia in PLWH are similar 
to that seen in the general population. These include old age, low BMI and malnutrition (Echeverria 
et al., 2018; Pinto Neto et al., 2016; Wasserman et al., 2014; Oliveira et al., 2020). In addition, these 
studies demonstrate that HIV-related factors such as duration with HIV infection increase the 
susceptibility to developing sarcopenia, most likely through increased inflammation, although CD4 
count and viral load appeared not to have an effect (Echeverria et al., 2018).  
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1.7 Skeletal muscle mitochondrial dysfunction in PLWH 
ART is extremely effective at reducing HIV viremia, and the advent of ART has dramatically reduced 
HIV and AIDS-related morbidity and mortality (GBD HIV collaborators, 2019). In addition, ART  
restores CD4 counts to near normal levels in the majority of individuals, although factors such as CD4 
count at ART initiation and being male (Maman et al., 2012), as well as older age (Fatti et al., 2014; 
Simms et al., 2018), duration on ART (He et al., 2016), hepatitis C (HCV) coinfection (Laskus et al., 
1998; Laskus et al., 2000) and other genetic and environmental factors like polymorphisms in TNF-α 
(Haas et al., 2006) prevent immune recovery in roughly 15-30% of ART-treated PLWH (Autran et al., 
1999).  
However, use of ARVs in monotherapy or in combination (cART) has been associated with various 
toxicities (Table 1.4). Although the exact mechanisms underpinning these toxicities has yet to be 
completely understood, it is widely regarded that ARV-induced mitochondrial dysfunction is 
significantly implicated in its pathogenesis (Lim & Copeland, 2001).  
The association between mitochondrial dysfunction and ART-related toxicities was first described in 
patients treated with the nucleoside reverse transcriptase inhibitor (NRTI) zidovudine (AZT), who 
presented with myopathy (Dalakas et al., 1990). Ex vivo histology work on tissue from AZT-treated 
myopathy patients subsequently demonstrated ragged-red fibres and abnormal mitochondria with 
loss of cristae - features characteristic of mitochondrial myopathy observed in some mitochondrial 
disease patients (Margolis et al., 2014; Gorman et al., 2015). This was shown to be due to the 
depletion of mtDNA content through the inhibition of the mtDNA PolG (Dalakas et al., 1990; 
Arnaudo et al., 1991). Further studies then demonstrated that other ARVs in the NRTI class (albeit it 
with different affinities) induce mitochondrial toxicities in various tissues, such as peripheral 
neuropathy, lactic acidosis and hepatotoxicity (Selvaraj et al., 2014). As a result, newer NRTIs with a 
reduced PolG-inhibiting capacity were developed and stavudine (d4T) (2018) has been discontinued. 
Additionally, whilst AZT is now only used in the prevention of neonatal HIV acquisition, either as a 
pre-exposure prophylaxis, or as a post-exposure prophylaxis (Kourtis & Bulterys, 2010), as it has 
consistently been shown to effectively prevent neonatal transmission of HIV compared to other 
ARVs such as nevirapine (NVP), in which resistance is more common (Eshleman et al., 2001). Whilst 
other ARVs such as tenofovir disoproxil fumarate (TDF) would appear to be safer whilst still being 
effective, AZTs continued use in preventing neonatal transmission is down to the accumulated 
demonstration of its efficiency (Shaffer et al., 1999; Hurst et al., 2016). However, previous studies 
around the effects of AZT on neonatal mitochondrial function are controversial, with some studies 
suggesting there is limited adverse effect, and conversely an upregulation in mtDNA content (Cote et 
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al., 2008; Desai et al., 2008). The discrepancy between the adverse effects of AZT on neonatal and 
adult mitochondrial function could be due to the short-term in which neonatal AZT is administered.   
In more recent years studies have demonstrated the presence of mitochondrial toxicities induced by 
other NRTIs, such as TDF-induced renal abnormalities (Kohler et al., 2009; Samuels et al., 2017), as 
well as toxicities induced by different classes of ARV, such as protease inhibitor (PI)-induced 
lipodystrophy (Domingo et al., 2014; Dragovic et al., 2014; Alikhani et al., 2019). This suggested that 
ARVs can induce mitochondrial dysfunction independent of PolG-inhibiting mechanisms, such as 
changes in mitochondrial membrane potential (ΔΨm), abnormal mitochondrial morphology, and 
increased oxidative stress.  
 
Clinical toxicity Tissue affected NRTIs implicated Reference 





ddI, ddC, d4T 
Dalkas, 2001; Fichtenbaum et 
al., 1995; Sacktor et al., 2009 
Lipoatrophy Subcutaneous fat d4T, AZT 
van Vonderen et al., 2009; Joly 
et al., 2002 
Pancreatitis Pancreas ddI Sarner et al., 2002 
Lactic acidosis Liver, skeletal muscle d4T, ddI  Boubaker et al., 2001 




Kohler et al., 2009; Samuels et 
al., 2017  
Table 1.4 – Mitochondrial toxicities associated with NRTIs. AZT = zidovudine; ddI = didanosine; ddC = zalcitabine; d4T = 





1.7.1 NRTI-induced skeletal muscle mitochondrial dysfunction in PLWH – the ‘PolG 
hypothesis’ 
As mentioned previously, early in vitro studies demonstrated that NRTIs inhibit PolG, which leads to 
the depletion of mtDNA, and subsequently mitochondrial dysfunction. This mechanism was dubbed 
the ‘PolG hypothesis’ (Brinkman et al., 1999). 
NRTI triphosphates competitively bind to the polymerase subunit of PolG (Lewis et al., 1996), 
responsible for DNA replication, but as they lack the 3’ hydroxyl group (3’OH) they induce chain 
termination and subsequently inhibit replication of nascent mtDNA, leading to a reduction in mtDNA 
content (Lewis & Dalkas 1995). This depletion of mtDNA leads to diminished energy production 
capabilities, namely through declines in the rate of oxidative phosphorylation and by undermining 
ETC complex formation, as well as increasing ROS production. Diminished energy production then 
leads to clinical toxicities (Arnaudo et al., 1991; Lewis et al., 1992; Wallace, 1992). This effect is 
similar to that seen in mitochondrial toxicities present in some hereditable mitochondrial disease 
patients, where reduced levels of mtDNA depletion become pathogenic (Moraes et al., 1991; 
Gorman et al., 2015). 
The various NRTIs have different steric conformations (Figure 1.28) and so inhibit PolG with different 
affinities. In vitro studies have demonstrated that zalcitabine (ddC), didanosine (ddI), and d4T have 
the strongest PolG inhibiting capacities, while AZT inhibits PolG weakly: ddC ≥ ddI ≥ d4T > lamivudine 
(3TC) > TDF > emtricitabine (FTC) > AZT > abacavir (ABC) (Hoschele et al., 2006; Kakuda et al., 2000). 
Conversely, though monophosphorylated AZT (AZT-MP) is inefficiently excised from the exonuclease 
domain of PolG, which could explain how AZT induces mtDNA depletion without strongly inhibiting 
the polymerase domain (Lim & Copeland, 2001). 
Although there are many factors and key unknowns about the exact mechanisms underpinning NRTI-
induced skeletal muscle mitochondrial dysfunction, largely due in part to the vast heterogeneity in 
HIV+ populations as well as mitochondrial dysfunction itself, a study by Hendrickson and colleagues 
(2009) demonstrated that the risk of developing mitochondrial toxicities may be modified by mtDNA 
haplogroup. In particular, having the mtDNA haplogroup H appears to increase the risk of developing 
ART-induced lipoatrophy (Hendrickson et al., 2009). In addition, studies have highlighted the risk that 
the presence of chronic diseases, which are highly prevalent in older PLWH, may predispose certain 
PLWH to increased mitochondrial dysfunction. For example, a large body of literature has 
demonstrated mitochondrial dysfunction in various tissues in type 2 diabetes mellitus (T2DM), such 
as heart (Ruegsegger et al., 2018; Montaigne et al., 2014; Mackenzie et al., 2013; Croston et al., 2014; 
Marciniak et al., 2014; Yan et al., 2013; Vazquez et al., 2015) and skeletal muscle (Meex et al., 2010; 
91 
 
Johnson et al., 2016; Rabol et al., 2009). Results from both human and mouse studies have 
demonstrated decreased oxidative metabolism and mitochondrial biogenesis in T2DM, leading to 
impaired lipid metabolism (Szendroedi et al., 2014 ). It is therefore likely that the presence of a chronic 
condition may predispose an ART-treated HIV+ individual to developing mitochondrial dysfunction in 
various tissues.  
The mechanisms of the PolG hypothesis suggest that NRTI toxicity is cumulative and the toxic 
manifestations increase with the duration of exposure (Chawla et al., 2018). As such, mitochondrial 
toxicities occurring in ART-treated patients often results in the temporary termination of treatment, 
as treatment termination of the culprit NRTI is suspected to reverse to mitochondrially-toxic effect 
(McComsey et al., 2005). In addition, switching to two-drug ART regimens as opposed to three or 
four-drug regimens has been shown to reduce the susceptibility to developing adverse events such 
as toxicities. However, these regimens may not be as effective at supressing the virus (Llibre et al., 
2018; Mondi et al., 2015; Perez-Molina et al., 2017 Margolis et al., 2017). However, there is limited 
data as to whether resumption of a potentially toxic ARV reinstates the toxicity. It would depend on 
the particular ARV, tissue effected, and how cumulative the toxicity itself is. For example, it has been 
suggested that myopathy may arise several years after cessation of treatment (Payne et al., 2011).  
 
 
Figure 1.28 – Chemical structures of the commonly used NRTIs.   
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1.7.2 NRTI-induced mitochondrial dysfunction beyond the PolG hypothesis 
The discrepancy between the poor PolG-inhibiting capabilities and severe clinical toxicities caused by 
AZT, as well as the fact that newer NRTIs that have weaker PolG inhibitory effect have been shown 
to induce mitochondrial toxicities, led to the questioning of the robustness of the PolG hypothesis. In 
addition, more recent in vitro studies have demonstrated mitochondrial dysfunction in the absence 
of mtDNA depletion, for example AZT-induced reduction of ATP production and simultaneous ROS 
increase in rat heart tissue (Enomoto et al., 2011), impaired fatty acid oxidation in d4T-treated 
cultured rat hepatocytes (Igoudjil et al., 2006), reduced ATP production in AZT-treated murine 
brown adipocytes (Viengchareun et al., 2007) and inhibition of mitochondrial respiration and ATP 
production in ABC-treated Hep3B cells (Blas-Garcia et al., 2010). The robustness of the PolG 
hypothesis has also been questioned by in vivo studies, whereby PBMCs from patients experiencing 
NRTI-induced mitochondrial toxicities had normal mtDNA levels (Lewis & Dalkas 1995; McComsey et 
al., 2002), as well as normal mtDNA levels in PBMCs from d4T-, AZT- and ddI-treated PLWH with 
lipodystrophy (McComsey et al., 2008). Some studies have in fact reported an increase in mtDNA 
content in patients treated with NRTIs (Oldfors et al., 1995). Moreover, PIs and NNRTIs, which do not 
directly inhibit PolG, are also associated with mitochondrial dysfunction (Deng et al., 2010; Blas-
Garcia et al., 2010; Apostolova et al., 2010).  
Another caveat to the questioning of the PolG hypothesis is the fact that PLWH who have been 
exposed to some of the early NRTIs have an excess of skeletal muscle mtDNA mutations, which can 
lead to declines in mitochondrial function at the individual myofibre level. Importantly, these defects 
are still seen years after cessation of treatment (Payne et al., 2011). This not only dismisses the 
hypothesis of mtDNA depletion as a result of PolG inhibition, preferring instead large-scale mtDNA 
deletions, but provides a basis for the hypothesis that there is a legacy effect of historical NRTI 
exposure, and PLWH who were exposed to these NRTIs are at a higher risk for developing 
mitochondrial dysfunction (Payne et al., 2011; Hunt & Payne, 2020). As such, the prevalence of 
mtDNA deletions in various tissues from PLWH exposed to various ARVs was investigated using 
quantitative real-time PCR in Chapter 4 and Chapter 8. 
Indeed, alternative mechanisms of NRTI-induced mitochondrial dysfunction beyond PolG inhibition 
have been proposed, including the formation of mtDNA deletions, depletion in ribonucleotide (RN) 
and deoxyribonucleotide (dRN) pools (Jordheim & Dumonet, 2007), and dysregulation of ETC 
complex formation (Lund & Wallace 2008) (Figure 1.29). 
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1.7.2.1 Perturbations in endogenous nucleotide pools 
As most NRTIs are administered as prodrugs, they need to be metabolised intracellularly into their 
active moieties (triphosphates) in order to exert their effects (Peter, 2004). This occurs via either the 
de novo or salvage pathways, similarly to how deoxynucleotide triphosphates (dNTPs) are produced 
from endogenous RNs and dRNs (Van Rompay et al., 2000). Due to the similarities in conformation 
and metabolism, unphosphorylated NRTIs compete with endogenous RNs for phosphorylation, 
which can reduce the size of RN and dRN pools (Jordheim & Dumonet, 2007; Selvaraj et al., 2014). 
NRTI-triphosphates (NRTI-TPs) also compete with endogenous dNTPs for incorporation into 
elongating DNA, in which the former induce chain termination (Jordheim & Dumonet, 2007). Both of 
these processes ultimately lead to impaired mtDNA replication and reduced mtDNA content 
(McComsey et al., 2002). Tissue-specific differences in the ratios of intracellular kinases (e.g. 
thymidine kinase 1 and 2 (TK1 and TK2 respectively)) could explain the discrepancy between mtDNA 
depletion levels in different tissues and in response to different NRTIs. For example, TK1 is 
predominantly expressed in the cytosol of active cells, while TK2 is expressed more in the 
mitochondria and in quiescent cells (Lemmon & Schlessinger, 2010). AZT has been shown to have a 
higher affinity to phosphorylation by TK1 rather than TK2, whilst ddI and ddC are the opposite 
(Feeney & Mallon, 2010). This suggests that AZT is more likely to deplete RN and dRN pools in more 
active cells, while ddC and ddI are more likely to deplete the pools in quiescent cells such as skeletal 
muscle fibres, although this is not necessarily reflected in clinical observations (Arnaudo et al., 1991; 
Lewis et al., 1992).  
1.7.2.2 ART and mitochondrial genomic alterations  
Another proposed alternative mechanism of NRTI-induced mitochondrial dysfunction is the 
formation and propagation of mtDNA mutations. As well as its polymerase functions, PolG contains a 
3’-5’ exonuclease domain which is responsible for proofreading activities (Stumpf & Copeland, 
2013). In vitro studies have shown that monophosphorylated NRTIs (NRTI-MP), particularly AZT-MP, 
have a high affinity to the exonuclease domain of PolG (Maagaard & Kvale 2009) and inhibit the 
proofreading capabilities once bound, subsequently lowering the fidelity of mtDNA replication and 
increasing the susceptibility of mtDNA mutation formation (Wang et al., 1996). Further studies from 
our lab have shown that large-scale mtDNA deletions induced by NRTIs clonally expand with age in 
skeletal muscle fibres, causing mitochondrial dysfunction (Payne et al., 2011). 
As well as the depletion of mtDNA content, NRTIs have also been shown to deplete mtRNA content. 
Although the mechanisms of mtRNA depletion are yet to be fully understood, a study by McComsey 
et al. (2008) demonstrated the reduction of mtRNA content in lipodystrophy affected PLWH and 
suggested the mechanism could be through limitations in the availability of cofactors needed for 
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mtRNA synthesis as well as through PolG inhibition. mtRNA and mtDNA depletion may be 
intertwined, as mtDNA synthesis requires RNA-primed DNA replication (Young & Copeland, 2016).  
1.7.2.3 Other proposed mechanisms of ART-induced mitochondrial dysfunction 
NRTIs, in particular AZT, have been shown to directly affect CI of the ETC and subsequently cause 
defects in oxidative phosphorylation capabilities. A study by Lund & Wallace (2004) demonstrated 
AZT-induced decoupling of CI (Lund & Wallace 2004), while other studies have suggested AZT 
disrupts electron flow through CI (Pereira et al., 2002), and both AZT and ddC cause disruptions in 
NADH linked respiration (Szabados et al., 1999). Although controversial, the likely mechanism 
behind this phenomenon is NRTI-induced inhibition of cyclic adenosine monophosphate (cAMP)-
mediated phosphorylation events responsible for ETC complex formation (Lund & Wallace 2008). To 
investigate this further, in this thesis I utilised a novel immunofluorescence assay that allows the 
quantification of CI proteins in individual myofibres in PLWH. 
Another proposed alternative theory which has gained more traction in recent years is the idea of 
increased ROS and oxidative stress being responsible for diminished oxidative capacity (Cote et al., 
2005; Schieber & Chandel, 2014). In vitro studies on various human cell lines have demonstrated 
that short-term exposure to NRTIs such as AZT + 3TC, d4T + 3TC (Ciccosanti et al., 2010) and AZT + 
d4T (Lagathu et al., 2007) has a direct effect on ROS production. A recent study using liver autopsies 
from AIDS patients and mice exposed to ARVs demonstrated a significantly higher proportion of 8-
oxo-G positive mtDNA in ART-treated cells (Liang et al., 2018). Although yet to be fully elucidated, 
the mechanisms underpinning this theory centre around the idea of oxidative damage to 
macromolecules involved in oxidative phosphorylation, such as PolG and mtDNA, which are highly 
susceptible to oxidative damage (Richter et al., 1988). This is supported by ex vivo studies on AZT-
treated mouse tissue (Nerurkar et al., 2001). In addition, ROS signalling is implicated in several 
physiological processes such as lipid metabolism and apoptosis, and an imbalance in redox potential 
has adverse effects on these processes. One of the key signalling pathways involved is thought to be 
that of PPAR-γ. Expression of the PGC-1α as well as PPAR-γ itself is reduced in ART-treated patients 
(Caron et al., 2009; Feeney & Mallon, 2010), as well as in in vitro studies (Viengchareun et al., 2007). 
A study by Kohler and colleagues, (2009) demonstrated that mitochondrial superoxide dismutase 
and mitochondrially-targeted catalase dismutase were reduced in AZT-induced cardiomyopathy 






Figure 1.29 – Intramitochondrial actions of ‘mitochondrially toxic’ NRTIs. (A) Triphosphorylated AZT (AZT-TP) competitively binds to the polymerase domain of PolG and induces chain 
termination of mtDNA replication as it lacks the ‘3 OH group. (B) Monophosphorylated AZT (AZT-MP) accumulates in the mitochondrial matrix and has a high affinity towards the exonuclease 
domain of PolG, where it inhibits exonuclease activities, subsequently reducing the fidelity of mtDNA replication. Unphosphorylated AZT and AZT-MP also increase the rate of ROS production, 
causing oxidative stress and oxidative damage to cellular kinases such as TK2. This then leads to the reduction in the rate of RN and dRN phosphorylation.  
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1.7.3 PI and NNRTI induced mitochondrial dysfunction 
Similarly to NRTIs, some PIs and NNRTIs have been shown to induce a range of adverse 
pathophysiological factors that are linked to mitochondrial dysfunction (Table 1.5). Unlike NRTIs, PIs 
and NNRTIs do not directly inhibit PolG and therefore do not induce mtDNA depletion via the 
mechanisms described in the PolG hypothesis (Deng et al., 2010; Blas-Garcia et al., 2010; Apostolova 
et al., 2010). Instead, the proposed mechanisms underpinning this mitochondrial dysfunction centre 
around alterations in the regulation of mitochondrial bioenergetics and apoptosis (Apostolova et al., 
2010).  
Due to the event of cART, where a PI or NNRTI is administered alongside a backbone of two NRTIs, it 
has become difficult to dissect the exact contributions of ARVs from these classes of drugs on ART-
induced mitochondrial toxicities seen in PLWH. As a result, most of the work on PI and NNRTI-
induced mitochondrial dysfunction has been done through in vitro studies.  
Clinical reports from PLWH treated with PIs described occurrences of lipodystrophy, insulin 
resistance (IR) and cardiovascular abnormalities (Bongiovanni et al., 2004; Koster et al., 2003). As 
mentioned above, PIs do not inhibit PolG, and so PI-induced mitochondrial defects are related to 
disturbances in redox regulation, mitochondrial membrane potential (ΔΨm) and energy production. 
Indinavir (IDV) and nelfinavir (NFV) have been shown to inhibit the glucose transporter isoform 4 
(GLUT4) in vitro (Kumar et al., 2010) and IDV was also found to reduce respiration and ATP 
production in brown and white murine adipocytes (Viengchareun et al., 2007). Both these effects are 
thought to contribute to PI-induced insulin resistance. In support of this, increased β cell apoptosis 
followed ΔΨm reduction and increased cytochrome c release in PI-treated INS-1 cells (Zhang et al., 
2009). Both ritonavir (RTV) (HPAEC cells) (Wang et al., 2009), and IDV (HPAEC and HUVEC cells) 
(Wang et al., 2009) increased ROS production in the respective cell lines, leading to increased 
apoptosis. PIs have also been shown to induce cell senescence in PLWH-derived fibroblasts and fat 
tissue as a result of elevated ROS levels (Caron et al., 2007). Saquinavir (SQV), RTV and NFV all 
induced mitochondrial fragmentation and disruption of the mitochondrial network in the same 
patient-derived cell lines (Roumier et al., 2006). Although the exact pathophysiological mechanisms 
remain controversial, it is thought that PI-induced inhibition of the MPP plays a key role 
(Mukhopadhyay et al., 2002). As with studies with NRTIs, PI-induced mitochondrial defects appear to 
be cell type-specific. In non-adipocyte related cell lines NFV, RTV, SQV, IDV and lopinavir (LPV) have 
all been found to exert anti-apoptotic effects (Badley, 2005), and NFV upregulated anti-apoptotic 
Bcl-2 family proteins in leukaemia cells (Bruning et al., 2010). 
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The NNRTI efavirenz (EFV) has been associated with lipodystrophy in clinical studies (Zaera et al., 
2001). NNRTI-induced lipodystrophy is thought to be caused by inhibition of adipocyte 
differentiation and reduced lipogenesis (Jemsek et al., 2006; Moyle et al., 2012). Several in vitro 
studies have reported disruption of the ΔΨm in EFV-treated cell lines, which lead to increased rates 
of apoptosis (Pilon et al., 2002). Another study demonstrated the EFV dose-dependent increase in 
ROS production and decrease in ΔΨm in vitro, again leading to increased apoptosis (Jamaluddin et 
al., 2010). EFV also caused increased ROS production and decreased ΔΨm as a result of CI inhibition 
in patient-derived hepatic cells (Blas-Garcia et al., 2010; Apostolova et al., 2010). Treatment with 
EFV also increased the rate of mitophagy in hepatic cells (Apostolova et al., 2011). Finally, EFV 
treatment has also been shown to induce ER stress in brain endothelial cells, leading to thinning of 
the blood-brain barrier (Bertrand et al., 2016). This mechanism is thought to underpin the 
pathophysiology of cerebrovascular pathology in EFV-treated PLWH (Bertrand et al., 2016). 
 
ART class Drug Adverse effects 
PI Saquinavir (SQV) CVR; Insulin resistance; Lipohypertrophy 
 Ritonavir (RTV) CVR; Insulin resistance; Lipohypertrophy; Dyslipidemia  
 Indinavir (IDV) 
CVR; Nephrotoxicity; HB; Insulin resistance; 
Lipohypertrophy; Dyslipidemia 
 Nelfinavir (NFV) CVR; CRs; Insulin resistance; Lipohypertrophy; Dyslipidemia  
 Atazanavir (ATV) CVR; Nephrotoxicity; HB; Lipohypertrophy 
 Darunavir (DRV) Hepatoxicity; CRs; Lipohypertrophy 
NNRTI Nevirapine (NVP) Hepatotoxicity; CRs; Dyslipidemia 
 Etravirine (EFV) 
Hepatotoxicity; CRs; CNS toxicity; Insulin resistance; 
Dyslipidemia; Lipodystrophy; Stroke 
 Delavirdine (DLV) CRs 
 Etravirine (ETR) CRs 
Table 1.5 – Pathologies associated with NNRTI and PI use. CVR = cardiovascular disease risk; HB = hyperbilirubinemia; CRs 




1.7.4 Mitochondrial dysfunction in ART-naïve PLWH 
Although the majority of mitochondrial defects and subsequent toxicities in PLWH are associated 
with ART, numerous reports have described mitochondrial abnormalities in ART-naïve PLWH. 
Maagaard and colleagues demonstrated mtDNA depletion in T and B lymphocytes in ART-naive 
PLWH (Maagaard et al., 2005). Although the mechanisms underpinning this mtDNA depletion are 
not fully understood, it is suggested that the pro-apoptotic effects of HIV proteins were heavily 
implicated either directly or indirectly (Fevrier et al., 2011; Rumlova et al., 2014).  
The HIV Env glycoprotein (gp120) is expressed on ER and has been shown to cause ER stress when 
misfolded Env accumulates (Fields et al., 2016). ER stress can then lead to mitochondrial membrane 
(ΔΨm) depolarisation and increased apoptosis as a result of BAX translocation to mitochondria (Ferri 
et al., 2000). The gp120 glycoprotein also increased MFN1 and DRP1 levels in vitro (Fields et al., 
2016) and induced cristae remodelling and mitochondrial swelling (Avdoshina et al., 2016).  
The viral protein Nef has also been shown to trigger apoptosis in vitro, either through decreasing the 
expression of Bcl-2 or by decreasing ΔΨm (Lenassi et al., 2010). Tat protein also induces apoptosis in 
Jurkat cells by decreasing the levels of Bcl-2 proteins, as well as increasing oxidative stress by 
downregulating the levels of superoxide dismutase 2 (SOD2) (Giacca, 2005). In addition, Tat proteins 
were also shown to trigger changes in mitochondrial structure and induce mitochondrial 
fragmentation, leading to disruptions in ΔΨm and accumulations of damaged mitochondria (Rozzi et 
al., 2018). Finally, Vpr proteins have also been shown in vitro to increase mitochondrially-mediated 
apoptosis by reducing levels of Bcl-2 and Bcl-XL (Deniaud et al., 2004; Huang et al., 2012). 
1.7.5 Impact of genetic and environmental factors  
The HIV+ population is extremely diverse genetically, demographically and in lifestyle factors. It is 
therefore difficult to determine the exact impact any potential confounding factors, such as smoking 
or alcohol intake, have on the development of mitochondrial defects. In addition, diversity in study 
protocols used in many of the current cohort studies make it difficult to extrapolate the exact impact 
many genetic or lifestyle factors have on increasing the susceptibility of developing mitochondrial 
dysfunction in PLWH. For example, there are potential confounding factors such as smoking, body 
composition, and levels of exercise activity which are either not routinely assessed, or assessment 
methods vary (Nansseu et al., 2020). 
However, it has been shown that chronic exposure to ethanol can increase the level of ROS 
production (Kukielka et al., 1994) whilst simultaneously decreasing the levels of the antioxidant 
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glutathione (Fernandez-Checa et al., 1998). This can lead to increased oxidative stress with 
consequences for mitochondrial function (Blas-Garcia et al., 2010).  
Finally, studies investigating mitochondrial haplogroups of PLWH in the AIDS clinical trials (ACTG) 
group have shown associations between the European haplogroup T and peripheral neuropathy 
(Hulgan et al., 2005), whilst having a mtDNA haplogroup H was associated with increased risk of 




1.8 Kidney function in the HIV setting 
As the average age of PLWH increases, kidney diseases are becoming more prevalent. In addition to 
HIV-associated kidney disease (HIVAN), kidney disease in PLWH can manifest as various pathologies, 
such as acute kidney injury (AKI), chronic kidney disease (CKD) and end-stage renal disease (ESRD). In 
particular, whilst the advent of ART has reduced the prevalence of HIVAN in PLWH, AKI, CKD, and 
ESRD pose now significant issues (Swanepoel et al., 2018). CKD is therefore seen as one of the most 
important age-associated comorbidities in older PLWH.  
1.8.1 Kidney structure and function 
Kidneys are responsible for the control of the body’s fluid levels, filtration of blood, removal of 
waste, and electrolyte regulation. As a result of blood filtration, urine is created and ultimately 
drained into the bladder via the pelvis (Smith, 1952). 
The kidney is composed of a fibrous outer layer termed the renal capsule, a peripheral layer called 
the cortex, and an interior layer called the medulla. The medulla is arranged into pyramidal 
structures which, in combination with the cortex, form the renal lobe (Figure 1.30). Nephrons are 
structures that span the cortex and medulla and are where the majority of kidney processes occur. 
In particular, nephrons contain a glomerular blood filter composed of podocytes and tubular 
epithelium, which can be further subdivided into proximal, intermediate, and distal segments 
(Smith, 1952; Davidson, 2009).  
 
 
Figure 1.30 – Kidney structure.   
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1.8.2 Kidney disease and HIV infection 
1.8.2.1 Renal diseases in PLWH 
AKI is a broad clinical condition describing acute kidney failure, often resulting in electrolyte 
imbalance and a significant decrease or elimination of urine, with the sufferer then requiring 
haemodialysis (Okusa & Davenport, 2014). Histologically, AKI is characterised by focal or diffuse 
tubular luminal dilation, loss of proximal tubule brush border, simplification of lining epithelium, and 
loss of nuclei (Gaut & Liapis, 2020). Although the prevalence of AKI in PLWH has fallen since the 
advent of ART, the prevalence still remains high, and these virally-supressed PLWH appear to 
experience higher rates of more severe AKI (Li et al., 2012; Nadkarni et al., 2015). Indeed, although 
the burden of AKI is not as significant as that of CKD in PLWH, AKI is recognised as being a risk factor 
for the initiation and progression of CKD (Chawla et al., 2014; Pannu, 2013; Coca et al., 2011). 
Similarly to AKI, the prevalence of CKD in virally-supressed PLWH remains high. The decline in eGFR 
(estimated glomerular filtration rate) with age is known to be enhanced in both virally-supressed 
and non-virally suppressed PLWH compared to the HIV-uninfected population (Wetzels et al., 2007; 
Choi et al., 2009; Scherezer et al., 2012). This increased prevalence of pathology appears to be down 
to the high prevalence of risk factors that are found in PLWH, as discussed below (Medapalli et al., 
2012).  
HIVAN was the first renal disease to be described in HIV+ individuals, and unlike AKI and CKD, the 
prevalence of HIVAN has significantly fallen since the advent of ART. HIVAN is now only commonly 
seen in newly-diagnosed PLWH with late-stage HIV infection, or those who have discontinued ART 
(Wyatt, 2017). 
1.8.2.2 Risk factors for renal disease in PLWH 
Risk factors for CKD include: black race, hypertension, age, recreational drug use, HCV as well as HBV 
coinfection, and diabetes. In particular, diabetes appears to increase the susceptibility for CKD onset 
and progression, primarily due to increased inflammation seen in diabetic individuals (Medapalli et 
al., 2012; Mallipattu et al., 2013). Notably, HBV and HCV coinfection with HIV is associated with a 2- 
to 3- fold increased risk of CKD (Lucas et al., 2013; Mocroft et al., 2012). 
Among the common risk factors for kidney disease, sepsis appears to increase the severity of AKI in 
PLWH (Nadkarni et al., 2015).  
Another major risk factor for renal disease is African ancestry (Kopp & Winkler, 2003). This is 
primarily due to pathogenic polymorphisms in the APOL1 gene, which encodes apolipoprotein 1 
(Lucas et al., 2014, Kasembeli et al., 2015). Although the mechanisms behind APOL1 mediated 
102 
 
kidney pathology are unknown, increased APOL1 expression is thought to cause podocyte injury by 
inducing apoptosis or autophagy in renal epithelium as a result of increased cellular and 
mitochondrial membrane permeability (Fu et al., 2017; Kruzel-Davila et al., 2017; Me et al., 2017).  
1.8.2.3 ART and renal disease in HIV 
Exposure to the nucleoside reverse transcriptase inhibitor tenofovir disoproxil fumarate (TDF) 
increases the susceptibility of developing renal disease (Woodward et al., 2009; Bonjoch et al., 2014; 
Flandre et al., 2011; Hall et al., 2011; Winston et al., 2006; Goicoechea et al., 2008).  
In addition, increased age, immunodeficiency, and concomitant use of didanosine or ritonavir-
boosted protease inhibitors are risk factors for AKI in PLWH (Hamzah et al., 2017). Finally, the 
incidence of CKD was increased 16% with every year of TDF exposure, 21% with every year of 
atazanavir (ATV) exposure, and 8% with every year of ritonavir-boosted lopinavir (LPV) in the 
EuroSIDA study of HIV+ individuals (Mocroft et al., 2010).  
1.8.2.4 Mitochondrial dysfunction in chronic kidney disease  
As mitochondria are responsible for various cellular processes essential for kidney function, as well 
as the fact that kidneys are second only to the heart in oxygen consumption and mitochondrial 
abundance (Wirthensohn & Guder, 1986), mitochondrial dysfunction has serious implications for 
kidney function and therefore kidney disease.  
Although the link between mitochondrial function and CKD is heavily suspected, the underlying 
mechanisms remain elusive. Various in vitro studies have sought to assess alterations in 
mitochondrial function in CKD disease models. This includes the demonstration of increased 
mitochondrial fragmentation in kidney tubules (Galloway et al., 2012; Zhan et al., 2015). In addition, 
studies have demonstrated increased phosphorylation of Drp1 and therefore increased 
mitochondrial fission in podocytes (Ayanga et al., 2016; Han et al., 2008). MtDNA mutations, and 
defective mitophagy have also been linked to CKD (Hartleben et al., 2010). 
Additionally, alterations in mitochondrial biogenesis have also been implicated in renal 
abnormalities (Tran et al., 2016; Hershberger et al., 2017; Yuan et al., 2012; Perico et al., 2016). Of 
note, deacetylation of PGC-1α was demonstrated to reduce aldosterone-induced podocyte injury, 
whist an activator of SIRT1 – Resveratrol – increased mitochondrial biogenesis and protected 
mitochondrial induced podocyte injury (Yuan et al., 2012). 
Importantly, the link between kidney mitochondrial dysfunction and diabetes gives insights into how 
mitochondrial dysfunction may induce CKD. In this instance, oxidative stress as the result of 
mitochondrial dysfunction is a common pathway behind CKD in in diabetic individuals (Brownlee, 
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2005). Here, the free radical theory of diabetic microvascular complications hypothesises that 
increased ROS production results in damage to renal epithelial cells and accelerates the progression 
of kidney disease (Brownlee, 2005). In support of this, both in vitro and in vivo studies have 
demonstrated increased ROS in diabetic mouse models displaying kidney abnormalities, including 
podocyte apoptosis and elimination (Brownlee, 2005; Wang et al., 2012; Dieter et al., 2015). Finally, 
several studies have demonstrated that administration of the mitochondrial-targeted antioxidant 
mitoTEMPO reduced the prevalence of pathological diabetic neuropathy features (Chen et al., 2015; 
Sims et al., 2014). 
Perturbations in mitochondrial dynamics are also thought to be associated with diabetic kidney 
abnormalities. For example, PGC-1α was significantly downregulated in streptozotocin-induced 
diabetic rat tubules, as well as in OVE26, Akt2 and db/db mice (Morigi et al., 2015; Dugan et al., 
2013; Nakatani & Ingani, 2016; Hasegawa et al., 2013; Platt & Coward, 2017). In addition, knockout 
of SIRT1 in non-diabetic mice resulted in albuminuria (Hasegawa et al., 2013). 
Given the importance of kidney disease as an age-associated comorbidity in PLWH, we therefore 




Chapter 2 – Thesis Aims and objectives 
Due to the successful virus-supressing effects of ART, PLWH now experience a lower prevalence of 
HIV-related morbidity and mortality. As a result, PLWH are now on average living longer, and the 
average age of the HIV+ population is increasing (GDB 2017 HIV collaborators, 2019; Public Health 
England, 2019).  
Some older PLWH exhibit features of unsuccessful ageing, such as frailty and sarcopenia (Desquilibet 
et al., 2007; Brothers et al., 2017; Erlandson et al., 2015; Echeverria et al., 2018; Pinto Neto et al., 
2016; Wasserman et al., 2014). This phenomenon has serious implications with regard to the effects 
a population experiencing adverse ageing phenotypes has on healthcare systems, and so focus has 
shifted towards trying to better understand the causes of this adverse ageing in virally-supressed 
PLWH (Kojima et al., 2019). 
Mitochondrial dysfunction is one of the best characterised pathways of human ageing (Lopez-Otin et 
al., 2013). Therefore, given the established role mitochondrial dysfunction plays in ART-mediated 
toxicities and other HIV-related comorbidities (Hunt & Payne, 2020), recent interest has been shown 
towards the potential role of mitochondrial dysfunction as a driver of unsuccessful ageing in older 
PLWH. However, few studies have investigated mitochondrial function in skeletal muscle of older 
PLWH and in particular, how age-related skeletal muscle mitochondrial dysfunction is linked to 
adverse ageing phenotypes and their underlying pathophysiological decline. 
The over-arching hypothesis of this thesis is therefore that: 
‘Mitochondrial dysfunction is an important driver of adverse ageing phenotypes in PLWH’. 
The primary aims of this thesis were therefore to: 
1. Better understand skeletal muscle mitochondrial dysfunction in PLWH in the contemporary cART 
era.  
2. Compare the prevalence of adverse ageing phenotypes and clinical factors between older PLWH 
and age-matched HIV- individuals.  
3. Determine whether older PLWH have greater levels of skeletal muscle mitochondrial dysfunction 
compared to age-matched HIV- individuals, and whether skeletal muscle mitochondrial 
dysfunction is associated with adverse ageing phenotypes in older PLWH. 
4. Investigate the levels of various other skeletal muscle pathophysiological factors in older PLWH, 
and subsequently compare whether any of these factors are more prevalent than in age-
matched HIV- individuals. 
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In addition, aside from skeletal muscle mitochondrial dysfunction and the adverse implications that 
has on the older PLWH, a growing concern in the field of mitochondrial dysfunction in the 
contemporary cART era is TDF-induced renal pathology (Guaraldi et al., 2011; Lucas et al., 2008; 
Samuels et al., 2017; Swanepoel et al., 2018). Due to the difficulty in obtaining renal biopsies from 
TDF-treated PLWH with renal pathology, in combination with the lack of validated techniques to 
investigate mitochondrial dysfunction at the individual cellular level in these individuals, the 
secondary aims of this thesis was to: 
1. Assess whether mitochondrial dysfunction can be investigated in renal tissue from TDF-treated 
PLWH at the cellular and molecular level using novel experimental techniques. 
2. Compare mechanisms of ART-induced mitochondrial dysfunction in renal tissue with that seen in 




Chapter 3 – Methods 
3.1 Ethical guidelines 
All participant samples were collected with informed written consent. All human tissue was stored in 
compliance with the Human Tissue Act (HTA licence number – 12534), on HTA licenced premises. 
Control skeletal muscle tissue was acquired with prior informed consent from the distal part of the 
hamstring of people undergoing anterior cruciate ligament (ACL) surgery. Approval for this was given 
by Newcastle biobank (NAHPB reference: 042). More detailed patient and control information is 
given in the relevant chapters and sections.  
Specific research ethics and NHS research governance arrangements are detailed in the following 
sections.  
3.2 Patient cohorts 
Data from the work presented in this thesis is derived from patients recruited as part of three 
studies. Two studies were set up with the aim of investigating mitochondrial function in skeletal 
muscle from HIV+ and HIV- people in various settings (MAGMA study and SMMFA study), whilst the 
other study aimed to investigate mitochondrial function in renal tissue from PLWH and HIV- 
individuals. This section describes the various cohorts. 
3.2.1 MAGMA study 
All research activity was conducted with permission from local research ethics committee (REC) and 
HRA (Health Research Authority), ref. 17/NE/0015. 
30 HIV+ and 15 HIV- males were recruited as part of the MAGMA study, with patients giving prior 
written permission. 38 patients were recruited at the Royal Victoria Infirmary (RVI) in Newcastle 
upon Tyne, UK, whilst 7 patients were recruited at St Marys Hospital in London, UK. All patients were 
50 years or older. HIV+ individuals were able to participate if they had been on ART and had a low or 
undetectable HIV-1 viral load (<200 copies/ml). Exclusion criteria included: being female, inability to 
give informed consent, life expectancy <6 months, known coagulation disorder or taking anti-
coagulant medication, known or suspected neuromuscular disorder of a genetic basis, and being 
unable to walk 4 meters (including with a walking aid). Further study details are in the MAGMA study 
protocol (Appendix 1). 
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Patient details for the MAGMA study subjects are described in Table 3.1, with delineation as to 
whether individuals were recruited as part of the MAGMA study or as part of the SMMFA study 
described in the following section.  
All participants completed a standardised interview and any missing clinical information as well as 
CD4+ lymphocyte count, HIV diagnosis, ART history and viral load were identified and confirmed 
through patient medical records where available. Laboratory results were the most recent values 
available. The presence or absence of the following comorbidities was self-reported and 
subsequently confirmed through medical records: stroke and CVD, neuropathy, diabetes, dementia, 
cancer, renal disease, fractures, hepatitis, peripheral vascular disease, joint disease or replacements, 
osteoporosis, and falls. Medications were self-reported and confirmed through medical records. In 
addition, patients underwent a dual-energy X-ray absorptiometry (DXA) scan in order to assess body 
composition and muscle mass . Patients were also asked to undertake a range of tests such as 
walking, grip strength, standing/sitting, and stair climb in order to assess frailty, sarcopenia and 
physical capabilities. In addition, percutaneous muscle biopsies were acquired from all 45 patients 
for research purposes and stored at -80°C.  
3.2.2 Skeletal muscle mitochondrial function and ART (SMMFA) study  
Samples were obtained from the Newcastle Academic Health Partners Biobank. Samples had 
previously been collected under REC and HRA approved research protocols and subsequently stored 
in the Biobank under REC approval 12/NE/0395 and 17/NE/0361. Donors had given prior consent for 
retention of residual tissue for the purposes of future research. Research activity on these samples 
was approved by the Biobank oversight committee and was conducted under REC approval 
17/NE/0015 (Appendix 5).  
Skeletal muscle samples were taken by tibialis anterior (TA) biopsy from adult PLWH (n = 37) for 
research purposes and obtained through the Newcastle Academic Health Partners Bioresource, with 
patients giving prior written consent. TA biopsies were stored at -80°C. Table 3.1 describes the 
patient cohort, with delineation as to whether patients were recruited as part of the SMMFA study 
or MAGMA study described above.  
Subjects were classified into three groups depending on whether they had been treated with ART 
and if so, further grouped depending on whether they had previous or current exposure to certain 
NRTIs: group 1 (‘naïve’) had no previous exposure to any ART; group 2 (‘contemporary’) had only 
ever received contemporary NRTIs – tenofovir (TDF), abacavir (ABC), lamivudine (3TC) or 
emtricitabine (FTC); group 3 (‘historical’) were currently being treated with contemporary NRTIs, but 
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had previously been exposed to one or more of the older NRTIs known to be associated with 
mitochondrial toxicity – zidovudine (AZT), zalcitabine (ddC), didanosine (ddI) or stavudine (d4T). 
3.2.3 Skeletal muscle biopsies  
Skeletal muscle samples were taken by tibialis anterior (TA) biopsy from adult PLWH (n = 37) and 
obtained through the Newcastle Academic Health Partners Bioresource as part of the SMMFA study, 
with patients giving prior written consent. In addition, percutaneous biopsies were obtained from 
PLWH (n = 30) and HIV- individuals (n = 15) as part of the MAGMA study. Table 3.1 delineates 
whether an individual was recruited as part of the MAGMA study or SMMFA study. 
Control skeletal muscle tissue required for the calibration of the multiplex immunofluorescence for 
CI, CIV and mitochondrial mass assay was acquired with prior informed consent from the distal part 
of the hamstring of HIV-uninfected individuals undergoing anterior cruciate ligament (ACL) surgery. 
Age and gender details for these individuals (n = 3) is described in Table 3.1. Approval for this was 
given by Newcastle biobank (NAHPB reference: 042).  
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ART naïve 37 M WB 64 0 64 1165 1033 4300 N/A N/A N N Y 
 
45 F BA 99 0 99 214 214 1050 N/A N/A N N Y 
 
49 M WB 227 0 227 223 199 18900 N/A N/A N N Y 
 
46 M BA 110 0 110 387 328 17000 N/A N/A N N Y 
 
27 M WB 45 0 45 391 283 34300 N/A N/A N N Y 
 
50 F WB 120 0 120 1358 541 40 N/A N/A N N Y 
 
32 F BA 27 0 27 380 380 13900 N/A N/A N N Y 
 
53 F WB // 0 // 1439 // 40 N/A N/A N N Y 
 
34 M WB 31 0 31 422 389 4700 N/A N/A N N Y 
 
32 F WB 44 0 44 626 522 41600 N/A N/A N N Y 
 
24 M WB 31 0 31 217 197 1250 N/A N/A N N Y 
 
27 M WB 37 0 37 633 438 12700 N/A N/A N N Y 
 
23 M WB 50 0 50 796 451 150 N/A N/A N N Y 
Contemporary 
NRTI 
55 M WB 96 48 48 503 117 <40 TDF/FTC/ATV/r TDF/FTC/ATV/r Y N Y 
 
39 M WB 40 12 28 417 187 <40 TDF/FTC/EFV TDF/FTC/EFV N N Y 
 
39 M WB // // // 687 405 // TDF/FTC/EFV TDF/FTC/EFV N N Y 
 
62 M WB 63 62 1 190 56 <40 TDF/FTC/NVP TDF/FTC/NVP Y N Y 
 
25 M WB 311 33 278 729 270 <40 TDF/FTC/ATV/r TDF/FTC/ATV/r/ABC/3TC N N Y 
 




54 M WB 79 38 41 638 244 <40 TDF/FTC/DRV/r TDF/FTC/EFV/DRV/r Y N Y 
 
53 M WB 73 48 25 804 301 <40 TDF/FTC/EFV TDF/FTC/EFV Y N Y 
 
34 F BA 21 18 3 265 // <40 TDF/FTC/EFV TDF/FTC/EFV N N Y 
 
57 M WB 145 21 124 432 379 <40 TDF/FTC/EFV TDF/FTC/EFV Y N Y 
 61 M WB 181 95 86 1049 200-350 <20 TDF/FTC/EFV TDF/FTC/EFV/LPV/r N Y Y 
 57 M WB 269 151 118 259 100-200 <20 ABC/3TC/DRV/r ABC/3TC/DRV/r/EFV/TDF/FTC N Y Y 
 71 M WB 87 86 1 549 100-200 31 
TDF/FTC/EFV/ABC
/3TC/DTG 
TDF/FTC/EFV/ABC/3TC/DTG/RPV N Y Y 
 52 M WB 96 82 14 // >350 // TDF/FTC/RPV TDF/FTC/RPV/EFV N Y Y 
 60 M WB 266 99 167 584 0-100 52 ABC/3TC/DTG ABC/3TC/DTG/TDF/FTC/ATV/r N Y Y 
 62 M WB 28 28 0 773 >350 63 TDF/FTC/DRV/c TDF/FTC/DRV/c/r N Y Y 
 54 M WB 155 155 0 744 100-200 355 ABC/3TC/DTG ABC/3TC/DTG/TDF/FTC/RAL/MVC/NVP N Y Y 
 51 M WB 99 // 99 598 200-350 118 TDF/FTC/EFV TDF/FTC/EFV N Y Y 
 54 M WB 81 22 59 1111 >350 <20 TDF/FTC/RAL TDF/FTC/RAL N Y Y 
 53 M WB 152 83 69 669 200-350 <20 TDF/FTC/RPV ABC/3TC/TDF/FTC/RPV N Y Y 
 68 M WB 373 65 308 878 0-100 <20 
ABC/3TC/DTG/TP
V/DTG/r 
ABC/3TC/DTG/TPV/TDF/FTC/r N Y Y 
 50 M WB 33 32 1 746 0-100 188 TDF/FTC/DRV/r TDF/FTC/DRV/r N Y Y 
 56 M WB 135 134 1 388 0-100 350 TDF/FTC/EFV TDF/FTC/EFV N Y Y 
 54 M WB 283 160 123 624 0-100 <20 ATV/c TDF/IDV/ATV/c N Y Y 
 65 M WB 297 120 157 781 >350 <20 TDF/FTC/DTG TDF/FTC/DTG/EFV N Y Y 
 60 M WB 176 99 77 // 200-350 <20 TDF/FTC/DRV/c TDF/FTC/DRV/c N Y Y 
 53 M WB 141 126 15 568 200-350 74 TDF/FTC/NVP TDF/FTC/NVP N Y Y 
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 51 M WB 64 60 4 446 200-350 63 TDF/FTC/RAL TDF/FTC/RAL N Y Y 
 65 M WB 162 6 156 737 >350 105 ABC/3TC/DTG ABC/3TC/DTG N Y Y 
Historical NRTI 71 M WB 130 130 0 530 // <40 TDF/FTC/EFV DDI/AZT/3TC/EFV/TDF/FTC Y N Y 
 
62 M WB 299 248 51 370 // <40 DRV/r/MVC/RAL 
AZT/DDC/3TC/SQV/IDV/DDI/D4T/ABC/EFV/APV/NFV/H
U/LPV/r/TDF/T20/FTC/NVP/DRV/r/MVC/RAL 
N N Y 
 
63 M WB 238 221 17 438 // <40 ABC/3TC/NVP AZT/DDI/D4T/3TC/DDC/IDV/NVP/ABC Y N Y 
 
49 M WB 193 193 0 762 120 <40 TDF/FTC/ATV/r 
AZT/DDI/D4T/3TC/SQV/NVP/IDV/NFV/ABC/TDF/LPV/F
TC/ATV/r 
Y N Y 
 
48 M WB 158 151 7 872 10 <40 TDF/ABC/NVP AZT/DDI/D4T/3TC/RTV/NVP/IDV/DDC/ABC/ATV/r/TDF Y N Y 
 
54 M WB 96 96 0 // // // DDI/3TC/NVP AZT/3TC/EFV/DDI/NVP N N Y 
 
62 M WB 284 202 82 422 // <40 ABC/NVP/LPV/r SQV/AZT/DDC/3TC/D4T/DDI/IDV/ABC/NVP/NFV/LPV/r Y N Y 
 
50 M WB 140 138 2 669 0 <40 TDF/FTC/NVP AZT/D4T/IDV/NFV/SQV/3TC/NVP/DDI/TDF/FTC N N Y 
 





Y N Y 
 
45 M WB 165 146 19 592 305 <40 RAL/ABC/ATV/r D4T/3TC/NVP/DDI/IDV/ABC/ATV/r/RAL Y N Y 
 
51 M WB 236 164 72 559 327 <40 TDF/FTC/EFV AZT/DDI/RTV/NFV/TDF/FTC/EFV Y N Y 
 
74 F WB 200 182 18 825 // <40 TDF/FTC/EFV AZT/DDI/D4T/SQV/TDF/3TC/EFV/FTC Y N Y 
 
60 F WB 145 144 1 666 96 <40 ABC/3TC/EFV D4T/ABC/EFV/3TC Y N Y 
 
63 F WB 182 153 29 865 300 <40 TDF/FTC/EFV D4T/3TC/NVP/NFV/EFV/AZT/TDF/FTC Y N Y 
 54 M WB 246 241 5 659 100-200 <20 TDF/FTC/EFV AZT/3TC/ddI/SQV/TDF/FTC/EFV N Y Y 
 58 M WB 252 240 12 994 200-350 <20 TDF/FTC AZT/3TC/TDF/FTC N Y Y 
 62 M WB 265 33 232 247 100-200 <20 ABC/3TC/DTG AZT/ABC/3TC/DTG/TDF/LPV/r N Y Y 
 61 M WB 444 163 281 571 0-100 <20 
TDF/FTC/DRV/EFV
/RAL/r 
ddC/TDF/FTC/DRV/EFV/RAL/NVP/NFV/ATV/TAF/r N Y Y 
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 55 M WB 314 85 229 650 >350 <20 TDF/FTC/NFV AZT/3TC/TDF/FTC/NFV N Y Y 
 56 M WB 227 156 71 589 0-100 83 TDF/FTC/ATV/r AZT/3TC/TDF/FTC/ATV/NFV/EFV/ddI/FPV/ATV/r N Y Y 
 85 M WB 306 253 53 451 100-200 30 ABC/3TC/DTG AZT/ddI/d4T/IDV/TDF/ABC/3TC/DTG N Y Y 
 70 M WB 200 184 16 357 0-100 <20 TDF/FTC/NVP AZT/3TC/TDF/FTC/NVP N Y Y 
 70 M WB 355 236 119 738 // <20 DRV/r AZT/ddC/3TC/SQV/ DRV/r N Y Y 
 67 M WB 124 123 1 486 0-100 84 TDF/FTC/NVP AZT/3TC/EFV/ddC/DRV/r/ TDF/FTC/NVP N Y Y 
 54 M WB 196 97 99 1118 200-350 <20 TDF/FTC AZT/3TC/TDF/FTC N Y Y 
HIV- 50 M WB // // // // // // // // N Y N 
 70 M WB // // // // // // // // N Y N 
 51 M MR // // // // // // // // N Y N 
 70 M WB // // // // // // // // N Y N 
 52 M WB // // // // // // // // N Y N 
 58 M WB // // // // // // // // N Y N 
 69 M WB // // // // // // // // N Y N 
 51 M WB // // // // // // // // N Y N 
 59 M WB // // // // // // // // N Y N 
 57 M WB // // // // // // // // N Y N 
 62 M WB // // // // // // // // N Y N 
 60 M WB // // // // // // // // N Y N 
 63 M WB // // // // // // // // N Y N 
 54 M BA // // // // // // // // N Y N 




Table 3.1 – Cohort characteristics. WB (white British); BA (black African); N/A (not applicable); TDF (tenofovir disoproxil fumarate); FTC (emtricitabine); /r (ritonavir boosted); ATV (atazanavir); 
EFV (efavirenz); NVP (nevirapine); ABC (abacavir); 3TC (lamivudine); DRV (darunavir); ddI (didanosine); AZT (zidovudine); MVC (maraviroc); RAL (raltegravir); ddC (zalcitabine); SQV 
(saquinavir); IDV (indinavir); d4T (stavudine); APV (amprenavir); NFV (nelfinavir); HU (hydroxyurea); LPV (lopinavir); T20 (enfuvirtide); RTV (ritonavir); ETR (etravirine); Y = yes; N = no; // = 
missing value.
Control ACL 24 M // // // // // // // // // N Y Y 
 20 M // // // // // // // // // N Y Y 
 22 M // // // // // // // // // N Y Y 
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3.2.4 Mitochondrial disease patients  
In order to qualitatively contextualise the level of skeletal muscle mitochondrial dysfunction in the 
HIV+ and HIV- individuals of the MAGMA study, post-mortem percutaneous muscle biopsies were 
acquired from mitochondrial disease patients (Table 3.2) from the Newcastle Mitochondrial 
Research Biobank (REC - 16/NE/0267) and stored at -80°C until use.  
 
Patient Age Gender Genotype Phenotype 
1 80 Male p.T251I/p.P587L and p.A467T  
POLG 
CPEO 
2 52 Male Homozygous p.(Ala467Thr) 
POLG 
Neuropathy; CPEO; 
progressive sensory ataxia  
Table 3.2 – Mitochondrial disease patient characteristics. Both patients had confirmed mitochondrial disease, with varying 
mutations in the nDNA-encoded maintenance gene POLG. Both patients were decease. CPEO = chronic progressive external 
ophthalmoplegia. 
 
3.2.5 Renal mitochondrial function study 
Renal biopsies were collected as diagnostic procedures, with additional consent obtained for 
subsequent research use of the tissue. These samples were supplied in anonymised form by the 
Cellular Pathology department of the Royal Free Hospital, London. The research performed on these 
samples as part of this thesis was conducted under REC permission 17/NE/0015.   
Percutaneous biopsies were taken from PLWH (n = 6) (supplied as residual diagnostic tissue from 
Royal Free Hospital London (RFH) Cellular Pathology Department) and open renal biopsies were 
taken from HIV- individuals (n = 5) (supplied by Dr Ashwin Sachdeva and Manchester University NHS 
Biobank as residual diagnostic tissue). All biopsies were formalin-fixed and paraffin-embedded. 
Of the PLWH, four were being treated with an ART regimen including TDF at the time of biopsy, 
while one had never been exposed to TDF, and clinical information was missing for one subject 
(Table 8.1). Of the four TDF-treated PLWH, only patient 3 had discontinued TDF treatment. 
Aside from their age, race and gender, little information was given to us about the HIV- control 
subjects. Biopsies came from ‘normal’ tissue adjacent to explanted renal masses, however, I did not 
know whether these individuals had been diagnosed with any renal pathologies and I have no 
information about potential co-morbidities or other adverse factors such as certain medications.  
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3.3 MAGMA study protocol and assessment of adverse ageing phenotypes 
3.3.1 Clinical interview  
All participants (n = 45), recruited in both Newcastle (n = 38) and London (n = 7), were asked to 
complete a health questionnaire during the sole study visit (Appendix 2). This was carried out by a 
clinical researcher and data was made available for examination alongside biological samples.  
This health questionnaire included: general questions about age, country of birth, ethnicity and 
sexual orientation; lifestyle questions about smoker status, whether they drink alcohol, and how 
many units a week, as well as whether they had used recreational drugs in the last 6 months, and 
which ones.  
Participants where then asked to list whether they suffered from any medical conditions including: 
heart disease, peripheral vascular disease, stroke, liver disease, diabetes, cancer, joint disease, 
fractures, osteoporosis, and falls. In addition, participants were asked to list what medications they 
were currently prescribed or buying over-the-counter. 
Finally, HIV+ participants (n = 30) were asked to list what HIV treatments they were currently or have 
previously been on, as well as when they started and finished the respective treatments. In addition, 
HIV+ participants were asked when they were first diagnosed with HIV, when they think they first 
became HIV positive, and what their lowest CD4 count was (either: 0-100; 100-200; 200-350, or 
more than 350 copies/µl). This information was subsequently confirmed through medical records 
where available.  
3.3.2 Determination of frailty 
A frailty phenotype was assessed using a modified five FFP criteria as previously described by Onen 
and colleagues (2009). Cut-offs for weakness and slow walking time are described in Table 3.3.  
For the self-reported unintentional weight loss, participants were asked (1) whether their weight 
had increased, decreased, or stayed the same in the last 12 months?; (2) if ‘decreased’, was the 
weight loss intentional?; (3) if ‘yes’, how much weight did they lose, in kg or lbs? Note, answers in lbs 
were covered to kg (1lbs = 0.45kg). 
For self-reported low physical activity, participants were asked whether their health limited their 
ability to do vigorous activities such as running or lifting heavy objects (Table 3.3). 
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For self-reported exhaustion, participants were asked to confirm whether ‘rarely or none of the time 
(<1 day)’, ‘some or a little of the time (1-2 days)’, ‘occasionally or a moderate amount of time (3-4 
days)’, or ‘most or all of the time (5-7 days)’ was most appropriate for the following two questions: 
(1) everything I did was an effort; (2) I could not get going (Table 3.3; Appendix 2). 
Missing clinical and HIV-related information were later identified and confirmed through patient 
medical records where available. Laboratory results were the most recent values available. 
 
 FFP criteria Definition 
Self-reported Low physical activity When subjects answer 3 to questions regarding whether their health 
limits their ability to conduct vigorous activities: 
1 = not at all; 2 = yes, limited a little; 3 = yes, limited a lot 
 Exhaustion 
When subjects answer 2 or 3 to either statement: 
How often have you felt that: 
(1) Everything you did was an effort 
(2) I could not get going 
0 = rarely (<1 day); 1 = some of the time (1-2 days); 2 = 
occasionally (3-4 days); 3 = most of the time (5-7 days) 
 Unintentional weight 
loss 
>4.5kg/10 lbs weight loss in the past 12 months or <5% of previous 
year’s body weight 
Clinical 
assessment 
Weak grip strength Male BMI (kg/m2) / Kg 
≤24 / ≤29 
24.1-26.0 / ≤30 
26.1-28.0 / ≤30 
>28 / ≤32 
 Slow walking time Male height (cm) / seconds 
≤173 / ≥7 
>173 / ≥6 





3.3.3 Short Physical Performance Battery (SPPB)  
Assessment of physical function was done by a SPPB, which consisted of a repeat chair stand 
(recorded as the time taken in seconds to complete 5 and 10 stands without using their arms); 
standing balance test (recorded as the time - up to 30 seconds – that the participant can hold a side-
by-side, semi-tandem, tandem and single-leg stands) (Figure 3.1); hand grip assessment (the average 
of three dominant hand grip measurements using a hand dynamometer, measured in kilograms (kg)) 
and 4m walk (recorded as the time taken, in seconds, for the participant to walk 4 meters in a 
straight line. Results were derived from the average of 3 repeats). SPPB was scored using a binary 
tally and scored out of 12 (Table 3.4), with 0 points indicating the individual’s inability to complete a 
task and 4 points demonstrating the optimal performance in the task (Guralnik et al., 1994) 
(Appendix 3).  
 
Figure 3.1 – Foot positions in the standing balance test component of the SPPB. (A) side-by-side, (B) semi-tandem, (C) 
tandem and (D) single-leg stand. 
  
Characterisation Score 
Robust > 11 
Intermediate physical performance 9-11 
Low physical performance < 9 
Table 3.4 – SPPB scoring classification. 
 
  
A B C D 
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3.3.4 MET score  
Metabolic equivalent (MET) expenditure per week was calculated as an additional surrogate for 
physical performance assessment. Patients were asked to answer how many days, hours and 
minutes a week they performed vigorous physical activities such as heavy lifting, aerobics or fast 
cycling; moderate physical activities such as carrying light loads, cycling at a moderate pace or 
doubles tennis etc; walking; and sitting (Appendix 4). Results were calculated as described in 
Ainsworth et al. (1993) and Ainsworth et al. (2000).  
3.3.5 Classification of sarcopenia  
According to the EWGSOP, sarcopenia can be classified in the clinical and research setting based on 
analyses of muscle mass, muscle strength and physical performance (Cruz-Jentoft et al. 2019). 
In our study, (1) muscle mass was quantified as appendicular skeletal muscle mass by dual-energy X-
ray absorptiometry (DXA). The cut-off point for this variable was having an appendicular skeletal 
muscle mass/height2 index (ASMI) of 7.26kg/m2. Subjects with an AMSI below the cut-off point were 
defined as having abnormal muscle mass; (2) muscle strength was assessed using a Jamar handheld 
dynamometer, with cut-off points described in Table 3.3, and (3) physical performance was assessed 
through the SPPB, as described in Section 3.3.3. 
Patients were classified as having presarcopenia if they had abnormal results for muscle mass; 
sarcopenia if they had abnormal results for muscle mass as well as either muscle strength or physical 
performance, and severe sarcopenia if they had abnormal results from all three criteria (Table 3.5). 
 





Presarcopenia X - - 
Sarcopenia X 
X - 
Severe sarcopenia X 
X X 
Table 3.5 – Variables used to characterise the presence of presarcopenia, sarcopenia and severe sarcopenia, as defined 




3.4 Immunofluorescence and fluorescence histochemistry 
3.4.1 Cryosectioning and microtome sectioning  
Snap-frozen skeletal muscle biopsies were cut into sections of various thicknesses onto glass slides 
using the Cryo-star HM 560 cryostat (Lecia), which was maintained at -20˚C. Sections were then left 
to air-dry at room temperature for one hour and then stored at -80˚C until required for use. After 
use, sections were stored at -20˚C. 
Formalin-fixed paraffin-embedded (FFPE) renal biopsies were sectioned at 4µm, 10µm and 15µm 
onto glass slides using a microtome and left to settle for 24 hours at 37˚C before being stored at 4˚C.  
3.4.2 Multiplex immunofluorescence for quantification of mitochondrial protein level 
in human skeletal muscle  
Multiplex immunofluorescence using antibodies for subunits of mitochondrial OXPHOS complexes 
and a mitochondrial outer membrane protein was carried out on frozen muscle sections (10μm) in 
order to quantify the levels of ETC complexes I and IV as well as mitochondrial mass in individual 
myofibres. Complex I was detected by an antibody against the NDUFB8 subunit and complex IV was 
detected with an antibody against MTCO1. An antibody against Porin (VDAC1) was used to quantify 
mitochondrial mass and the basement membrane glycoprotein laminin was used to label myofibril 
boundaries (Table 3.6). Firstly, the sections were air-dried at room temperature (RT) before fixation 
in cold 4% paraformaldehyde (PFA) (Sigma) in phosphate buffered saline (PBS) (ChemCruz) for 3 
minutes. After washes for 3 x 5 minutes in tris-buffered saline with Tween 20 (TBST), the antigenic 
sites were exposed through a graded methanol series (Fisher Chemical): 10 minutes 70% methanol, 
10 minutes 95% methanol, 20 minutes 100% methanol, 10 minutes 95% methanol, 10 minutes 75% 
methanol, then washed 3 x 5 minutes in TBST. Sections were then incubated in 10% normal goat 
serum (NGS) to prevent non-specific protein binding before another 3 x 5 minute wash cycle. Next, 
endogenous biotin was blocked by incubating the sections for 15 minutes in avidin, followed by 2 x 5 
minute washes, then 15 minutes in biotin from the Avidin/Biotin blocking kit (Vector Laboratories). 
Sections were then incubated in the primary antibody cocktail diluted in 10% NGS overnight in a 4°C 
humidified chamber (Table 3.6). Initially on day 2 the sections were washed in TBST for 3 x 5 minute 
wash cycles before being incubated in the secondary antibody cocktail for two hours in a humidified 
chamber at 4°C. All secondary antibodies were diluted in 10% NGS. Sections were then incubated in 
streptavidin-conjugated Alexa 647 (Thermo Fisher Scientific) at 1:100 diluted in 10% NGS for two 
hours in at 4°C in a dark humidified chamber (Table 3.7). After a final round of 3 x 5 minute TBST 
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washes, the sections were mounted in Prolong Gold Antifade Mountant (Thermo Fisher Scientific) 
and stored at -20°C until required for imaging. 
3.4.3 Multiplex immunofluorescence for quantification of mitochondrial protein level 
in human renal tissue  
A novel multiplex immunofluorescence assay was used to quantify levels of complexes I, III, IV and V 
of the ETC as well as mitochondrial mass in proximal tubules.  
Serial 4um renal sections were cut and allowed to air dry for an hour at RT, deparaffinised in 2 
changes of Histoclear then taken to water for 5 minutes. Next, the sections were rehydrated in a 
graded ethanol (EtOH) series (10 minutes 100% EtOH, 5 minutes 95% EtOH, 5 minutes 70% EtOH) 
then taken to water for 5 minutes. Antigen retrieval of the sections was performed with 1mM EDTA 
pH8.0 buffer for 40 minutes. Sections were incubated in 10% NGS for 1 hour to block endogenous 
protein activity and then covered in the primary antibody cocktail (see Table 3.6) overnight at 4°C. 
Following washes in TBST, sections were incubated in a secondary antibody cocktail for 2 hours at RT 
(Table 3.7). Sections were then washed again in TBST, and for the CI and CIV assay, were incubated 
in the tertiary antibody cocktail for 2 hours at room temperature then washed in TBST. All sections 
were then subjected to incubation in 0.1% Sudan Black B (BDH) for 25 minutes in order to minimise 
autofluorescence, then washed in deionised water (dH2O) for 10 minutes. Sections were then 
mounted in ProLong Gold Antifade Mountant (Thermo Fisher Scientific) and stored at -20°C until 
imaged. Separate panels were used to analyse mitochondrial OXPHOS complexes I/IV (CI, CIV) and 




Assay Antibody Target Host Isotype Manufacturer Product # Dilution 




Mouse IgG1 Abcam ab110242 1:100 




Mouse IgG2a Abcam ab14705 1:200 




Mouse IgG2b Abcam ab14746 1:200 




Mouse IgG1 Abcam ab14730 1:200 
Both VDAC1 
Mitochondrial 
mass marker - 
Porin 











Table 3.6 – Antibodies used in the primary antibody cocktail for multiplex immunofluorescence staining of human 












Assay Antibody Conjugate Target Host Isotype Specificity Manufacturer Dilution 
CI + CIV 
Anti-IgG1-
biotin 






CI + CIV 
AlexaFluor 
647 





CI + CIV 
AlexaFluor 
488 





CIII + CV 
AlexaFluor 
647 





CIII + CV 
AlexaFluor 
488 























Table 3.7 – Antibodies used in the secondary and tertiary antibody cocktail for multiplex immunofluorescence  staining 
of human skeletal muscle (CI/CIV assay) and human renal tissue (CI/CIV and CIII/CV assays). 
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3.4.4 Image acquisition and determination of ETC complex activity in skeletal muscle 
Fluorescent images were acquired using a Zeiss Axio Imager M1 and Zen 2011 (blue edition) 
software with a Monochrome Digital Camera (AxioCam MRm) at 20x magnification. Filter cubes for 
Alexa Fluor dyes at wavelengths 405nm, 488nm, 546nm and 647nm were used for laminin, MTCO1, 
VDAC1 and NDUFB8 respectively. Exposure time was set for the four channels and maintained 
between cases in order to avoid pixel saturation. Images were tiled and then processed at 16-bit czi 
files and exported as Tagged-Image File Format (TIFF) files. The tiled images were then processed by 
Zen 2011 (blue edition) software using the stitching function.  
Stitched images were analysed with the Quadruple Immunofluorescence Analyser developed in our 
lab (Rocha et al., 2015). Briefly, the raw intensity values for MTCO1, VDAC1 and NDUFB8 in 
individual myofibres were corrected for background signal by subtracting the mean optical density 
(OD) from the no primary control (NPC) for each fluorophore, respectively.   
An in-house R Shiny script software was then used to generate z-scores indicating how many 
standard deviations a fibre deviated from the control population, and was initially used to assess 
mitochondrial mass in the patient myofibres. Individual myofibres were classified into mitochondrial 
mass groups depending on their z-score: ‘very low’ (VDAC1_z < -3); ‘low’ (-3 < VDAC1_z < -2); 
‘normal’ (-2 < VDAC1_z < +2); ‘high’ (+2 < VDAC1_z < +3) and ‘very high’ (3 < VDAC1_z). Individual 
myofibres were then classified into groups based on their z-scores for MTCO1 and NDUFB8: 
‘positive’ (z > -3); ‘intermediate positive (+)’ (-3 > z > -4.5); ‘intermediate negative (-)’ (-4.5 > z > -6) 
and ‘deficient’ (z < -6).  
3.4.5 Image acquisition and determination of ETC complex activity in renal tissue  
Fluorescent images were acquired using a Zeiss Axio Imager M1 and Zen 2011 (blue edition) 
software with a Monochrome Digital Camera (AxioCam MRm) at 20x magnification. Filter cubes for 
Alexa Fluor dyes at wavelengths 405nm, 488nm, 546nm and 647nm were used for DAPI, MTCO1 or 
ATPB, VDAC1 and NDUFB8 or UQCRSF1, respectively. Exposure time was established from a case 
with the putatively highest signalling intensity for the four channels and maintained between cases. 
As the renal tissue from HIV+ subjects was taken by needle biopsy, the sections were small enough 
to tile, whereas the open biopsy sections taken from HIV- subjects were much larger and so were 
imaged as snaps. 40 PCTs were randomly manually identified per subject, except for patient 6 where 
a maximum of 23 PCTs were present. Each PCT was marked in order to prevent multiple imaging of 
the same PCT. 
124 
 
Stitched images were analysed with the Quadruple Immunofluorescence Analyser developed in the 
Wellcome Centre for Mitochondrial Research (Rocha et al., 2015). Briefly, the raw intensity values 
for MTCO1, ATPB, VDAC1, UQCRFS1 and NDUFB8 in individual PCTs was corrected for background 
signal by subtracting the mean OD from the NPC for each fluorophore, respectively.   
An in-house R Shiny based web application was then used to generate z-scores indicating how many 
standard deviations a PCT deviated from the control population. This was initially used to assess 
mitochondrial mass in the patient PCTs. Individual PCTs were then classified into mitochondrial mass 
groups depending on their z-score: ‘very low’ (VDAC1_z < -3); ‘low’ (-3 < VDAC1_z < -2); ‘normal’ (-2 
< VDAC1_z < +2); ‘high’ (+2 < VDAC1_z < +3) and ‘very high’ (3 < VDAC1_z). Individual PCTs were 
then classified into groups based on their z-scores for MTCO1, NDUFB8, UQCRFS1 and ATPB. 
Respective z-scores were calculated after normalisation to VDAC1 staining intensity: ‘positive’ (z > -
3); ‘intermediate positive (+)’ (-3 > z > -4.5); ‘intermediate negative (-)’ (-4.5 > z > -6) and ‘deficient’ (z 
< -6). Subsequently, the ‘deficient’, ‘intermediate -‘ and ‘intermediate +’ groups were pooled 
together to create the ‘deficient’ group (i.e. z < -3 = deficient). 
3.4.6 Duplex fluorescence histochemistry for the quantification of intramyocellular 
lipid accumulation 
Fluorescence histochemistry was carried out on 10μm frozen transverse muscle sections in order to 
detect and quantify intramyocellular lipid droplets in skeletal muscle fibres. BODIPY (493/503) 
(ThermoFisher) is a lipid-soluble fluorescent dye used to detect and measure intramyocellular lipid 
droplets, and was diluted in DMSO to create a stock at a concentration of 1mg/mL. Cryosections 
were air-dried at RT for 30 minutes and then fixed by incubation in 3.7% formaldehyde (ChemCruz) 
in PBS for 30 minutes at RT. Sections underwent a wash cycle of PBS for 5 minutes, followed by 5 
minutes in 0.25% Triton x-100 (ThermoFisher) diluted in PBS. Next, the sections were incubated in 
IgG Goat-anti-rabbit Laminin antibody (Sigma) diluted at 1:100 in 0.05% Tween 20/PBS, for 60 
minutes in a humidified chamber. Sections then underwent another wash cycle followed by 
incubation in the secondary cocktail (Table 3.8) for 90 minutes in a dark humidified chamber at RT. 








Isotype Product # Dilution Secondary 
antibody/dye 
Isotype Product #  Dilution 
















Table 3.8 – Antibodies and dyes used in the duplex fluorescence histochemistry assay for the quantification of 
intramyocellular lipid accumulation. 
 
3.4.7 Image acquisition and analysis for quantification of intramyocellular lipid 
accumulation 
Fluorescent images were acquired using a Zeiss Axio Imager M1 and Zen 2011 (blue edition) 
software with a Monochrome Digital Camera (AxioCam MRm) at 20x magnification. Filter cubes at 
wavelengths 405nm and 488nm were used for laminin and BODIPY (493/503) respectively. Exposure 
time for the two channels was set and maintained between cases in order to remove pixel 
saturation. Images were then tiled and processed at 16-bit czi files and exported as TIFF files and 
then processed by Zen 2011 (blue edition) software using the stitch function.  
Stitched images were then analysed on the Zen 2011 (blue edition) software. Briefly, each individual 
fibre was qualitatively classified into one of four categories depending on the extent of BODIPY 
staining coverage and staining intensity – BODIPY+++; BODIPY++; BODIPY+ and BODIPY-.  
3.4.8 Duplex immunofluorescence for quantification of Pax7+ satellite cells  
Duplex immunofluorescence was carried out on 10µm transverse muscle cryosections in order to 
quantify the frequency of quiescent Pax7+ muscle satellite cells. Cryosections were air-dried for 1 
hour at RT before fixation in cold 4% PFA for 4 minutes. Sections were then washed in a cycle of 
three, 5 minute washes in PBST before endogenous protein was blocked by incubation in 5% 
NGS/0.2% Triton-x100 diluted in PBST for 1 hour at RT. Sections were then washed for 5 minutes in 
PBST before the Pax7 primary antibody (DSHB) was applied and sections were incubated overnight 
at 4˚C in a dark humidified chamber (Table 3.9). After incubation with Pax7 primary antibody, the 
sections went through a washing cycle before the secondary antibody cocktail (diluted in 10% NGS) 
was applied for 2 hours at RT in a humidified chamber. Sections were then washed again in PBST and 
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incubated with Hoerst for 15 minutes in a dark humidified chamber in order to counter stain for 
nuclei. Finally, the sections went through another wash cycle, mounted using ProLong Gold Antifade 




Isotype Product # Concentration 
Secondary 
antibody 
Isotype Product # Dilution 








- - - - Hoerst  - - 1:1200 
Table 3.9 – Antibodies used in the duplex immunofluorescence assay to quantify Pax7+ satellite cells. 
 
3.4.9 Image acquisition and analysis for quantification of Pax7+ satellite cells 
Fluorescent images were acquired using a Zeiss Axio Imager M1 and Zen 2011 (blue edition) 
software with a Monochrome Digital Camera (AxioCam MRm) at 20x magnification. Filter cubes at 
wavelengths 405nm and 488nm were used for Hoerst and Pax7, respectively. Exposure time for the 
two channels was set and maintained between cases in order to remove pixel saturation. Images 
were then tiled and processed as 16-bit czi files and exported as TIFF files and then processed by Zen 
2011 (blue edition) software using the stitch function.  
Stitched images were then analysed on Zen 2011 (blue edition) software. Here, a Pax7+ satellite cell 
was confirmed by co-localised staining of Pax7 and nuclei identified Hoerst. The number of Pax7+ 
satellite cells was then quantified and expressed as the proportion of Pax7+ satellite cells per 100 
fibres. These values were then log10 transformed in order to normalise the data sets.  
3.4.10 Multiplex immunofluorescence for fibre type quantification  
A multiplex immunofluorescence assay to quantify the proportions of fibre types I, IIa and IIx, as well 
as their cross-sectional area, was performed on patients biopsies. 10µm transverse cryosections 
were removed from -80˚C and air-dried for 1 hour at room temperature before fixation with cold 4% 
PFA for 3 minutes. Sections underwent a 3 x 5 minute washing cycle in TBST and then incubated in 
10% NGS for 1 hour at room temperature in order to block non-specific protein binding. Following 
another cycle of washes, the sections were incubated overnight at 4˚C in the primary antibody 
cocktail (Table 3.10), diluted in 5% NGS. Following another cycle of washes the sections were 
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incubated in the secondary antibody cocktail (Table 3.10) for 90 minutes at RT in a dark humidified 
chamber. Finally, sections were subjected to a washing cycle and mounted in ProLong Gold Antifade 










BA-F8 Type I 1:100 DSHB 10572253 Anti-IgG2b-488 1:200 Invitrogen 
A31141  
SC-71 Type IIa 1:100 DSHB 2147165 Anti-IgG1-546 1:200 Invitrogen 
A21123 




1:100 Sigma L9393 Anti-rabbit-405 1:200 Invitrogen 
A31556  
Table 3.10 – Antibodies used in the primary and secondary cocktails for the detection and quantification of fibre types I, 
IIa and IIx. 
 
3.4.11 Image acquisition and analysis of fibre type quantification  
Fluorescent images were acquired using a Zeiss Axio Imager M1 and Zen 2011 (blue edition) 
software with a Monochrome Digital Camera (AxioCam MRm) at 20x magnification. Filter cubes at 
wavelengths 405nm, 488nm, 546nm and 647nm were used for laminin, BE-F8, SC-71 and 6H1 
antibodies, respectively. Exposure time for the four channels was set and maintained between cases 
in order to remove pixel saturation. Images were then tiled and processed as 16-bit czi files and 
exported as TIFF files, then processed by Zen 2011 (blue edition) software using the stitch function.  
Stitched images were then analysed on the in-house R script Quadruple Immunofluorescence 
Analyser developed in our lab (Rocha et al., 2015). Briefly, each individual fibre was qualitatively 
characterised as one of the three fibre types (I, IIa and IIx) based on staining pattern. In addition, the 
cross-sectional area (CSA) (µm2) of each fibre was quantified using the in-house drawing tool.   
3.4.12 Preparation of slides for lipofuscin quantification, and image acquisition and 
analysis 
In order to quantify the frequency of, and area (µm2) covered by lipofuscin granules, 10µm 
transverse cryo-sections were removed from -80°C storage and air-dried for 1 hour. Sections were 
then immediately cover-slipped with Prolong gold and stored at -20°C until imaged. 
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Fluorescent images were acquired using a Zeiss Axio Imager M1 and Zen 2011 (blue edition) 
software with a Monochrome Digital Camera (AxioCam MRm) at 20x magnification. Filter cubes at 
wavelengths 546nm and 647nm were used for the identification of autofluorescent lipofuscin 
granules. Exposure time for the four channels was set and maintained between cases in order to 
remove pixel saturation. Images were then tiled and processed as 16-bit czi files and exported as 
TIFF files and then processed by Zen 2011 (blue edition) software using the stitch function.  
Stitched images were then analysed on Columbus Image Data Storage and Analysis System software. 
Briefly, thresholds for the positive identification of lipofuscin granules were set for both 546nm and 
647nm channels, and lipofuscin granules were confirmed by co-localisation in both respective 
channels. Lipofuscin is identifiable by its auto fluorescence across multiple wavelengths. The 
frequency, as well as CSA (µm2) covered by co-localised lipofuscin granules was then automatically 





3.5.1 Haematoxylin & Eosin histochemistry staining and imaging for renal tissue 
FFPE sections (4µm) were dewaxed at 60°C for 1 hour and then immediately deparaffinised in two 
changes of Histoclear. Next, sections were dehydrated in a graded ethanol series (10 minutes 100% 
EtOH, 5 minutes 95% EtOH, 5 minutes 70% EtOH) before being taken to water for 10 minutes. 
Sections were then stained with haematoxylin for 10 minutes then rinsed clear in dH2O followed by 
staining with Scott’s tap water for one minute in order to blue the nuclei. Sections were then stained 
with Eosin for one minute for cytoplasmic staining. Finally, sections were rinsed clear in dH2O then 
rehydrated through a graded ethanol series (10 dips 70% EtOH, 10 dips 95% EtOH, 20 dips 100% 
EtOH) followed by two changes of 20 dips in Histoclear, then mounted in DPX. Sections were stored 
at RT until imaged. 
For imaging, sections were imaged using Zeiss Axio Scope A1 (brightfield) at 10x magnification. 
Sections were tiled and then stitched using the ’stitch’ function in Zeiss Zen blue edition to acquire 
an image of the full section. 
3.5.2 Haematoxylin & Eosin histochemistry staining and imaging for skeletal muscle 
tissue 
Haematoxylin & Eosin histochemistry was undertaken in order to identify and quantify the 
proportions of degenerated and regenerated fibres. Here, 10µm cryosections were removed from -
80˚C and air-dried for 1 hour at room temperature. Sections were then initially fixed with cold 4% 
PFA for 3 minutes and before being rinsed clear in dH2O. Next, sections were stained with 
Haematoxylin for 10 minutes in order to stain nuclei and then rinsed clear in dH2O. Next, sections 
were washed in Scott’s tap water for 1 minute to blue the nuclei and then rinsed clear in dH2O. 
Sections were then stained with Eosin for 1 minute in order to stain the cytoplasm. Finally, sections 
were rinsed clear in dH2O then rehydrated through an ethanol gradient (10 dips 70% EtOH, 10 dips 
95% EtOH, 20 dips 100% EtOH) followed by 2 changes of 20 dips in Histoclear and mounted in DPX. 
Sections were stored at RT until imaged. 
3.5.3 Masson’s trichrome histochemistry for skeletal muscle fibrosis  
Masson’s trichrome histochemistry was undertaken in order to quantify skeletal muscle fibrosis. 
10µm cryosections were removed from -80˚C and air-dried for 1 hour at room temperature. Sections 
were then initially fixed with cold 4% PFA for 3 minutes and then further fixed in Bouin’s Fluid 
(Sigma), heated to 60˚C for 30 minutes, before being rinsed clear in dH2O. Next, sections were 
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stained with Weigert’s Iron Haematoxylin (Abcam) for 5 minutes in order to stain nuclei and then 
rinsed clear in dH2O.  Next, sections were stained for 15 minutes in acid fuscin (Abcam) in order to 
stain cytoplasm and then differentiated in phoshotunsic acid solution (Abcam) for 10 minutes 
following a rinse in dH2O. Sections were then rinsed and incubated in alanine blue (Abcam) for 7 
minutes in order to stain collagenous tissue, before being rinsed clear in dH2O and subsequently 
differentiated in acetic acid (Abcam) for 3 minutes. Finally, sections were rehydrated through an 
ethanol gradient (10 dips 70% EtOH, 10 dips 95% EtOH, 20 dips 100% EtOH) followed by 2 changes of 
20 dips in Histoclear and mounted in DPX. Sections were stored at RT until imaged. 
3.5.4 Succinate dehydrogenase histochemistry  
Tissue was subjected to succinate dehydrogenase histochemistry in order to prepare tissue for laser 
capture microdissection. 15µm serial skeletal muscle cryo-sections were removed from -80°C and 
left to air dry for one hour. Sections were then rinsed in 1M PBS whilst the succinate dehydrogenase 
(SDH) reaction medium was prepared: 100µl sodium succinate, 100µl PBS, 10µl sodium azide and 
800µl NBT. SDH reaction medium reagents were defrosted in at 55°C. Once prepared, sections were 
covered with SDH reaction medium and incubated for 40 minutes at 37°C. Sections were then 
washed in a cycle of three, 5 minute rinses with 1M PBS then dehydrated in an ethanol gradient of 
10 minutes in 70%, then 90% then two 10 minute incubations in 100%, followed by two changes in 
Histoclear and stored at 4°C.  
3.5.5 Brightfield microscopy 
Brightfield images were acquired using a Zeiss Axio Imager M1 and Zen 2011 (blue edition) software 
with a chromatic digital camera (AxioCam MRm) at 10x magnification. Exposure time was set and 
maintained between cases in order to avoid pixel saturation. Images were processed as 16-bit czi 
files and exported as TIFF files. The tiled images were then processed by Zen 2011 (blue edition) 
software using the stitching function.  
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3.6 Laser capture microdissection of single cells 
In order to isolate tissue for subsequent quantitative PCR analysis, laser capture microdissection was 
performed, followed by amplification of isolated tissue lysate.    
3.6.1 Single cell lysis buffer and lysate amplification  
Lysis buffer (0.5M Tris-HCl, 0.5% Tween 20 and 1% Proteinase K) was made fresh into autoclaved 
1.5ml Eppendorf tubes and kept on ice. 
Cells were captured into 15µl of lysis buffer and kept on ice. Immediately before amplification, cells 
were centrifuged on a short cycle and then amplified at 55˚C for 16 hours followed by a 10 minute 
incubation at 95˚C. 
3.6.2 Laser capture microdissection 
Cells were isolated from histochemically stained tissue sections by laser capture microdissection 
using a Ziess Laser Capture Microdissection microscope with Palm Robo v4.6 using either the 
Closecut + AutoLPC function for glass slides and RoboLPC for membrane slides (Zeiss).  
15µl of lysis buffer was added into the cap of two 0.2ml Eppendorf tubes, which were then inserted 




3.7 Quantitative PCR for the detection of mtDNA mutations 
In order to detect and quantify mtDNA mutations in human homogenate tissue, a qualitative real-
time PCR (qPCR) assay was utilised. The mitochondrially encoded NADH-dehydrogenase core subunit 
1 gene (MT-ND1, Genbank accession ID: NC_012920.1) and NADH-dehydrogenase core subunit 4 
gene(MT-ND4, Genebank accession ID: NC_012920.1) were used respectively as mtDNA targets.  
3.7.1 Preparation of PCR reagents 
Stock probes (IDT) and primers to be used in qPCR assays were resuspended using Ambion nuclease-
free water (ThermoFischer Scientific) under a UV sterilizing PCR cabinet (UVP) to the working 
concentration of 10µM and the stored at -20˚C. 
3.7.2 Generation of qPCR standard templates  
Quantitative standards of qPCR assays were prepared by PCR generated templates.  
MT-ND1 and MT-ND4 standards were generated using a control DNA sample. Primer sequences are 
described in Table 3.11.  
PCR reactions were performed in a mastermix containing:- 1X MyTaq Reaction Buffer, one unit of 
MyTaq HS DNA Polymerase (Bioline), 400nM of each respective forward and reverse primer and 
dH2O. Approximately 30ng of DNA was loaded into each reaction well of 8-strip PCR tubes (StarLab) 
and ran on an Applied Biosystems Veriti 96 well thermal cycler (ThermoFischer Scientific). Run 
conditions were: initial denaturation at 95˚C for one minute followed by 30 cycles of denaturation at 











1040 CAGCCGCTATTAAAGGTTCG AGAGTGCGTCATATGTTGTTX 61 
MT-
ND4 
1072 ATCGCTCACACCTCATATCC TAGGTCTGTTTGTCGTAGGC 61 




3.7.3 Agarose gel electrophoresis  
Amplified template PCR products were pooled together and mixed with Orange G loading buffer 
(50% glycerol, Orange G powder (Sigma) and 50% water) and loaded into a 1% agarose gel (1g 
agarose (Bioline) in 100ml 1X TAE buffer and 0.4mg/µl UltraPure ethidium bromide (Invitrogen)). As 
a ladder, I used a GeneRuler 1kb Plus DNA Ladder (ThermoFischer Scientific) as well as a negative 
PCR product, both mixed with Orange G dye. Agarose gels were electrophoresed at 75V for one hour 
in 1X TAE buffer. 
3.7.4 Purification and quantification of standards  
Agarose gels were imaged with the UVP GelDoc-It imaging system (UVP) and the gel-extracted 
fragment was extracted with a QIAquick gel extraction kit (Qiagen). Concentrations of the templates 
were measured using a Nanodrop ND-1000 Spectrophotometer and template DNA copy number 
concentrations were calculated using Equation 3.1. Template DNA was then multiplexed together to 
obtain a single copy number of 1010ng/µl, then diluted by a factor of 10 to achieve a starting copy 
number stock of 109ng/µl. Stock template were then stored at -20˚C. 
𝐶𝑜𝑝𝑦 𝑛𝑢𝑚𝑏𝑒𝑟 = [
𝐶
(𝐿 𝑥 2 𝑥 300)
] 𝑥 𝐴 
Equation 3.1 – Formula used to calculate the starting copy number stocks (copies/µl). C is the DNA concentration in 
nanolitres, L is the amplicon length in base pairs and A is Avogadro’s constant (6.023 x 1023). 
 
3.7.5 Quantitative PCR for the detection and quantification of large-scale mtDNA 
mutations 
All qPCR reaction plates were set up in a UV hood to minimise DNA contamination. qPCR was 
performed on a CFX96 Touch Real-Time PCR Detection System (Bio-Rad). mtDNA from the single-cell 
lysate was quantified using a probe-based multiplex assay targeting mitochondrial MT-ND1 and MT-
ND4 genes. MT-ND4 is in the major arc of the mtDNA genome and is usually lost through large-scale 
mtDNA mutations. In contrast, MT-ND1 lies on the minor arc as is rarely deleted. Primers for both 
MT-ND1 and MT-ND4 are described in Table 3.12. 2μl of DNA lysate from individual muscle fibers 
were amplified separately in triplicate using the ND1/ND4 combination, mixed with 18μl mastermix: 
10μl iTaq (Bio-Rad, catalog #172-5134); 75nM ND1 forward primer; 75nM ND1 reverse primer; 
75nM ND4 forward primer; 75nM ND4 reverse primer; 200nM HEX probe; 200nM Cy5 probe; 5.8μl 
deionised water. Amplification conditions were: three minutes at 95°C (for activation of iTaq), then 
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39 cycles of 10 seconds at 95°C followed by one minute at 62°C (for probe/primer hybridization and 
DNA synthesis). We screened for mtDNA deletions in individual myofibres by determining the ratio 
of MT-ND1 to MT-ND4 relative to a calibrator sample (δδCt), as previously described (He et al., 2002; 
Bury et al., 2017). We screened for mtDNA depletion in individual cells by considering the calculated 






Forward primer sequence (5’-3’) Reverse primer sequence (5’-3’) Fluorophore 
MT-
ND1 
111 ACGCCATAAAACTCTTCACCAAAG GGGTTCATAGTAGAAGAGCGATGG HEX 
MT-
ND4 
107 ACGCCATAAAACTCTTCACCAAAG GGGTTCATAGTAGAAGAGCGATGG Cy5 
Table 3.12 – Primers for the qPCR amplification of mitochondrial and nuclear genes used in the large-scale mtDNA 





3.8 Phosphorus magnetic resonance spectroscopy (31P-MRS) 
31P-MRS analysis was performed by Dr Brendan Payne (Newcastle University) in a previous study 
(Payne et al., 2014) in order to quantify skeletal muscle oxidative potential in vivo in response to 
short bouts of exercise. Briefly, MR studies were performed on calf muscle using a 3T Intera Achieva 
magnet (Philips). 31P-MRS measurements were obtained using a calf coil with a voxel within soleus 
muscle throughout a cycle of: a 1 minute baseline resting period; a 3 minute period of calf flexion 
exercise at 25% of maximal voluntary contractile force; and a 6 minute recovery period (Trenall et 
al., 2006, Hollingworth et al., 2008), which was designed to keep metabolism within the aerobic 
phase. Analysis was performed in jMRUI v3.0 (Java Magnetic Resonance User Interface) using 
AMARES with appropriate prior knowledge parameters for skeletal muscle (Naressi et al., 2001) and 
metabolite levels were calculated as previously described (Hollingworth et al., 2008). 
Phosphorylation potential was calculated from the concentration of ATP, buffered at 8.2 mM, and 
the empirically calculated concentrations of adenosine diphosphate (ADP) and inorganic phosphate 










3.9 Statistical analyses 
Statistical analysis was performed in Prism v5.04, IBM SPSS Statistics v23 and Microsoft Excel 2016. 
Graphs were produced in Prism v5.04.  
The chosen sample size for the MAGMA study was well-powered to detect a mean difference of 0.33 
log10 between groups (α 0.05, 1-β 0.8) based on past experience of SD for this measure. The sample 
size was also chosen in order to detect a moderate correlation (r = 0.5) (α 0.05, 1-β 0.8) between 
treatment parameters and mitochondrial dysfunction (Lachin, 1981). 
Normality was determined by Shapiro-Wilk tests. Unpaired t tests were performed to assess 
differences in means between parametric data from two experimental groups. Mann-Whitney tests 
assessed differences between non-parametric data from two experimental groups. One-way ANOVA 
was used to determine differences between the means of three or more groups, with Tukey’s 
multiple comparison post hoc test used to determine differences between respective individual 
groups. Fisher’s exact test or chi-squared tests determined differences between nominal data. 
Linear regression analysis was performed in order to determine the associations between factors. 
Pearson’s correlation was performed on parametric data, while Spearman’s correlation was 
performed on non-parametric data sets. Multivariate linear regression was used to determine 
associations between factors after adjustment for other variables. Of note, unstandardised 
regression coefficients and their significance were reported, as well as the fit of the models and how 
much variance (adjusted r2) they accounted for. Multivariate linear regression models and their 
components are described in more detail in the relevant sections.  
Statistical significance was set at p ≤ 0.05. 
Finally, description of the specific tests used to handle specific data sets relevant to the respective 





Chapter 4 – Skeletal muscle mitochondrial dysfunction in 
PLWH in the contemporary ART setting 
4.1 Introduction 
As discussed in Section 1.7, whilst the advent of antiretroviral therapy (ART) has been successful at 
suppressing HIV viral loads and restoring immune function in the majority of treated PLWH, several 
clinical reports and cohort studies have demonstrated the presence of ART-related mitochondrial 
toxicities in different tissues (Dalakas et al., 1990; Dalakas et al., 2001; Arnaudo et al., 1991; Lewis et 
al., 2003; Kakuda et al., 1999).  
The first of these studies demonstrated the presence of myopathy in PLWH treated with the 
nucleotide reverse transcriptase inhibitor (NRTI) zidovudine (AZT), in a monotherapy. This toxicity 
appeared to be underpinned by mtDNA depletion caused by the inhibition of the mitochondrial 
polymerase - PolG (Dalakas et al., 1990). In the following years, numerous reports surfaced of NRTI-
treated PLWH presenting with various other toxicities in several tissues, all of which were linked to 
mechanisms involving PolG, leading to mitochondrial dysfunction (Brinkman et al., 1999; Lim & 
Copeland, 2001; Dalakas et al., 2001; Arnaudo et al., 1991). As such, several of the older NRTIs 
associated with these toxicities were either discontinued or phased out of HIV treatments, and 
replaced with newer NRTIs that had a safer profile and lower binding affinity to PolG (Venter et al., 
2019; Venhoff et al., 2007).  
Aside from the PolG hypothesis, several other proposed mechanisms underpinning ART-induced 
mitochondrial dysfunction have been hypothesised (Selvaraj et al., 2014; Apostolova et al., 2011), 
including depletion of the endogenous dRN and RN pools (Jordhiem & Dumonet, 2007), and 
increased oxidative stress (Cote et al., 2005; Schieber & Chandel, 2014; Apostolova et al., 2010). 
Additionally, in recent years, reports of mitochondrial toxicities have surfaced in PLWH treated with 
these newer NRTIs (Payne et al., 2014; Samuels et al., 2017; Fields et al., 2019), PLWH treated with 
protease inhibitors (PIs) (Deng et al., 2010; Apostolova et al., 2011; Domingo et al., 2014; Dragovic et 
al., 2014; Alikhani et al., 2019; Carr et al., 1999), and non-nucleoside reverse transcriptase inhibitors 
(NNRTIs) (Zaera et al., 2001). In addition, mitochondrial dysfunction has been demonstrated in tissue 
from ART-naïve PLWH (Maagaard et al., 2005).  
However, due to the fact that the vast majority of PLWH are now on one of numerous variations of 
combination ART (cART), in combination with the large heterogeneity of the HIV+ population, it has 
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become difficult to determine the exact effect certain ARVs have on mitochondrial function. In 
addition, the demonstration from our group of the presence of clonally expanded mtDNA deletions 
in PLWH who were previously treated with the older, supposedly ‘mitochondrially-toxic’ NRTIs has 
led to the questioning of whether there is a ‘legacy effect’ in HIV+ individuals who were treated with 
these ARVs (Payne et al., 2011), further complicating the understand in the field.  
As the average age of the HIV+ population is steadily increasing, in combination with the fact that 
older PLWH exhibit a higher prevalence of age-related phenotypes such as frailty (Guaraldi et al., 
2011; Piggott et al., 2016; Kooij et al., 2016), and age-related pathologies (Guaraldi et al., 2011), the 
better understanding of mitochondrial dysfunction in the contemporary ART era is vital.  
As such, by examining mitochondrial dysfunction in skeletal muscle tissue from PLWH treated with 
various ART regimens through novel techniques, I sought to better understand ART-associated 




4.2 Experimental aims 
Various studies have demonstrated a ‘mitochondrially toxic’ effect of several of the early NRTIs in a 
range of tissues, including skeletal muscle (Dalakas et al., 1990; Arnaudo et al., 1991; Payne et al., 
2011). In contrast, few studies have sought to investigate whether PLWH who have only been 
exposed to newer NRTIs with a lower PolG-binding affinity develop skeletal muscle mitochondrial 
dysfunction. In addition, it is not fully understood whether previous treatment with older NRTIs 
leads to an excess of mitochondrial defects in a ‘legacy effect’. Therefore, in this study I aimed to:  
• Determine whether ART-treated PLWH have cellular defects of mitochondrial complex I and 
IV in skeletal muscle. 
• Determine the nature of mtDNA defects responsible for mitochondrial CI and CIV deficiency 
in skeletal muscle of PLWH at the single cell level. 
• Determine the proportion of myofibres showing deficiency of mitochondrial CI and CIV in 
the skeletal muscle of PLWH who have been exposed only to those NRTIs in contemporary 
usage, and to compare this with those PLWH who have also been exposed to older NRTIs. 
• Assess whether previous exposure to older NRTIs is responsible for a ‘legacy effect’, 
whereby PLWH previously treated with ‘mitochondrially-toxic’ NRTIs have an excess of 






4.3.1 Patient cohort 
Skeletal muscle biopsies obtained from 67 HIV+ individuals from both the MAGMA and SMMFA 
studies were included in this study cohort, with subject clinical and HIV-related characteristics 
described fully in Table 3.1. Subjects were combined from both MAGMA and SMMFA cohorts in 
order to increase the power to detect inter- and intra-group differences. Specifically, 30 subjects 
were derived from the MAGMA study, whilst 37 were derived from the SMMFA study. 
Control skeletal muscle tissue (for calibration of the multiplex immunofluorescence assay) was 
acquired with prior informed consent from the distal part of the hamstring of people undergoing 
anterior cruciate ligament (ACL) surgery. Approval for this was given by Newcastle biobank (NAHPB 
reference: 042), as described in Section 3.2.3. 
4.3.2 Multiplex immunofluorescence for quantification of skeletal muscle 
mitochondrial complex I and IV activity and mitochondrial mass  
10µm cryosections were subjected to multiplex immunofluorescence staining for the quantification 
of mitochondrial CI and CIV activity as well as mitochondrial mass in skeletal muscle, as described in 
Section 3.4.2. 
4.3.3 Image acquisition and analysis of mitochondrial complex I and IV activity and 
mitochondrial mass  
Fluorescent images were acquired using a Zeiss Axio Imager M1 and Zen 2011 (blue edition) 
software with a Monochrome Digital Camera (AxioCam MRm) at 20x magnification, as described in 
Section 3.4.4. The ‘intermediate –’, ‘intermediate +’ groups were pulled together to create a 
‘intermediate’ group (-3 > z > -6). 
4.3.4 Succinate dehydrogenase histochemistry 
Prior to laser capture microdissection of individual myofibres, 15µm cryosections were subjected to 




4.3.5 Laser capture microdissection of individual myofibres  
Laser capture microdissection of tissue of interest was undertaken in order to acquire tissue for 
downstream qPCR analysis. Serial 15µm cryo-sections were cut onto membrane slides (as described 
in Section 3.4.1) from the skeletal muscle biopsies of interest and before SDH histochemistry (as 
described in Section 3.5.4 and above). CI positive, intermediate and deficient myofibres from 
patients in both the ‘contemporary’ and ‘historical’ groups were laser microdissected as described in 
Section 3.6.2 and captured into 15µm lysis buffer, as described in Section 3.6.1.  
4.3.6 Quantitative PCR for the detection and quantification of mtDNA mutations  
A duplex quantitative real-time PCR assay targeting the mitochondrial genes MT-ND1 and MT-ND4 
was used to detect and quantify deletions in the mitochondrial genome, as described in Section 
3.7.5. By assuming that MT-ND1 was not deleted through mutations I was also able to calculate 
mtDNA copy number. Details of all primers and standards used, as well as their preparation, are 
described in Section 3.7. 
4.3.7 Phosphorus magnetic resonance spectroscopy (31P-MRS) 
31P-MRS analysis was performed by Dr Brendan Payne (Newcastle University) in a previous study 
(Payne et al., 2014) in order to quantify skeletal muscle oxidative potential in vivo in response to 
short bouts of exercise, as described in Section 3.8.  
4.3.8 Statistical analyses  
Statistical tests were performed in Prism v5.04 and IBM SPSS Statistics v23. Graphs were also made 
in Prism v5.04.  
Shapiro-Wilk tests were performed in order to determine normality of data sets. The percentage of 
myofibres classified as either deficient, intermediate, or positive for both CI and CIV was quantified 
and subsequently log-transformed in order to normalise the data. The average VDAC1 z-score for 
each subject was also quantified, although not log-transformed. Differences in the proportion of 
myofibres with CI and CIV deficiency was compared between NRTI patient groups using a one-way 
ANOVA with Tukey’s multiple comparison post hoc test to compare differences between groups. In 
addition, unpaired t tests were used to determine differences in proportional CI and CIV deficiency 
between PI and NNRTI groups. Fisher’s exact test was used to determine differences between the 
prevalence of current PI and NNRTI treatment between the two ART-treated groups. Finally, chi-
squared test was performed in order to determine if there was significant differences in sex between 
the treatment groups.  
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Unadjusted linear regression analysis between CI deficiency and clinical as well as HIV-related factors 
was done using Pearson’s correlation analyses in order to assess the relationship between 
mitochondrial dysfunction in the form of CI deficiency and the respective factors. Multivariate linear 
regression analysis was also undertaken, with models including factors determined to be significant 
from univariate analysis as independent variables and CI deficiency as the dependant variable. 
Unstandardised regression coefficients and their significance were reported, as well as the fit of the 
models and how much variance (adjusted r2) they accounted for. 
Statistical significance was set at p ≤ 0.05. 
mtDNA deletions in individual myofibres were determined by the ratio of MT-ND1 to MT-ND4 
relative to a calibrator sample (δδCt method). We screened for mtDNA depletion in individual cells by 
considering the calculated starting quantity (SQ) of mtDNA relative to the 5th centile of SQ in CI-




4.4 Results  
4.4.1 Cohort clinical characteristics  
The full clinical characteristics of the subjects (n = 67) are described in Table 3.1 in Section 3.2.3. All 
subjects were HIV+ and the mean age of the cohort was 53.1 (range 23-85) years. 13% were female 
and 92.5% of participants were white British (Table 4.1). Subjects were derived from both the 
MAGMA and SMMFA study cohorts.  
The subjects were divided into three groups depending on the form of ART they have been exposed 
to. Subjects in the ‘naïve’ group (n = 13) had no previous exposure to any form of ART, while subjects 
in the ‘contemporary’ group (n = 29) had only been exposed to those NRTIs which are currently in 
common use in the UK (abacavir (ABC), lamivudine (3TC), emtricitabine (FTC) and tenofovir 
disoproxil fumarate (TDF)), and subjects in the ‘historical’ group (n = 25) were currently being 
treated with these contemporary ARVs, but had previous exposure to those older NRTIs which are 
generally considered as being mitochondrially-toxic (zidovudine (AZT), zalcitabine (ddC), didanosine 
(ddI) and stavudine (d4T)).  
The mean age of the naïve group was 36.8 years (range 23-53), contemporary group was 54.5 years 
(range 25-71) and historical group 60 years (45-85). As expected, patients in the historical group had 
a higher mean duration on ART compared to the contemporary group. In addition, patients in the 
historical group also had a significantly higher duration since diagnosis and duration with untreated 
HIV infection compared to the naïve and contemporary groups. The vast majority of individuals in 
the two ART treated groups had suppressed plasma HIV viral load (<200 copies/mL). In the untreated 











 Naïve (n = 13) Contemporary (n = 29) Historical (n = 25) P 
Age+ 38.6 (23-53) 54.5 (25-71) 60.0 (45-85) <0.0001 
Female sex^ 5 (38%) 1 (3%) 3 (12%) 0.009 
Months since 
diagnosis* 
74 (58) 142 (96) 225 (80) <0.0001 
Months on ART* 0 71 (47) 168 (57) <0.0001 
Months untreated* 74 (58) 73 (82) 57 (80) 0.72 
CD4 count (copies/µl)* 635 (431) 616 (223) 618 (213) 0.98 
Nadir CD4 (copies/µl)* 415 (228) 221 (111) 162 (112) <0.0001 
Viral load (copies/ml)* 11533 (13607) 71 (89) 37 (20) <0.0001 
Current treatment 
with PIs^ 
0 9 (31%) 7 (24%) 0.98 
Current treatment 
with NNRTIs^ 
0 14 (48%) 15 (60%) 0.42 
 
Table 4.1 – Cohort clinical and HIV-related characteristics. + = values are given as the mean (with range). * = values are 
given as the mean (± SD). ^ = nominal value (%). P values calculated by one-way ANOVA, or chi-squared for nominal values. 
Differences in the prevalence of current treatment with PIs and NNRTIs was determined by Fisher’s exact test between the 









4.4.2 Mitochondrial respiratory chain complex I and IV dysfunction in ART-treated 
PLWH 
Previous studies using COX/SDH histochemistry have demonstrated possible persistent 
mitochondrial defects in skeletal muscle of PLWH who have been treated with older, supposedly 
mitochondrially-toxic NRTIs (Payne et al., 2011). To further investigate whether these NRTIs produce 
a legacy effect whereby skeletal muscle mitochondrial dysfunction, underpinned by clonally 
expanded mtDNA deletions, persists even after the cessation of treatment with those NRTIs, I 
subjected skeletal muscle sections (10µm) to a multiplex immunofluorescence assay (Figure 4.1a). 
As well as being more objective and quantitative than COX/SDH histochemistry, this validated assay 
has the advantage of simultaneously quantifying CI protein levels and mitochondrial mass in addition 
to CIV protein levels. 
A mean of 1229 myofibres were examined per subject. Initially, I compared the proportions of CI and 
CIV deficient myofibres between ART treatment groups. The data was skewed and so subsequently 
log-transformed in order to normalise the data. The proportion of myofibres with CI deficiency was 
significantly different between the three groups (p = 0.017, one-way ANOVA) (Figure 4.1c), with 
both the historical (p = 0.0061, Tukey’s multiple comparisons) and contemporary (p = 0.046) groups 
having a significantly higher proportion than the naïve group. Whilst there was no significant 
difference in the proportion of myofibres with CIV deficiency across the three groups (p = 0.12 one-
way ANOVA), patients in the contemporary group had a significantly higher proportion of CIV 
deficiency compared to the naïve group (p = 0.025, Tukey’s multiple comparisons) (Figure 4.1d).  
Next, I assessed mitochondrial mass by VDAC1 staining intensity in individual myofibres. Here, there 
was no significant difference in the average myofibre mitochondrial mass between the three groups 






Figure 4.1 – Skeletal muscle mitochondrial function in various NRTI regimens. (A) Example of multiplex 
immunofluorescence for CI (NDUFB8), CIV (MTCO1), mitochondrial mass (VDAC1) and laminin in ART-naïve, contemporary 
NRTI, and historical NRTI-treated PLWH. The bright red fibre (arrow in the overlay channel) is deficient in CI and CIV but 
shows VDAC1 hyperintensity, indicating compensatory mitochondrial proliferation. Scale bar = 100µm. (B) Dot plots 
depicting the fibre z-scores for example plot of quantitative CI (x-axis) and CIV (y-axis) deficiency in a participant exposed to 
historical NRTIs. Each dot represents an individual myofibre plotted by NDUFB8 and MTCO1 z-score. Dots are coloured 
according to mitochondrial mass: cream (‘normal’), orange (‘high’) and red (‘very high’). Dotted lines indicate the cut off 
points of -1.5SD, -3SD, -4.5SD and -6SD. Each dot represents an individual fibre. (C-E) Proportional levels of (C) CI-deficient, 
and (D) CIV-deficient myofibres by ART exposure group (mean ± SEM). Each dot represents an individual subject and is 
plotted by the (log10) proportion of myofibres with the respective mitochondrial defects. (E) Mitochondrial mass (expressed 
as mean VDAC1 z-score) (mean ± SEM). Each dot represents the mean of all fibres examined in an individual subject. 
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Finally, I performed unadjusted linear regression analysis in order to determine whether CI and CIV 
skeletal muscle mitochondrial deficiency was synergistic. I found that CI deficiency was significantly 
associated with CIV deficiency when investigated in all participants (n = 67; r = 0.68; p < 0.0001, 
Pearson’s correlation) (Figure 4.2).  
As the proportion of myofibres with CI defects was higher than those with CIV defects, I focussed 
subsequent analyses on CI deficient myofibres. This finding is also significant as it is the first time 
that CI defects have been shown to be more predominant than CIV defects in skeletal muscle of 




Figure 4.2 – Correlation between CI and CIV skeletal muscle deficiency in PLWH. Dot plot demonstrating the significant 
positive association (r = 0.68; p < 0.0001) between the proportion of CI- and CIV-deficient myofibres in our cohort of PLWH 
(n = 67) (Pearson’s correlation and linear regression for line). Each dot represents an individual subject in either the ART 




4.4.3 Mitochondrial function in PI or NNRTI-treated PLWH 
As previous in vitro studies have demonstrated a potential mitochondrially-toxic effect induced by 
various protease inhibitors (PIs) and non-nucleoside reverse transcriptase inhibitors (NNRTIs), I 
wanted to investigate whether there was evidence of skeletal muscle mitochondrial dysfunction in 
PLWH currently treated with ARVs from either of these classes. 
Here, there was no significant difference in the proportion of myofibres with either CI or CIV 
deficiency (unpaired t test) between PLWH who were treated with PIs (n = 16) and those who were 
treated with an ART regimen that did not include a PI (n = 38) (Figure 4.3a, b). In addition, there was 
also no significant difference in the proportion of myofibres with CI and CIV deficiency between 
PLWH who were treated with NNRTIs (n = 29) and those who were not (n = 25) (Figure 4.3d, e). 
Finally, there was no significant difference in myofibre mitochondrial mass between PI and non-PI-
treated PLWH or NNRTI and non-NNRTI-treated PLWH (Figure 4.3c, f). 
 
 
Figure 4.3 – Skeletal muscle mitochondrial dysfunction in PI and NNRTI-treated PLWH. Dot plots (mean ± SEM) showing 
proportional (A) CI, or (B) CIV deficiency, and (C) average myofibre mitochondrial mass in PLWH who were on PI treatment 
and those who were not. (D) proportional CI, (E) proportional CIV deficiency, and (F) average mitochondrial mass in NNRTI-
treated and non-NNRTI-treated PLWH. Each dot represents an individual patient.    
A B C 
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4.4.4 Comparison of mitochondrial defects in PLWH quantification methods 
COX/SDH histochemistry has long been the gold standard for assessing mitochondrial dysfunction in 
skeletal muscle fibres, through quantification of the percentage of mtDNA-encoded COX deficient 
fibres. It has also been a powerful tool for assessing mitochondrial dysfunction in skeletal muscle 
from PLWH (Payne et al., 2011). Here, I wanted to assess whether the results from multiplex 
immunofluorescence (Section 3.4.2) agreed with COX/SDH histochemistry results. 
Unadjusted linear regression analysis using data from COX/SDH histochemistry (previously 
performed by Dr Brendan Payne, Newcastle University) and multiplex immunofluorescence (Section 
4.4.2), both performed on skeletal muscle serial sections cut from the same SMMFA patient samples 
(n = 37), showed that proportional CI (r = 0.70; p < 0.0001, Pearson’s correlation) and CIV (r = 0.56; p 
= 0.0003) deficiency both had a statistically significant positive correlation with the percentage COX 
defect (Figure 4.4). 
  
 
Figure 4.4 – NDUFB8 and MTCO1 deficiency correlates with COX defect level. The log-transformed proportion of COX 
defect level was significantly associated with the log-transformed proportion of (A) NDUFB8-deficient fibres (r = 0.70; p < 





4.4.5 31P-MRS quantification of skeletal muscle respiratory capacity 
For 17 of the subjects in this study (listed in Table 3.1), data on in vivo mitochondrial function was 
available from 31P-MRS. These measurements had been taken as part of a previous study conducted 
in our lab (Payne et al., 2014), and reanalysed by me. These 17 PLWH included individuals from the 
contemporary NRTI (n = 6) and historical NRTI (n = 11) groups, along with 23 age-matched HIV- 
controls. 31P-MRS data were therefore compared with cellular skeletal muscle mitochondrial defects 
measured by multiplex immunofluorescence.  
There was a statistically significant difference in resting-state ADP/ATP ratio across the three groups 
(p = 0.0015, one-way ANOVA), with both the historical NRTI (p = 0.0077, Tukey’s multiple 
comparison) and contemporary NRTI (p = 0.011, Tukey’s multiple comparison) exposed HIV+ groups 
having a higher resting ADP/ATP ratio than the HIV-uninfected group (Figure 4.5a). There was no 
significant difference between the NRTI exposure groups.  
In order to assess whether higher levels of skeletal muscle mitochondrial dysfunction at the cellular 
level translated to mitochondrial dysfunction at the physiological level, I performed unadjusted 
linear regression analysis between the proportion of CI-deficient myofibres and the resting-state 
ADP/ATP ratio in the paired HIV+ subjects (n = 17). Surprisingly, I found that proportional CI-
deficiency did not significantly predict diminished mitochondrial respiratory capacity in the form of 
ADP/ATP ratio (r = 0.35; p = 0.17, Pearson’s correlation) (Figure 4.5b), suggesting that cellular 
OXPHOS deficiency does not necessarily predict declines in physiological respiratory capacity.   
 
Figure 4.5 – Skeletal muscle mitochondrial respiratory capacity. (A) ADP/ATP ratio in skeletal muscle through 31P-MRS 
analysis. Each dot represents an individual subject in either the contemporary NRTI (n = 6), historical NRTI (n = 11), or HIV-
uninfected control (n = 23) group. Dotted lines indicate the mean. (B) Correlation of proportional CI deficiency in skeletal 
muscle biopsies and ADP/ATP ratio in calf muscle (Pearson’s correlation and linear regression for line). Each dot represents 





4.4.6 Clinical and HIV-related predictors of skeletal muscle mitochondrial dysfunction,  
After demonstrating that mitochondrial dysfunction is present in skeletal muscle fibres from PLWH 
with exposure to contemporary ART, I next assessed whether HIV-related clinical factors or general 
clinical characteristics predicted myofibre mitochondrial CI defects (Table 4.2). These clinical 
parameters included age (Figure 4.6a), current (Figure 4.6b) as well as nadir CD4 count (copies/µl) 
(Figure 4.6c), viral load (copies/ml) (Figure 4.6d), time since HIV diagnosis (Figure 4.6e), duration on 
ART (Figure 4.6f), and duration with untreated HIV infection (Figure 4.6g).  
Through univariate linear regression analysis, I found that duration on ART significantly predicted 
proportional CI deficient myofibres (r = 0.29; p = 0.017, Pearson’s correlation) (Figure 4.6d).  
The association between CI deficiency and age did not quite reach statistical significance (p = 0.056) 
(Pearson’s correlation). Further, as the age of both the historical and contemporary groups was 
higher than the ART-naïve group, I performed linear regression analysis between age and 
proportional CI deficiency within each of the individual groups in order to better understand the 
predictive significance of age on mitochondrial function in ART-treated PLWH. Importantly, age did 
not significantly predict proportional CI deficiency in either the historical (n = 25; r = -0.33; p = 0.11, 
Pearson’s correlation), or contemporary (n = 29; r = 0.25; p = 0.19) ART groups. In addition, age did 
not significantly predict CI deficiency when the two groups were combined (n = 54; r = 0.02; p = 
0.88).  
There was no significant correlation between CD4 count and proportional CI deficiency, suggesting 
that CD4 count is not a reliable predictor of mitochondrial defects in skeletal muscle of the general 
PLWH population. In addition, there was no significant association between proportional CI 
deficiency and age, months since diagnosis, months with untreated HIV infection, nadir CD4 count, 
or viral load.  
As this was an observational study, factors such as age and duration on ART were highly dependent 
of treatment group. This is inevitable, as choices of NRTIs used in ART have changed over time as 
new agents became available. Hence, I then performed multivariate linear regression to see if the 
effect of duration of ART treatment was independent of the effect of age. Here, both variables were 
positively associated with CI deficiency (unstandardised regression coefficients, age = 0.011; 
duration on ART = 0.02) but neither was independently statistically significant (p = 0.24 and p = 0.23 
respectively, multivariate linear regression). Overall model fit was statistically significant (p = 0.04), 




 CI deficiency 
 r p 
Age 0.23 0.056 
CD4 count (copies/µl) -0.012 0.93 
Nadir CD4 count (copies/µl) -0.11 0.43 
Viral load (copies/ml) -0.24 0.061 
Months since diagnosis 0.073 0.56 
Months on ART 0.29 0.017 
Months untreated -0.24 0.051 
 
Table 4.2 – HIV-related clinical predictors of proportional myofibre CI deficiency. Table depicting the unadjusted linear 
regression analysis (Pearson’s correlation) between proportional log10(CI deficiency) and HIV-related clinical parameters. 






                 
Figure 4.6 – Correlations between proportional CI deficiency and clinical parameters. Scatter plots depicting linear 
regression analysis (Pearson’s correlation) between proportional CI deficiency and (A) age, (B) CD4 T cell count (cells/µl), (C) 
nadir CD4 T cell count (cells/µl), (D) viral load (copies/ml), (E) time since HIV diagnosis (months), (F) duration on ART (r = 
0.29; p = 0.0017), and (F) months untreated. Pearson’s correlation and linear regression for the correlation and line. Black 















4.4.7 Molecular basis of skeletal muscle mitochondrial dysfunction in ART-treated 
PLWH 
Finally, to better understand the molecular mechanisms underpinning the skeletal muscle 
mitochondrial dysfunction demonstrated in ART-treated PLWH, I subjected individual myofibres to 
laser capture microdissection (n = 90) and qPCR analyses (described in Section 3.5.5). In particular, 
CI-deficient (n = 24), CI-intermediate (n = 27) and CI-positive (n = 39) myofibres were dissected from 
subjects in both the historical (n = 5) and contemporary (n = 4) groups. 
Initially, I excluded mtDNA depletion as a cause of CI deficiency in myofibres. In keeping with our 
VDAC1 data for mitochondrial mass at the myofibre level, there was no evidence of reduced mtDNA 
content in individual CI deficient fibres (Figure 4.7).  
 
 
Figure 4.7 – mtDNA copy number in individual myofibres. Dot plot demonstrating no significant levels of mtDNA depletion 
in individual CI-deficient (n = 24, blue), CI-intermediate (n = 27, orange) and CI-positive (n = 39, green) myofibres from PLWH 
exposed to only contemporary NRTIs (circle) or contemporary NRTIs but previously historical NRTIs (square). Dots are 
plotted by MT-ND1 and MT-ND4 copy number (Ct). Dotted line indicates the mean MT-ND1 and MT-ND4 copy number of 




MT-ND1 lies on the minor arc of the mitochondrial genome and so is rarely deleted in large-scale 
mtDNA deletions. I therefore used MT-ND1 copy number as a measure of whole mtDNA copy 
number using the standard curve method and compared MT-ND1 and MT-ND4 copy number to 
determine the presence of mtDNA deletions.  
Published data in the HIV and ageing field has previously demonstrated the presence of large-scale 
mtDNA deletions in skeletal muscle from PLWH (Payne et al., 2011). Here, by quantifying the copy 
number of the two mitochondrially-encoded genes MT-ND1 and MT-ND4, expressed relative to a 
control, I found that 64% of CI-deficient myofibres contained large-scale mtDNA deletions. In 
addition, 22% of CI-intermediate fibres had mtDNA deletions as well as 8% of CI-positive fibres 
(Figure 4.8a).  
Interestingly, mtDNA deletions in the minor arc (MT-ND1) of the mitochondrial genome were 
present in all three groups of myofibres, albeit at a significantly less prevalent frequency than major 
arc deletions (MT-ND4). Briefly, 79% of deletions in CI-deficient fibres were in the major arc, while 
21% were in the minor arc. 67% of deletions in both CI-intermediate and CI-positive fibres were in 
the major arc while 33% were in the minor arc. Interestingly, I found that there was a significant 
difference in the mtDNA deletion heteroplasmy (as measured by ddCt) across the three groups of 
fibres (p < 0.0001, one-way ANOVA) (Figure 4.8a), with mtDNA deletion heteroplasmy in CI-deficient 
fibres being significantly greater than mtDNA deletion heteroplasmy seen in both the CI-
intermediate (p = 0.0089, Tukey’s multiple comparison), and CI-positive fibres (p , 0.0001, Tukey’s 
multiple comparison). Further studies should look to map the exact locations and sizes of the 
mtDNA deletions.  
I next wanted to assess whether there were any differences in the patterns of mtDNA deletions 
occurring in CI-deficient and CI-intermediate myofibres isolated from PLWH in the historical (n = 45) 
and contemporary (n = 45) ART treatment groups. I subsequently found that there was no significant 
difference in the pattern of mtDNA deletion locations (unpaired t test) (Figure 4.8b). This suggests 
that the type of ARV or exposure to a particular NRTI has no discernible implication with regards to 






           
Figure 4.8 – mtDNA deletions detected by qPCR in single myofibres. (A) Distribution of mtDNA deletion levels in CI-
deficient (n = 24), CI-intermediate (n = 27) and CI-positive (n = 39) single myofibres. Lightly shaded dots represent myofibres 
from historical NRTI-treated PLWH and darkly shaded dots represent fibres form contemporary NRTI-treated PLWH. (B) 
Distribution of mtDNA deletions in all fibres from PLWH exposed to historical NRTIs (n = 45) and contemporary NRTIs (n = 
45). For both (A) and (B) each dot represents an individual myofibre and deletion sizes are expressed as δδCt (difference in 
MT-ND1 and MT-ND4 Ct values relative to control). Myofibres with a δδCt above 2 standard deviations (thin dotted line) 
from the control were classified as having minor arc deletions, and myofibres with a δδCt below 2 standard deviations (thin 







Whilst early clinical reports and subsequent cohort studies have demonstrated a mitochondrially-
toxic effect of various NRTIs used in the monotherapy era of ART (Dalakas et al., 1990; Arnaudo et 
al., 1991), few studies have investigated whether newer NRTIs developed to overcome the toxic 
profile of these NRTIs similarly induce mitochondrial dysfunction, particularly in skeletal muscle. This 
is primarily due to the fact that clinical trials and in vitro studies demonstrated that these newer 
NRTIs have a low PolG-binding affinity and few clinical reports of associated toxicities have surfaced 
(Venter et al., 2019; Venhoff et al., 2007). With regards to the growing interest in adverse ageing in 
older PLWH and the strong association between mitochondrial dysfunction and ageing (Lopez-Otin 
et al., 2013), this study sought to better characterise mitochondrial function in a functionally 
relevant tissue in PLWH in the contemporary ART era. These included PLWH who have never been 
on ART, PLWH who have been exposed to older, mitochondrially-toxic NRTIs but are now on ‘safer’ 
NRTIs, and PLWH who have only ever been exposed to the NRTIs that remain in contemporary use.  
4.5.1.1 ART-treated PLWH have greater cellular, molecular and physiological mitochondrial 
dysfunction than ART-naive PLWH 
This is the first study to demonstrate a defect of cellular mitochondrial function in skeletal muscle of 
PLWH who have only ever been exposed to contemporary ART regimens, despite the perception 
that contemporary NRTIs are free from mitochondrial toxicity (Venhoff et al., 2007). This statement 
is supported by both cellular and molecular findings from skeletal muscle tissue biopsies, as well as 
in vivo functional evidence from 31P-MRS.  
I demonstrate that PLWH who have been exposed to only contemporary NRTIs as well as PLWH who 
are currently on contemporary NRTIs but have previously been exposed to older NRTIs both 
displayed a significantly higher proportion of myofibres with CI deficiency compared to ART-naïve 
PLWH. PLWH who have been exposed to contemporary NRTIs also had a significantly higher 
proportion of myofibres with CIV deficiency compared to ART-naïve PLWH. In addition, there was no 
significant difference in proportional CI or CIV deficiency between age-matched patients in the 
historical or contemporary groups, suggesting that the levels of CI and CIV deficiency are similar in 
both ART-treated groups. Finally, as none of the HIV-related or clinical parameters significantly 
predicted greater CI deficiency through adjusted multivariate linear regression analyses, these 
findings indicate that ARVs themselves play a significant role in mitochondrial dysfunction (Dalakas 
et al., 1990, Arnaudo et al., 1991; Payne et al., 2011; Lim et al., 2001).   
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Another aim of this study was to better understand the molecular mechanisms underpinning 
mitochondrial dysfunction at the cellular level. qPCR analysis demonstrated the presence of large-
scale mtDNA deletions, primarily in the major arc portion of the mtDNA genome, in the majority of 
CI-deficient myofibres. This supports previous data which demonstrated mtDNA deletions in skeletal 
muscle fibres with mitochondrial dysfunction, as determined by COX/SDH histochemistry, in ART-
treated PLWH (Payne et al., 2011). mtDNA deletions were also found in the minor arc of the 
mitochondrial genome. As these findings have not previously been described in skeletal muscle from 
ART-treated PLWH, this merits future research. 
qPCR analysis also failed to identify alterations in mtDNA content. This finding is supported by 
immunofluorescence analysis whereby no increase or decline in average myofibre mitochondrial 
mass was observed. Together, these findings suggest the absence of a compensatory upregulation in 
mitochondrial mass in response to OXPHOS defects.   
Additionally, through 31P-MRS analysis previously performed by Dr Brendan Payne on subjects 
included in the SMMFA cohort (Payne et al., 2014) and further analysed by me, it was demonstrated 
that contemporary and historical NRTI-treated PLWH had a significantly diminished resting-state 
ADP/ATP level when compared to age-matched HIV- individuals. This observation provides an 
important validation of our cellular and molecular findings, as well as pointing to a possible non-
invasive read-out for future studies. However, ADP/ATP ratio was not significantly predicted by 
proportional CI deficiency. This is most likely due to the small number of subjects with paired 31P-
MRS measurements, thereby limiting the power to detect an association with CI deficiency. These 
findings support previous observations of decreased phosphocreatine concentrations in skeletal 
muscle from AZT-treated PLWH (Sinwell et al., 1995).  
4.5.1.2 Potential causes of mitochondrial dysfunction in ART-treated PLWH 
These novel findings raise a number of mechanistic questions. In both the historical and 
contemporary NRTI exposure groups I observed that the mitochondrial ETC complex defects seen in 
individual myofibres were predominantly explained by mtDNA deletions. This is surprising as most in 
vitro data suggest that contemporary NRTIs have a low PolG-binding affinity (Venhoff et al., 2007) 
and do not inhibit mtDNA replication (Birkus et al., 2002). Nevertheless, it is conceivable that very 
prolonged exposure to a contemporary NRTI in vivo, and/or cell-type specific effect could be 
sufficient to promote mtDNA deletions, potentially via chronic oxidative stress. These mtDNA 
deletions would subsequently clonally expand after an extended period of time, even after cessation 
of treatment (Payne et al., 2011). For example, work from our group has recently demonstrated the 
presence of mtDNA deletions in the renal tract in the setting of TDF exposure (Samuels et al., 2017).  
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Another possibility is that other ART classes such as protease inhibitors (PIs) or non-nucleoside 
reverse transcriptase inhibitors (NNRTIs) might contribute to mitochondrial dysfunction in 
contemporary cART treatment. For example, limited in vitro data suggests that the NNRTI efavirenz 
may impair mitochondrial function (Funes et al., 2014). I therefore stratified PLWH in both the 
contemporary and historical NRTI groups into whether they were on an ART regimen that included a 
PI or NNRTI, but subsequently found no difference in skeletal muscle CI or CIV deficiency. In addition, 
there was no difference in average myofibre mitochondrial mass. Additionally, it is possible that 
long-term treated HIV infection itself might be having a detrimental effect on mitochondrial 
function. However, the lack of any mitochondrial defects in the ART-naïve group argues against this 
being a major effect.  
Finally, as mitochondrial dysfunction is known to increase with age (Barazzoni et al., 2000; Welle et 
al., 2003; Short et al., 2005; Lopez-Otin et al., 2013), another hypothesis could be that the skeletal 
muscle mitochondrial defects seen in the ART-treated groups could be due to increased age and age-
related effects such as chronic inflammation, immunosenescence, and oxidative stress, which could 
be propagating the formation of mtDNA mutations, among other damaging effects (Melov et al., 
1999; Zorov et al., 2014; Rao et al., 2014; Massaad & Klann, 2011). Indeed, CI defects have been 
reported in different tissues from Parkinson’s Disease patients (Franco-Iborra et al., 2016; Kraytsberg 
et al., 2006; Balaban et al., 2005). However, adjusted linear regression analysis demonstrated that 
the mitochondrial defects were not explained by age itself. It would therefore be interesting to 
investigate the effect of these other age-related factors such as chronic inflammation or 
immunosenescence.  
4.5.1.3 Is there a legacy effect in PLWH treated with historical NRTIs? 
The final objective of this study was to assess whether there is a ‘legacy effect’ induced by exposure 
to older NRTIs. Although this theory needs to be tested in a larger, ideally longitudinal cohort of 
PLWH and HIV- individuals, this study suggests against the presence of a legacy effect. This is due to 
the fact that PLWH in the historical NRTI group did not have an excess of cellular mitochondrial 
defects compared to age-matched PLWH in the contemporary group. In addition, isolated CI-
deficient myofibres from patients in both groups were seen to have a similar prevalence and pattern 
of mtDNA deletions underpinning the cellular defects. However, the levels of ART-induced 
mitochondrial dysfunction can vary between tissue types, and so whilst these findings suggest 
against a legacy effect in skeletal muscle, this may not be the case in other relevant tissue such as 
the liver or PBMCs.  
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4.5.1.4 Significance of predominant CI deficiency  
An important strength of this study was that I employed techniques that can objectively quantify 
mitochondrial deficiency with single-fibre resolution. Given the stochastic nature of somatic 
(acquired) mtDNA defects within postmitotic tissues such as skeletal muscle, studies of homogenised 
tissue may miss these defects (Murphy et al., 2012). As opposed to the current gold-standard in 
histologically detecting cellular mitochondrial defects, sequential COX/SDH histochemistry, our assay 
allows for the objective quantification of CI defects and mitochondrial mass, as well as CIV defects. 
This is a significant advantage as genes encoding CI subunits form the greatest proportion of the 
mtDNA genome and are therefore the most commonly deleted genes in the event of large-scale 
mtDNA deletions. Our observation that CI defects, as opposed to CIV defects, predominate in 
skeletal muscle of PLWH could be of potential therapeutic relevance. Interestingly, CI deficiency is 
the most commonly observed biochemical defect in child-onset mitochondrial disease (Fassone & 
Rahman, 2012), and can result in a range of clinical phenotypes, such as leigh syndrome, lactic 
acidosis, hypertrophic cardiomyopathy and significantly, myopathy (Distelmaier et al., 2009). 
Unfortunately though, treatment strategies for isolated CI deficiency in mitochondrial disease are 
limited due to poor understanding of the underlying pathophysiology, and are therefore restricted 
to symptomatic treatment (Rodenburg, 2016). However, limited in vitro data demonstrate that 
targeting ROS production may alleviate some of the detrimental consequences of CI deficiency, such 
as mitochondrial membrane (ΨΔ) depolarisation (Distelmaier et al., 2009). In addition, the 
hypothesis that impaired calcium homeostasis as the result of CI deficiency is a significant 
pathophysiological mechanism underpinning CI-related pathology is being explored (Rodenburg, 




4.5.2 Summary of experimental findings  
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• Not investigated  • PLWH currently treated with a PI had no 
difference in proportional CI or CIV 
deficiency compared to ART-treated PLWH 
not currently treated with a PI 










• Not investigated • PLWH currently treated with a NNRTI had 
no difference in proportional CI or CIV 
deficiency compared to ART-treated PLWH 
not currently treated with a NNRTI 










The work presented in this chapter demonstrates an array of novel findings and a convincing 
hypothesis that ART leads to an accelerated onset of skeletal muscle mitochondrial defects in ART-
treated PLWH compared to ART-naïve PLWH. However, as mentioned previously, there were a 
number of limitations to our study.  
Our study was limited to only 67 subjects who participated in only one study visit. Although this 
sample size provided enough materials and data in order to demonstrate novel findings, it does limit 
the scope of investigations. A larger, longitudinal study group recruited based on exposure to 
particular combinations of ARVs (e.g. two NRTIs + PI vs two NRTIs + NNRTI, or subdividing the 
contemporary group into patients with and without exposure to tenofovir disoproxil fumarate (TDF), 
or subdividing the historical group into patients with and without exposure to zidovudine (AZT)) 
would give us greater power to detect differences in mitochondrial defects over a period of time.  
As both age and NRTI exposure type are difficult to control due to the strong correlation between 
these factors, studies like those mentioned above would also allow us to better understand the exact 
effects of particular NRTIs in vivo (Venhoff et al., 2007). Indeed, the limitation regarding being 
unable to extract the specific effects of factors such as age from individual groups promoted the 
recruitment of the MAGMA study, discussed in the following chapters, whereby older age-matched 
HIV+ and HIV-uninfected males were recruited in an observational study. 
As mentioned above, the significantly lower age of the ART-naïve group compared to both ART-
treated groups is a limitation. However, as the majority of ART-naive PLWH are younger, this would 
be very difficult to control. Indeed, a major strength of this study is that it included an ART-naïve 
comparator group, due to the fact that the majority of newly-diagnosed PLWH begin ART soon after 
diagnosis and so ART-naive individuals are difficult to recruit.  
Of particular note, the 31P-MRS study was limited by the fact that not enough ART-naïve PLWH 
participated, and although contemporary ART and historical ART-treated PLWH participated, 
numbers were low.  
Whilst the multiplex immunofluorescence assay that was used to quantify mitochondrial protein 
levels in individual skeletal muscle fibres has many advantages over other assays such as COX/SDH 
histochemistry, it too has some disadvantages. Primarily, as the assay measures protein levels of 
subunits of the ETC complexes I and IV, it cannot measure the actual activity of the electron 
transport chain, which is instead inferred by antibody level. The qPCR analysis is also limited by 
issues in detecting very small mtDNA deletions. 
163 
 
4.5.4 Future work 
As mentioned above, this study was limited by the size of the patient cohort and that fact that it was 
an observational study. Future work should look to perform these analyses on a larger group of 
PLWH and ideally at numerous time points (perhaps every 2-5 years).  
Another potential aspect of future work should be to investigate the power of individual NRTIs to 
induce mitochondrial dysfunction through mtDNA deletion mutation formation. In the current study 
I have demonstrated the presence of defects in oxidative phosphorylation in skeletal muscle fibres 
from PLWH exposed to both historical and contemporary NRTIs, predominantly underpinned by 
mtDNA deletions. It is impossible to extract the effects of individual NRTIs from our cohort, and so in 
vitro assessments using fibroblasts, myofibre-derived cell lines or induced pluripotent stem cells 
treated with individual NRTIs, as well as combinations of NRTIs over various periods of time, should 
be performed. In addition, some previous studies have performed similar investigations, but none 
have looked specifically at the effect of various ARVs on myofibre-derived cell lines. Another 
alternative would be to perform similar work to that mentioned previously but in mouse models 
treated with various ARVs.  
In order to further investigate the cellular and molecular mechanisms underpinning skeletal muscle 
fibre mitochondrial defects, future studies should look to directly quantify and map the size and 
locations of mtDNA deletions. This could potentially be performed through long-range PCR or 
southern blot studies or if available, next-generation sequencing analysis (Taylor et al., 2014). As the 
mitochondrial defects were not explained by mtDNA depletions via the PolG hypothesis, future work 
should look to explore the viability of other mechanisms of mitochondrial dysfunction and induction 
of mtDNA mutations. One potential aspect could be to investigate the frequency of oxidatively 
damaged macromolecules, either histochemically or through molecular assessments (Liang et al., 
2018). 
Finally, as it was difficult to extract the specific effects of factors such as age and HIV-related 
parameters on skeletal muscle mitochondrial dysfunction, further work was undertaken on the 





Chapter 5 – Ageing phenotypes in older PLWH 
5.1 Introduction 
Due to the success of antiretroviral therapy (ART), the average age of the HIV+ population in 
developed countries is increasing, with the proportion of PLWH over the age of 50 expected to be an 
estimated 73% by 2030 (Centres for Disease Control and Prevention, 2013; Smit et al., 2015).  
In combination with the fact that virally-supressed PLWH appear to have an excess of risk factors for 
adverse ageing (Brothers et al., 2017; Onen et al., 2014; Desquilbet et al., 2007) and chronic 
conditions such as elevated chronic inflammation (Deeks, 2011; Justice et al., 2012; Erlandson et al., 
2013; Erlandson et al., 2017a; Leng et al., 2011; Margolick et al., 2013; Onen et al., 2014), this 
population of ageing PLWH appear to be undergoing accelerated ageing (Pathai et al., 2014). A result 
of this phenomenon is that the HIV+ population exhibit declining physical function and a higher 
prevalence of adverse ageing phenotypes such as frailty and sarcopenia (Guaraldi et al., 2011; Kooij 
et al., 2016; Desquilbet et al., 2007; Desquilbet et al., 2009; Brothers et al., 2017; Echeverria et al., 
2018; Pinto Neto et al., 2016; Wasserman et al., 2014; Oliveira et al., 2020). This may have serious 
adverse implications for both the healthcare system and PLWH themselves (Kim et al., 2019; Smit et 
al., 2015).  
As such, a better understanding of the risk factors and causes underpinning this biological 
phenomenon are needed in order to develop optimal intervention and preventative strategies for 
PLWH with adverse ageing phenotypes.  
As a result, the MAGMA study was set up with the aim of developing pathologically-defined 
subgroups for stratified interventional trials. This study includes 45 males over the age of 50, both 
HIV+ and HIV-uninfected, and sought to better understand the underlying pathophysiological 
mechanisms behind accelerated ageing in PLWH, with a special interest in the role of age-related 
mitochondrial dysfunction.  
In this chapter, I quantified physical function as well as the prevalence of frailty and sarcopenia in 
older (≥ 50 years) PLWH and age-matched HIV- individuals using a range of clinically-validated 
assessments, and sought to identify potential links with both clinical parameters and body 




5.2 Experimental aims 
The significant medical, functional, and socioeconomic consequences of adverse ageing phenotypes 
such as frailty in HIV-infected individuals (Kim et al., 2019; Smit et al., 2015) means that a better 
understanding of the causes and consequences of these conditions in PLWH is imperative.  
By utilising an array of clinical assessments that measure physical functional capabilities, as well as 
assessments of frailty, sarcopenia and body composition, in addition to data obtained from health 
records detailing general and HIV-related clinical data, in this study I sought to: 
• Quantify the prevalence of frailty and sarcopenia in older PLWH and age-matched HIV- 
individuals.  
• Determine whether any HIV-related or general clinical parameters are predictive of 
reduced physical function and adverse ageing phenotypes in older PLWH. 
• Determine whether body composition changes and physical activity levels are predictive 




5.3.1 Patient cohort and ethical guidelines  
This study was approved by the research ethics committee (Newcastle and North Tyneside 2 (17-NE-
0015)), as detailed in Section 3.1.  
30 HIV+ and 15 HIV- males were recruited as part of the MAGMA study, with patients giving prior 
written permission. All patients were 50 years or older and therefore classed as ‘older’. Full inclusion 
criteria and study visit details are described in Section 3.2.1 and Section 3.3. 
5.3.2 Clinical interview  
In order to assess clinical parameters and undertake physical performance assessments, all 
participants (n = 45), recruited in both Newcastle (n = 37) and London (n = 8), were asked to 
complete a health questionnaire during the sole study visit, as described in Section 3.3.1 (further 
described in Appendix 2).  
5.3.2 Determination of frailty 
A frailty phenotype was assessed as previously described using a modified five FFP criteria (Onen et 
al., 2009), as described in Section 3.3.2.  
5.3.3 Short Physical Performance Battery (SPPB) assessment 
Assessment of physical function was done through a short physical performance battery (SPPB) test, 
as described in Section 3.3.3. 
5.3.4 MET score  
Metabolic equivalent (MET) expenditure per week was calculated as a surrogate for physical activity 
assessment. Criteria and cut-offs are described in Section 3.3.4.  
5.3.5 Classification of sarcopenia  
According to the EWGSOP, sarcopenia can be classified in the clinical and research setting based on 
analyses of muscle mass, muscle strength, and physical performance (Cruz-Jentoft et al. 2019), as 
described in Section 3.3.5. 
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5.3.6 Statistical analysis  
Statistical analysis was performed in Prism v5.04, IBM SPSS Statistics v23 and Microsoft Excel 2016. 
Graphs were produced in Prism v5.04.  
Normality was assessed through Shapiro-Wilk tests. Statistical differences between the HIV+ and 
HIV- individuals were determined by Fisher’s exact test for nominal data and unpaired t tests for 
ordinal data. One-way ANOVA was performed to assess differences between factors with three or 
more variables, such as smoker category or SPPB category.  
Unadjusted linear regression analysis between clinical factors, body composition factors and HIV-
related factors was performed using Pearson’s correlation for normally distributed data, or 
Spearman correlation for non-normally distributed data. Multivariate linear regression analysis with 
adjustment for age was also conducted, with models described in more detail in the relevant 
sections. As outcomes of multivariate linear regression analysis, unstandardised regression 
coefficients and their statistical significance were reported, as well as the fit of the models and how 
much variance (adjusted r2) they accounted for.  
Initially, differences in the various clinical, HIV-related, and body composition parameters between 
frail, prefrail, and robust, as well as sarcopenic, presarcopenic, and non-sarcopenic PLWH was 
determined through one-way ANOVA analysis. However, as the size of some groups was small, the 
prefrail HIV+ group was combined with the frail HIV+ group to create the frail/prefrail HIV+ group 
and the presarcopenia HIV+ group was combined with the sarcopenia HV+ group to form the 
sarcopenic/presarcopenic HIV+ group, as done in a recent study (Kooij et al., 2016). Differences 
between the frail/prefrail and robust groups, as well as the sarcopenic/presarcopenic and non-
sarcopenic groups were determined by unpaired t tests for normally-distributed data and Mann-




5.4 Results  
5.4.1 MAGMA study cohort characteristics 
Table 5.1 summarises the general clinical characteristics of both the HIV+ (n = 30) and HIV- (n = 15) 
groups. The median age of the HIV+ group was 58 (range 50-85) compared to 59 (range 50-70) years 
in the HIV- group, confirming excellent age-matching, as expected from the study design.  
As described in Table 5.2, individuals in the HIV+ group were virally-supressed and had good 
immune function. 11 (37%) individuals had previously been exposed to older, supposedly 
mitochondrially-toxic NRTIs (stavudine (d4T), didanosine (ddI), zalcitabine (ddC), zidovudine (AZT)). 9 
(30%) were being treated with protease inhibitors (PI), and 11 (37%) were being treated with non-
nucleoside reverse transcriptase inhibitors (NNRTI) at time of study visit.  
Aside from waist circumference (p = 0.0043) and BMI (p = 0.0003) (unpaired t test) (Figure 5.1b, c), 
the HIV+ and HIV- groups were well matched for body composition factors as well as prevalence of 




 HIV+ (n = 30) HIV- (n = 15) p  
Age (years) 58 (54-65) 59 (52-69) 0.99 
Race (white) 30 (100%) 13 (87%) 0.11 
Alcohol consumption (current) 16 (53%) 13 (87%) 0.046 
Tobacco use:   0.14 
Current 11 (37%) 2 (13%)  
Former 11 (37%) 5 (33%)  
Never 8 (27%) 8 (53%)  









HBV or HCV infection 5 (17%) 2 (13%) 0.98 
Diabetes mellitus (Type 2) 3 (10%) 3 (20%) 0.38 
Chronic kidney disease 3 (10%) 0 (0%) 0.54 
Number of Comorbidities* 1.2 (1.1) 1.1 (0.8) 0.67 
Number of medications* 3.7 (3.0) 2.5 (2.1) 0.18 
Polypharmacy 18 (60%)  7 (47%) 0.53 
BMI (kg/m2)* 
Body composition: 
27.2 (3.3) 32.8 (6.3) 0.0003 
Waist circumference (cm)* 97 (9.9) 108 (14.3) 0.0043 
% Fat mass+ 30 (7.8) 34 (7.9) 0.15 
% Muscle mass+ 70 (7.8) 66 (7.9) 0.15 
Table 5.1 – Clinical characteristics. Nominal data expressed as the number (%). Ordinal data expressed as the median (± 
interquartile range). * Expressed as mean (SD). + = Missing information from two HIV- patients who were unable to 
undertake a DXA scan. P values were determined by Fisher’s exact test for nominal data, unpaired t test for ordinal data, 




 HIV+ (n = 30) 
CD4 count (copies/µl) 656 (231) 
Nadir CD4 count (copies/µl) 72 (86) 
Viral load (copies/ml) 66 (91) 
Historical NRTI exposure (AZT, ddI, d4T, ddC) 11 (37%) 
PI treated 9 (30%) 
NNRTI treated 11 (37%) 
Months since diagnosis 200 (105) 
Months on ART 118 (69) 
Months untreated 86 (89) 






Figure 5.1 – Clinical characteristics by HIV status. Dot plot graphs (mean ± SEM) depicting the differences between the 
HIV+ and HIV- groups with regard to (A) age, (B) waist circumference (cm) (p = 0.0043, unpaired t test), (C) BMI (kg/m2) (p = 
0.0003), (D) percentage fat mass, and (E) percentage lean mass. Each dot represents an individual subject. 
  




5.4.2 Physical performance capabilities, frailty, and sarcopenia in older HIV+ and HIV- 
individuals  
4 (13%) individuals from the HIV+ group (n = 30) were classified as frail according to the modified 
FFP assessment, while 15 (50%) were classified as prefrail. None of the HIV- group (n = 15) were 
classified as frail and 7 (53%) HIV- individuals were classified as prefrail (Table 5.3). Excess of frailty 
and sarcopenia in the HIV+ group did not reach statistical significance (Fisher’s exact test), nor was 
there a statistically significant difference in FFP score between the two groups (Figure 5.2a).  
In the HIV+ group, 5 (17%) individuals were defined as being sarcopenic and 6 (20%) as 
presarcopenic according to the EWGSOP classification (Cruz-Jentoft et al., 2019), whilst no 
individuals in the HIV- group were classified as either sarcopenic or presarcopenic. There was a 
significantly higher prevalence of combined sarcopenic and presarcopenic (n = 11) individuals in the 
HIV+ group compared to the HIV- group (n = 0; p = 0.0093, Fisher’s exact test) (Table 5.3). 15 (100%) 
individuals from the HIV- group were non-sarcopenic, which was significantly higher compared to 
the HIV+ group (p = 0.008, Fisher’s exact test). Although the HIV+ group had a slightly lower mean 
grip strength (35.3 ± 8.91 kg) compared to the HIV- group (37.5 ± 6.60 kg), this difference was not 
statistically significant (p = 0.39, unpaired t test) (Figure 5.2d). In addition, the percentage of 
individuals with pathologically low grip strength (as defined in the FFP assessment) was not 
significantly different between the two groups (Fisher’s exact test). 
The two groups were well matched for physical performance results in the form of SPPB score 
(Fisher’s exact test) (Figure 5.2b) and physical activity levels in the form of MET score (Figure 5.2e).   
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 HIV+ (n = 30) HIV- (n = 15) p  
Frailty status:   0.61 
Frail 4 (13%) 0 (0%)  
Pre-frail 15 (50%) 8 (53%)  
Robust 11 (37%) 7 (47%)  
FFP Score^ 1 (0-2) 0 (0-1) 0.12 
Physical performance (SPPB):   0.87 
Low 1 (3%) 0 (0%)  
Intermediate 10 (34%) 4 (27%)  
High 19 (63%) 11 (73%)  
SPPB Score^ 10 (9-11)  10 (9-12) 0.53 
MET score^*  1446 (497-4100) 1446 (630-5172) 0.44 
Muscle function:    
Sarcopenia*+ 5 (17%) 0 (0%) 0.0093 
Pre-sarcopenia*+ 6 (20%) 0 (0%)  
Non-sarcopenic*+ 18 (60%) 13 (100%) 0.008 
Grip strength (kg)* 35.3 (8.9) 37.5 (6.6) 0.39 
Low grip strength*  11 (37%) 3 (20%) 0.25 
ASMI (kg/m2)+ 8.1 (1.4) 8.6 (1.0) 0.21 
Table 5.3 – Cohort physical function, frailty, and sarcopenia results. Nominal data expressed as the number (%). * 
Expressed as mean (SD) for parametric data and median (IQR) for non-parametric tests (denoted by ^). + Missing 
information from two HIV- patients who were unable to undertake a DXA scan. P values were determined by Fisher’s exact 
test for nominal data, unpaired t test for ordinal data, and ANOVA for categories such as SPPB category. Statistically 







Figure 5.2 – Physical assessment characteristics by HIV status. Dot plot graphs (mean ± SEM) depicting the differences 
between the HIV+ and HIV- groups with regard to (A) FFP score, (B) SPPB score, (C) ASMI (kg/m2), (D) grip strength (kg), and 
(E) MET score. Each dot represents an individual subject. 
  




5.4.3 Determinants of physical function in older PLWH 
Initially, I wanted to investigate whether HIV-related factors such as CD4 count and months since 
diagnosis predicted abnormalities in clinical characteristics and physical function such as 
comorbidities, FFP score, MET score, SPPB score, and body composition factors in the HIV+ group (n 
= 30) (Table 5.4). In addition, as age is a well-known risk factor for adverse physical outcomes, I 
additionally sought to determine whether age predicted these outcomes. 
Interestingly, unadjusted linear regression analysis demonstrated that a greater duration of 
untreated HIV infection significantly predicted poorer grip strength (r = -0.41; p = 0.023, Pearson’s 
correlation) (Figure 5.3a). As such, in order to investigate the effect of greater months with 
untreated HIV infection after adjustment for age, I developed a multivariate linear regression model 
with grip strength as the dependant variable and age, as well as months untreated, as the 
independent variables. Here, multivariate linear regression confirmed that the association between 
grip strength and duration of untreated infection was independent of age (unstandardised 
regression coefficient = -0.039; p = 0.037, multivariate linear regression) (Table 5.4). The overall 
model fit was significant (p = 0.037), but only predictive of a small amount of variation (r2 = 0.22).  
In addition, a greater CD4 count significantly predicted a higher appendicular skeletal muscle mass 
index (ASMI) (r = 0.40; p = 0.035, Pearson’s correlation) (Figure 5.3b). This was then adjusted for age 
in a multivariate linear regression model. Here, multivariate linear regression confirmed that the 
significant association between CD4 count and ASMI was independent of age (unstandardised 
regression coefficient = 0.002; p = 0.046, multivariate linear regression) (Table 7.4). However, the 
overall model fit was not significant (p = 0.11) and was only predictive of a small amount of variation 
(r2 = 0.094). 
Finally, there were no other significant associations between physiological factors mentioned above 
and HIV-related factors such as duration of HIV and ART, or exposure to mitochondrially-toxic NRTIs 




Figure 5.3 – Linear regression analysis of physical determinants in older PLWH. Scatter plots representing the linear 
regression analysis (Pearson’s correlation) between (A) months with untreated HIV infection and grip strength (kg), and (B) 









Months on ART Months untreated CD4 count (copies/µl) 
Mitochondrially toxic 
NRTI 
r p r p r p r p MV p r p MV p r p 
Age - - 0.34 0.065 0.29 0.12 0.17 0.37 - -0.18 0.35 - - 0.082 
BMI (kg/m2) 0.038 0.84 -0.11 0.57 -0.29 0.13 0.072 0.70 - 0.33 0.09 - - 0.10 
Waist circumference 
(cm) 
0.01 0.96 -0.12 0.52 -0.072 0.71 -0.11 0.57 - 
-
0.014 
0.95 - - 0.34 
Number of 
comorbidities 
0.10 0.58 0.078 0.68 0.10 0.61 0.018 0.92 - 0.14 0.47 - - 0.78 
Number of medications -0.11 0.58 0.25 0.19 0.12 0.53 0.21 0.28 - 0.12 0.54 - - 0.68 
Polypharmacy - 0.17 - 0.48 - 0.60 - 0.20 - - 0.32 - - - 
Grip strength (kg) -0.27 0.15 -0.34 0.064 0.038 0.84 -0.41 0.020 0.037 -0.14 0.50 - - 0.50 
ASMI (kg/m2) -0.14 0.47 -0.095 0.62 -0.14 0.45 -0.01 0.96 - 0.40 0.035 0.046 - 0.81 
% Fat mass -0.25 0.18 -0.29 0.16 -0.15 0.43 -0.23 0.23 - 0.15 0.46 - - 0.59 
% Lean mass 0.25 0.18 0.29 0.16 0.15 0.43 0.23 0.23 - -0.15 0.46 - - 0.59 
FFP score^ -0.007 0.97 0.19 0.32 -0.15 0.44 0.34 0.065 - 0.10 0.61 - - 0.86 
MET score^ 0.26 0.89 -0.13 0.48 -0.006 0.98 -0.15 0.44 - -0.19 0.35 - - 0.44 
SPPB score^ -0.082 0.67 -0.22 0.24 0.097 0.61 -0.16 0.40 - 
-
0.014 
0.95 - - 0.49 
 
Table 5.4 – Predictors of physical function. Table depicting associations between clinical and HIV-related parameters in older HIV+ (n = 30) individuals. Linear regression and correlation 
analysis was determined by Pearson’s correlation for normal data and Spearman’s correlation for non-normal data (denoted by ^). Individuals were grouped into mitochondrially-toxic NRTI (n 
= 11) and non-mitochondrially toxic NRTI (n = 19), and statistical differences determined were by unpaired t test (parametric) and Mann-Whitney test (non-parametric). Statistically significant 
values are in bold. MV = multivariate.
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5.4.4 Determinants of ageing phenotypes in older PLWH 
To better understand the associations between the various clinical factors, body composition 
factors, and HIV-related factors with frailty and sarcopenia in older PLWH, I stratified the HIV+ group 
(n = 30) into frail (n = 4), prefrail (n = 15) and robust (n = 11) HIV+ groups, as well as sarcopenic (n = 
5), presarcopenic (n = 6) and non-sarcopenic (n = 19) HIV+ groups.  
There was no significant difference in any of the clinical, HIV-related, body composition, physical 
performance, or lifestyle factors between the frail, prefrail, and robust PLWH (one-way ANOVA) 
(Figure 5.4). Nor was there any significant difference in any these factors between the sarcopenia, 





Figure 5.4 – Clinical parameters in frail PLWH. Dot plots (mean ± SEM) showing (A) age, (B) months since diagnosis, (C) 
months on ART, (D) months untreated, (E) BMI (kg/m2), and (F) MET score in frail PLWH (n = 4), prefrail PLWH (n = 15) and 
robust PLWH (n = 11). Each dot represents an individual subject. 
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Figure 5.5 – Clinical parameters in sarcopenic PLWH. Dot plots (mean ± SEM) showing (A) age, (B) months since diagnosis, 
(C) months on ART, (D) months untreated, (E) BMI (kg/m2), and (F) MET score in sarcopenic PLWH (n = 5), presarcopenic 








Although frailty and sarcopenia were only seen in the HIV+ group, they were nevertheless 
uncommon. Therefore, in order to increase the power to detect differences between PLWH with 
normal ageing phenotypes and those with adverse ageing phenotypes, I grouped the HIV+ group (n = 
30) into frail/prefrail HIV+ (n = 19) and sarcopenic/presarcopenic HIV+ (n = 11) groups, as has been 
done in previous studies (Kooij et al., 2016). The frail/prefrail HIV+ group was then compared to the 
robust HIV+ group (n = 11) (Table 5.5), whilst the sarcopenia/presarcopenia HIV+ group was 
compared to the non-sarcopenic HIV+ group (n = 19) (Table 5.6). Of note, measurements of grip 
strength were not included as part of these assessments as they are important components of both 
frailty and sarcopenia classification criteria. In addition, measurements of fat and lean mass were 
not included in the assessments in sarcopenic/presarcopenic PLWH as they are also important 
components of the sarcopenia diagnostic criteria. 
Interestingly, MET score was significantly lower in the frail/prefrail group (n = 19) compared to the 
robust group (n = 11; p = 0.0097, Mann-Whitney test) (Figure 5.6f).  
Notably, there was no significant difference in any other factor tested between the frail/prefrail HIV+ 
and robust HIV+ groups, or the sarcopenia/presarcopenia HIV+ (n = 11) and non-sarcopenia HIV+ 





 Frail/Pre-frail HIV+ (n = 19) Robust HIV+ (n = 11) P  
Age 59 (6.6) 60 (10.0) 0.85 
Months since diagnosis 218 (108.3) 181 (92.9) 0.36 
Months on ART 110 (58.3) 133 (81.6) 0.36 
Months untreated 107 (92.1) 48 (72.2) 0.077 
CD4 count (copies/µl) 691 (240.9) 592 (207.6) 0.28 
MET score^ 1040 (198-3050) 4158 (1386-6336) 0.0097 
SPPB score^ 10 (9-11) 10 (9-11) 0.84 
BMI (kg/m2) 27 (3.6) 27 (2.8) 0.94 
Waist circumference (cm) 96 (11.3) 98 (7.2) 0.54 
% Fat mass+ 30 (9.2) 30 (4.5) 0.85 
% Lean mass+ 70 (9.2) 70 (4.5) 0.85 
Number of comorbidities 1 (1.1) 1 (1) 0.26 
Number of medications 4 (3.4) 3 (2) 0.27 
Table 5.5 – Clinical characteristics in frail/prefrail PLWH. Expressed as mean (SD) for parametric data, and median (IQR) 
for non-parametric data (denoted by ^). + = Missing information from two HIV- patients who were unable to undertake a 
DXA scan. P values were determined by unpaired t test for normalised data and Mann-Whitney test for non-normalised 




Sarcopenic/Pre-sarcopenic HIV+  
(n = 11) 
Non-sarcopenic HIV+ (n = 19) P  
Age 61 (7.6) 59 (8.1) 0.54 
Months since diagnosis 242 (120.1) 182 (87.4) 0.12 
Months on ART 134 (63.3) 104 (67) 0.12 
Months untreated 97 (110.5) 79 (76.3) 0.59 
CD4 count (copies/µl) 664 (182.9) 650 (262.5) 0.88 
MET score^ 1040 (495-2772) 3050 (498-4212) 0.18 
FFP score^ 1 (1-2) 1 (0-2) 0.59 
BMI (kg/m2) 27 (3.6) 27 (3.2) 0.59 
Waist circumference (cm) 97 (11.4) 97 (9.3) 0.91 
Number of comorbidities 1 (0.7) 1 (1.2) 0.79 
Number of medications 3 (2.7) 4 (3.1) 0.40 
Table 5.6 – Clinical characteristics in sarcopenic/presarcopenic PLWH. Expressed as mean (SD) and median (IQR) for non-
parametric data (denoted by ^). P values were determined by unpaired t test for normalised data and Mann-Whitney test 






Figure 5.6 – Clinical characteristics in frail/prefrail PLWH. Dot plots (mean ± SEM) showing (A) age, (B) months since 
diagnosis, (C) months on ART, (D) months untreated, (E) BMI (kg/m2), and (F) MET score in frail/prefrail PLWH (n = 19) and 
robust PLWH (n = 11). Each dot represents an individual subject. 
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Figure 5.7 – Clinical characteristics in sarcopenic/presarcopenic PLWH. Dot plots (mean ± SEM) showing (A) age, (B) 
months since diagnosis, (C) months on ART, (D) months untreated, (E) BMI (kg/m2), and (F) MET score in 
sarcopenic/presarcopenic PLWH (n = 19) and non-sarcopenic PLWH (n = 19). Each dot represents an individual subject. 
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In this chapter, as well as in later chapters of this thesis (Chapters 6 and Chapter 7), data collected 
and analysed as part of the MAGMA study is presented for the first time.  
Here, using a range of validated clinical assessments such as the assessment of sarcopenia using the 
EWGSOP diagnostic criteria, modified FFP assessment (Onen et al., 2009), SPPB, and MET score, I 
demonstrated that our cohort of older PLWH have a higher prevalence of frailty, sarcopenia, and 
pre-sarcopenia compared to the age-matched HIV- individuals. Although due to the small cohort size 
and therefore limitation in the statistical power, this was not statistically significant. However, the 
prevalence of combined sarcopenic and presarcopenic HIV+ individuals compared to 
sarcopenic/presarcopenic HIV- individuals was significantly higher. These data support various 
previous observations of a higher prevalence of frailty (Desquilbet et al., 2007; Kooij et al., 2016; 
Brothers et al., 2017) and sarcopenia (Echeverria et al., 2018; Pinto Neto et al., 2016; Wasserman et 
al., 2014; Oliveira et al., 2020) in PLWH compared to age-matched HIV- individuals, as well as a 
decline in physical performance capabilities in this group (Onen et al., 2009; Erlandson et al., 2014).  
One of the experimental aims of this study was to investigate the links between adverse ageing 
phenotypes such as frailty and sarcopenia, and clinical, HIV-related, as well as body composition 
factors in older PLWH. As HIV-related clinical parameters such as low CD4 count (Guaraldi et al., 
2019a; Erlandson et al., 2012; Onen et al., 2014), months on ART (Brothers et al., 2017; Althoff et al., 
2014), and exposure to particular ARVs (Onen et al., 2014; Erlandson et al., 2017a) are known risk 
factors for frailty in PLWH, through linear regression analyses I sought to identify whether these 
factors predicted adverse outcomes in the physiological factors mentioned above. Interestingly, of 
these factors, a longer duration of untreated HIV infection significantly predicted poorer grip 
strength. This was confirmed in a multivariate linear regression model after adjustment for age. In 
addition, a lower CD4 count was significantly associated with lower adjusted muscle mass, as 
assessed through ASMI. However, this association was not independent of the effect of age, and was 
driven mainly by one outlier. Together, these findings suggest that a longer duration of untreated 
HIV infection may lead to a decline in physical strength, which may subsequently produce an 
increased susceptibility to developing adverse ageing phenotypes, supporting previous data 
(Brothers et al., 2017; Althoff et al., 2014; Desquilbet et al., 2009; Guaraldi et al., 2019a; Erlandson 
et al., 2012a; Branas et al., 2017; Erlandson et al., 2017b). Indeed, as the majority of these HIV+ 
patients have been virally-supressed as the result of cART, this physiological phenomenon is likely to 
be due to a ‘legacy effect’ of untreated HIV infection, whereby incomplete immune recovery may 
induce residual chronic inflammation and immune activation that may predispose the individual to 
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complications and morbidity (Wilson & Sereti, 2013; Guaraldi et al., 2011). These findings may also 
have clinical significance when determining whether PLWH are more at risk of developing frailty or 
whether they will progress through the frailty phenotypes faster. However, more work, including 
longitudinal study, needs to be undertaken in order to better understand these associations.  
Finally, by initially stratifying the HIV+ group by whether they are frail, prefrail, or robust, as well as 
whether they were sarcopenic, presarcopenic, or non-sarcopenic, I assessed whether any of the 
clinical, HIV-related, or body composition factors were significantly altered in PLWH with adverse 
ageing phenotypes. Notably, there were no statistically significant associations, and so in order to 
increase the power to detect differences in these factors, I next stratified the HIV+ individuals into 
frail/prefrail or sarcopenic/presarcopenic groups, as done recently in a study by Kooij and colleagues 
(Kooij et al., 2016). Here, I investigated whether any of the clinical, HIV-related, or body composition 
factors were significantly altered in frail and sarcopenic older PLWH compared to age-matched 
robust PLWH. Interestingly, MET score was significantly higher in robust PLWH compared to 
frail/prefrail PLWH. Importantly, although the relationship between frailty/prefrailty and physical 
activity is complex and bidirectional, this novel finding supports previous observations regarding the 
potential therapeutic advantages of exercise training programmes in preventing the onset of frailty 
(Walston et al., 2018; Cameron et al., 2013; Silva et al., 2017). Notably, there was no significant 
difference in any of the factors mentioned above when comparing sarcopenic/presarcopenic older 
PLWH and age-matched non-sarcopenic PLWH.  
An important advantage of this study compared to other cohort studies conducted in this field is the 
large array of clinical tests performed in order to assess not only frailty and sarcopenia in older 
PLWH and age-matched HIV- individuals, but also body composition factors and numerous 
surrogates for physical function capability. This allowed for a more comprehensive analysis of the 












• Well matched for age, comorbidities, and most lifestyle factors. 
• HIV- group had higher BMI and waist circumference 






• Higher prevalence of frailty and sarcopenia in HIV+ group compared to HIV- group, 
although not statistically significant.  
• Prevalence of combined sarcopenic and presarcopenic HIV+ individuals 
significantly higher compared to sarcopenic/presarcopenic HIV- individuals. 
• Well matched for physical performance results. 
 
Prediction of HIV 
parameters on 
clinical factors 
• Months untreated HIV infection predicted poor grip strength, after adjustment for 
age. 





phenotypes in PLWH 
• MET score was significantly lower in frail/prefrail PLWH compared to robust 
PLWH. 
Table 5.7 – Summary of experimental findings.  
 
5.5.2 Limitations  
Whilst this study has advantageous aspects, it is limited by the fact that it is not a longitudinal study. 
As frailty is a dynamic state, the frailty status of our cohort could change over time, and this 
phenomenon is therefore not accounted for in this study.  
Another limitation lies in the fact that our cohort is composed solely of males. This was a deliberate 
aspect of the study protocol design, as older HIV+ women are more heterogeneic than older HIV+ 
men, owing to the effects of menopause. Furthermore, the majority of the older HIV+ population in 
England is male. Finally, body composition and skeletal muscle changes in ageing differ between 
men and women. This ultimately means that the findings are not generalisable to older HIV+ 
women, and a separate study should be conducted in this group.  
5.5.3 Future work 
As mentioned above, any future studies should aim to be longitudinal cohort studies. In addition, the 
cohort size should be increased to increase the in which power to investigate effects within groups. 
Comparable studies should ideally also be undertaken in older HIV+ and HIV- females.  
In the next chapter I go on to examine the effect of mitochondrial dysfunction in these ageing 
phenotypes in PLWH.   
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Chapter 6 – Skeletal muscle mitochondrial dysfunction in 
older PLWH and adverse ageing phenotypes 
6.1 Introduction 
The link between mammalian mitochondrial dysfunction and ageing in several tissues is well 
acknowledged. This link appears, in part, to be underpinned by an accumulation of mtDNA 
mutations with age, with resultant age-related decreases in oxidative capacity amongst other 
mitochondrial functions, ultimately leading to a decline in cellular function (Kujoth et al., 2005; 
Nooteboom et al., 2010; Lopez-Otin et al., 2013; Park & Larsson, 2011; Kauppila et al., 2017; Lawless 
et al., 2020). Indeed, mitochondrial dysfunction was noted as one of the nine cellular and molecular 
hallmarks of ageing (Lopez-Otin et al., 2013). Importantly, recent data also appear to suggest a 
causal link between age-related mitochondrial dysfunction and frailty, as well as sarcopenia (Alway 
et al., 2017; Andreux et al., 2018; Brierley et al., 1998). 
Mitochondrial dysfunction is well described in PLWH. In particular, early studies demonstrated a 
reduction in mtDNA content in PLWH who were exposed to certain older NRTIs that inhibited the 
mitochondrial polymerase – PolG (Dalakas et al., 1990; Arnaudo et al., 1991; Lim & Copeland, 2001). 
In addition, later studies by our group demonstrated an excess of mtDNA deletions in PLWH exposed 
to those ARVs, even after they have switched to supposedly less harmful, newer, ARVs (Payne et al., 
2011). In further support, data presented in Chapter 4 indicated that skeletal muscle from PLWH 
treated with both newer and older ARVs also had an excess of mitochondrial dysfunction. 
Taken together, there is a strong hypothesis that the increased prevalence of adverse ageing 
phenotypes experienced by older (≥50 years) PLWH compared to the age-matched general 
population (Desquilbet et al., 2007; Kooij et al., 2016; Curcio et al., 2016; Echeverria et al., 2018) may 
be underpinned by both age-related and HIV-related mitochondrial dysfunction. Due to the 
increasing age of the HIV+ population and the adverse impact this will have on healthcare, attempts 
to better understand the underlying pathophysiological mechanisms of adverse ageing in this 




6.2 Experimental aims  
Mitochondrial dysfunction is widely recognised as one of the key hallmarks of the ageing process in 
the general population (Lopez-Otin et al., 2013). In addition, the established role of mitochondrial 
dysfunction in toxicities experienced by PLWH exposed to older nucleoside reverse transcriptase 
inhibitors suggests that mitochondrial dysfunction may be a driver of adverse ageing seen in older 
PLWH (Dalakas et al., 1990; Arnaudo et al., 1991; Dalakas et al., 2001; Ashar et al., 2015; Hunt & 
Payne, 2020).  
Researchers in the field of ageing with HIV are now giving more attention to the hypothesis that 
mitochondrial dysfunction plays a causative role in adverse ageing phenotypes in PLWH. However, 
few studies have investigated mitochondrial function at the cellular level in tissues heavily 
implicated in the ageing process, such as skeletal muscle. As such, using clinical data and tissue 
collected as part of the MAGMA study, in this chapter I aimed to: 
• Determine if there is mitochondrial CI and CIV deficiency at the individual myofibre level 
in older PLWH compared with age-matched HIV- controls. 
• Determine if there is an alteration in mitochondrial mass at the individual myofibre level 
in older PLWH compared with age-matched HIV- controls.  
• Determine whether skeletal muscle mitochondrial CI and CIV deficiency is associated 
with adverse ageing phenotypes such as frailty and sarcopenia.  
• Determine whether skeletal muscle mitochondrial CI and CIV deficiency is predicted by 




6.3.1 Patient cohort  
This study was approved by the research ethics committee (Newcastle and North Tyneside 2 (17-NE-
0015)). Skeletal muscle samples were taken by percutaneous biopsy from HIV-infected males (n = 
30) as well as HIV-uninfected males (n = 15) as part of the MAGMA study (Table 3.1), with patients 
giving prior written permission.  
Control skeletal muscle tissue (for calibration of the multiplex immunofluorescence assay) was 
acquired with prior informed consent from the distal part of the hamstring of people undergoing 
anterior cruciate ligament (ACL) surgery. Approval for this was given by Newcastle biobank (NAHPB 
reference: 042) (described in Section 3.2.3). 
In addition, percutaneous skeletal muscle biopsies from the two mitochondrial disease patients 
described in Section 3.2.4 were also subjected to the multiplex immunofluorescence assay for 
quantification of Complex I (CI) and IV (CIV) deficiency as a positive control group, in order to provide 
additional context to the levels of CI/CIV deficiency observed. 
6.3.2 Multiplex immunofluorescence for the quantification of mitochondrial protein 
level in human skeletal muscle  
Transverse cryo-sections (10µm) were subjected to a validated multiplex immunofluorescence assay 
in order to objectively quantify the abundance of mitochondrial ETC complexes I and IV as well as 
mitochondrial mass within individual myofibres, using the CI + CIV assay described in Section 3.4.2 
(Rocha et al., 2015). 
6.3.3 Image acquisition and analysis for mitochondrial protein level 
Fluorescent images were acquired using a Zeiss Axio Imager M1 and Zen 2011 (blue edition) 
software with a Monochrome Digital Camera (AxioCam MRm) at 20x magnification, as described in 
Section 3.4.4. The ‘intermediate –’, ‘intermediate +’ and ‘deficient’ groups were pooled together to 
create the ‘abnormal’ group (z > -3). 
6.3.4 Statistical analysis  
Statistical analysis was performed in Prism v5.04, IBM SPSS Statistics v23 and Microsoft Excel 2016. 
Graphs were produced in Prism v5.04.  
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Normality was assessed by Shapiro-Wilk tests. Statistical differences in mitochondrial function 
between the HIV+ and HIV- individuals as well as PLWH stratified by frailty/prefrailty and 
sarcopenia/presarcopenia were determined by unpaired t tests for normalised data and Mann-
Whitney tests for non-normal data sets. One-Way ANOVA was used to determine differences in 
mitochondrial parameters between frail, prefrail, and robust PLWH, as well as sarcopenic, 
presarcopenic, and non-sarcopenic PLWH. Fisher’s exact test was performed in order to determine 
differences in mitochondrial deficiency in nominal data sets such as stratification by smoker status. 
Linear regression analysis between mitochondrial dysfunction and clinical as well as body 
composition factors was performed using Pearson’s correlation for normal data, or Spearman’s 
correlation for non-normal data. Finally, multivariate linear regression analysis was undertaken with 
factors of interest. Here, these multivariate models included (1) average myofibre mitochondrial 
mass as the dependant variable, and age, percentage fat mass and proportional CI deficiency as the 
independent variables; (2) proportional CI deficiency as the dependant variable and age as well as 
number of medications as the independent variables. Unstandardised regression coefficients and 
their statistical significance were reported, as well as the fit of the models and how much variance 
(adjusted r2) they accounted for. 




6.4 Results  
6.4.1 Cohort characteristics  
Patient characteristics for both the HIV+ (n = 30) and HIV- (n = 15) groups are described in Table 5.1 
in Chapter 5. Briefly, the median age of the HIV+ group was 58 years (range 50-85) compared to 59 
years (range 50-70) in the HIV- group. 4 (13%) individuals from the HIV+ group were classified as frail 
according to the FFP assessment, while 15 (50%) were classified as prefrail. None of the HIV- group 
were classified as frail and 7 (53%) HIV- individuals were classified as prefrail. In the HIV+ group, 5 
(17%) individuals were defined as being sarcopenic and 6 (20%) as presarcopenic, whilst 15 (100%) 
were classified as non-sarcopenic in the HIV- group 
In addition, the HIV-related characteristics of the HIV+ individuals are described in Table 5.2 in 
Chapter 5. Briefly, individuals in the HIV+ group were virally-supressed and had restored CD4 counts. 
11 (37%) individuals had previously been exposed to older, supposedly mitochondrially-toxic NRTIs 
(stavudine (d4T), didanosine (ddI), zalcitabine (ddC), zidovudine (AZT)). 9 (30%) were being treated 
with protease inhibitors (PIs) and 11 (37%) were being treated with non-nucleoside reverse 
transcriptase inhibitors (NNRTIs) at time of study visit.  
Skeletal muscle biopsies from two post-mortem mitochondrial disease patients (described in Section 
3.2.4) were included in the multiplex immunofluorescence quantification of mitochondrial function 




6.4.2 Skeletal muscle mitochondrial dysfunction in older PLWH 
The HIV+ group (n = 30) had a significantly higher proportion of myofibres with mitochondrial 
dysfunction in the form of CI (p = 0.049, unpaired t test) and CIV (p = 0.001) deficiency compared to 
the HIV- group (n = 15) (Figure 6.1b, c). For a contextual comparison, I also included results from two 
individuals with diagnosed mitochondrial disease (Table 3.2, Section 3.2.4). In general, proportional 
levels of both CI and CIV deficiency were higher in the mitochondrial disease patients than both the 
HIV+ and HIV- groups, although the cases with the highest levels of proportional CI and CIV 
deficiency were comparable with these disease controls (Figure 6.1b, c).  
 
 
Figure 6.1 – Skeletal muscle mitochondrial dysfunction. (A) Representative images of multiplex immunofluorescence  
staining on 10µm skeletal muscle sections from a HIV+ and HIV- individual. Markers include laminin, VDAC1 (mitochondrial 
mass marker), NDUFB8 (CI subunit) and MTCO1 (CIV subunit). Scale bar = 100µm. (B) Dot plot (mean ± SEM) showing 
significantly higher proportion of muscle fibre CI defects in the HIV+ group (n = 30) compared to the HIV- group (n = 15; p = 
0.049). The mitochondrial disease group (n = 2) had a significantly higher proportion of CI defects compared to both the 
HIV+ group (p = 0.04) and HIV- group (p = 0.02). Each dot represents an individual patient. (C) Dot plot (mean ± SEM) 
showing a significantly higher proportion of fibres with CIV deficiency in the HIV+ group compared to the HIV- group (p = 
0.001). The mitochondrial disease group also had a significantly higher proportion of fibres with CIV deficiency compared to 
both the HIV+ (p = 0.01) and HIV- groups (p < 0.0001). (D) Example dot plot of a HIV+ individual depicting the CI and CIV z-
score of each individual fibre. Fibres with a z < -3 were classified as abnormal and z > -3 were classified as normal. Dots are 
coloured depending on mitochondrial mass status: dark blue = very low; light blue = low; pale yellow = normal; orange = 






Using a marker for voltage-dependant anion channel 1 (VDAC1) in our multiplex 
immunofluorescence assay allowed for the quantification of the average mitochondrial mass in 
individual myofibres. Here, there was no significant difference in the average skeletal muscle 
mitochondrial mass between the HIV+ and HIV- groups (unpaired t test) (Figure 6.2).  
 
 
Figure 6.2 – Skeletal muscle mitochondrial mass. Dot plot (mean ± SEM) representing average mitochondrial mass for each 
subject. Z-scores were calculated for each individual fibre and the mean score was calculated for each patient. There was no 
significant difference in mitochondrial mass between the HIV+ (n = 30) and HIV- (n = 15) groups (p = 0.16, unpaired t test). 




Finally, unadjusted linear regression analysis was undertaken in both the HIV+ and HIV- groups in 
order to determine if proportional CI and CIV deficiency was significantly associated with each other.  
Here, proportional CI deficiency was highly significantly associated with proportional CIV deficiency 
in both the HIV+ (n = 30; r = 0.61; p < 0.0001) (Pearson’s correlation) and HIV- groups (n = 15; r = 
0.79; p = 0.001) (Figure 6.3a). 
Additionally, there was a strong association between proportional CI deficiency and mitochondrial 
mass in the HIV+ group, although this was not statistically significant (n = 30; r = 0.33; p = 0.074) 
(Pearson’s correlation). The association between proportional CI deficiency and mitochondrial mass 
was also not statistically significant in the HIV- group (n = 15; r = 0.30; p = 0.28) (Figure 6.3b). Nor 
was proportional CIV deficiency significantly associated with mitochondrial mass in either the HIV+ 
(n = 30; r = 0.17; p = 0.37) or HIV- groups (n = 15; r = 0.18; p = 0.51) (Figure 6.3c). 
 
Figure 6.3 – Associations between mitochondrial parameters. Scatter plots depicting the linear regression (Pearson’s 
correlation) between log10(CI abnormal) and (A) log10(CIV abnormal) and (B) VDAC1 z-score; and between log10(CIV 
abnormal) and (C) VDAC1 z-score. Each dot represents an individual patient. Black dots represent HIV+ individuals, and grey 






6.4.3 Clinical factors predicting skeletal muscle mitochondrial dysfunction in older 
PLWH 
In order to better understand whether clinical factors (such as age and number of medications), 
body composition, or environmental factors (such as smoker status) predicted the greater skeletal 
muscle mitochondrial dysfunction seen in older PLWH, linear regression analyses were undertaken 
in the HIV+ group (n = 30).  
Results from the various unadjusted linear regression analyses are described in Table 6.1. Of these 
analyses, proportional CI deficiency was significantly predicted by a lower number of medications (n 
= 30; r = -0.42; p = 0.02, Pearson’s correlation) (Figure 6.4e). However, multivariate linear regression 
demonstrated that the association between proportional CI deficiency and number of medications 
was not independent of age (unstandardised regression coefficient = 0.38; p = 0.28, multivariate 
linear regression) (Table 6.1). Indeed, the model fit was not significant (p = 0.10), and subsequently 
only predictive of a small amount of variation in proportional CI deficiency (r2 = 0.094). 
Additionally, average mitochondrial mass in individual myofibres (determined by VDAC1 z-score) was 
significantly predicted by a higher percentage lean mass (r = 0.43; p = 0.0018, Pearson’s correlation) 
(Figure 6.6d), and subsequently a lower percentage fat mass (r = -0.43; p = 0.0018) (Figure 6.6c).  
Mitochondrial mass is known to be linked with both age and OXPHOS deficiency. Hence, in order to 
determine if average myofibre mitochondrial mass was predicted by lower percentage fat mass 
independently of the effect of both age and proportional CI deficiency, a multivariate linear 
regression model was developed with VDAC1 z-score as the dependant variable and age, percentage 
fat mass, and proportional CI deficiency as the independent variables. Here, multivariate linear 
regression confirmed that the association of mitochondrial mass and percentage fat mass was 
independent of both age and proportional CI deficiency (unstandardised regression coefficient = -
0.044; p = 0.043, multivariate linear regression) (Table 6.2). Model fit was marginally above 
statistical significance (p = 0.053), and only predictive of a small amount of variance in VDAC1 z-score 
(r2 = 0.17). 
There were no significant clinical predictors of proportional CIV deficiency in the HIV+ group (Figure 
6.5). 
Finally, supporting previous work in this thesis (Section 4.4.6), unadjusted linear regression analyses 
demonstrated that none of the HIV-related clinical parameters significantly predicted proportional CI 
or CIV deficiency, or mitochondrial mass (Table 6.1).  
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 HIV+ (n = 30) 
 CI abnormal CIV abnormal VDAC1 z-score 
 r p 
adjusted 
p 
r p r p 
Age 0.18 0.33 - 0.33 0.077 0.22 0.25 
BMI (kg/m2) 0.18 0.35 - -0.066 0.73 -0.085 0.66 
Waist 
circumference (cm) 
0.077 0.69 - -0.17 0.37 -0.14 0.45 
# Comorbidities -0.24 0.20 - 0.31 0.093 -0.18 0.35 
# Medications -0.42 0.020 0.28 0.29 0.12 -0.19 0.31 
Polypharmacy* - 0.98 - - 0.66 - 0.49 
% Fat mass+ -0.34 0.064 - -0.31 0.094 -0.43 0.018 
% Lean mass+ 0.34 0.064 - 0.31 0.094 0.43 0.018 
Smokers* - 0.45 - - 0.75 - 0.45 
Alcohol drinkers* - 0.91 - - 0.60 - 0.41 
Recreational drug 
use* 
- 0.54 - - 0.32 - 0.47 
Months since 
diagnosis 
0.27 0.15 - 0.19 0.31 -0.16 0.40 
Months on ART 0.24 0.21 - 0.20 0.30 0.011 0.96 
Months untreated 0.13 0.48 - 0.08 0.67 -0.20 0.30 
CD4 count 
(copies/µl) 
-0.17 0.39 - -0.034 0.87 -0.21 0.29 
Mitochondrially-
toxic NRTIs* 
- 0.98 - - 0.51 - 0.38 
Table 6.1 – Mitochondrial dysfunction and clinical characteristics linear correlation. Table depicting the associations 
between proportional skeletal muscle CI and CIV deficiency in older HIV+ (n = 30) and age-matched HIV- (n = 15) individuals. 
Linear regression and correlation analysis was determined by Pearson’s correlation for normal data and Spearman’s 
correlation for non-normal data (denoted by ^). * = ordinal data in which individuals were stratified by yes/no, and 






















Age, CI deficiency, 
% fat mass 
-0.004 0.41 -0.044 0. 85 0.18 0.043 
Table 6.2 – Multivariate linear regression models. Table depicting the dependant and independent variables, as well as the 
corrected coefficients and p value outputs from a multivariate linear regression model to determine predictive factors of 




Figure 6.4 - Clinical predictors of proportional CI deficiency. Scatter plots showing linear correlation analysis (Pearson’s 
correlation) between proportional CI deficiency and (A) age, (B) BMI (kg/m2), (C) percentage fat mass, (D) percentage lean 








Figure 6.5 - Clinical predictors of proportional CIV deficiency. Scatter plots showing linear correlation analysis (Pearson’s 
correlation) between proportional CIV deficiency (A) age, (B) BMI (kg/m2), (C) percentage fat mass, and (D) percentage lean 







Figure 6.6 - Clinical predictors of VDAC1 z-score. Scatter plots showing linear regression analysis (Pearson’s correlation) 
between average VDAC1 z-score and (A) age, (B) BMI (kg/m2), (C) percentage fat mass, and (D) percentage lean mass. Each 







6.4.4 Physical function outcomes of skeletal muscle mitochondrial dysfunction 
Next, I sought to investigate the relationship between skeletal muscle mitochondrial dysfunction and 
outcomes of the physical function and ageing phenotype assessments (Table 6.3).  
Here, through unadjusted linear regression analyses it was found that proportional CI deficiency did 
not significantly predict any of the respective physical outcomes such as MET score (Figure 6.7a), 
SPPB score (Figure 6.7b), FFP score (Figure 6.7c), grip strength (Figure 6.7d) or ASMI (Figure 6.7e) 
(Pearson’s correlation). 
In addition, proportional CIV deficiency did not significantly predict any of the respective physical 
factors (Figure 6.8a-e). 
Finally, it was also found that mean myofibre mitochondrial mass (determined by VDAC1 z-score) did 
not significantly predict any of the respective physical factors (Figure 6.9a-e). 
 HIV+ (n = 30) 
 CI abnormal CIV abnormal VDAC1 z-score 
 r p r p r p 
MET score^ 0.014 0.94 0.22 0.24 0.26 0.16 
SPPB score^ 0.17 0.38 -0.037 0.84 0.22 0.25 
FFP score^ 0.11 0.094 0.11 0.99 -0.17 0.38 
Grip strength (kg) 0.015 0.94 -0.17 0.36 0.21 0.20 
ASMI (kg/m2) -0.29 0.12 0.14 0.46 0.056 0.77 
Table 6.3 – Mitochondrial dysfunction and physical function parameters. Table depicting the correlation between 
proportional CI and CIV deficiency as well as average VDAC1 z-score and physical function and adverse ageing phenotype 
parameters. ^ indicate non-parametric data. Pearson’s correlation performed on parametric data and Spearman’s 




Figure 6.7 – Physical performance predictors of proportional CI deficiency. Scatter plots showing linear correlation analysis 
between proportional CI deficiency and (A) MET score^, (B) SPPB score^, (C) FFP score^, (D) grip strength (kg), and ASMI 
(kg/m2). ^ indicates non-parametric data. Correlation for parametric data determined by Pearson’s correlation, and non-







Figure 6.8 – Physical performance predictors of proportional CIV deficiency. Scatter plots showing linear correlation 
analysis between proportional CI deficiency and (A) MET score^, (B) SPPB score^, (C) FFP score^, (D) grip strength (kg), and 
ASMI (kg/m2). ^ indicates non-parametric data. Correlation for parametric data determined by Pearson’s correlation, and 








Figure 6.9 – Physical performance predictors of myofibre mitochondrial mass. Scatter plots showing linear correlation 
analysis between average VDAC1 z-score and (A) MET score^, (B) SPPB score^, (C) FFP score^, (D) grip strength (kg), and 
ASMI (kg/m2). ^ indicates non-parametric data. Correlation for parametric data determined by Pearson’s correlation, and 






6.4.5 Skeletal muscle mitochondrial function in frail and sarcopenic PLWH 
I next investigated whether skeletal muscle mitochondrial dysfunction was higher in PLWH with the 
adverse ageing phenotypes of frailty and sarcopenia.  
Therefore, I stratified the HIV+ group (n = 30) into frail (n = 4), prefrail (n = 15), and robust (n = 11), 
as well as into sarcopenic (n = 5), presarcopenic, (n = 6), and non-sarcopenic (n = 19), and compared 
mitochondrial parameters between the respective groups.  
There was no significant difference in proportional CI deficiency between frail, prefrail, and robust 
HIV+ individuals (p = 0.15, one-way ANOVA) (Figure 6.10a). Although the frail HIV+ individuals had 
numerically higher proportional CI deficiency compared to robust and prefrail PLWH, this was not 
statistically significant, most likely due to the small number in the group. There was also no 
significant difference in proportional CI deficiency between sarcopenic, presarcopenic, and non-
sarcopenic HIV+ individuals (p = 0.32) (Figure 6.10b). 
In addition, there was also no significant difference in proportional CIV deficiency between the frail, 
prefrail and robust HIV+ groups (p = 0.17, one-way ANOVA) (Figure 6.10c). Again, the levels of 
proportional CIV deficiency were higher in the frail group compared to both the prefrail and robust 
groups, but due to the small size of the group, this difference was not statistically significant. There 
was also no significant difference in proportional CIV deficiency between the sarcopenic, 
presarcopenic, and non-sarcopenic HIV+ groups (p = 0.46) (Figure 6.10d). 
Finally, there was also no significant difference in average myofibre mitochondrial mass between the 
frail, prefrail, and robust HIV+ individuals (p = 0.29, one-way ANOVA) (Figure 6.10e), or between the 







Figure 6.10 – Mitochondrial function in adverse ageing phenotypes in older PLWH. Dot plots (mean ± SEM) showing no 
significant difference in log10(CI abnormal) between (A) frail (n = 4), prefrail (n = 15) and robust (n = 11) PLWH, or (B) 
sarcopenic (n = 5), presarcopenic (n = 6) or non-sarcopenic (n = 19) PLWH. log10(CIV abnormal) between (C) frail, prefrail 
and robust PLWH or (D) sarcopenic, presarcopenic and non-sarcopenic PLWH; average VDAC1 z-score between (E) frail, 






Similarly to analyses performed in Section 5.4.4, in order to increase the power to detect differences 
between the groups, in combination with the fact that prefrailty and presarcopenia are more 
physiologically related to frailty and sarcopenia than being robust, HIV+ patients classified as prefrail 
(n = 15) were grouped with the HIV+ frail individuals (n = 4) to form the frailty/prefrailty HIV+ group 
(n = 19), and HIV+ subjects classified as presarcopenic (n = 6) were grouped with sarcopenic PLWH (n 
= 5) to form the sarcopenia/presarcopenia HIV+ group (n = 11).  
Interestingly, frail/prefrail HIV+ individuals (n = 19) did not have a significantly higher proportion of 
myofibres with CI (p = 0.72, unpaired t test) or CIV deficiency (p = 0.67) (Figure 6.11a, b) compared 
to robust HIV+ individuals (n = 11). Nor was there a significant difference in average myofibre 
mitochondrial mass, as measured by VDAC1 z-score (p = 0.19) (Figure 6.11c). 
In addition, there was no difference in proportional CI deficiency (p = 0.38, unpaired t test), CIV 
deficiency (p = 0.27), or average myofibre mitochondrial mass (p = 0.50) between 





Figure 6.11 – Mitochondrial dysfunction in frail/prefrail and sarcopenic/presarcopenic older PLWH. Dot plots (mean ± 
SEM) showing mitochondrial dysfunction in frail/prefrail HIV+ (n = 19) and robust HIV+ (n = 11) in the form of (A) 
proportional CI and (B) CIV deficiency, in addition to (C) mitochondrial mass (VDAC1 z score). Proportional (D) CI and (E) CIV 
deficiency and (F) mitochondrial mass (VDAC1 z score) in sarcopenia/presarcopenia HIV+ (n = 11) and no-sarcopenia HIV+ (n 
= 19) individuals. Each dot represents an individual patient.  
  
A B C 




Here, I presented data regarding skeletal muscle mitochondrial dysfunction in adverse ageing 
phenotypes in older HIV+ and HIV- individuals recruited to the MAGMA study. This study is the first 
study to comprehensively investigate skeletal muscle mitochondrial dysfunction (in the form of 
OXPHOS subunit protein deficiency and mitochondrial mass) in the context of the highly 
heterogenous pathophysiology of frailty, sarcopenia, and physical function decline in older PLWH.  
6.5.1 Conclusions 
6.5.1.1 Older PLWH have higher skeletal muscle mitochondrial mass compared to age-
matched HIV- individuals 
Importantly, this cohort study demonstrated that older (≥ 50 years) PLWH have higher levels of 
skeletal muscle mitochondrial dysfunction compared to age-matched HIV- individuals. Notably, this 
increase in CI and CIV deficiency in older PLWH did not seem to be compensated by an upregulation 
in mitochondrial mass. Interestingly, whilst other studies have found higher levels of skeletal muscle 
mitochondrial dysfunction in PLWH compared to HIV-uninfected individuals, this study 
demonstrated mitochondrial defects at the individual myofibre level, in contrast to the tissue 
homogenate level (Jankowski et al., 2019). In addition, as a result of utilising a novel multiplex 
immunofluorescence assay developed in our lab (Rocha et al., 2015), this study is the first to 
objectively quantify and subsequently demonstrate significantly higher levels of CI deficiency as well 
as CIV deficiency in older PLWH compared to age-matched HIV- individuals. Previous studies have 
been limited by only being able to qualitatively quantify cytochrome oxidase (COX) activity at the 
myofibre level through COX/succinate dehydrogenase (SDH) histochemistry (Payne et al., 2011).    
6.5.1.2 Determinants of skeletal muscle mitochondrial dysfunction in older PLWH 
An important aim of this study following the quantification of skeletal muscle mitochondrial 
(dys)function was to investigate whether this mitochondrial dysfunction was predicted by clinical or 
environmental factors in older PLWH, as several of these factors are thought to impair mitochondrial 
function through potential mechanisms such as chronic inflammation and oxidative stress 
(Hollensworth et al., 2000; Voets et al., 2012; Castro Mdel et al., 2012; Andreazza et al., 2010; Sun et 
al., 2016; Harman, 1972). As such, through unadjusted linear regression analyses I demonstrated 
that a greater average myofibre mitochondrial mass was significantly associated with a higher 
percentage of lean body mass and simultaneously associated with a lower percentage of fat body 
mass. As percentage lean and fat body mass are inverses of each other, and the fact that fat mass is 
more detrimental to age-related physiology than lean body mass in PLWH (Erlandson et al., 2017a; 
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Onen et al., 2009), I assessed the association between myofibre mitochondrial mass and percentage 
fat mass after adjustment for skeletal muscle CI deficiency and age. Here, this association remained 
significant after adjustment for these factors, suggesting that a lower proportion of fat tissue 
promotes a more efficient regulation of mitochondrial content in older PLWH, even in the event of 
OXPHOS decline. As increased physical activity is associated with both decreased fat mass and 
enhanced mitochondrial function in the general population (Menshikova et al., 2006; Distefano et 
al., 2018), it could be that greater levels of physical activity were promoting the upregulation of 
skeletal muscle mitochondrial mass. However, the lack of significant association between MET score 
and either CI and CIV deficiency, or mitochondrial mass in the older PLWH suggests that this is not 
the case. Altogether, these findings support previous work demonstrating the harmful effects excess 
fat tissue has on mitochondrial function in the general population (Shetty et al., 2009; Winalawansa, 
2019; Li et al., 2017; Slawik & Vidal-Puig, 2006).  
In addition, in older PLWH, proportional CI deficiency was surprisingly significantly predicted by a 
lower number of medications through unadjusted linear regression analysis. However, through 
multivariate linear regression analysis it was demonstrated that this significant association was 
dependant on age. As older people are generally prescribed with more medications and generally 
have a higher prevalence of comorbidities (Divo et al., 2016), this result makes sense.  
6.5.1.3 Potential other underlying pathophysiological mechanisms underpinning skeletal 
muscle mitochondrial dysfunction in older PLWH in the contemporary ART era 
Importantly, data from a previously discussed chapter of this thesis (Chapter 4) demonstrated that 
there was no difference in skeletal muscle mitochondrial dysfunction between ART-treated PLWH 
who have been exposed to mitochondrially-toxic NRTIs and those who have not, as well as PLWH 
who are on protease inhibitors (PIs) or non-nucleoside reverse transcriptase inhibitors (NNRTIs) 
compared to those who were not. In addition, adjusted multivariate linear regression analysis 
conducted in that chapter demonstrated that there was no significant associations between skeletal 
muscle mitochondrial dysfunction and HIV-related factors (Section 4.4.6). However, a key strength 
of the MAGMA study was that it recruited age-matched HIV+ and HIV- individuals, and so allowed 
for the better understanding of the effect of age on mitochondrial function in older PLWH. 
Therefore, linear regression analyses was again performed in order to assess the predictive effect of 
HIV-related clinical parameters on skeletal muscle mitochondrial function. Importantly, none of the 
HIV-related factors significantly predicted either proportional CI and CIV deficiency, or mitochondrial 
mass. Additionally, previous exposure to older NRTIs that have been shown to induce mitochondrial 
toxicities, or current exposure to PIs or NNRTIs, also did not significantly predict skeletal muscle 
mitochondrial defects. These are important findings, as together with the data presented in a larger 
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cohort in Chapter 4, they comprehensively demonstrate that ART-treated PLWH have higher levels 
of skeletal muscle mitochondrial dysfunction compared to age-matched HIV- individuals, although 
there is no direct effect of previous exposure to older, supposedly mitochondrially-toxic NRTIs on 
skeletal muscle function. Indeed, they suggest that the underlying pathophysiological mechanisms 
behind age-related physiological decline are more likely to be indirect effects of HIV infection, such 
as chronic inflammation, immunosenescence, or oxidative stress (Melov et al., 1999; Zorov et al., 
2014; Rao et al., 2014; Massaad & Klann, 2011; Deeks, 2011; Erlandson et al., 2017a). 
6.1.5.4 Frail and sarcopenic PLWH do not have significantly greater levels of skeletal muscle 
mitochondrial dysfunction than robust and non-sarcopenic PLWH 
Finally, another important experimental aim was to determine whether PLWH with adverse ageing 
phenotypes such as frailty and sarcopenia have excess skeletal muscle mitochondrial dysfunction 
compared to age-matched PLWH who did not have these phenotypes. To do this, I firstly stratified 
the HIV+ group into frail, prefrail and robust groups, as well as sarcopenic, presarcopenic and non-
sarcopenic groups and assessed differences in proportional CI and CIV levels, as well as 
mitochondrial mass. Here, although the frail HIV+ group appeared to have higher levels of 
proportional CI deficiency, this was not statistically significant. This is most likely due to the small 
size of the group meaning analysis was underpowered to detect group differences. Hence, I further 
classified the HIV+ individuals into whether they were defined as frail and prefrail as well as those 
defined as sarcopenic and presarcopenic, as similarly done in a previous study (Kooij et al., 2016), 
and compared proportional CI, CIV levels and mitochondrial mass against robust and non-sarcopenic 
PLWH. Again, I found that there was no significant differences in skeletal muscle mitochondrial 
dysfunction between the experimental groups. These findings indicate that although older PLWH 
have greater levels of skeletal muscle mitochondrial dysfunction compared to age-matched HIV- 
individuals, this mitochondrial dysfunction is not a significant direct causative factor of the greater 
risk of frailty and sarcopenia in PLWH (Onen et al., 2012; Desquilbet et al., 2009; Brothers et al., 




6.5.2 Summary of experimental findings 
 Older PLWH Older HIV-  individuals Conclusions 
Proportional CI and 
CIV deficiency 
• Higher proportional CI 
and CIV deficiency than 
HIV- individuals 
• Highest levels of 
deficiency comparable 
with levels seen in 
mitochondrial disease 
patients 
• Lower proportional CI 
and CIV deficiency than 
HIV+ individuals 
• Highest levels of 
deficiency comparable 
with levels seen in 
mitochondrial disease 
patients 
• Older PLWH have 
significantly higher CI 




Mitochondrial mass • Comparable to HIV- 
individuals 
• Comparable to HIV+ 
individuals 
• No difference in 
average myofibre 
mitochondrial mass 
between older HIV+ 
and HIV- individuals 
Associations with 
clinical factors in older 
PLWH 
• Higher prevalence of medications predicted unadjusted CI deficiency, but not after 
adjustment for age 
• Higher percentage lean mass predicted higher mitochondrial mass independently of 
age and CI deficiency 
• Lower percentage of fat mass predicted higher mitochondrial mass independently of 




physical factors in 
older PLWH 
• No significant associations  
Mitochondrial 
dysfunction in adverse 
ageing phenotypes in 
older PLWH 
• No difference in mitochondrial dysfunction between frail and robust, or sarcopenic and 
presarcopenic PLWH 





As discussed in Section 5.5, the MAGMA study was an observational study. Due to the fact that 
frailty is dynamic, a longitudinal cohort study in which the participants undertake several study visits 
would allow for a better understanding of the role of skeletal muscle mitochondrial dysfunction in 
the pathophysiology of adverse ageing phenotypes such as frailty or sarcopenia. In addition, both 
the HIV+ and HIV- participants were male, limiting our capabilities to understand the role of skeletal 
muscle mitochondrial dysfunction in adverse ageing phenotypes in older HIV+ women.  
6.5.4 Future work 
As mentioned above, this study was limited by the cohort size and the fact that it was not a 
longitudinal study. Therefore, future work should look to perform these analyses on a larger cohort 
with both older male and female PLWH and ideally at numerous time points. In addition, as the 
prevalence of individuals over 65 years old was small, future studies should look to include more of 
these patients.  
Whilst this study utilised a novel multiplex immunofluorescence assay which allowed the objective 
quantification of CI and CIV deficiency at the individual myofibre level (Rocha et al., 2015), skeletal 
muscle mitochondrial function could also be assessed with other assays (Fraizer et al., 2020; Hunt & 
Payne, 2020). In light of the fact that greater skeletal muscle mitochondrial mass was associated 
with lean body mass, these studies could include homogenate tissue studies which quantify levels of 
enzymes involved in mitochondrial biogenesis, such as PGC-1α, or markers of other mitochondrial 
dynamics such as fission and fusion molecules. Additionally, investigating the levels of other OXPHOS 
complexes III and V, or levels of proteins and enzymes involved in other forms of mitochondrial 
metabolism such as citrate would be of interest.  
As mitochondrial dysfunction was not significantly predictive of adverse ageing phenotypes in older 
PLWH, I subsequently went on to investigate other aspects of age-associated skeletal muscle 





Chapter 7 – Assessment of age-related skeletal muscle 
pathophysiological mechanisms in older PLWH  
7.1 Introduction 
The average age of the HIV-infected population is increasing, and the prevalence of adverse ageing 
phenotypes such as frailty and sarcopenia is also greater in the HIV+ population compared to the 
age-matched general population (Centers for Disease Control and Prevention, 2013; Desquilibet et 
al., 2007; Piggott et al., 2016; Kooij et al.,2016; Echeverria et al., 2018).  
Both frailty and sarcopenia are known to be a multisystem conditions involving the metabolic, 
musculoskeletal, neuroendocrine, immune, and cognitive systems (Clegg et al., 2013; Fried et al., 
2001). Although the exact pathophysiological mechanisms underpinning frailty have yet to be fully 
elucidated, factors such as chronic inflammation (Soysal et al., 2016; Leng et al., 2007), 
immunosenescence (Dihn et al., 2019), cell senescence (Lehman et al., 2018; Xu et al., 2018), 
decreased stem cell availability (Sousa-Victor et al., 2016; Fry et al., 2015; Gonen & Toledana, 2014; 
Larrick & Mendelson, 2017), insulin resistance (Cacciatore et al., 2013; Hubbard et al., 2010; Perez-
Tasigchana et al., 2017), and mitochondrial dysfunction (Ferrucci & Zampino, 2020; Ashar et al., 
2015; Andreux et al., 2018) have been implicated as causative factors. In addition, declines in 
mitochondrial function are known to contribute to the pathogenesis and pathophysiology of each 
respective factor (Ferruci & Zampino, 2020).  
Age-related declines in skeletal muscle function is widely acknowledged to be a significant causative 
factor in both frailty and sarcopenia (Mitchell et al., 2012; Cruz-Jentoft et al., 2019). Whilst many of 
the pathophysiological factors are known, such as changes in fibre type composition (Murgia et al., 
2017; Ubaida-Mohien et al., 2019), intramyocellular lipid accumulation (St-John-Pelletier et al., 2017, 
lipofuscin accumulation (Reeg & Grune, 2015), or decreased stem cell prevalence (Fry et al., 2015; 
Lopez-Otin et al., 2013), no previous studies have investigated the specific link between these factors 
and the potential role they play in the context of frailty and sarcopenia in the older HIV+ population.  
Whilst the preceding chapters have investigated adverse ageing phenotypes in older PLWH (Chapter 
5) and the impact of skeletal muscle mitochondrial dysfunction in these individuals (Chapter 6), this 
chapter aims to better understand the role of several other potential pathophysiological  processes 
affecting skeletal muscle, and the role that these factors may play in adverse ageing phenotypes in 
older PLWH.   
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7.1.1 Fibre type composition 
Skeletal muscle fibres are multinucleated single cells, and in human skeletal muscle there are three 
types of fibres – one ‘slow twitch’ (type I) and two ‘fast twitch’ (type IIa and IIx). Each respective 
fibre type is composed of specific isoforms of myosin heavy chain (MHC), and this determines the 
fibre type functions, contractile capabilities and metabolic profile (Scott et al., 2001).  
Type I fibres are slow twitch due to their oxidative metabolism, while type IIa fibres are composed of 
a mix of slow and fast twitch MHCs, and type IIx are fast twitch and so completely glycolytic (Burke 
et al., 1971; Berchtold et al., 2000). Due to their oxidative metabolism, type I fibres have a higher 
abundance of mitochondria, mtDNA, mtrRNA, and mtmRNA compared to both type IIa and type IIx 
fibres, and thus have a higher oxidative capacity (Howald et al., 1985; Picard et al., 2012; Picard et 
al., 2008). As expected, there is a higher activity of PGC-1a in type I fibres, and it has been suggested 
that PGC-1a expression could drive the conversion of the fast twitch fibres into type I fibres through 
upregulation of various transcription factors (calcineurin signalling; Mef2; MAPK signalling) (Lin et 
al., 2002; Olson et al., 2008; Murgia et al., 2017). Adult skeletal muscle displays impressive plasticity, 
and as well as in response to degeneration from ageing, fibre type conversion and increase in 
mitochondrial content can occur in response to endurance training and mechanical overload (Chin, 
1998; Olson, 2008; Nielsen et al., 2010).  
Importantly, the selected atrophy of certain fibres and fibre type switching occurs with ageing 
(Larsson et al., 2019). The proportion of type I fibres increases with age, whilst the proportion of 
type IIa and IIx decrease with age (Brunner et al., 2007; Grimby, 1995; Murgia et al., 2017; Ubaida-
Mohien et al., 2019; Roberts et al., 2018; Verdijk et al., 2009; 2010; 2012; 2014; McKay et al., 2012; 
2013), and this is suspected to contribute to frailty and prefrailty (St-Jean Pelletier et al., 2017; 
Sonjak et al., 2019). Whilst the exact mechanisms are unknown, it has previously been demonstrated 
that there is a general upregulation in the expression of ribosomal proteins in type I fibres, and a 
simultaneous downregulation in their expression in both type IIa and IIx fibres (Rose et al., 2009), as 
well as increased denervation with age (Rowan et al., 2012). This suggests a decline in sarcomere 
quality control in both type IIa and IIx fibres. Another alternative mechanism could be the declining 
fuel sources available to fast twitch fibres with age. As such, fast twitch fibres contain a higher 
concentration of glycogen (required for glycolysis) than slow twitch fibres, and muscle glycogen 
contents are known to decrease with age (Nielsen et al., 2011).  
As mentioned previously, skeletal muscle mass and strength decline with age. At the cellular level, 
larger fibres are commonly the more glycolytic type IIa and IIx fibres, indicating an inverse 
relationship between VO2max and fibre size (Van Der laarse et al., 1998). Muscle fibre size has also 
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been shown to decrease with age, although this decrease primarily occurs in both type II fibres 
compared to type I fibres (St-Jean Pelletier et al., 2017; Sonjak et al., 2019). This could be due to the 
fact that the fast twitch fibre types are generally smaller (Dreyer et al., 2006; Van Der Laarse et al., 
1998). As type II fibres are primarily glycolytic and heavily involved in resistance activities, this age-
related decrease in fibre size has been suggested to contribute to the decline in muscle function with 
age (Miljkovic et al., 2015). In addition to the decrease in average fibre size with age, the total 
number of muscle fibres also decreases with age, suggesting an age-related increase in fibre atrophy 
(Lexell et al., 1983).  
A recent investigation into the proteomics of the fibres type in both old and young individuals 
demonstrated a reduction in the expression of OXPHOS complexes in both slow and fast twitch 
fibres with age, although this was more pronounced in the fast twitch fibres (Murgia et al., 2017). In 
addition, the expression of proteins involved in regulating mitochondrial dynamics such as MFN2 
and OPA1 (involved in mitochondrial fusion) is decreased in older fibres, whilst the expression of 
proteins involved in proteolysis and autophagy are increased. Finally, enzymes involved in the TCA 
cycle were also elevated in older fibres. This coincided with the age-related increase in the 
expression of proteins involved in glycolytic metabolism in type I fibres, indicating a general decline 
in skeletal muscle mitochondrial homeostasis with age (Murgia et al., 2017; Murgia et al., 2019). As a 
result, both skeletal muscle oxidative function in the form of OXPHOS complex prevalence, as well as 
fibre type proportions, were investigated in a cohort of older PLWH in this study.  
Type I fibres are more likely to undergo hypertrophy compared to type II fibres. One reason for this 
is due to the fact that the highly oxidative type I fibres contain more myonuclei per mm of fibre 
length than the glycolytic fibres, and hypertrophy is dependent on newly formed myonuclei (Sayegh 
& Lajtha, 1989). In addition, a higher proportion of type I MHC mRNA compared to type IIa MHC 
mRNA, as seen in type I fibres, is associated with a faster rate of protein synthesis and better 
regulated protein homeostasis (Toth & Tchernof, 2006). Interestingly, type I fibres have a higher rate 




7.1.2 Skeletal muscle satellite cell decline with age  
Declines in tissue homeostatic and regenerative capacity are a common characteristic of ageing, 
which is driven at the cellular level by the reduction in functioning stem cell capacity (Jones & Rando, 
2011; Dorshkind et al., 2009). Tissue repair and regular homeostasis in adults requires a functioning 
population of undifferentiated pluripotent stem cells within fully differentiated tissue. These stem 
cells are contained in a systemically controlled microenvironment termed the ‘niche’, where various 
trophic and growth factors, as well as cytokines, regulate and maintain the stem cells (Jasper & 
Kennedy, 2012).  
In skeletal muscle, stem cells are termed satellite cells (SCs) and are located beneath the basal 
lamina of mature myofibres (Mauro, 1961). SC niches are established in early development and 
remain in a quiescent state, characterised by expression of the paired-box protein (Pax7), until 
induced by injury or stress (Yin et al., 2013; Dell’Orso et al., 2019). In response to injury or stress, 
these Pax7+ SCs become activated and begin to proliferate, before committing to one of three 
pathways: (a) exiting the cell cycle; (b) differentiation and fusion in order to repair damaged 
myofibres or form new myofibres, or (c) self-renewal in order to replenish and maintain the SC pool 
(Weissman, 2000). In addition, the myogenic regulatory factors Myf5 and MyoD, which are involved 
in embryonic muscle development, are required for skeletal muscle regeneration in adults 
(Yamamota et al., 2018). In the past few years single cell RNA sequencing and proteomics have 
confirmed the heterogeneity of SCs within SC pools in normal resting adult muscle, and has 
confirmed the presence of the core cell types -  quiescent SCs, activated SCs, primary myoblasts and 
committed progenitors (Porpiglia et al., 2017; Rubenstein et al., 2020; Dell’Orso et al., 2019; Barruet 
et al., 2020).    
With regards to pathway (b), quiescent Pax7+ SCs become activated, enter the cell cycle and acquire 
MyoD expression, which facilitates their expansion. Next, activated SCs will then either commit to 
differentiation, and in doing so downregulate Pax7 expression, or alternatively return to quiescence 
in the niche by losing MyoD expression and undertake MyoD-induced Myogenin activation (pathway 
(c)). Differentiating SCs then further proliferate and express Myogenin, which in combination with 
other myogenic differentiation factors such as myocyte enhancer factor 2 (Mef2), activates 
downstream genes. This allows differentiated myoblasts to fuse with either an existing fibre or 
contribute to the development of new and growing myotubes (Almada & Wagers, 2016) (Figure 7.1).  
As mentioned above, ageing is characterised by the decline in stem cell function (Lopez-Otin et al., 
2013). The regenerative potential of SCs has been shown to decline with age, and this decline is 
particularly pronounced in sarcopenic muscle, where there is an increased formation of fibrotic 
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tissue (Zwetsloot et al., 2013; Sousa-Victor et al., 2014; Fry et al., 2015). The consequences of 
dysfunctional SC dynamics will reduce the individual’s capacity to respond to hypertrophic stimuli 
such as exercise, or respond to stressors and injury (Blau et al., 2015; Cartee et al., 2016). 
Interestingly, work from in vitro studies has demonstrated that Pax7 null muscles are smaller, 
contain less nuclei, have a narrower diameter compared to normal Pax7+ SCs, and have an earlier 
mortality (Oustanina et al., 2004; Kuang et al., 2006). 
7.1.2.1 Mechanisms of age-related Pax+ SC decrease 
Whilst the exact mechanism for the age-related decline in skeletal muscle SCs is yet to be fully 
elucidated, several mechanisms have been proposed. These include changes in the niche leading to 
poor trophic signalling response, or declines in the systemic signalling modulation (Conboy et al., 
2005; Brack et al., 2007; Rando & Chang et al., 2012; Carlson et al, 2009). The underlying genetic 
mechanisms for these phenomena are the increased expression of genes associated with FOXO 
regulation, which is responsible for atrophy. In addition, aged SCs have abhorrently altered genes 
associated with mitochondrial function and protein homeostasis (Pietrangelo et al., 2009; Bortoli et 
al., 2003). Herein, a recent in vitro study demonstrated that SCs with a higher burden of somatic 
mutations proliferate and differentiate slower than SCs with a lower mutational burden (Franco et 
al., 2018). Alternatively, aged SCs display declines in Notch signalling. This is due to the age-
associated downregulation of Notch ligands, which are responsible for regulating the proliferation of 
activated SCs (Conboy et al., 2003). These age-related changes have been shown to decrease the 
activation, proliferative and differentiation potential of SCs (Shadrach & Wagers, 2001; Roth et al., 
2000; Shefer et al., 2006; Day et al., 2010; Charge et al., 2002).  
Additionally, the proportion of Pax7+ SCs in skeletal muscle is roughly 30% at birth but falls to 
roughly 5% in adults and 2% in older mice (Gopinath & Rando, 2008).  
Age-related increases in cell senescence and apoptosis are also known to affect SC populations. Age-
associated decline in the proliferation potential and function of stem cells has been shown to be 
associated with increased senescence (Sousa-Victor et al., 2014) and subsequently attenuated by 
ablation of p16INK4a (Janzen et al., 2006), whilst telomere shortening has been reported in several 
stem cell compartments (Flores et al., 2008). In addition, age-related DNA damage accumulation 
impairs several mechanisms of SC function such as quiescence, self-renewal, and regeneration (Rossi 
et al., 2007; Sousa-Victor et al., 2014). Interestingly, SCs have been shown to enter alternative 
differentiation programmes such as those towards adipogenic or fibrogenic fates, with increasing 
frequency with age, thereby reducing the functional capacity of the niche whilst simultaneously 
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increasing adiposity and fibrosis in skeletal muscle, both of which significantly contribute to 
sarcopenia and frailty (Taylor-Jones et al., 2002).   
The final set of factors that affect SC function with age are changes in extrinsic signals from the SC 
microenvironment. In particular, age-related declines in transforming growth factor β inhibit SC 
proliferation by altering Notch signalling (Baltgalvis et al., 2008), whilst declines in Wnt, responsible 
for differentiation following Notch-dependant proliferation, and Transforming Growth Factor (TGF- 
β) signalling have also been demonstrated in aged individuals (Brack et al., 2007; Conboy et al., 
2003; Conboy et al., 2005; Carlson et al., 2009).  
Adult SC niches are often under hypoxic conditions and so utilise glycolysis as a metabolic pathway 
when quiescent (Suda et al., 2011; Escribese et al., 2012; Chandel et al., 2016). When undergoing 
proliferation and differentiation, myoblasts switch from glycolysis to OXPHOS. This metabolic switch 
is mediated by high levels of mitophagy (Domenech et al., 2015; Esteban-Martinez et al., 2017; 
Rajasekaran et al., 2020). Differentiation can also be impaired by the age-associated dysregulation of 
redox status and oxidative stress (Rajasekaran et al., 2020). Collectively, these factors suggest that 
the age-related dysregulation of mitochondrial dynamics could have an adverse effect on SC 
function in adult skeletal muscle, hence why I investigated pax7+ SC prevalence and skeletal muscle 
mitochondrial dysfunction in the form of OXPHOS complex deficiency in older PLWH. 
Finally, SCs require a tightly coordinated regulation of epigenetic modifications, such as DNA 
methylation (Carrio et al., 2015; Carrio et al., 2016), histone modifications (Asp et al., 2011), and 
transcription factor activation of MRFs via specific muscle miRNA (myomiRs) (Chen et al., 2006; Chen 
et al., 2010; Rao et al., 2006) in order retain SC niche dynamics and function. Therefore, the age-
related decline in epigenetic regulation contributes to the dysregulation of SC niches with age. 
Altogether, previous research in the field of muscle stem cells and ageing has demonstrated that 
there are various factors that contribute to the  age-related decline of Pax7+ SCs. However, in this 
study I will be focusing on whether age-related declines in skeletal muscle mitochondrial function 
contribute to muscle stem cell declines, and whether these factors predict physiological decline and 








7.1.3 Neuromuscular junction decline with age 
Age is associated with a decline in neurophysiological functions, and this decline is implicated in the 
progressive loss of muscle mass and strength with age.  
Autopsy and clinical studies have demonstrated that ageing skeletal muscle undergo greater levels 
of denervation, which leads to a loss of muscle mass and function (Hepple & Rice, 2016; Mosole et 
al., 2014; Messi et al., 2016; Rowan et al., 2012). Denervation is regularly compensated by a re-
innervation programme which aims to replace the damage from denervation in a continuous cycle. 
As individuals age the rate of reinnervation deteriorates and denervated fibres thus become 
apoptotic. This leads to muscle atrophy and contractile dysfunction (Rowan et al., 2012; Gonzalez-
Freire et al., 2014). This ageing phenomenon has been supported by studies showing the age-
dependant increase in muscle fibres positive for denervation-responsive sodium channels (Rowan et 
al., 2012) (Figure 7.2). The denervation-reinnervation cycle is also an important process as it can 
alter fibre type conformations and remodels the spatial domain of motor units (Hepple & Rice, 
2016). 
Mitochondria play important roles in the NMJ, as they provide energy and act as the buffer for the 
large calcium ion loads needed to conduct an action potential (Barrett et al., 2011). Mitochondrial 
abnormalities have been identified in the pre-synaptic region of the NMJ. These abnormalities 
include cristae swelling and fragmentation, formation of megamitochondria in aged rats, and 
reduction in mitochondrial respiratory capacity. Importantly, these factors appear to correlate with 
denervation (Garcia et al., 2013; Spendiff et al., 2016). In axon terminals that contain abnormal 
mitochondria there is a reduction in ETC efficiency, an increase in ROS and an increased 
susceptibility to permeability transition (Garcia et al., 2013; Trounce et al., 1989; Hepple & Rice, 
2016). Whilst it is well understood how age-related mitochondrial abnormalities may contribute to 
NMJ denervation, the extent of which it actually contributes to the physiology of age-related 
declines remain controversial. Hence, a study of aged human limb segments found that 95% of 
muscle fibre segments with high levels of pathogenic mtDNA mutations did not exhibit atrophy (Bua 
et al., 2006). In contrast, an alternative study of post-mortem spinal cord motoneurons of elderly 
individuals found evidence of mtDNA depletion, but not mtDNA deletions (Rygiel et al., 2014).  
As it has been difficult to study the dynamics of the NMJ in humans, several mouse models originally 
developed to study neurodegenerative diseases have been increasingly utilised. One of the foremost 
mouse models is one with a homozygous deletion of the Cu/Zn superoxide dismutase (Cu/Zn SOD), 
which develops age-related muscle atrophy as a result of mitochondrial dysfunction, a switch to type 








7.1.4 Skeletal muscle insulin resistance  
Under basal conditions, skeletal muscle is responsible for approximately 80% of insulin-stimulated 
glucose uptake as well as regulation of several metabolic functions (Petersen et al., 2002; Petersen 
et al., 2007). Insulin resistance (IR) is defined as the decline in the ability of insulin to stimulate 
glucose uptake from peripheral tissues, such as skeletal muscle and the liver. 
In physiological conditions, insulin promotes glucose uptake via the canonical IRS-PI3K-Akt pathway 
as well as stimulating glucose transported type (GLUT) 4 translocation to the membrane by 
inactivating the Akt substrate 160 (AS160). This in turn promotes GLUT4 fusion with the plasma 
membrane and subsequent uptake of glucose (Sakamoto & Holman, 2008) (Figure 7.3).  
Skeletal muscle IR is primarily caused by the prolonged exposure to high levels of fatty acids such as 
palmitic and stearic acids (Hirabara et al., 2010; Yuzefovych et al., 2010). In brief, this leads to 
oxidative stress, alterations in gene transcription, as well as increases in inflammation and 
mitochondrial dysfunction (Hirabara et al., 2007; Griffin et al., 1999; Randle et al., 1963; Calvalho-
Filho et al., 2005). 
The first proposed mechanism for the pathogenesis of skeletal muscle IR was from Randle and 
colleagues, who demonstrated that elevated fatty acid oxidation increased acetyl-CoA production. 
Elevated levels of acetyl-CoA then inhibited pyruvate dehydrogenase activity and increased citrate 
levels. Next, citrate in combination with a higher ATP:ADP ratio inhibited phosphofructokinase, 
which subsequently reduced glucose flux and resulted in hexokinase II inhibition, increased cellular 
glucose content, and therefore a reduction in glucose uptake (Randle et al., 1963; Randle, 1998; 
Dresner et al., 1999). This finding has been further supported by several in vivo and in vitro studies 
(Jenkins et al., 1988; Boden & Chen, 1995; Griffin et al., 1999; Roden et al., 1996; Rothman et al., 
1992).  
Several studies have additionally demonstrated the ability of saturated fatty acids to alter insulin 
signalling (Hirabara et al., 2010; Roden et al., 1996; Hawley et al., 2000; Savage et al., 2007). As such, 
elevated levels of saturated fatty acids have been shown to reduce the activation of PI3-kinase, JNK, 
mTOR, and Akt signalling pathway activation due to decreased Insulin Receptor Substrate 1 (IRS-1) 
phosphorylation (Yu et al., 2002, Kim et al., 2000). These signalling pathways are involved in growth 
and glucose sensitivity and so decreased activation of these signalling pathways subsequently 
contribute to declines in insulin sensitivity and tissue dysfunction (Zisman et al., 2000).  
Another pathophysiological mechanism underpinning fatty acid-induced IR is the induction of 
lipotoxicity. This occurs as a result of levels of circulating fatty acids exceeding uptake and storage 
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capabilities in white adipose tissue (Consitt et al., 2009). This lipotoxicity and increased levels of 
circulating fatty acids and fatty acid derivatives such as diacylglycerol, ceramides, triacylglycerol and 
sphingosines are associated with glucose intolerance and therefore IR (Chavez et al., 2003; Holland 
& Summers, 2008; Lipina & Hundal, 2011).  
Increased levels of circulating fatty acids also increase the activation of inflammatory pathways 
through the interaction with members of the Toll-like receptor (TLR) family, in addition to increasing 
the production and secretion of cytokines such as IL-6, IL-1 and TNF-α (Haversen et al., 2009; Wen et 
al., 2011; Dali-Yousef et al., 2013). One example is the increased activation of the NF-κB pathway in 
skeletal muscle via JNK and IKK complex activation, which indirectly promotes IRS-1 inhibition 
(Hotamisiligil et al., 1993). Importantly, increased macrophage and T cells levels have also been 
demonstrated in skeletal muscle of type 2 diabetes mellitus (T2DM) and obese-induced IR patients 
(Khan et al., 2015; Varma et al., 2009; Patsouris et al., 2014; Fink et al., 2014), and a mice fed with a 
high-fat diet to induce IR also exhibited increased accumulation of skeletal muscle immune cells, 
indicating increased inflammation in IR (Olefsky & Glass, 2010; Patsouris et al., 2014; Nguyen et al., 
2007; Fink et al., 2013; Hong et al., 2009; Lee et al., 2011). Importantly, immune cell accumulation 
and increased TNF-α signalling have both been shown to adversely impact IR by contributing to the 
inhibition of IRS-1 signalling (Khan et al., 2015; Austin et al., 2008; Schmitz-Peiffer & Biden, 2008). 
7.1.4.1 Links between age-related mitochondrial dysfunction and insulin resistance  
One of the most significant responses to increased saturated fatty acid levels is the alteration in 
gene expression. Examples include alterations to enzymes involved in the glycolysis pathway such as 
pyruvate dehydrogenase kinase isozyme 1 (PDK-1) and lactate dehydrogenase (LDHA) (Xu et al., 
2006; Lopez et al., 2004). Additionally, the downregulation of PCG-1α expression, as well as 
downregulation of mtDNA genes encoding OXPHOS complexes (Sparks et al., 2005; Heilbronn et al., 
2007) and other genes involved in regulating mitochondrial function, such as NRF-1 and NRF-2, also 
occurs (Scarpulla, 2008). Taken together, these findings indicate that altered gene expression in 
response to increased levels of saturated fatty acids results in the dysregulation of normal 
mitochondrial and metabolic function, resulting in decreased insulin sensitivity and therefore IR. As a 
result, in this study I investigated intramyocellular lipid accumulation and ETC CI and CIV prevalence 
in the context of adverse ageing phenotypes in older PLWH.  
Another important pathogenic factor is increased ROS production and oxidative stress. ROS are 
involved in several signalling pathways implicated in modulating insulin sensitivity and other 
metabolic functions, and so significantly elevated ROS levels are associated with impaired IRS-1 
activation and therefore decreased GLUT4 transcription and function (Bloch-Damti & Bashan, 2005; 
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Anderson et al., 2009). In addition, oxidative stress causes molecular damage to proteins and DNA, 
which will lead to the abhorrent processes described above. Taken together, imbalances to the 
redox potential will result in impaired glucose tolerance (Rains & Jain, 2011). This theory has been 
supported by in vitro studies which demonstrated the reduction in insulin-stimulated glucose uptake 
in response to elevated H2O2 levels (Maddux et al., 2001). This is also supported by the 
demonstration of elevated ROS levels in cellular models for IR (Houstis et al., 2006), and the fact that 
overexpression of the antioxidant mitochondrial superoxide dismutase (MnSOD) in rodent models 
improved insulin sensitivity and glucose uptake (Hoehn et al., 2009; Boden et al., 2012). Importantly, 
T2DM, metabolic syndrome and obesity are all associated with increased ROS in skeletal muscle 
(Abdul-Ghani et al., 2008; Bonnard et al., 2008; Kumashiro et al., 2008).  
Significantly, several studies have demonstrated a decline in mitochondrial content and function in 
T2DM and insulin-resistant obese individuals (Holloway et al., 2007; Schrauwen-Hinderling et al., 
2007). Decreased mitochondrial fatty acid oxidative capacity was also demonstrated in primary 
myocytes derived from T2DM patients (Kim et al., 2000; Hulver et al., 2003; Ukropcova et al., 2005), 
and humans and rats supplemented with a high-fat diet displayed decreases in PGC-1 signalling, 
oxygen consumption and ATP synthesis (Brehm et al., 2006; Sparks et al., 2005; Desco et al., 2002; 
Erdei et al., 2006; Szendroedi et al., 2009). One of the pathogenic mechanisms underpinning these 
abnormalities is the increased prevalence of mtDNA mutations in T2DM and insulin-resistant obese 
individuals (Lim et al., 2001; Guo et al., 2005; Juo et al., 2010). These could cause alterations in 
mitochondrial homeostasis and ultimately lead to increased inflammation and oxidative stress, as 
mentioned above. As such, fatty acid induced mitochondrial fission has been shown to be associated 
with reduced insulin-stimulated glucose uptake. Finally, a recent study demonstrated lower 
mitochondrial oxidative capacity (as measured by 31P-MRS) was associated with a more severe 
HOME-IR score, as well as decreased insulin sensitivity (Fabrri et al., 2017). This finding is supported 
by other patient-based studies which have shown the positive correlation between mitochondrial 





Figure 7.3 – Normal insulin signalling and insulin signalling in IR muscle. (A) Insulin binds to the insulin receptor, which subsequently induces its conformational change and phosphorylation, 
leading to the recruitment and phosphorylation of insulin receptor substrate (IRS) and Shc proteins. Shc then activates the RAS/RAF/MAPK pathway which leads to the upregulation in mRNA 
translation and protein synthesis. IRS activates the PI3K/AKT signalling pathway which leads to mitochondrial-induced gluconeogenesis as well as cell growth and differentiation, and glycogen 
synthesis. In addition, this pathway induces the production of GLUT4 transporters and increased GLUT4 signalling. (B) In the presence of increased free fatty acids there is a decline in baseline 
insulin signalling due to increased competition for the insulin receptor. This prevents the signalling pathways activated in normal insulin signalling and thus prevents the downstream effects of 




7.1.5 Lipofuscin accumulation  
Lipofuscin granules are autofluorescent pigments composed of highly oxidised, cross-linked lipids 
and misfolded proteins (Hohn et al., 2010; Konig et al., 2017; Rodolfo et al., 2018). Due to the highly-
oxidised nature of lipofuscin granules, they cannot be degraded and so accumulate with age in 
lysosomes and cytoplasm in post-mitotic tissues such as neurons, cardiac and skeletal muscle (Brunk 
& Terman 2002, Hohn & Grune 2013, Moreno-Garcia 2018).  
Previous studies have indicated that lipofuscin accumulation accentuates age-related 
pathophysiological factors by inhibiting the proteasome, and therefore proteolytic removal of 
damaged proteins - leading to an increase in ROS production, cytotoxicity and inflammation (Reeg & 
Grune, 2015). Lipofuscin accumulation in lysosomes also adversely impacts protein homeostasis and 
decreases the efficiency of autophagy, which can lead to the inefficient clearance of damaged 
mitochondria (Terman & Bunk 2004; Ryhanen et al., 2009; Hohn et al., 2011; Reeg & Grune, 2015; 
Terman et al., 2010). Both these mechanisms lead to further oxidation of proteins and lipids, 
increasing the formation and accumulation of lipofuscin pigments, and subsequent dysregulation of 
lysosomal activities. In addition, previous studies have demonstrated that the accelerated 
accumulation of lipofuscin is linked to the pathogenesis of Parkinson’s disease (Ulfig, 1989) and 
Alzheimer’s Disease (Mountjoy et al., 2005). 
Although not extensively proven, Terman and Brunk postulated the ‘mitochondrial-lysosomal axis 
theory of aging’, which states that the incomplete degradation of mitochondria through mitophagy 
is the primary cause of lipofuscin accumulation (Brunk & Terman, 2002; Terman et al., 2010; Konig et 
al., 2017).  
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7.2 Experimental aims  
Age-related decline in skeletal muscle function is recognised as one of the significant causative 
factors in adverse ageing phenotypes seen in the general population and PLWH (Mitchell et al., 
2012; Cruz-Jentoft et al., 2019).  
Whilst numerous observational and longitudinal cohort studies have identified several risk factors 
that contribute to the age-related decline in skeletal muscle function, such as mitochondrial 
dysfunction and intramyocellular lipid accumulation (IMCL), the underlying pathophysiological 
mechanisms remain not fully understood. In addition, few studies have investigated the level and 
role of several of these skeletal muscle pathophysiological factors in the ageing with HIV setting. 
Therefore, in this study I sought to: 
• Determine the prevalence of several age-related skeletal muscle pathophysiological 
factors including IMCL, quiescent stem cell prevalence, fibre type composition, fibrosis, 
lipofuscin accumulation, and the proportion of regenerated and degenerated fibres, in 
older PLWH compared with age-matched HIV- individuals. 
• Determine whether skeletal muscle CI and CIV deficiency as well as mitochondrial mass 
is predictive of these age-related skeletal muscle pathophysiological factors in older 
PLWH.  
• Determine the associations between these pathophysiological skeletal muscle factors, 
and whether they are predicted by any of the clinical, HIV-related, physical, or lifestyle 
parameters.   
• Determine whether any of these pathophysiological factors are associated with adverse 





7.3.1 Patient cohort  
This study was approved by the research ethics committee (Newcastle and North Tyneside 2 (17-NE-
0015)). Skeletal muscle samples were taken by percutaneous biopsy from older (≥ 50 years) HIV-
infected males (n = 30) as well as HIV-uninfected males (n = 15) as part of the MAGMA study (Table 
3.1), with patients giving prior written permission.  
7.3.2 Immunofluorescence and fluorescence histochemistry 
7.3.2.1 Duplex fluorescence histochemistry for the quantification of intramyocellular lipid 
accumulation 
Fluorescence histochemistry was carried out on 10μm frozen transverse muscle sections in order to 
detect and quantify intramyocellular lipid droplets in skeletal muscle fibres, as described in Section 
3.4.6. 
7.3.2.2 Image acquisition and analysis of intramyocellular lipid accumulation 
Fluorescent images were acquired using a Zeiss Axio Imager M1 and Zen 2011 (blue edition) 
software with a Monochrome Digital Camera (AxioCam MRm) at 20x magnification, and analysed as 
described in Section 3.4.7. 
7.3.2.3 Duplex immunofluorescence for the quantification of Pax7+ satellite cells  
10µm cryosections were subjected to a duplex immunofluorescence staining assay, as described in 
Section 3.4.8 in order to quantify the prevalence of quiescent Pax7+ satellite cells. 
7.3.2.4 Image acquisition and analysis for quantification of Pax7+ satellite cells 
Fluorescent images were acquired and the prevalence of Pax+ satellite cells was quantified as 
described in Section 3.4.9. Briefly, the number of myofibres per biopsy as well as the prevalence of 
Pax7+ cells (characterised by colocalised staining in the DAPI and Pax7 channels) was quantified in 
each subject in order to determine the proportion of Pax7+ satellite cells per 100 fibres.  
7.3.2.5 Multiplex immunofluorescence for fibre type quantification  
Multiplex immunofluorescence for the quantification of fibre types I, IIa, and IIx as well as fibre 
cross-sectional area (µm2) was performed as described in Section 3.4.10. 
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7.3.2.6 Image acquisition and analysis of fibre type quantification  
Fluorescent images were acquired using a Zeiss Axio Imager M1 and Zen 2011 (blue edition) 
software with a Monochrome Digital Camera (AxioCam MRm) at 20x magnification, as described in 
Section 3.4.11. 
7.3.2.7 Preparation of slides for lipofuscin quantification, image acquisition and analysis 
For the quantification of skeletal muscle lipofuscin accumulation, 10µm transverse cryo-sections 
were removed from -80°C storage and air-dried for 1 hour. Sections were then immediately cover-
slipped with Prolong gold and stored at -20°C until imaged. Image acquisition and analysis was 
performed using Columbus Image Data Storage and Analysis System software as described in Section 
3.4.12. 
7.3.3 Histochemistry  
7.3.3.1 Haematoxylin & Eosin histochemistry staining and imaging for the quantification of 
regenerated and degenerated skeletal muscle fibres 
10µm cryosections were subjected to haematoxylin & eosin histochemistry in order to quantify to 
proportion of regenerated and degenerated myofibres, as described in Section 3.5.2. 
7.3.3.2 Masson’s trichrome histochemistry for skeletal muscle fibrosis  
Masson’s trichrome histochemistry was performed on 10µm cryosections in order to quantify 
skeletal muscle fibrosis, as described in Section 3.5.3. 
7.3.3.3 Brightfield microscopy 
Brightfield images were acquired using a Zeiss Axio Imager M1 and Zen 2011 (blue edition) software 
with a chromatic digital camera (AxioCam MRm) at 10x magnification, as described in Section 3.5.5. 
7.3.4 Statistical analysis  
Statistical analysis was performed in Prism v5.04, IBM SPSS Statistics v23 and Microsoft Excel 2016. 
Graphs were produced in Prism v5.04.  
Normality was assessed by Shapiro-Wilk tests. Statistical differences in the various pathogenic 
muscle parameters between the HIV+ and HIV- individuals as well as PLWH stratified by 
frailty/prefrailty and sarcopenia/presarcopenia was determined by unpaired t tests for normalised 
data and Mann-Whitney tests for non-normally distributed data sets. Differences in skeletal muscle 
pathogenic factors between frail, prefrail, and robust PLWH as well as between sarcopenic, 
presarcopenic, and non-sarcopenic PLWH were determined by one-way ANOVA with Tukey’s 
multiple comparisons test to investigate differences between the comparator groups. Fisher’s exact 
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test was performed in order to determine differences in the various pathogenic muscle parameters 
in nominal data sets such as stratification by smoker status. 
Unadjusted linear regression analysis between pathophysiological skeletal muscle factors and clinical 
as well as physical factors was performed using linear regression and Pearson’s correlation for 
normally distributed data, or Spearman correlation for non-normally distributed data. Adjusted 
linear multivariate regression analysis was also undertaken, with respective models including age 
and factors determined to be significant from univariate analysis as independent variables and 
predicted factors as the dependant variable. Reported outcomes of multivariate linear regression 
analysis included unstandardised regression coefficients and their significance, as well as the fit of 
the models and how much variance (adjusted r2) they accounted for. This is described further in the 
relevant results sections.  
Statistical significance was set at p ≤ 0.05.   
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7.4 Results  
7.4.1 No difference in intramyocellular lipid accumulation between older HIV+ and 
HIV- individuals  
In order to investigate intramyocellular lipid accumulation (IMCL), I initially qualitatively classified 
individual muscle fibres into one of four groups depending on expression of Bodipy: Bodipy+++ for 
fibres with very high expression of punctate bodipy-stained granules, then Bodipy++, Bodipy+ and 




Figure 7.4 – Example fluorescence image depicting the qualitative classification system used to quantify IMCL. Bodipy+++ 
fibres display extensive and bright Bodipy staining coverage; Bodipy++ fibres display slightly less coverage with less intense 
staining; Bodipy+ fibres display patchy coverage with weak staining intensity, and Bodipy- fibres display no Bodipy granules. 
Scale bars = 50µm. 
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The percentage of fibres in each respective Bodipy class was quantified for the individual subjects (n 
= 45). This data was then subsequently log transformed and normalised to allow the use of 
parametric tests (Figure 7.5).  
 
 
Figure 7.5 – Proportion of fibres with IMCL. Dot plot (mean ± SEM) representing Log10 percentage of Bodipy+++, Bodipy++, 
Bodipy+ and Bodipy- fibres for both the HIV+ (n = 30) and HIV- (n = 15) individuals. Each dot represents an individual 
patient.  
 
There were no significant differences in expression of any of the bodipy categories between the HIV+ 
and HIV- groups (unpaired t tests).  
I next grouped the Bodipy+++ and Bodipy++ categories together to generate a classification of 
abnormal bodipy expression. This was the used as the primary group for compassions – the ‘Bodipy 
abnormal (BodipyAbn)’ group.  
Here, there was no significant difference in the proportion of BodipyAbn fibres between the HIV+ or 
HIV- groups (unpaired t test) (Figure 7.6b), nor the proportion of Bodipy- fibres between the 







Figure 7.6 – Proportion of BodipyAbn and Bodipy- fibres. (A) Representative images of skeletal muscle sections from a 
HIV+ and HIV- individual depicting Bodipy (493/503) staining. Scale bar = 50µm; Dot plots (mean ± SEM) depicting (B) the 
log10 proportion of BodipyAbn fibres for HIV+ (n = 30) and HIV- (n = 15) individuals, and (C) the log10 proportion of Bodipy- 







7.4.2 Impact of NRTI and PI use on IMCL in older PLWH 
I wanted to investigate whether IMCL was predicted by current exposure to particular ARVs, such as 
nucleoside reverse transcriptase inhibitors (NRTIs) or protease inhibitors (PIs), as previous studies 
have demonstrated a link between these classes of ARV and lipodystrophy (Glidden et al., 2018; Carr 
et al., 1999; Dragovic et al., 2014; Miller et al., 2003; McComsey et al., 2016). Herein, HIV+ 
individuals who had been exposed to mitochondrially toxic NRTIs (didanosine (ddI), zalcitabine (ddC), 
stavudine (d4T), and zidovudine (AZT)) (n = 11) had a significantly lower proportion of IMCL (defined 
as BodipyAbn, see above) compared to HIV+ individuals who had not been exposed to those 
respective NRTIs (n = 19, p = 0.024, unpaired t-test) (Figure 7.7a). There was no significant 
difference in IMCL between HIV+ individuals who had been exposed to PIs (n = 9) and those who had 
not (n = 21) (Figure 7.7b). 
Of the mitochondrially-toxic NRTIs, AZT and d4T have in particular been shown to be associated with 
fat redistribution elsewhere in the body (Moyle et al., 2006; Jones et al., 2005; Domingo et al., 2014; 
Dragovic et al., 2014; de Waal et al., 2013). I therefore tested the association between 
current/previous exposure to AZT and/or d4T and IMCL. Interestingly, I found that HIV+ subjects 
exposed to AZT/d4T (n = 10) had a significantly lower proportion of BodipyAbn fibres than the HIV+ 
















Figure 7.7 – Proportion of BodipyAbn fibres and ART regimens. Dot plots (mean ± SEM) depicting the log10 proportion of 
BodipyAbn fibres in (A) HIV+ individuals who have been exposed to mitochondrially-toxic NNRTIs (n = 11) and those who 
have not (n = 19), (B) HIV+ individuals who have been exposed to PIs (n = 9) and those who have not (n = 21), and (C) HIV+ 
individuals who have been exposed to either AZT or d4T (n = 10) against those who have not (n = 20). Each dot represents 





7.4.3 Predictors of intramyocellular lipid accumulation in older PLWH 
Next, I wanted to investigate whether IMCL was significantly predicted by any of the clinical, HIV-
related, body composition, or lifestyle factors assessed as part of the MAGMA study, in older HIV+ 
individuals (n = 30). 
7.4.3.1 Clinical predictors of IMCL  
Here, I performed unadjusted bivariate linear regression analysis and Fisher’s exact tests in order to 
assess whether any clinical, HIV-related, or lifestyle factors significantly predicted increased IMCL, 
with results depicted in Table 7.1.  
Notably, greater IMCL was not significantly predicted by any of the clinical, lifestyle or body 
composition factors such as age (Figure 7.8a), BMI (Figure 7.8b), percentage lean mass (Figure 7.8c), 
or percentage fat mass (Figure 7.8d) in older PLWH (n = 30) (Pearson’s correlation and Fisher’s 
exact test) (Table 7.1).  
Interestingly, none of the HIV-related factors such as CD4 count or duration on ART significantly 

















 HIV+ (n = 30) 
 r p 
Age 0.017 0.93 
BMI (kg/m2) 0.19 0.31 
Waist circumference (cm) -0.026 0.89 
# Comorbidities 0.30 0.11 
# Medications 0.12 0.52 
Polypharmacy* - 0.67 
% Fat mass -0.23 0.22 
% Lean mass 0.23 0.22 
Months since diagnosis 0.090 0.64 
Months on ART -0.043 0.82 
Months untreated  0.13 0.50 
CD4 count (copies/µl) 0.21 0.28 
Smokers* - 0.93 
Alcohol drinkers* - 0.77 
Recreational drug use* - 0.80 
 
Table 7.1 – Clinical predictors of IMCL in older PLWH. Table depicting the associations between proportional 
Log10(BodipyAbn) and various clinical factors. Linear regression and correlation analysis was performed by Pearson’s 






Figure 7.8 – Clinical determinants of IMCL in older PLWH. Scatter plots depicting the linear regression analysis (Pearson’s 
correlation) between log10(BodipyAbn) and (A) age, (B) BMI (kg/m2), (C) percentage lean mass, and (D) percentage fat mass 






7.4.3.2 Physical determents of IMCL 
Next, I performed linear regression analysis to determine if any of the physical parameters such as 
FFP score or grip strength predicted IMCL in older PLWH (Table 7.2).  
As such, there were no statistically significant associations between IMCL and any of the respective 
factors (Pearson’s and Spearman’s correlation) (Figure 7.9a-e).  
 
 IMCL 
 HIV+ (n = 30) 
 r p 
FFP score^ 0.23 0.22 
SPPB score^ 0.085 0.65 
MET score^ -0.25 0.19 
Grip strength (kg) -0.24 0.21 
ASMI (kg/m2) 0.21 0.26 
 
Table 7.2 – Physical factors predicting IMCL in older PLWH. Table depicting the associations between proportional 
Log10(BodipyAbn) and various factors. Linear regression and correlation analysis was determined by Pearson’s correlation 





Figure 7.9 – Physical determinants of IMCL. Scatter plots depicting the linear regression between log10(BodipyAbn) and (A) 
FFP score, (B) SPPB score, (C) MET score, (D) grip strength (kg), and (E) ASMI (kg/m2) in older PLWH (n = 30). Pearson’s 
correlation was performed for parametric data (D and E), and spearman’s correlation was performed on non-parametric 







7.4.3.3 Pathophysiological skeletal muscle determinants of IMCL in older PLWH  
Finally, unadjusted linear regression analysis between IMCL and results from the various other 
muscle pathophysiology assessments such as Pax7+ SC prevalence and fibrosis was undertaken in 
order to investigate pathophysiological determinants of IMCL in older PLWH (full data for these 
parameters are presented later in this chapter).  
Again, there was no statistically significant associations between these factors in the HIV+ individuals 
(n = 30 (Pearson’s correlation) (Table 7.3). 
 
 IMCL 
 HIV+ (n = 30) 
 r p 
Type I % 0.040 0.83 
Type IIa % -0.27 0.15 
Type IIx % 0.35 0.059 
Fibre CSA (µm2) 0.046 0.81 
Log10(Pax7+ SC) -0.026 0.89 
Log10(% Fibrosis) -0.13 0.49 
Log10(Lipofuscin CSA)+ -0.008 0.97 
Log10(Lipofuscin frequency)+ 0.10 0.62 
Regenerated fibres 0.060 0.76 
Degenerated fibres -0.067 0.73 
 
Table 7.3 – Pathophysiological skeletal muscle determinants of IMCL. Table depicting the associations between 
proportional Log10(BodipyAbn) and various skeletal muscle pathophysiological factors. Linear regression and correlation 
analysis was determined by Pearson’s correlation. + = data missing from 1 patient.
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7.4.4 IMCL in older frail and sarcopenic PLWH 
After demonstrating that there was no significant difference in IMCL between older HIV+ and HIV- 
individuals, I stratified the HIV+ group into whether they were frail (n = 4), prefrail (n = 15), or robust 
(n = 11), as well as whether they were classified as sarcopenic (n = 5), presarcopenic (n = 6), or non-
sarcopenic (n = 19) and compared IMCL between the respective groups.  
Here, although IMCL was numerically higher in frail PLWH, there was no significant difference in 
IMCL between the frail, prefrail and robust HIV+ groups (p = 0.090, one-way ANOVA) (Figure 7.10a), 
or between the sarcopenic, presarcopenic and non-sarcopenic groups (p = 0.22) (Figure 7.10b).  
However, to increase the power to detect differences, the robust and prefrail groups were pooled 
together (n = 26), and IMCL was compared against frail individuals (n = 4). Here, it was demonstrated 
that frail PLWH had significantly higher IMCL compared to robust/prefrail PLWH (p = 0.027, unpaired 
t test) (Figure 7.10c). 
 
 
Figure 7.10 – IMCL differences in frailty and sarcopenia classification. Dot plots (mean ± SEM) depicting proportional 
Log10(BodipyAbn) differences between (A) frail (n = 4), prefrail (n = 15), and robust PLWH (n = 11) and (B) sarcopenic (n = 5), 
presarcopenic (n = 6), and non-sarcopenic (n = 19) PLWH. (C) Frail PLWH (n = 4) had a statistically significant greater level of 
IMCL compared to robust/prefrail PLWH (n = 26). Each dot represents an individual patient.   
A B C 
244 
 
Next, in order to overcome limitations regarding the small prevalence of frail and sarcopenic HIV+, in 
combination with the fact that prefrailty and presarcopenia is more physiologically related to frailty 
and sarcopenia than being robust or non-sarcopenic, HIV+ patients classified as prefrail (n = 15) were 
grouped with the frail HIV+ individuals (n = 4), and HIV+ patients classified as presarcopenic (n = 6) 
were grouped with sarcopenic PLWH (n = 5). Here, I determined if there were differences in IMCL 
between the respective groups and robust HIV+ (n = 11) and non-sarcopenic HIV+ individuals (n = 
19).  
Notably, there was no significant difference in IMCL between frail/prefrail PLWH (n = 19) and robust 
PLWH (n = 11) (p = 0.60, unpaired t test) (Figure 7.11a) or between sarcopenic/presarcopenic PLWH 
(n = 11) and non-sarcopenic PLWH (n = 19) (p = 0.093) (Figure 7.11b). 
 
 
Figure 7.11 – IMCL in frail/prefrail older PLWH and sarcopenic/presarcopenic PLWH. Dot plots (mean ± SEM) depicting 
proportional Log10(BodipyAbn) in (A) frail/prefrail HIV+ (n = 19) and robust HIV+ (n = 11), as well as (B) 
sarcopenic/presarcopenic HIV+ (n = 11) and non-sarcopenic HIV+ (n = 19). There were no significant differences between 




7.4.5 No difference in Pax7+ satellite cell prevalence between older PLWH and HIV- 
individuals 
In order to quantify the frequency of undifferentiated satellite cells (SCs) in skeletal muscle of our 
subjects, and subsequently investigate the role of SCs in the pathophysiology of frailty and 
sarcopenia in older PLWH, I stained the 10µm skeletal muscle sections with a duplex 
immunofluorescence assay with a nuclei marker (DAPI) and SC marker (Pax7) (Figure 7.12). 
 
 
Figure 7.12 – Example fluorescence image of Pax7+ satellite cells. 10µm skeletal muscle sections from HIV+ and HIV- 
individuals were stained with immunofluorescence markers for nuclei (DAPI) and quiescent SCs (Pax7). Pax7+ SCs were 
confirmed by co-localisation with a nuclei (e.g. white arrows). Scale bar = 20µm. 
 
A Pax7+ SC was determined by the strong staining intensity in the Pax7 channel and co-localisation 
with the nuclear marker DAPI (white arrows in Figure 7.12). 
The number of Pax7+ SCs and the total number of fibres were quantified, allowing us to determine 
the frequency of Pax7+ SCs per 100 fibres. In order to normalise the distribution of the data these 
values were then log transformed.  
Notably, there was no significant difference in the frequency of Pax7+ SCs per 100 fibres between the 





Figure 7.13 – No difference in Pax7+ satellite cell frequency per 100 fibres between the HIV+ and HIV- groups. Dot plot 
(mean ± SEM) depicting the log10(frequency of Pax7+ satellite cells per 100 fibres) for both the HIV+ (n = 30) and HIV- (n = 




7.4.6 Predictors of Pax7+ satellite cell abundance 
Next, I wanted to investigate whether the frequency of Pax7+ SCs was significantly predicted by any 
HIV-related or clinical factors, as well as body composition, environmental factors, and other skeletal 
muscle pathophysiological factors. To do this I performed linear regression analyses and unpaired t 
test analysis between the log10-transformed frequency of Pax7+ SCs per 100 fibres and the respective 
comparator factors. Pearson’s correlation was performed on normally distributed data sets whilst 
Spearman’s correlation was performed on non-normally distributed data sets. 
7.4.6.1 Clinical predictors of Pax7+ SC prevalence in older PLWH 
Notably, Pax7+ SC prevalence was not significantly predicted by any clinical, body composition, HIV-
related, or environmental factors (Table 7.4). This included age (Figure 7.14a), BMI (Figure 7.14b), 
percentage lean mass (Figure 7.14c) or percentage fat mass (Figure 7.14d) (Pearson’s correlation). 
 
 Pax7 SC prevalence 
 HIV+ (n = 30) 
 r p 
Age 0.15 0.43 
BMI (kg/m2) 0.30 0.88 
Waist circumference (cm) 0.087 0.65 
# Comorbidities 0.022 0.91 
# Medications 0.067 0.73 
Polypharmacy* - 0.90 
% Fat mass -0.07 0.72 
% Lean mass 0.07 0.72 
Months since diagnosis 0.24 0.20 
Months on ART 0.15 0.43 
Months untreated 0.15 0.42 
CD4 count (copies/µl) 0.08 0.69 
Smokers* - 0.27 
Alcohol drinkers* - 0.23 
Recreational drug use* - 0.80 
 
Table 7.4 – Clinical predictors of Pax7+ SC prevalence in older PLWH. Table depicting the associations between Log10(Pax7+ 
SCs per 100 fibres) and various clinical factors. Linear regression and correlation analysis was determined by Pearson’s 






Figure 7.14 – Clinical determinants of Pax7+ SC prevalence. Scatter plots depicting the linear regression (Pearson’s 
correlation) between proportional Log10(Pax7+ SCs per 100 fibres) and (A) age, (B) BMI (kg/m2), (C) percentage lean mass, 






7.4.6.2 Physical determinants of Pax7+ SCs in older PLWH 
Next, in order to determine whether there were any physical determinants of the prevalence of 
Pax7+ SCs, I performed unadjusted linear regression analyses between Pax7+ SC prevalence and 
physical parameters. Again, there was no significant associations between these factors and Pax7+ SC 




Pax7 SC prevalence 
 HIV+ (n = 30) 
 r p 
FFP score^ -0.066 0.73 
SPPB score^ -0.25 0.19 
MET score^ 0.059 0.76 
Grip strength (kg) 0.076 0.69 
ASMI (kg/m2) 0.019 0.92 
 
Table 7.5 – Physical factors predicting Pax7+ SC prevalence in older PLWH. Table depicting the associations between 
proportional Log10(Pax7+ SCs per 100 fibres) and various factors. Linear regression and correlation was determined by 





Figure 7.15 – Physical determinants of Pax7+ SC prevalence. Scatter plots depicting the linear regression between 
Log10(Pax7+ SCs per 100 fibres) and (A) FFP score, (B) SPPB score, (C) MET score, (D) grip strength (kg), and (E) ASMI (kg/m2) 
in older PLWH (n = 30). Pearson’s correlation was performed for parametric data (D and E), and spearman’s correlation was 








7.4.6.3 Pathophysiological skeletal muscle determinants of Pax7+ SC prevalence in older PLWH 
Finally, linear regression analyses was performed in order to determine whether Pax7+ SC prevalence 
was predicted by other pathophysiological skeletal muscle factors (full data for these parameters are 
presented later in this chapter) (Table 7.6). 
Interestingly, Pax7+ SC prevalence was significantly predicted by skeletal muscle fibrosis (r = 0.57; p = 
0.001, Pearson’s correlation) (Figure 7.16a) and a greater proportion of regenerated fibres (r = 0.52; 
p = 0.003) (Figure 7.16b) in older PLWH (n = 30). 
As the prevalence of Pax7+ SCs is linked with age, multivariate linear regression models were 
developed with Pax7+ SCs as the dependant variable, and age as well as either fibrosis or percentage 
of regenerated fibres as the independent variables.  
Here, multivariate linear regression confirmed that the association between Pax7+ SC prevalence and 
fibrosis was independent of the effect of age (unstandardised regression coefficient = 0.62; p = 
0.002, multivariate linear regression) (Table 7.6). Indeed, the overall model fit was statistically 
significant (p = 0.005), and was predictive of roughly a third of the variation in Pax7+ SC prevalence 
(r2 = 0.32). 
In addition, multivariable linear regression analysis also confirmed that the association between 
Pax7+ SC prevalence and the proportion of regenerated fibres was independent of the effect of age 
(unstandardised regression coefficient = 0.013; p = 0.005, multivariate linear regression) (Table 7.6). 
The overall model fit was statistically significant (p = 0.012), although only predictive of a small 






Pax7 SC prevalence 
 HIV+ (n = 30) 
 r p Age-adjusted p 
Type I % -0.072 0.71 - 
Type IIa % -0.017 0.93 - 
Type IIx % 0.19 0.32 - 
Fibre CSA (µm2) 0.18 0.34 - 
Log10(BodipyAbn) -0.026 0.89 - 
Log10(% Fibrosis) 0.57 0.001 0.002 
Log10(Lipofuscin CSA)+ 0.052 0.79 - 
Log10(Lipofuscin frequency)+ 0.10 0.60 - 
Regenerated fibres 0.52 0.003 0.005 
Degenerated fibres 0.031 0.87 - 
 
Table 7.6 – Skeletal muscle determinants of Pax7+ SC prevalence. Table depicting the associations between proportional 
Log10(Pax7+ SC per 100 fibres) and various skeletal muscle pathophysiological factors. Linear regression and correlation 
analysis was determined by Pearson’s correlation. Multivariate linear regression with adjustment for age was performed for 
determinants significantly associated with Pax7+ SC prevalence through univariate regression analyses. Statistically 




Figure 7.16 – Pathophysiological determinants of Pax7+ SC prevalence. Scatter plots depicting linear regression analysis 
(Pearson’s correlation) between proportional Log10(Pax7+ SCs per 100 fibres) and (A) Log10(% fibrosis), and (B) percentage 





7.4.7 Pax7+ satellite cell prevalence in frail and sarcopenic older PLWH 
To investigate differences in quiescent Pax7+ SC prevalence between PLWH in the respective frailty 
and sarcopenic classification groups, the HIV+ individuals (n = 30) were stratified into frail (n = 4), 
prefrail (n = 15), and robust (n = 11) groups, as well as sarcopenic (n = 5), presarcopenic (n = 6), and 
non-sarcopenic (n = 19) groups, and the prevalence of log10(Pax7+ SCs per 100 fibres) was compared.  
Here, there was no significant difference in the prevalence of Pax7+ SCs between the frail, prefrail 
and robust HIV+ groups (p = 0.78, one-way ANOVA) (Figure 7.17a). In addition, there was also no 
significant difference between the sarcopenia, presarcopenic and no-sarcopenia HIV+ groups (p = 
0.22) (Figure 7.17b). 
 
 
Figure 7.17 – Quiescent Pax7+ SC prevalence in frail and sarcopenic PLWH. Dot plots (mean ± SEM) showing no significant 
difference in log10(Pax7+ SCs per 100 fibres) between HIV+ (A) frail (n = 4), prefrail (n = 15) and robust (n = 11) individuals, or 






Next, the HIV+ group (n = 30) was stratified into frail/prefrail HIV+ (n = 19) and 
sarcopenic/presarcopenic HIV+ (n = 11) groups in order to assess whether quiescent satellite cell 
prevalence was altered in these groups compared to robust HIV+ (n = 11) and non-sarcopenic PLWH 
(n = 19) respectively.  
Importantly, there was no statistically significant difference in the proportion of Pax7+ SCs between 
frail/prefrail PLWH and robust PLWH (p = 0.48, unpaired t test) (Figure 7.18a). In addition, there was 
also no significant difference in proportional Pax7+ SC prevalence between sarcopenic/presarcopenic 
PLWH and non-sarcopenic PLWH (p = 0.65) (Figure 7.18b). 
 
 
Figure 7.18 – Pax7+ SC prevalence in adverse ageing phenotypes in older PLWH. Dot plots (mean ± SEM) depicting no 
significant difference in log10(Pax7+ SCs) between (A) frail/prefrail PLWH (n = 19) and robust PLWH (n = 11), and between 





7.4.8 No difference in fibre type proportions or fibre CSA between older HIV+ and 
HIV- individuals 
Using a multiplex immunofluorescence assay I quantified the proportions of fibre types I, IIa, and IIx, 




Figure 7.19 – Example fluorescence image of cryosections stained with fibre type markers. Representative images of 
skeletal muscle sections from HIV+ and HIV- individuals stained with fibre type markers. Each skeletal muscle section was 
stained with markers to distinguish type I (BA-F8), type IIa (SC-71), type IIx (6H1) as well as a myofibre boundary marker 




Here, the percentage of the three fibre types was significantly different in HIV+ individuals (n = 30; p 
< 0.0001, one-way ANOVA), with the percentage of type I fibres being significantly greater than that 
of both type IIa (p = 0.0001, Tukey’s multiple comparison) and type IIx fibres (p < 0.0001), as well as 
the percentage of type IIa fibres being significantly greater than the percentage of type IIx fibres (p < 
0.0006). However, there was no significant difference in the proportions of any of the respective 
fibre types between HIV+ and HIV- individuals (unpaired t tests) (Figure 7.20a). 
In addition, the average fibre CSA was significantly different between the three fibres types in HIV+ 
individuals (n = 30; p < 0.0001, one-way ANOVA), with the fibre CSA of type IIa fibres being 
significantly greater than type I fibres (p = 0.0006, Tukey’s multiple comparison). However, there 
was no significant difference in the average fibre CSA of the three fibre types individually, or when 




Figure 7.20 – No difference in fibre type proportions or fibre CSA between the HIV+ and HIV- groups. Dot plots (mean ± 
SEM) representing (A) the proportion of type I, IIa, and IIx fibres for the HIV+ (n = 30) and HIV- (n = 15) patients. There was 
no significant difference in the proportion of the respective fibre types between the two groups, although there was a 
significantly higher proportion of type I fibres in both the HIV+ and HIV- groups compared to type IIa and type IIx fibres. (B) 
The average CSA (µm2) of each fibre type for both the HIV+ and HIV- groups, as well as the average CSA of all fibre types 





7.4.9 Determinants of fibre type proportions and average fibre CSA 
Here, I wanted to investigate whether the prevalence of fibre types I, IIa, IIx and average fibre CSA 
(µm2) was predicted by any clinical, HIV-related, environmental, or body composition factors, as well 
as other skeletal muscle pathophysiological factors such as fibrosis or IMCL.  
7.4.9.1 Clinical determinants of fibre type proportions and fibre CSA in older PLWH 
Of the clinical factors and HIV-related parameters, an increased percentage of type IIx fibres was 
significantly predicted by a greater number of comorbidities in older PLWH (n = 30; r = 0.52; p = 
0.003, Pearson’s correlation) (Figure 7.23e). In addition, a greater number of medications also 
significantly predicted a higher proportion of type IIx fibres (r = 0.46; p = 0.011) (Figure 7.23f).  
The percentage of type I fibres was also significantly lower in HIV+ individuals with polypharmacy (n 
= 19; p = 0.038, unpaired t test) (Table 7.7).  
Hence, as the proportion of fibre type IIx is known to decline with age, and the prevalence of 
prescribed medications and comorbidities generally increases with age, I generated multivariate 
linear regression models with the percentage fibre type IIx as the dependant variable, and age as 
well as either number of medications, or number of comorbidities as the independent variables. 
Here, multivariate linear regression confirmed that the association between the proportion of type 
IIx fibres and number of comorbidities was independent of the effect of age (unstandardised 
regression coefficient = 3.33; p = 0.004, multivariate linear regression) (Table 7.7). The model fit 
was significant (p = 0.014), although it only explained a reasonably small amount of variation in the 
proportion of type IIx fibres (r2 = 0.27). 
Similarly, multivariate linear regression confirmed that the association between the proportion of 
type IIx fibres and number of medications was independent of age (unstandardised regression 
coefficient = 1.07; p = 0.011, multivariate linear regression) (Table 7.7). Again, the model fit was 
statistically significant (p = 0.035), although it only predicted a small amount of variation in the 
proportion of type IIx fibres (r2 = 0.22).  
There were no significant associations between clinical determinants and fibre type IIa proportions 




 Type I Type IIa Type IIx Fibre CSA 
 HIV+ (n = 30) HIV+ (n = 30) HIV+ (n = 30) HIV+ (n = 30) 




Age 0.055 0.77 -0.11 0.55 0.065 0.74 - 0.052 0.79 
BMI (kg/m2) -0.20 0.30 0.11 0.57 0.26 0.17 - 0.06 0.75 
Waist circumference (cm) -0.25 0.18 0.24 0.21 0.16 0.39 - 0.096 0.61 
# Comorbidities -0.29 0.12 0.070 0.71 0.52 0.003 0.004 -0.022 0.91 
# Medications -0.31 0.094 0.14 0.47 0.46 0.011 0.011 -0.24 0.20 
Polypharmacy* - 0.038 - 0.10 - 0.070 - - 0.19 
% Fat mass -0.055 0.77 0.13 0.50 -0.085 0.66 - -0.031 0.87 
% Lean mass 0.055 0.77 -0.13 0.50 0.085 0.66 - 0.031 0.87 
Months since diagnosis -0.21 0.26 0.083 0.66 0.33 0.076 - 0.071 0.71 
Months on ART -0.041 0.83 0 0.99 0.092 0.63 - 0.001 0.99 
Months untreated -0.21 0.26 0.095 0.62 0.30 0.10 - 0.069 0.72 
CD4 count (copies/µl) -0.047 0.81 -0.007 0.97 0.12 0.56 - -0.15 0.44 
Smokers* - 0.45 - 0.77 - 0.77 - - 0.24 
Alcohol drinkers* - 0.76 - 0.91 - 0.91 - - 0.62 
Recreational drug use* - 0.98 - 0.90 - 0.90 - - 0.90 
Table 7.7 – Clinical predictors of fibre type proportion and fibre CSA in older PLWH. Table depicting the associations 
between proportional fibre types as well as average fibre CSA (µm2) and various clinical factors. Linear regression and 
correlation analysis was determined by Pearson’s correlation. * = ordinal data in which individuals were stratified by yes/no 






Figure 7.21 – Clinical determinants of fibre type I prevalence. Scatter plots depicting the linear regression (Pearson’s 
correlation) between the percentage of type I fibres and (A) age, (B) BMI (kg/m2), (C) percentage lean mass, and (D) 








Figure 7.22 – Clinical determinants of fibre type IIa prevalence. Scatter plots depicting the linear regression (Pearson’s 
correlation) between the percentage of type IIa fibres and (A) age, (B) BMI (kg/m2), (C) percentage lean mass, and (D) 







Figure 7.23 – Clinical determinants of fibre type IIx prevalence. Scatter plots depicting the linear regression (Pearson’s 
correlation) between the percentage of type IIx fibres and (A) age, (B) BMI (kg/m2), (C) percentage lean mass, (D) 









Figure 7.24 – Clinical determinants of average fibre CSA. Scatter plots depicting the linear regression (Pearson’s 
correlation) between the average fibre CSA (µm2) and (A) age, (B) BMI (kg/m2), (C) percentage lean mass, and (D) 






7.4.9.2 Physical determinants of  fibre type proportions and fibre CSA in older PLWH 
Next, I sought to determine whether physical parameters predicted the proportions of the 
respective fibre types or average fibre CSA (Table 7.8). 
Notably, there were no significant associations between physical factors and proportions of either 
fibre type I (Figure 7.25), type IIa (Figure 7.26) or type IIx (Figure 7.27), as well as average fibre CSA 
(Figure 7.28) (Table 7.8). 
 
 Type I Type IIa Type IIx Fibre CSA 
 HIV+ (n = 30) HIV+ (n = 30) HIV+ (n = 30) HIV+ (n = 30) 
 r p r p r p r p 
FFP score^ -0.027 0.89 -0.14 0.48 0.19 0.35 -0.034 0.86 
SPPB score^ 0.18 0.35 -0.17 0.36 -0.13 0.50 0.21 0.28 
MET score^ 0.21 0.27 -0.13 0.50 -0.14 0.47 0.065 0.73 
Grip strength (kg) -0.043 0.82 0.17 0.36 -0.19 0.33 0.050 0.79 
ASMI (kg/m2) 0.062 0.74 -0.09 0.64 0.009 0.96 0.006 0.98 
 
Table 7.8 – Physical factors predicting fibre type proportions and fibre CSA in older PLWH. Table depicting the 
associations between proportional fibre types and average fibre CSA (µm2) and various factors. Linear regression and 
correlation was determined by Pearson’s correlation for normally distributed data and Spearman’s correlation for non-




Figure 7.25 – Physical determinants of type I percentage. Scatter plots depicting the linear regression between the 
percentage of type I fibres and (A) FFP score, (B) SPPB score, (C) MET score, (D) grip strength (kg), and (E) ASMI (kg/m2) in 
older PLWH (n = 30). Pearson’s correlation was performed for parametric data (D and E), and spearman’s correlation was 








Figure 7.26 – Physical determinants of type IIa percentage. Scatter plots depicting the linear regression between the 
percentage of type IIa fibres and (A) FFP score, (B) SPPB score, (C) MET score, (D) grip strength (kg), and (E) ASMI (kg/m2) in 
older PLWH (n = 30). Pearson’s correlation was performed for parametric data (D and E), and spearman’s correlation was 








Figure 7.27 – Physical determinants of type IIx percentage. Scatter plots depicting the linear regression between the 
percentage of type IIx fibres and (A) FFP score, (B) SPPB score, (C) MET score, (D) grip strength (kg), and (E) ASMI (kg/m2) in 
older PLWH (n = 30). Pearson’s correlation was performed for parametric data (D and E), and spearman’s correlation was 








Figure 7.28 – Physical determinants of fibre CSA. Scatter plots depicting the linear regression between the average fibre 
CSA (µm2) and (A) FFP score, (B) SPPB score, (C) MET score, (D) grip strength (kg), and (E) ASMI (kg/m2) in older PLWH (n = 
30). Pearson’s correlation was performed for parametric data (D and E), and spearman’s correlation was performed on non-







7.4.9.3 Pathophysiological skeletal muscle determinants of fibre type proportions and fibre 
CSA in older PLWH 
Finally, linear regression analyses was performed in order to determine whether pathophysiological 
skeletal muscle factors assessed as part of the MAGMA study (full data presented later in the 
chapter) predicted the proportions of the respective fibre types or average fibre CSA (Table 7.9).  
Here, fibre CSA was significantly associated with percentage regenerated fibres in older PLWH (n = 
30; r = 0.45; p = 0.014) (Pearson’s correlation) (Figure 7.29).  
Subsequently, as fibre CSA is known to decline with age, a multivariate linear regression model was 
developed with average fibre CSA as the dependant variable, and age and the proportion of 
regenerated fibres as the independent variables. Here, this multivariate linear regression model 
confirmed that the association between fibre CSA and the proportion of regenerated fibres was 
independent of age (unstandardised regression coefficient = 0.45; p = 0.016, multivariate linear 
regression) (Table 7.9). However, the model fit was marginally not statistically significant (p = 0.051), 
and subsequently only predicted a small amount of variation in fibre CSA (r2 = 0.20). 
 
 Type I Type IIa Type IIx Fibre CSA 
 
HIV+ (n = 30)  HIV+ (n = 30) HIV+ (n = 30) HIV+ (n = 30) 




Log10(Pax7+ SC) -0.072 0.71 -0.017 0.93 0.19 0.32 0.18 0.34 - 
Log10(BodipyAbn) 0.040 0.83 -0.27 0.15 0.35 0.059 0.046 0.81 - 
Log10(% Fibrosis) 0.072 0.71 -0.12 0.54 0.02 0.92 0.23 0.22 - 
Log10(Lipofuscin CSA)+ -0.025 0.90 0.11 0.59 -0.12 0.54 -0.001 0.99 - 
Log10(Lipofuscin frequency)+ 0.017 0.93 0.023 0.91 -0.076 0.69 0.14 0.46 - 
Regenerated fibres -0.11 0.55 -0.028 0.88 0.29 0.12 0.45 0.014 0.016 
Degenerated fibres 0.32 0.087 -0.31 0.098 -0.19 0.31 0.34 0.064 - 
Table 7.9 – Skeletal muscle determinants of fibre type proportions and average fibre CSA. Table depicting the associations 
between fibre type proportions and average fibre CSA (µm2) and various skeletal muscle pathological factors. Linear 
regression and correlation analysis was determined by Pearson’s correlation. Multivariate linear regression with adjustment 
for age was performed for determinants significantly associated through univariate regression analyses. Statistically 




Figure 7.29 – Pathophysiological determinants of fibre CSA. Scatter plots depicting linear regression analysis (Pearson’s 




7.4.10 Fibre type proportions and fibre CSA in frail and sarcopenic older PLWH 
Next, in order to better understand fibre type proportions and fibre CSA specifically in frailty and 
sarcopenia in older PLWH, I stratified the HIV+ group (n = 30) into frail (n = 4), prefrail (n = 15), and 
robust (n = 11) groups, as well as sarcopenic (n = 5), presarcopenic (n = 6), and non-sarcopenic (n = 
19) groups.  
With regards to the frail, prefrail, and robust HIV+ groups, there was no significant differences 
between the proportion of type I (p = 0.70, one-way ANOVA) (Figure 7.30a) and type IIa fibres (p = 
0.83) (Figure 7.30c), as well as average fibre CSA (p = 0.37) (Figure 7.30g). However, there was a 
statistically significant difference in the proportion of type IIx fibres between the three groups (p = 
0.021) (Figure 7.30e). In particular, frail PLWH had a significantly higher proportion of type IIx fibres 
compared to both the prefrail (p = 0.033, Tukey’s multiple comparison) and robust (p = 0.019) 
groups (Figure 7.30e). 
There was no significant difference in the proportions of fibre type I (p = 0.42, one-way ANOVA) 
(Figure 7.30b), type IIa (p = 0.24) (Figure 7.30d) and type IIx fibres (p = 0.87) (Figure 7.30f), or 
average fibre CSA (p = 0.96) (Figure 7.30h) between the sarcopenic, presarcopenic, and non-






Figure 7.30 – Fibre type proportions and fibre CSA in frail and sarcopenic PLWH. Dot plots (mean ± SEM) showing the differences between frail (n = 4), prefrail (n = 15) and robust (n = 11) 
PLWH in the proportions of (A) % fibre type I, (C) % fibre type IIa, (E) % fibre type IIx and (G) fibre CSA (µm2). No differences between sarcopenic (n = 5), presarcopenic (n = 6) and non-
sarcopenic (n = 19) PLWH in the proportions of (B) % fibre type I, (D) % fibre type IIa, (F) % fibre type IIx and (H) fibre CSA (µm2). Each dot represent an individual patient.  
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Next, the HIV+ group (n = 30) was stratified into frail/prefrail HIV+ (n = 19) and 
sarcopenic/presarcopenic HIV+ (n = 11) groups. Here, I determined whether there were differences 
in the proportion of fibre types I, IIa, and IIx, as well as average fibre CSA between the respective 
groups and robust HIV+ (n = 11) and non-sarcopenic HIV+ individuals (n = 19).  
Again, there was no significant difference in the proportion of type I fibres between frail/prefrail 
PLWH and robust PLWH (p = 0.96, unpaired t test) (Figure 7.31a), nor was there a significant 
difference between sarcopenic/presarcopenic PLWH and non-sarcopenic PLWH (p = 0.26) (Figure 
7.31e). In addition, there was no significant difference in the proportion of type IIa fibres between 
frail/prefrail PLWH and robust PLWH (p = 0.66) (Figure 7.31b) or between sarcopenic/presarcopenic 
PLWH and non-sarcopenic PLWH (p = 0.11) (Figure 7.31f).  
There was also no statistically significant difference in the proportion of type IIx fibres between 
frail/prefrail PLWH and robust PLWH (p = 0.55, unpaired t test) (Figure 7.31c) or between 
sarcopenic/presarcopenic PLWH and non-sarcopenic PLWH (p = 0.92) (Figure 7.31g). Finally, there 
was also no significant difference in average fibre CSA between frail/prefrail PLWH and robust PLWH 
(p = 0.96) (Figure 7.31d), or between sarcopenic/presarcopenic PLWH and non-sarcopenic PLWH (p 







Figure 7.31 – Fibre type proportions and fibre CSA in adverse ageing phenotypes in older PLWH. Dot plots (mean ± SEM) 
depicting the differences between frail/prefrail HIV+ individuals (n = 19) and robust HIV+ individuals (n = 11) in (A) fibre type 
I proportion, (B) fibre type IIa proportion, (C) fibre type IIx proportion, or (D) average fibre CSA (µm2). And between 
sarcopenic/presarcopenic HIV+ individuals (n = 11) and non-sarcopenic HIV+ individuals (n = 19) in (E) fibre type I 
proportion, (F) fibre type IIa proportion, (G) fibre type IIx proportion, or (H) average fibre CSA (µm2). Each dot represents an 
individual patient.  
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7.4.11 Greater skeletal muscle fibrosis in older PLWH compared to age-matched HIV- 
individuals 
10µm skeletal muscle sections (n = 45) were subjected to Masson’s trichrome histochemistry (Figure 
7.32a) in order to quantify the levels of tissue fibrosis and to subsequently investigate whether 
increased levels of fibrosis were contributing to declines in physical and muscle specific function. 
The CSA (µm2) of each section was measured, as well as the area of fibrotic tissue (µm2), allowing for 
the quantification of the proportion of fibrotic tissue for each subject. In order to normalise the 
distribution of the results, the data was log transformed.   
Interestingly, the HIV+ group (n = 30) had a significantly higher proportion of fibrotic tissue 




     
      
Figure 7.32 – Elevated skeletal muscle fibrosis in PLWH. (A) Example brightfield image of a skeletal muscle section from a 
HIV+ and HIV- individual stained with Masson’s trichrome histochemistry. Fibrotic tissue appears blue. Scale bar = 50µm. (B) 
Dot plot (mean ± SEM) showing the significantly higher levels of fibrosis in skeletal muscle from HIV+ individuals (n = 30) 






7.4.12 Determinants of skeletal muscle fibrosis 
Following this result, I next wanted to investigate whether the elevated levels of tissue fibrosis was 
predicted by any of the various clinical, lifestyle, or body composition factors, as well as any of the 
pathophysiologic skeletal muscle factors such as IMCL or quiescent satellite cell prevalence.  
7.4.12.1 Clinical predictors of skeletal muscle fibrosis in older PLWH 
Notably, increased skeletal muscle fibrosis was not significantly predicted by any of the clinical, body 
composition, or lifestyle factors (Pearson’s correlation) (Table 7.10/Figure 7.33). In addition, 
skeletal muscle fibrosis was not significantly predicted by any of the HIV-related factors, although it 
was marginally associated with both percentage lean and fat mass.  
 
  Log10(%Fibrosis) 
 HIV+ (n = 30) 
 r p 
Age  0.20 0.30 
BMI (kg/m2) 0.03 0.87 
Waist circumference (cm) 0.012 0.95 
# Comorbidities 0.11 0.57 
# Medications 0.14 0.46 
Polypharmacy* - 0.45 
% Fat mass -0.35 0.059 
% Lean mass 0.35 0.059 
Months since diagnosis 0.19 0.31 
Months on ART -0.044 0.82 
Months untreated  0.25 0.19 
CD4 count (copies/µl) -0.013 0.95 
Smokers* - 0.059 
Alcohol drinkers* - 0.57 
Recreational drug use* - 0.45 
 
Table 7.10 – Clinical predictors of skeletal muscle fibrosis in older PLWH. Table depicting the associations between 
Log10(%Fibrosis) and various clinical factors. Linear regression and correlation analysis was determined by Pearson’s 





Figure 7.33 – Clinical determinants of fibrosis. Scatter plots depicting the linear regression (Pearson’s correlation) between 
log10(% fibrosis) and (A) age, (B) BMI (kg/m2), (C) percentage lean mass, and (D) percentage fat mass in older PLWH (n = 






7.4.12.2 Physical determinants of skeletal muscle fibrosis in older PLWH 
Next, I investigated whether parameters of physical function predicted skeletal muscle fibrosis in 
older PLWH through unadjusted linear regression analysis (Table 7.11).  
Here, there were no significant associations between the proportion of skeletal muscle fibrosis and 
any of the physical parameters (Pearson’s and Spearman’s correlation) (Figure 7.34). 
 
  Log10(%Fibrosis) 
 HIV+ (n = 30) 
 r p 
FFP score^ -0.083 0.66 
SPPB score^ -0.003 0.99 
MET score^ 0.07 0.71 
Grip strength (kg) -0.022 0.91 
ASMI (kg/m2) 0.11 0.58 
 
Table 7.11 – Physical factors predicting skeletal muscle fibrosis in older PLWH. Table depicting the associations between 
Log10(%Fibrosis) and various factors. Linear regression and correlation analysis was determined by Pearson’s correlation for 





Figure 7.34 – Physical factors predicting skeletal muscle fibrosis. Scatter plots depicting the linear regression between 
log10(% fibrosis) and (A) FFP score, (B) SPPB score, (C) MET score, (D) grip strength (kg), and (E) ASMI (kg/m2) in older PLWH 
(n = 30). Pearson’s correlation was performed for parametric data (D and E), and Spearman’s correlation was performed on 








7.4.12.3 Pathophysiological determinants of skeletal muscle fibrosis in older PLWH 
Finally, linear regression analysis was performed in order to determine if any pathophysiological 
skeletal muscle parameters significantly predicted skeletal muscle fibrosis (Table 7.12). 
As demonstrated previously in Section 7.4.6.3, through univariate linear regression analysis it was 
found that greater skeletal muscle fibrosis was significantly associated with the prevalence of Pax7+ 
SCs (r = 0.57; p = 0.001, Pearson’s correlation) (Figure 7.35a). In addition, fibrosis was significantly 
associated with and the percentage of regenerated fibres (r = 0.59; p = 0.001) (Figure 7.35b). 
Next, multivariate linear regression models were developed with fibrosis as the dependant variable, 
and age, as well as either pax7+ SC prevalence, or the percentage of regenerated fibres as the 
independent variables.  
Here, multivariate linear regression analysis confirmed that the association between skeletal muscle 
fibrosis and Pax7+ SC prevalence was independent of the effect of age (unstandardised regression 
coefficient = 0.49; p = 0.002, multivariate linear regression) (Table 7.12). Overall model fit was 
statistically significant (p = 0.004), and the model was predictive of a third of the variation in fibrosis 
(r2 = 0.33). 
In addition, the association between fibrosis and the proportion of regenerated fibres was also 
independent of age (unstandardised regression coefficient = 0.013; p = 0.001, multivariate linear 
regression) (Table 7.12). Again, the overall model fit was significant (p = 0.02) and predictive of a 




  Log10(%Fibrosis) 
HIV+ (n = 30)  
 r p Age-adjusted p 
Type I % 0.078 0.68 - 
Type IIa % -0.12 0.54 - 
Type IIx % 0.020 0.92 - 
Fibre CSA (µm2) 0.23 0.22 - 
Log10(Pax7+ SC) 0.57 0.001 0.002 
Log10(% BodipyAbn) -0.13 0.49 - 
Log10(Lipofuscin CSA)+ 0.037 0.85 - 
Log10(Lipofuscin frequency)+ -0.097 0.62 - 
Regenerated fibres 0.59 0.001 0.001 
Degenerated fibres 0.07 0.71 - 
 
Table 7.12 – Skeletal muscle pathophysiological determinants of fibrosis. Table depicting the associations between 
log10(%Fibrosis) and various skeletal muscle pathophysiological factors. Linear regression and correlation analysis was 
determined by Pearson’s correlation. Multivariate linear regression with adjustment for age was performed for 
determinants significantly associated through univariate regression analyses. Statistically significant associations are bold. 







Figure 7.35 – Pathophysiological determinants of skeletal muscle fibrosis. Scatter plots depicting linear regression analysis 
(Pearson’s correlation) between log10(%Fibrosis) and (A) percentage regenerated fibres and (B) log10(Pax7+ SCs per 100 






7.4.13 Skeletal muscle fibrosis in frail and sarcopenic older PLWH 
Next, I sought to determine whether there were differences in skeletal muscle fibrosis between frail 
(n = 4), prefrail (n = 15), and robust (n = 11) PLWH, as well as sarcopenic (n = 5), presarcopenic (n = 
6), and non-sarcopenic PLWH (n = 19).  
Here, there was no significant difference in the proportion of fibrotic skeletal muscle tissue between 
the frail, prefrail, and robust HIV+ individuals (p = 0.42, one-way ANOVA) (Figure 7.36a). In addition, 
there was also no significant difference in skeletal muscle fibrosis between the sarcopenic, 
presarcopenic, and non-sarcopenic HIV+ individuals (p = 0.27) (Figure 7.36b). 
 
Figure 7.36 – Skeletal muscle fibrosis differences across the frailty and sarcopenic spectrum. Dot plots (mean ± SEM) 
showing no significant differences in log10(fibrosis) between (A) frail (n = 4), prefrail (n = 15), and robust (n = 11) PLWH, or 





As performed previously, I next stratified the HIV+ group (n = 30) into frail/prefrail HIV+ (n = 19) and 
sarcopenic/presarcopenic HIV+ (n = 11) groups and compared the proportion of skeletal muscle 
fibrosis in the respective groups against robust HIV+ (n = 11) and non-sarcopenic HIV+ individuals (n 
= 19).  
Notably, there was no significant difference in the level of skeletal muscle fibrosis between older 
frail/prefrail PLWH (n = 19) and age-matched robust PLWH (n = 11; p = 0.35, unpaired t test) (Figure 
7.37a). Similarly, there was also no significant difference in skeletal muscle fibrosis between 
sarcopenic/presarcopenic PLWH (n = 11) and non-sarcopenic PLWH (n = 19; p = 0.26) (Figure 7.37b). 
 
 
Figure 7.37 – Skeletal muscle fibrosis in adverse ageing phenotypes in older PLWH. Dot plots (mean ± SEM) depicting no 
significant difference in log10(% fibrosis) between (A) frail/prefrail PLWH (n = 19) and robust PLWH (n = 11), as well as (B) 





7.4.14  H&E histochemistry for assessment of regenerated and degenerated 
myofibres 
H&E histochemistry was performed on 10µm cryo-sections (n = 45) in order to quantify the 
proportion of muscle fibres with central nuclei, indicative of regenerated fibres, and the proportion 
of degenerated fibres (Figure 7.38).  
Interestingly, the HIV- group (n = 15) had a significantly higher proportion of regenerated fibres 
compared to the HIV+ group (n = 30; p = 0.02, unpaired t test) (Figure 7.39a). Whilst there was no 




Figure 7.38 – Example H&E histochemistry for degenerated and regenerated fibres. (A) Degenerated fibres (indicated by 





Figure 7.39 – Greater proportion of regenerated fibres in HIV- individuals. Dot plots (mean ± SEM) showing (A) a 
significantly higher level of proportional regenerated fibres in the HIV- group (n = 15) compared to the HIV+ group (n = 30; p 
= 0.02), and (B) no significant difference in the proportion of degenerated fibres between the HIV+ and HIV- groups. Each 





7.4.15 Predictors of the proportion of regenerated and degenerated fibres in older 
PLWH 
I next sought to investigate whether the proportion of regenerated fibres and degenerated fibres 
was predicted by any of the clinical, HIV-related, lifestyle, body composition, or pathogenic skeletal 
muscle factors in older PLWH. To this end, I performed linear regression analysis and unpaired t tests 
between these factors.  
7.4.15.1 Clinical predictors of regenerated and degenerated fibres in older PLWH  
With regards to the HIV-related factors, the proportion of regenerated fibres was significantly 
predicted by a greater duration of untreated HIV infection (n = 30; r = 0.39; p = 0.035) (Figure 7.40e). 
As such, through a multivariate linear regression model which included the proportion of 
regenerated fibres as the dependant variable and age as well as months untreated as the 
independent variables, the association between regenerated fibres and months of untreated HIV 
infection was confirmed to be independent of age (unstandardised regression coefficient = 0.041; p 
= 0.045, multivariate linear regression) (Table 7.13). However, the overall model fit was not 
statistically significant (p = 0.11) and was subsequently predictive of only a small amount of variation 
in the percentage of regenerated fibres (r2 = 0.15). 
Of the lifestyle factors, smokers had a significantly lower proportion of regenerated fibres compared 
to non-smokers (p = 0.039, unpaired t test) (Table 7.13).  





 % Regenerated fibres % Degenerated fibres 
 HIV+ (n = 30) HIV+ (n = 30) 




Age 0.11 0.55 - 0.033 0.86 
BMI (kg/m2) 0.31 0.92 - -0.14 0.45 
Waist circumference (cm) 0.52 0.056 - -0.091 0.63 
# Comorbidities 0.21 0.26 - -0.15 0.42 
# Medications 0.032 0.87 - -0.093 0.63 
Polypharmacy* - 0.92 - - 0.32 
% Fat mass -0.10 0.78 - -0.028 0.93 
% Lean mass 0.10 0.78 - 0.028 0.93 
Months since diagnosis 0.35 0.061 - -0.10 0.60 
Months on ART -0.012 0.95 - 0.12 0.53 
Months untreated 0.39 0.035 0.045 -0.20 0.28 
CD4 count (copies/µl) -0.085 0.67 - -0.22 0.27 
Smokers* - 0.039 - - 0.28 
Alcohol drinkers* - 0.83 - - 0.48 
Recreational drug use* - 0.44 - - 0.93 
 
Table 7.13 – Clinical predictors of regenerated and degenerated fibre prevalence in older PLWH. Table depicting the 
associations between the percentage of regenerated and degenerated fibres and various clinical factors. Linear regression 
and correlation analysis was determined by Pearson’s correlation. * = ordinal data in which individuals were stratified by 




Figure 7.40 - Clinical determinants of percentage regenerated fibres. Scatter plots depicting the linear regression 
(Pearson’s correlation) between the percentage of regenerated fibres and (A) age, (B) BMI (kg/m2), (C) percentage lean 









Figure 7.41 – Clinical determinants of percentage degenerated fibres. Scatter plots depicting the linear regression 
(Pearson’s correlation) between the percentage of degenerated fibres and (A) age, (B) BMI (kg/m2), (C) percentage lean 






7.4.15.2 Physical determinants of regenerated and degenerated fibre percentages in older 
PLWH 
Through linear regression analysis, I next determined whether physical parameters significantly 
predicted the percentage of regenerated and degenerated fibres in older PLWH.  
As described in Table 7.14, MET score was significantly associated with the proportion of 
degenerated fibres in the older PLWH (n = 30; r = 0.41; p = 0.025, Spearmans’s correlation) (Figure 
7.43c). Subsequently, in a multivariate linear regression model where the predictive value of MET 
score for the proportion of degenerated fibres was adjusted for age, the association between 
degenerated fibre proportion and MET score was demonstrated to be independent of the effect of 
age (unstandardised regression coefficient = 0.000078; p = 0.009, multivariate linear regression) 
(Table 7.14). Indeed, the overall model fit was statistically significant (p = 0.030) but was only 
predictive of a modest amount of variance in the percentage of degenerated fibres (r2 = 0.29). 
There were no other significant associations between physical parameters and either the percentage 
of regenerated (Figure 7.42) or degenerated fibres (Figure 7.43). 
 
 % Regenerated fibres % Degenerated fibres 
 HIV+ (n = 30) HIV+ (n = 30) 
 r p r p 
Age-
adjusted p 
FFP score^ -0.083 0.66 -0.21 0.26 - 
SPPB score^ -0.19 0.31 0.32 0.081 - 
MET score^ 0.081 0.67 0.41 0.025 0.009 
Grip strength (kg) -0.20 0.47 0.30 0.10 - 
ASMI (kg/m2) 0.38 0.84 0.087 0.65 - 
 
Table 7.14 – Physical factors predicting percentage regenerated and degenerated fibres in older PLWH. Table depicting 
the associations between the percentage of regenerated and degenerated fibres, and various physical factors. Linear 
regression and correlation analysis was determined by Pearson’s correlation for normally distributed data and Spearman’s 





Figure 7.42 – Physical factors predicting percentage regenerated fibres. Scatter plots depicting the linear regression 
between percentage regenerated fibres and (A) FFP score, (B) SPPB score, (C) MET score, (D) grip strength (kg), and (E) 
ASMI (kg/m2) in older PLWH (n = 30). Pearson’s correlation was performed for parametric data (D and E), and Spearman’s 








Figure 7.43 – Physical factors predicting percentage degenerated fibres. Scatter plots depicting the linear regression 
between percentage degenerated fibres and (A) FFP score, (B) SPPB score, (C) MET score, (D) grip strength (kg), and (E) 
ASMI (kg/m2) in older PLWH (n = 30). Pearson’s correlation was performed for parametric data (D and E), and Spearman’s 







7.4.15.3 Pathophysiological skeletal muscle determinants of the percentage regenerated and 
degenerated fibres in older PLWH 
Finally, linear regression analyses was performed in order to determine whether pathophysiological 
skeletal muscle factors significantly predicted the proportion of regenerated and degenerated fibres 
in older PLWH (Table 7.15). 
Here, unadjusted linear regression analysis demonstrated that the proportion of regenerated fibres 
was significantly associated with average fibre CSA (r = 0.45, p = 0.014, Pearson’s correlation) 
(Figure 7.44a), and predicted by the prevalence of Pax7+ SCs (r = 0.52; p = 0.003) (Figure 7.44b), and 
skeletal muscle fibrosis (r = 0.59; p = 0.001) (Figure 7.44c).  
Next, as these pathophysiological factors are linked with age, multivariate linear regression models 
were developed with the percentage regenerated fibres as the dependant variable, and age as well 
as either Pax7+ SC prevalence, fibre CSA, or fibrosis percentage as the independent variables.   
Firstly, multivariate linear regression analysis confirmed that the association between the 
percentage of regenerated fibres and fibre CSA was independent of the effect of age 
(unstandardised regression coefficient = 0.01; p = 0.016, multivariate linear regression) (Table 7.15), 
and that the overall model fit was statistically significant (p = 0.044). However, the model was 
predictive of a small amount of variation in the percentage of regenerated fibres (r2 = 0.21).  
Additionally, the association between the percentage of regenerated fibres and fibrosis was also 
independent of the effect of age in a model with fibrosis and age as the independent variables 
(unstandardised regression coefficient = 26.9; p = 0.001) (Table 7.15). The overall model fit was 
statistically significant (p = 0.003) and predictive of a modest amount of variation in the percentage 
of regenerated fibres (r2 = 0.35).  
Next, in a multivariate linear regression model with Pax7+ SC prevalence and age as the independent 
variables, the association between the percentage of regenerated fibres and the prevalence of Pax7+ 
SC was also independent of the effect of age (unstandardised regression coefficient = 20.87; p = 
0.005) (Table 7.15). Again, the overall model fit was significant (p = 0.014), although predictive of 
only a small amount of variation in the percentage of regenerated fibres (r2 = 0.27). 
In univariate linear regression analysis, the proportion of degenerated fibres was significantly 
associated with the area covered by lipofuscin granules (r = -0.60; p = 0.001, Pearson’s correlation) 
(Figure 7.44d). Next, a multivariate linear regression model with the percentage of degenerated 
fibres as the dependant variable and age as well as lipofuscin CSA as the independent variables, the 
significant association between degenerated fibres and lipofuscin CSA was independent of the effect 
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of age (unstandardised regression coefficient = -0.28; p = 0.001, multivariate linear regression) 
(Table 7.15). Again, the overall model fit was statistically significant (p = 0.003) and was predictive of 
a reasonably small amount of variation in the percentage of degenerated fibres (r2 = 0.37). 
 
 HIV+ (n = 30) 
 % Regenerated fibres % Degenerated fibres 








Type I % -0.11 0.55 - 0.32 0.087 - 
Type IIa % -0.028 0.88 - -0.31 0.098 - 
Type IIx % 0.29 0.12 - -0.19 0.30 - 
Fibre CSA (µm2) 0.45 0.014 0.016 0.34 0.064 - 
Log10(Pax7+ SC) 0.52 0.003 0.001 0.031 0.87 - 
Log10(% BodipyAbn) 0.059 0.76 - -0.067 0.73 - 
Log10(Lipofuscin CSA)+ 0.097 0.62 - -0.60 0.001 0.001 
Log10(Lipofuscin frequency)+ -0.006 0.93 - -0.096 0.62 - 
Log10(% Fibrosis) 0.59 0.001 0.005 0.07 0.71 - 
 
Table 7.15 – Skeletal muscle determinants of regenerated and degenerated fibre proportions. Table depicting the 
associations between the percentage of regenerated and degenerated fibres and various skeletal muscle pathological 
factors. Linear regression and correlation analysis was determined by Pearson’s correlation. Multivariate linear regression 
with adjustment for age was performed for determinant significantly associated through univariate regression analyses.+ = 






Figure 7.44 – Pathophysiological determinants of regenerated and degenerated fibres. Scatter plots depicting linear 
regression analysis (Pearson’s correlation) between the percentage of regenerated fibres and (A) fibre CSA (µm2), (B) 
log10(Pax7+ SCs per 100 fibres), and (C) log10(% fibrosis); percentage of degenerated fibres and (D) log10(lipofuscin CSA 






7.4.16 Regenerated and degenerated fibre proportions in frail and sarcopenic older 
PLWH 
Here, in order to better understand proportions of regenerated and degenerated fibres in frailty and 
sarcopenia in older PLWH, I grouped the HIV+ group (n = 30) into frail (n = 4), prefrail (n = 15), and 
robust PLWH (n = 11), as well as sarcopenic (n = 5), presarcopenic (n = 6), and non-sarcopenic PLWH 
(n = 19).  
There was no significant difference in the proportion of either regenerated (p = 0.80, one-way 
ANOVA) (Figure 7.45a) or degenerated fibres (p = 0.42) between the frail, prefrail and robust groups 
(Figure 7.45c). There was also no significant difference in the proportion of either regenerated (p = 
0.41) (Figure 7.45b) or degenerated fibres (p = 0.80) between the sarcopenia, presarcopenia or no-







Figure 7.45 – Differences in the proportion of regenerated and degenerated fibres across the frailty and sarcopenia 
spectrum. Dot plots (mean ± SEM) depicting no significant differences in the proportion of regenerated fibres between (A) 
frail (n = 4), prefrail (n = 15) and robust (n = 11) PLWH, or (B) sarcopenic (n = 5), presarcopenic (n = 6) and non-sarcopenic (n 
= 19) PLWH; no significant differences in the proportion of degenerated fibres between (C) frail, prefrail and robust PLWH, 






Next, in an attempt to improve the power to detect differences between PLWH characterised by the 
adverse ageing phenotypes, I stratified the HIV+ group (n = 30) into frail/prefrail HIV+ (n = 19) and 
sarcopenic/presarcopenic HIV+ (n = 11) groups, as done in previous sections and studies (Kooij et al., 
2016). I then determined if there were differences in the proportion of regenerated and 
degenerated fibres between the respective groups and robust HIV+ (n = 11) and non-sarcopenic 
HIV+ individuals (n = 19).  
Here, there was no significant difference in the proportion of regenerated fibres between the 
frail/prefrail HIV+ group and the robust HIV+ group (p = 0.81, unpaired t test) (Figure 7.46a), or 
between the sarcopenia/presarcopenia HIV+ group and the no-sarcopenia HIV+ group (p = 0.99) 
(Figure 7.46b). 
Additionally, there was also no significant difference in the proportion of degenerated fibres 
between the frail/prefrail HIV+ group (n = 19) and the robust HIV+ group (n = 11; p = 0.21, unpaired t 
test) (Figure 7.46c), or between the sarcopenia/presarcopenia HIV+ group (n = 11) and the no-






Figure 7.46 – Regenerated and degenerated fibres in adverse ageing phenotypes in older PLWH. Dot plots (mean ± SEM) 
showing no significant difference in the proportion of regenerated fibres between (A) frail/prefrail PLWH (n = 19) and robust 
PLWH (n = 11), or (B) sarcopenic/presarcopenic PLWH (n = 11) and non-sarcopenic PLWH (n = 19); degenerated fibre 
proportion between (C) frail/prefrail PLWH (n = 19) and robust PLWH (n = 11), or (D) sarcopenic/presarcopenic PLWH (n = 






7.4.17 No difference in lipofuscin accumulation between older PLWH and HIV- 
individuals 
Due to the autofluorescent nature of lipofuscin granules I was able to observe and quantify granules 
in 10µm skeletal muscle sections simply by air-drying, fixing, cover-slipping, and imaging the sections 
at two different wavelengths (546nm and 647nm). Unlike with antibody-targeting 
immunofluorescence in which a no primary control (NPC) can be used, the autofluorescence aspect 
of lipofuscin imaging means all imaged sections contain lipofuscin granules and so there are no 
NPCs. Therefore, lipofuscin granules were confirmed by co-localisation in both the 546 and 647 
channels (Figure 7.47). Once imaged, I subsequently quantified the CSA (µm2) covered by the 
lipofuscin granules as well as the frequency of granules per µm2 for HIV+ (n = 29) and HIV- (n = 13) 
individuals. One subject from the HIV+ group and two from the HIV- group were excluded due to 
poor tissue quality.  
 
 
Figure 7.47 – Example fluorescence image of lipofuscin granules. 10µm skeletal muscle sections from HIV+ and HIV- 
individuals were imaged at 546nm and 647nm channels and merged. Lipofuscin granules were confirmed by localisation in 








For both the frequency and area of lipofuscin granules, data was normalised through log 
transformation. 
Notably, neither the frequency (Figure 7.48a) nor area covered by lipofuscin granules (Figure 7.48b) 
was significantly different between the HIV+ and HIV- groups (unpaired t tests). 
 
 
Figure 7.48 – No difference in proportional frequency of lipofuscin granules or proportional area covered by lipofuscin 
granules. Dot plots (mean ± SEM) showing (A) no significant difference in the proportional frequency of lipofuscin granules 
between the HIV+ (n = 29) and HIV- (n = 13) groups; (B) no significant difference in proportional CSA (µm2) covered by 





7.4.18 Determinants of lipofuscin accumulation 
7.4.18.1 Clinical determinants of lipofuscin coverage in older PLWH 
I next sought to assess whether the area covered by of lipofuscin granules was predicted by clinical 
parameters collected as part of the MAGMA study, such as HIV-related and clinical characteristics, 
body composition, and lifestyle factors (Table 7.16).  
Here, in unadjusted regression analysis, the area covered by lipofuscin granules was significantly 
greater in PLWH with higher CD4 counts (r = 0.48; p = 0.012, Pearson’s correlation) (Figure 7.49e). 
As lipofuscin accumulation is linked with age, a multivariate linear regression model was developed 
with lipofuscin CSA as the dependant variable, and age as well as CD4 count as the independent 
variables. Thus, multivariate linear regression confirmed that the significant association between 
lipofuscin area and CD4 count was independent of age (regression coefficient = 0.003; p = 0.012, 
multivariate linear regression) (Table 7.16). The overall fit of this model was statistically significant 
(p = 0.039) and was predictive of a small amount of the variation in lipofuscin CSA (r2 = 0.24).  
In addition, PLWH with polypharmacy had a significantly higher lipofuscin area than those who do 
not have polypharmacy (p = 0.044, unpaired t test) (Table 7.16). Finally, HIV+ smokers had a 
significantly higher area covered by lipofuscin granules compared to older PLWH who do not smoke 




 Log10(Lipofuscin CSA (µm2)) 
 HIV+ (n = 29) 
 r p 
Age-
adjusted p  
Age -0.21 0.88 - 
BMI (kg/m2) 0.24 0.21 - 
Waist circumference (cm) 0.21 0.28 - 
# Comorbidities 0.13 0.51 - 
# Medications -0.092 0.64 - 
Polypharmacy* - 0.044 - 
% Fat mass 0.18 0.36 - 
% Lean mass -0.18 0.36 - 
Months since diagnosis -0.076 0.69 - 
Months on ART -0.19 0.32 - 
Months untreated 0.047 0.81 - 
CD4 count (copies/µl) 0.48 0.012 0.012 
Smokers* - 0.012 - 
Alcohol drinkers* - 0.30 - 
Recreational drug use* - 0.37 - 
Table 7.16 – Clinical predictors of lipofuscin accumulation in older PLWH. Table depicting the associations between 
log10(lipofuscin CSA) and various clinical factors. Linear regression and correlation analysis was determined by Pearson’s 
correlation. * = ordinal data in which individuals were stratified by yes/no and differences determined by unpaired t test. 




Figure 7.49 - Clinical determinants of lipofuscin accumulation. Scatter plots depicting the linear regression (Pearson’s 
correlation) between log10(lipofuscin CSA) and (A) age, (B) BMI (kg/m2), (C) percentage lean mass, (D) percentage fat mass, 







7.4.18.2 Physical determinants of lipofuscin accumulation in older PLWH 
Next, I sought to determine whether physical parameters significantly predicted increased lipofuscin 
area in skeletal muscle from the HIV+ group (n = 30). Hence, unadjusted linear regression analysis 
was performed between lipofuscin area and physical function results (Table 7.17). In particular, 
Pearson’s correlation was performed on normalised data sets whilst Spearman’s correlation was 
performed on non-normalised data sets, which is denoted in Table 7.17.   
Here, there was no significant association between the area covered by lipofuscin granules and any 
of the physical parameters such as FFP score, SSPB score or grip strength (Figure 7.50). 
  
 Log10(Lipofuscin CSA (µm2)) 
 HIV+ (n = 29) 
 r p 
FFP score^ -0.14 0.46 
SPPB score^ 0.20 0.31 
MET score^ -0.30 0.11 
Grip strength (kg) -0.11 0.58 
ASMI (kg/m2) 0.22 0.24 
 
Table 7.17 –  Physical factors predicting lipofuscin CSA in older PLWH. Table depicting the associations between 
log10(lipofuscin CSA), and various physical factors. Linear regression and correlation analysis was determined by Pearson’s 





Figure 7.50 – Physical factors predicting lipofuscin accumulation. Scatter plots depicting the linear regression between 
log10(lipofuscin CSA (µm2)) and (A) FFP score, (B) SPPB score, (C) MET score, (D) grip strength (kg), and (E) ASMI (kg/m2) in 
older PLWH (n = 30). Pearson’s correlation was performed on parametric data (D and E), and Spearman’s correlation was 







7.4.18.3 Skeletal muscle pathophysiological determinants of lipofuscin accumulation in older 
PLWH 
Finally, linear regression analysis was undertaken in order to determine whether any of the 
pathophysiological skeletal muscle factors previously discussed in this chapter significantly predicted 
an increased area covered by lipofuscin granules (Table 7.18). 
As demonstrated in the previous sections (Section 7.4.15.3), lipofuscin CSA was significantly 
associated with a lower proportion of degenerated fibres (n = 29; r = -0.60; p = 0.001, Pearson’s 
correlation) (Figure 7.51). Hence, another multivariate linear regression model was developed with 
lipofuscin CSA as the dependant variable and age, as well as percentage degenerated fibres as the 
independent variables. Here, the overall model fit was significant (p = 0.003) and was predictive of a 
reasonably modest amount of variation in lipofuscin CSA (r2 = 0.37). Indeed, the association between 
lipofuscin CSA and the percentage of degenerated fibres remained significant independently of the 
effect of age (unstandardised regression coefficient = -1.30; p = 0.001, multivariate linear 























 Log10(Lipofuscin CSA (µm2)) 
 HIV+ (n = 29) 
 r p Age-adjusted p 
Type I % -0.025 0.90 - 
Type IIa % 0.11 0.59 - 
Type IIx % -0.12 0.54 - 
Fibre CSA (µm2) -0.001 0.99 - 
Log10(Pax7+ SC) 0.052 0.79 - 
Log10(% BodipyAbn) -0.008 0.97 - 
% Regenerated fibres 0.097 0.62 - 
% Degenerated fibres -0.60 0.001 0.001 
Log10(% Fibrosis) 0.037 0.85 - 
 
Table 7.18 – Skeletal muscle determinants of lipofuscin accumulation. Table depicting the associations between the 
log10(lipofuscin CSA) and various skeletal muscle pathophysiological factors. Linear regression and correlation analysis was 
determined by Pearson’s correlation. Multivariate linear regression with adjustment for age was performed for 




Figure 7.51 – Pathophysiological determinants of lipofuscin accumulation. Scatter plot depicting linear regression analysis  
(Pearson’s correlation) between log10(lipofuscin CSA (µm2)) and percentage degenerated fibres. Each dot represents an 
individual patient.  
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7.4.19 Lipofuscin in adverse ageing phenotypes in older PLWH 
To investigate whether there is increased skeletal muscle lipofuscin accumulation in older PLWH 
with adverse ageing phenotypes such as frailty and sarcopenia, I stratified the HIV+ group (n = 29) 
into frail (n = 4), prefrail (n = 14), and robust (n = 11) HIV+, as well as sarcopenic (n = 5), 
presarcopenic (n = 5), and non-sarcopenic (n = 19) HIV+ groups. 
Here, there was no significant difference in the area covered by lipofuscin granules between frail, 
prefrail and robust individuals (p = 0.083, one-way ANOVA) (Figure 7.52a) or sarcopenic, 
presarcopenic and non-sarcopenic individuals (p = 0.77) (Figure 7.52c).  
In addition, there was no significant difference in the frequency of lipofuscin granules between frail, 
prefrail and robust PLWH (p = 0.13) (Figure 7.52b), or between sarcopenic, presarcopenic and non-






Figure 7.52 – Differences in lipofuscin accumulation across the frailty and sarcopenia spectrum in older PLWH. Dot plots 
(mean ± SEM) showing no significant difference between frail (n = 4), prefrail (n = 14) or robust (n = 11) PLWH in either (A) 
log10(lipofuscin CSA (µm2)) or (C) log10(lipofuscin frequency); no significant difference between sarcopenic (n = 5), 
presarcopenic (n = 5) or non-sarcopenic (n = 19) PLWH in either (B) log10(lipofuscin CSA (µm2)) or (D) log10(lipofuscin 






Next, I further stratified the HIV+ group into frail/prefrail HIV+ (n = 18) and sarcopenic/presarcopenic 
HIV+ (n = 10) groups, and compared both the CSA covered by and frequency of lipofuscin granules in 
the respective groups against robust HIV+ (n = 11) and non-sarcopenic HIV+ individuals (n = 19). 
Again, there was no significant difference in either the area covered by lipofuscin granules (p = 0.51, 
unpaired t test) (Figure 7.53a), or the frequency of lipofuscin granules (p = 0.37) (Figure 7.53c) 
between the frail/prefrail PLWH (n = 18) and robust PLWH (n = 10). Similarly, there was also no 
significant difference in the area covered by lipofuscin granules (p = 0.89) (Figure 7.53b) or 
frequency of lipofuscin granules (p = 0.94) (Figure 7.53d) between sarcopenic/presarcopenic PLWH 





Figure 7.53 – Lipofuscin accumulation in adverse ageing phenotypes in older PLWH. Dot plots (mean ± SEM) depicting no 
significant difference in log10(lipofuscin CSA (µm2)) between (A) frail/prefrail PLWH (n = 18) and robust PLWH (n = 11) and, 
(B) sarcopenic/presarcopenic PLWH (n = 10) and non-sarcopenic PLWH (n = 19); no significant difference in the frequency of 
lipofuscin granules between (C) frail/prefrail PLWH and robust PLWH and, (B) sarcopenic/presarcopenic PLWH and non-








7.4.20 Links between skeletal muscle mitochondrial dysfunction and 
pathophysiological skeletal muscle factors 
Work undertaken in Chapter 6 demonstrated that skeletal muscle mitochondrial dysfunction in the 
form of CI and CIV deficiency was significantly higher in older PLWH compared to age-matched HIV- 
individuals (Section 6.4.2). Here, I sought to assess whether skeletal muscle mitochondrial 
dysfunction significantly predicted any of the respective skeletal muscle pathophysiological factors 
previously discussed in this chapter. To this end, I performed linear regression analysis between 
proportional CI and CIV deficiency, as well as mitochondrial mass (represented as VDAC1 z-score) 
and the various respective skeletal muscle pathophysiological factors (Table 7.19).  
Interestingly, proportional CI deficiency significantly predicted a lower percentage of type I fibres in 
older PLWH (n = 30; r = -0.39; p = 0.033, Pearson’s correlation) (Figure 7.54a), as well as a greater 
percentage of type IIx fibres (r = 0.51; p = 0.004) (Figure 7.54b).  
Subsequently, as both fibre type proportions and mitochondrial dysfunction are linked with age, I 
developed multivariate linear regression models with either the percentage of type I fibres or the 
percentage of type IIx fibres as the dependant variable and age, as well as proportional CI deficiency 
as the independent variables. Here, multivariate linear regression confirmed that the association 
between proportional CI deficiency and the lower percentage of type I was independent of the 
effect of age (unstandardised regression coefficient = -12.18; p = 0.018, multivariate linear 
regression) (Table 7.19). The overall model fit was marginally not significant (p = 0.055) and 
predicted only a small amount of variation in the percentage of type I fibres (r2 = 0.19).  
Next, another multivariate linear regression model with the percentage of type IIx fibres as the 
dependant variable, and proportional CI deficiency and age as the independent variables 
demonstrated that the association between the percentage of type IIx fibres and proportional CI 
deficiency was independent of the effect of age (unstandardised regression coefficient = 6.70; p = 
0.003) (Table 7.19). The overall fit of this model was statistically significant (p = 0.012) although was 
only predictive of a small amount of variation in the percentage of type IIx fibres (r2 = 0.28). 
In addition, as the percentage of type IIx fibres was also significantly predicted by a higher number of 
comorbidities (Section 7.4.9.1), a multivariate linear regression model with the percentage of type 
IIx fibres as the dependant variable, and independent variables including age, proportional CI 
deficiency, and number of comorbidities was developed. Here, multivariate linear regression 
confirmed that the association between proportional CI deficiency and the percentage of type IIx 
fibres was independent of the effect of age and greater number of comorbidities (unstandardised 
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regression coefficient = 5.26; p = 0.013, multivariate linear regression) (Table 7.20). In addition, the 
association between percentage type IIx fibres and greater number of comorbidities remained 
significant after adjustment for age and proportional CIV deficiency (unstandardised regression 
coefficient = 0.26; p = 0.015) (Table 7.20). The overall fit of this model was statistically significant (p 
= 0.002) and predictive of a moderate amount of variation in the percentage of type IIx fibres (r2 = 
0.36). 
Finally, proportional CIV deficiency significantly predicted a greater prevalence of quiescent Pax7+ 
SCs (r = 0.49; p = 0.006, Pearson’s correlation) (Figure 7.54c). Again, in a multivariate linear 
regression model with adjustment for age, the association between proportional CIV deficiency and 
Pax7+ SC prevalence was demonstrated to be independent on the effect of age (unstandardised 
regression coefficient = 0.22; p = 0.009, multivariate linear regression) (Table 7.19). Here, the 
overall fit of this model was significant (p = 0.023) although was only predictive of a small amount of 
variation in Pax7+ SC prevalence (r2 = 0.24).  
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 HIV+ (n = 30) 
 CI abnormal CIV abnormal VDAC1 z-score 







Type I % -0.39 0.033 0.018 -0.17 0.82 - -0.059 0.76  
Type IIa % 0.21 0.27 - 0.009 0.96 - 0.030 0.88  
Type IIx % 0.51 0.004 0.003 0.35 0.061 - 0.078 0.68  
Fibre CSA (µm2) -0.14 0.47 - -0.18 0.34 - -0.18 0.35  
Log10(Pax7+ SC) 0.29 0.12 - 0.49 0.006 0.009 -0.081 0.67  
Log10(% BodipyAbn) 0.050 0.79 - 0.19 0.31 - 0.024 0.90  
% Regenerated fibres 0.19 0.32 - 0.056 0.77 - 0.018 0.93  
% Degenerated fibres 0.086 0.65 - 0.11 0.56 - 0.088 0.64  
Log10(% Fibrosis) 0.10 0.59 - 0.32 0.085 - -0.036 0.85  
Log10(Lipofuscin CSA)+ -0.093 0.63 - -0.067 0.73 - 0.031 0.87  
Log10(Lipofuscin frequency)+ 0.25 0.19 - 0.12 0.54 - 0.044 0.82  
 
Table 7.19 – Skeletal muscle determinants of mitochondrial dysfunction. Table depicting the associations between the proportion of log10(CI abnormal), log10(CIV abnormal) fibres, as well as 
average myofibre VDAC! Z-score, and various skeletal muscle pathological factors. Linear regression and correlation analysis was determined by Pearson’s correlation. Multivariate linear 





Figure 7.54 - Pathophysiological determinants of skeletal muscle mitochondrial dysfunction. Scatter plot depicting linear 
regression analysis (Pearson’s correlation) between log10(CI abnormal) and (A) percentage type I fibres, and (B) percentage 



















% Type IIx 
Age, CI abnormal, 
# comorbidities,  
5.26 -0.11 2.60 0.013 0.42 0.015 
Table 7.20 – Fibre type IIx multivariate linear regression model. Table depicting the dependant and independent variables, 
as well as the unstandardised regression coefficients and p value outputs from a multivariate linear regression model used 






7.4.21 Is there a compensatory upregulation in myofibre regenerative capacity in 
older PLWH? 
Pax7+ SC prevalence was previously demonstrated to be predicted by mitochondrial dysfunction (in 
particular CIV deficiency) (Section 7.4.20), as well as the increased fibrosis in older PLWH (Section 
7.4.6.3). This therefore suggests that muscle damage through both mitochondrial dysfunction and 
fibrosis may be stimulating a regenerative response, mediated by an increased prevalence of 
quiescent satellite cells. As such, through various multivariate linear regression analyses I next 
investigated the hypothesis that increased fibrosis and CIV deficiency was underpinning an 
upregulated skeletal muscle regenerative response in older PLWH.  
Firstly, I wanted to determine whether a greater prevalence of Pax7+ SCs was dependant on factors 
found to be significantly predicitive of Pax7+ SC prevalence through unadjusted linear regression 
analysis. As such, a multivariate linear regression model was developed with Pax7+ SC prevalence as 
the dependant variable and age, fibrosis, and proportional CIV deficiency as the independent 
variables. Here, the overall fit of the model was statistically significant (p = 0.002) and predicted a 
reasonably large amount of variation in Pax7+ SC prevalence (r2 = 0.37). Interestingly, a greater 
prevalence of Pax7+ SCs was significantly predicted by proportional CIV deficiency independently of 
the effect of age and fibrosis (unstandardised regression coefficient = 0.16; p = 0.033, multivariate 
linear regression) (Table 7.21). In addition, Pax7+ SCs prevalence was also significantly predicted by 
fibrosis independently of the effect of age and proportional CIV deficiency (unstandardised 
regression coefficient = 0.52; p = 0.007) (Table 7.21).  
Next, I wanted to investigate whether a greater prevalence of regenerated fibres was directly 
predicted by an increased prevalence of Pax7+ SCs, or whether other factors of muscle damage such 
as fibrosis independently predicted increased regeneration, irrespective of an increased prevalence 
of Pax7+ SCs. As such, a multivariate linear regression model was developed with the percentage of 
regenerated fibres as the dependant variable and age, months untreated HIV infection, proportional 
CIV deficiency, fibrosis, and Pax7+ SC prevalence as independent variables (Table 7.22). Of note, the 
proportion of degenerated fibres was not included in the model as it was not significantly predictive 
of the percentage of regenerated fibres. 
Here, the overall fit of the model was statistically significant (p = 0.002), and was predictive of a large 
amount of variation in the percentage of regenerated fibres (r2 = 0.52). Notably, a greater 
prevalence of regenerated fibres was indeed significantly predicted by a greater prevalence of Pax7+ 
SCs independently of the effect of age, greater months untreated HIV infection, fibrosis, and CIV 
deficiency (unstandardised regression coefficient = 16.43; p = 0.041, multivariate linear regression) 
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(Table 7.22). In addition, increased fibrosis also significantly predicted a greater prevalence of 
regenerated fibres independently of the effects of age, CIV deficiency, months untreated HIV 
infection, and importantly, Pax7+ SC prevalence (unstandardised regression coefficient = 17.72; p = 
0.037) (Table 7.22).  
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Dependant variable Independent variables 









Age, fibrosis, proportional CIV 
deficiency 
-0.002 0.16 0.52 0.70 0.033 0.007 
Table 7.21 – Pax7+ SC prevalence multivariate linear regression analysis model. Table depicting the dependant and independent variables included in the multivariate model used to 

























0.040 -5.30 17.72 16.43 0.030 0.83 0.093 0.037 0.041 0.11 
Table 7.22 – Skeletal muscle regeneration multivariate linear regression analysis models. Table depicting the dependant and independent variables included in the multivariate model used 




Data on skeletal muscle pathophysiological factors in older (≥ 50 years) PLWH and age-matched HIV- 
individuals recruited as part of the MAGMA study was presented for the first time in this chapter.  
Other studies conducted as part of the MAGMA study and discussed in previous chapters (Chapter 5 
and 6) demonstrated that older HIV-infected males had a higher prevalence of adverse ageing 
phenotypes such as frailty and sarcopenia when compared to age and sex-matched HIV-uninfected 
individuals. In addition, these older HIV+ individuals had a significantly higher proportion of skeletal 
muscle mitochondrial dysfunction in the form of CI and CIV deficiency compared to the matched 
HIV- individuals.  
However, as this skeletal muscle mitochondrial dysfunction did not appear to directly explain the 
observed frailty and sarcopenia in older PLWH, I wanted to investigate the effect of other 
pathogenic muscle factors that are known to be involved in the pathophysiology of age-related 
muscle decline, such as stem cell availability and intramyocellular lipid accumulation (Wu & 
Ballantyne, 2017; Collins et al., 2007; Sousa-Victor et al., 2014). Importantly, I also aimed to 
determine whether skeletal muscle mitochondrial dysfunction was predictive of any of these 
pathophysiological factors, and additionally whether any of these factors were implicated in frailty 
and sarcopenia in older PLWH.  
7.5.1 Study findings 
7.5.1.1 Insulin resistance and adverse ageing phenotypes in older PLWH 
Initially, I sought to investigate the role of insulin resistance (IR) in adverse ageing conditions in older 
PLWH, as IR has been shown to be associated with physiological decline (Wu & Ballantyne, 2017; 
Phielix et al., 2012). Firstly, I assessed whether there were differences in skeletal muscle IR between 
the HIV+ and HIV- individuals. Here, by staining skeletal muscle sections with the fluorescent 
histochemical dye BODIPY (493/503), I quantified a surrogate for IR – IMCL – in both the HIV+ and 
HIV- individuals and found that there was no statistically significant difference in the proportion of 
IMCL between the respective serostatus groups. Importantly, this is the first study to demonstrate 
that there is no significant difference in IMCL at the individual myofibre level between older PLWH 
and age-matched HIV- individuals.  
Next, I assessed whether exposure to particular ARV classes predicted IMCL. Surprisingly, PLWH who 
had been exposed to older, mitochondrially-toxic nucleoside reverse transcriptase inhibitors (NRTIs) 
had significantly lower IMCL than PLWH who had not been exposed to these ARVs. As zidovudine 
(AZT) and stavudine (d4T) in particular have been shown to be associated with fat redistribution 
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elsewhere in the body (Moyle et al., 2006; Jones et al., 2005; Glidden et al., 2018; Carr et al., 1999; 
Dragovic et al., 2014; Miller et al., 2003; McComsey et al., 2016), I further stratified the HIV+ group 
into those who had been exposed to those two NRTIs and those who had not. Again, PLWH who had 
been exposed to these NRTIs had significantly lower IMCL compared to those who had not. This 
suggests that any potential abnormalities in fat distribution seen in PLWH exposed to these drugs 
did not contribute to an increased insulin resistance and IMCL accumulation in skeletal muscle, and 
exposure to these ARVs may in fact result in increased metabolism of fats in skeletal muscle. It is  
plausible that because these drugs cause loss of subcutaneous limb fat (lipoatrophy) (Innes et al., 
2012), they might also reduce IMCL. 
Finally, through unadjusted linear regression analysis I demonstrated that increased IMCL was not 
significantly predicted by any of the clinical, HIV-related, physical, or lifestyle factors assessed as part 
of the MAGMA study. Even though the average BMI of the HIV- group was significantly higher 
compared to the HIV+ group, this did not predict IMCL. In addition, IMCL was not significantly 
altered in PLWH with adverse ageing phenotypes such as frailty and sarcopenia, nor did skeletal 
muscle mitochondrial dysfunction appear to predict IMCL in the older HIV+ individuals. This was 
surprising as mitochondrial dysfunction is thought to be associated with IR (Kelley et al., 2002; 
Hwang et al., 2010; Heilbronn et al., 2007; Ritov et al., 2005; Phielix et al., 2008), which in turn is a 
risk factor for the age-associated decline in muscle function (Wu & Ballantyne, 2017). In addition, 
these results suggest that metabolic abnormalities do not significantly contribute to the 
pathophysiology of adverse ageing phenotypes in older PLWH, as they do in diabetics (Park et al., 
2009; Cacciatore et al., 2013). As IR is associated with oxidative stress (Rains & Jain, 2011) and 
chronic inflammation (Patsouris et al., 2014), it would therefore be interesting to investigate 
whether there were differences in systemic, or skeletal muscle specific oxidative stress, as well as 
inflammatory markers between the HIV+ and HIV- groups.  
7.5.1.2 Lipofuscin accumulation does not contribute to the pathophysiology of adverse ageing 
phenotypes in older PLWH 
Another pathophysiological skeletal muscle factor assessed was lipofuscin accumulation. In the 
general population, age-associated skeletal muscle lipofuscin accumulation has been associated with 
declining muscle function through proteolytic mechanisms (Hutter et al., 2007; Sitte et al., 2000; 
Hohn et al., 2011; Sugano et al., 2006; Powell et al., 2005; Stroiken et al., 2004), and there are 
possible links to the causative role of age-associated mitochondrial dysfunction in this phenomenon 
(Terman & Brunk, 2006; Konig et al., 2016; Terman & Sandberg, 2002; Couve et al., 2012). As such, I 
quantified both the area covered by, and frequency of lipofuscin granules in both the HIV+ and HIV- 
individuals, and found that there was no significant difference in either parameter between the two 
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respective groups. In addition, older PLWH with the adverse ageing phenotypes of frailty and 
sarcopenia did not have a significantly different amount of either parameter compared to age-
matched robust and non-sarcopenic PLWH respectively.  
The discrepancy between my results and results from previous studies are possibly explained by the 
fact that I measured lipofuscin accumulation through the quantification of the area covered as well 
as by the frequency of lipofuscin granules, and imaged lipofuscin autofluorescence in two different 
channels. In contrast, the Hutter et al. (2007) study only measured lipofuscin by the raw 
autofluorescence intensity in one channel (488nm), and in only 6 individual fibres. The variation in 
participant ages was also much larger in the Hutter et al. (2007) study compared to this study.  
Surprisingly, through unadjusted and age-adjusted linear regression analyses it was also 
demonstrated that an increased area covered by lipofuscin granules was significantly predicted by a 
higher CD4 count and a lower proportion of degenerated fibres. However, there was no significant 
association between lipofuscin accumulation and skeletal muscle mitochondrial dysfunction, again 
contradicting previous studies (Terman & Bunk, 2006). 
Notably, this was the first study to investigate skeletal muscle lipofuscin accumulation in the context 
of ageing in HIV. As such, the demonstration that there was no significant difference either the area 
covered by or frequency of lipofuscin granules between older PLWH and age-matched HIV- 
individuals is novel.  
7.5.1.3 Skeletal muscle CI deficiency predicts decreased fibre type conversion in older PLWH 
In addition to IR and decreased stem cell prevalence, age-related changes in fibre type composition 
have previously been implicated in the age-associated decline in muscle function (Manini, 2011; 
Milijkovic et al., 2015). In particular, older individuals in the general population have lower 
proportions of the glycolytic fibre types IIa and IIx, and an increased prevalence in fibre type I 
proportions, which account for loss of muscle mass and strength with age (Brunner et al., 2007; 
Grimby, 1995; Murgia et al., 2017; Ubaida-Mohien et al., 2019; Roberts et al., 2018; Verdijk et al., 
2009; 2010; 2012; 2014; McKay et al., 2012; 2013). Therefore, in both the HIV+ and HIV- groups, I 
quantified the proportions of the three fibre types, as well as their cross-sectional area, as this is also 
associated with muscle function (van Wessel et al., 2010; Frontera et al., 2000; Milijkovic et al., 
2015). Whilst the proportion of type I fibres was higher than that of both types IIa and IIx fibres in 
both the HIV+ and HIV- groups, there was no significant difference in the proportions of the 
respective fibres types between the HIV+ and HIV- individuals themselves. In addition, there was no 
significant difference in average fibre cross-sectional area between the HIV and HIV- groups. 
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Importantly, this study is the first to investigate differences in fibre type proportions between older 
PLWH and age-matched HIV- individuals.   
I then wanted to determine if altered proportions of any of the fibre types or average fibre cross-
sectional area was linked to frailty or sarcopenia in older PLWH. Here, frail PLWH had a significantly 
higher proportion of type IIx fibres compared to both prefrail and robust PLWH, contradicting 
previous observations (St-Jean Pelletier et al., 2017; Sonjak et al., 2019).  
Additionally, through unadjusted and age-adjusted linear regression analysis, the proportions of the 
fibre types were investigated in relation to the other pathogenic skeletal muscle factors, as well as 
clinical, physical, and lifestyle parameters. Here, it was also found that a higher average fibre cross-
sectional area was significantly associated with the proportion of regenerated fibres, suggesting that 
those older PLWH with higher regenerative capacity have increased muscle mass and potentially 
therefore, muscle strength (Verdijk et al., 2007; van Wessel et al., 2010). In addition, individuals with 
a higher prevalence of comorbidities, as well as those prescribed with more medications, had a 
significantly higher proportion of type IIx fibres. Together, this suggests that increased age-related 
pathology in older PLWH may impair fibre type switching with age, potentially through increased 
chronic inflammation or poorer neuromuscular junction dynamics, leading to inadequate fibre type 
switching (D’Antona et al., 2003; Gonzalez-Freire et al., 2014). This therefore merits further 
investigation.  
Interestingly, greater proportional skeletal muscle CI deficiency also appeared to predict a higher 
proportion of type IIx fibres, as well as a lower proportion of type I fibres through unadjusted and 
age-adjusted linear regression analysis. Further, multivariate linear regression models also 
demonstrated that greater proportional CI deficiency significantly predicted a lower percentage of 
type I fibres and a simultaneous increase in the percentage of type IIx fibres, independently of the 
effect of both age and a greater number of comorbidities. As type IIx fibres have a lower 
mitochondrial content compared to type I fibres, as well as the fact that type IIx fibres are glycolytic 
and type I fibres are oxidative (Murgia et al., 2019; Howald et al., 1985; Picard et al., 2012; Picard et 
al., 2008), these findings suggest that age-related skeletal muscle mitochondrial dysfunction may be 
preserving type IIx fibres from age-related atrophy. Conversely, these findings may also be 
suggestive of a phenomenon whereby instead type I fibres are preferentially selected for atrophy as 
a result of metabolic and functional decline (Murgia et al., 2017; Murgia et al., 2019). Unfortunately 
it was not possible to precisely determine which of these processes were occurring, or whether both 
were occurring in the older PLWH, and so further work is required.  
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7.5.1.4 Elevated skeletal muscle fibrosis does not directly contribute to the onset of adverse 
ageing phenotypes in older PLWH 
Next, as age-associated mitochondrial dysfunction induces skeletal muscle apoptosis and potentially 
fibrosis (Marzetti et al., 2006; Powers et al., 2012), I investigated and compared the level of skeletal 
muscle fibrosis in both the older HIV+ and HIV- individuals. Notably, HIV+ individuals had a 
significantly higher level of skeletal muscle fibrosis compared to age-matched HIV- individuals. As 
this was a novel result, I undertook unadjusted and age-adjusted linear regression analysis in order 
to determine the factors that predicted this increased fibrosis in the older HIV+ individuals.  
Surprisingly, greater fibrosis did not seem to be explained by any of the clinical, HIV-related, 
physical, or lifestyle factors assessed in the MAGMA study. Nor was fibrosis associated with skeletal 
muscle mitochondrial dysfunction. This later finding is surprising, as mitochondrial dysfunction is 
linked with increased skeletal muscle atrophy in the general population (Powers et al., 2012). 
However, atrophy is not solely dependent on fibrosis, and other factors not investigated in this 
study, such as inflammation, may be contributing. 
Additionally, by stratifying the HIV+ individuals into whether they were frail/prefrail or 
sarcopenic/presarcopenic, and comparing levels of fibrosis against robust and non-sarcopenic PLWH, 
it was demonstrated that there was no significant difference in skeletal muscle fibrosis in PLWH with 
these adverse ageing phenotypes.  
Importantly, as previously mentioned, fibrosis was significantly associated with a higher prevalence 
of Pax7+ SCs and regenerated fibres. In this circumstance, even though a greater prevalence of 
quiescent Pax7+ SCs allows for a greater regeneration potential in response to injury, there will be 
some abhorrent skeletal muscle healing that results in fibrosis (Mann et al., 2011).  
7.5.1.5 Older PLWH with adverse ageing phenotypes did not have higher prevalences of 
regenerated or degenerated fibres compared to normal older PLWH 
Loss of muscle mass is a contributing factor to the development of sarcopenia (Cruz-Jentoft et al., 
2019), and the age-associated decline in muscle regenerative capacity contributes to both the 
decline in muscle mass and strength (Garcia-Prat et al., 2013; Li et al., 2019). Here, by subjecting 
muscle sections to H&E histochemistry, I determined the proportions of regenerated and 
degenerated muscle fibres in both the HIV+ and HIV- groups. Notably, HIV+ individuals had a 
significantly lower proportion of regenerated fibres when compared to the HIV- individuals. This is 
the first time this result has been demonstrated and this novel finding may be explained by the fact 
that greater duration (months) of untreated HIV infection was significantly predictive of a lower 
proportion of regenerated fibres in unadjusted and age-adjusted linear regression analysis. Here, 
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individuals with a greater duration of untreated HIV infection may be predisposed to residual 
chronic inflammation and immunosenescence, impairing muscle regenerative capabilities (Wilson & 
Sereti, 2013; Guaraldi et al., 2011).  
As expected, the proportion of regenerated fibres was also significantly associated with the 
prevalence of Pax7+ SCs as well as average fibre CSA in unadjusted and age-adjusted linear 
regression, supporting previous observations (Sambasivan et al., 2011). A higher percentage of 
regenerated fibres was also significantly predicted by fibrosis in unadjusted and age-adjusted linear 
regression. There were no other significant associations between the proportion of regenerated 
fibres and any of the clinical, HIV, physical, or lifestyle parameters. Overall, these findings suggest 
that older PLWH with a long duration of untreated HIV infection have a reduced regenerative 
capacity. This may be due to an impaired immune system and residual chronic inflammation (Wilson 
& Sereti, 2013; Guaraldi et al., 2011; Fornica et al., 2020). 
Finally, there was no significant difference in either the proportion of regenerated, or degenerated 
fibres between PLWH with the adverse ageing phenotypes of frailty and sarcopenia, and those who 
did not have these adverse ageing phenotypes.  
7.5.1.6 Potential compensatory mechanisms inducing the upregulation of skeletal muscle 
regenerative capacity in older PLWH 
Another factor associated with declining muscle and physical function with age is the reduced 
prevalence of quiescent stem cells (Lopez-Otin et al., 2013; Verdijk et al., 2007). As such, I sought to 
investigate the prevalence of Pax7+ satellite cells (SCs) in the older HIV+ and HIV- individuals.  
Indeed, there was no statistically significant difference in Pax7+ satellite cell prevalence between the 
two respective groups. This result is this first demonstration that there is no significant difference in 
the prevalence of quiescent skeletal muscle stem cells between older PLWH and age-matched HIV- 
individuals.  
I next sought to determine whether the prevalence of Pax7+ SCs was significantly predicted by any of 
the clinical, HIV-related, or lifestyle parameters. As such, through unadjusted linear regression 
analysis it was shown that none of these factors significantly predicted the prevalence of Pax7+ SCs. 
Additionally, linear regression analysis also determined that Pax7+ SC prevalence was not 
subsequently predictive of physical function or indeed that Pax7+ SC prevalence was significantly 




However, it was determined through unadjusted and age-adjusted linear regression analysis that 
mechanisms of skeletal muscle damage in the form of mitochondrial dysfunction (specifically CIV 
deficiency) and fibrosis were both significantly predictive of a greater prevalence of Pax7+ SCs in 
older PLWH. Indeed, in a multivariate linear regression model developed to determine the predictive 
value of both CIV deficiency and fibrosis independently of age and the other respective factor, both 
factors remained statistically significant after adjustment.  
Interestingly, as mentioned previously, both increased fibrosis and prevalence of regenerated 
myofibres were significantly predicted by an increased prevalence of Pax7+ SCs independently of age 
in older PLWH. Additionally, a higher proportion of regenerated fibres was also significantly 
predicted by a greater prevalence of Pax7+ SCs following adjustment for the effect of other factors 
shown to be predictive of fibre regeneration, such as age, greater months untreated HIV infection, 
fibrosis, and CIV deficiency. Finally, a greater percentage of regenerated fibres was also significantly 
predicted by increased fibrosis after adjustment for age, months untreated, CIV deficiency, and stem 
cell prevalence – further supporting the idea that muscle damage is stimulating regeneration.  
Altogether, these findings are strongly suggestive of phenomenon in older PLWH whereby both 
fibrosis and mitochondrial dysfunction are independently inflicting muscle damage, which is 
subsequently stimulating the compensatory increase in quiescent satellite cell prevalence. However, 
this increased prevalence of Pax7+ SCs is leading to increased levels of both normal muscle healing, 
via the regeneration of myofibres, as well as abhorrent healing, in the form of fibrosis formation. 
This would indicate a reduction in the functional efficiency of Pax7+ SCs in older PLWH, as the Pax7+ 
SC pool is not necessarily depleted (Sacco et al., 2010; Attia et al., 2017; Dumont et al., 2015). 
Indeed, elevated residual chronic inflammation as the result of HIV infection may be contributing to 
this phenomenon (Wanschitz et al., 2013; McKay et al., 2013; Rudnicki et al., 2008; Collins et al., 
2007; Yang et al., 2011; Conboy et al., 2005; Merritt et al., 2013). In addition, exhaustion of satellite 
cells could be due to continued activation in response to muscle damage, as is the case in studies of 
Duchenne Muscular Dystrophy using the mdx mouse model (Lu et al., 2014; Sacco et al., 2010). 
Indeed, it is likely that chronic inflammation is a primary driver of continued SC activation and 
exhaustion (Fornica et al., 2020). This therefore requires further investigation.      
Finally, as none of fibrosis, the percentage of regenerated fibres, or the prevalence of Pax7+ SCs was 
significantly different in frail/prefrail or sarcopenic/presarcopenic PLWH compared to robust and 
non-sarcopenic PLWH, this would suggest that none of these factors are directly responsible for the 
greater prevalence of adverse ageing conditions seen in PLWH compared to age-matched HIV- 
individuals. Altogether, these findings subsequently suggest that the proposed compensatory 
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upregulation in regenerative capacity may not be fully efficient, but is functional enough to 
attenuate the onset of adverse ageing in PLWH. Indeed, as mentioned several times previously 
throughout this thesis, it also suggests that other factors known to be present in ART-treated PLWH, 
such as elevated chronic inflammation or immune senescence, are likely to be playing a significant 
causative role in age-related pathogenesis.  
Importantly, these findings could have significant clinical and therapeutic relevance, as they suggest 
that age-related muscle decline could potentially be attenuated in older PLWH through exercise 
regimens (Lo et al., 2020; Zampieri et al., 2015; Marzetti et al., 2008; Rowe et al., 2014; Walston et 
al., 2018; Cameron et al., 2013; Silva et al., 2017; Li et al., 2019). Notably, these findings also support 
recent studies which have suggested that the transplantation of functional Pax7+ SCs may be 
beneficial in preventing declining muscle function (Yang et al., 2017; Berberoglu et al., 2017). 
7.5.1.7 Study conclusions 
In conclusion, whilst there were several key age-associated pathogenic skeletal muscle parameters 
that were significantly altered in older HIV+ individuals compared to age-matched HIV- individuals, 
such as increased skeletal muscle fibrosis and the decreased proportion of regenerated fibres, only a 
greater proportion of type IIx fibres appeared to be directly linked to the adverse ageing phenotype 
of frailty, whilst none were linked to sarcopenia in older PLWH.  
Interestingly however, results from this chapter did demonstrate the presence of some potential 
compensatory regenerative mechanisms in older PLWH. Here, a higher prevalence of quiescent 
Pax7+ SCs was significantly predicted by both increased proportional CIV deficiency and skeletal 
muscle fibrosis, suggesting a compensatory upregulation in the stimulation of regeneration. 
Normally, this increased prevalence of quiescent Pax7+ SCs would consequently then induce 
increased muscle healing. However, as the increased prevalence of quiescent Pax7+ SCs was 
significantly predictive of both fibre regeneration and abhorrent healing in the form of increased 
fibrosis, this would instead suggest that regenerative mechanisms are not fully efficient in older 
PLWH – most likely to a decline in Pax7+ SC function. Importantly though, as there was not a 
significantly lower level of quiescent Pax7+ SCs or regenerated fibres in frail and sarcopenic PLWH, 
these findings together suggest that the attempted compensatory upregulation in muscle 
regeneration in response to muscle damage is attenuating the pathogenic decline in muscle function 
and onset of adverse ageing phenotypes in older PLWH. However, these findings do not explain the 
exact mechanisms behind this compensation. Hence, as chronic inflammation is known to be linked 
to declining muscle function with age (Perandini et al., 2018), as well as the fact that inflammation is 
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known to regulate stem cell function (McKay et al., 2013; Rudnicki et al., 2008; Collins et al., 2007; 
Yang et al., 2011; Conboy et al., 2005) this should be investigated in future studies. 
Another interesting finding was that, through investigations into the proportions of skeletal muscle 
fibre types, it was demonstrated that mitochondrial dysfunction in the form of CI deficiency 
significantly predicted a greater proportion of type IIx fibres, independently of the number of 
comorbidities, as well as a decrease in the proportion of type I fibres. Importantly, the proportion of 
type IIx fibres was significantly higher in frail PLWH compared to prefrail and robust PLWH. Taken 
together, as the age-related decrease in the proportion of glycolytic type IIx fibres is associated with 
declining muscle function (Brunner et al., 2007; Grimby, 1995; Murgia et al., 2017; Ubaida-Mohien et 
al., 2019; Roberts et al., 2018; Verdijk et al., 2009; 2010; 2012; 2014; McKay et al., 2012; 2013), as 
well as frailty and prefrailty (St-Jean Pelletier et al., 2017; Sonjak et al., 2019), these results indicate 
that another compensatory mechanism could also involve attenuated fibre type switching in 
response to age-related mitochondrial dysfunction, ultimately slowing down the onset of adverse 
ageing phenotypes. Alternatively, these findings could also suggest that declining skeletal muscle 
mitochondrial function may induce the selective atrophy of type I fibres in older PLWH. To better 
understand this phenomenon, other factors such as chronic inflammation, oxidative stress, immune 
senescence, and neuromuscular junction decline should be investigated in order to better 
understand these pathophysiological mechanisms.  
The design of the MAGMA study, in particular the range of clinical parameters and skeletal muscle 
factors investigated, has meant that several novel observations have been made. Of note, this is the 
first study to simultaneously investigate whether physical parameters such as percentage fat mass or  
MET score are associated with pathogenic factors such as IMCL or stem cell availability in the context 
of HIV in ageing. In addition, whether HIV-related clinical parameters such as CD4 count or duration 
on antiretroviral therapy contributed to these pathogenic factors was also investigated for the first 
time. 
Importantly, the utilisation of a novel immunofluorescence assay which objectively quantifies 
mitochondrial mass as well as CI and CIV deficiency at the individual myofibre level (Rocha et al., 
2015) afforded the ability to investigate the role skeletal muscle mitochondrial dysfunction plays in 
these pathophysiological mechanisms. Whilst previous studies have demonstrated that 
mitochondrial dysfunction is present in some virally-supressed PLWH (Cote et al., 2002; Payne et al., 
2011; Martin et al., 2013; Morse et al., 2012; McComsey et al., 2008; Samuels et al., 2017; Lewis & 
Dalkas, 2003), this is the first study to assess whether mitochondrial dysfunction is implicated in the 
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 Older PLWH Older HIV- individuals Conclusions 
IMCL  • Comparable to HIV- individuals 
• No associations with clinical parameters 
• No difference between frail and robust, or 
sarcopenic and non-sarcopenic PLWH 
• Not predicted by mitochondrial 
dysfunction 
• ARV regimen did not predict increased 
IMCL 
• Comparable to HIV+ individuals  • IMCL was not significantly different in 
HIV+ and HIV- individuals 
• IMCL did not appear to contribute to 
adverse ageing phenotypes  
Quiescent Pax7+ SC prevalence  • Comparable to HIV- individuals 
• Predictive of age-adjusted fibrosis and 
regenerated fibre percentage 
• No difference between frail and robust, or 
sarcopenic and non-sarcopenic PLWH 
• Predicted by age-adjusted CIV deficiency 
and fibrosis, independently of various 
other pathophysiological factors 
• Comparable to HIV+ individuals • Pax7+ SC prevalence was not significantly 
different in HIV+ and HIV- individuals 
• No difference between frail and robust, or 
sarcopenic and non-sarcopenic PLWH 
• CIV deficiency appeared to predict greater 
Pax7+ SC prevalence independently of 
age-related pathophysiologic factors 
Fibre type proportions and fibre CSA • Comparable to HIV- individuals 
• Frail PLWH had higher levels of type IIx 
fibres than prefrail and robust PLWH 
• Type I percentage was negatively 
predicted by age-adjusted CI deficiency 
• Type IIx percentage predicted by age-
adjusted CI deficiency, number of 
comorbidities, and number of 
medications 
• Fibre CSA predicted by age-adjusted 
percentage of regenerated fibres 
• Comparable to HIV+ individuals • Fibre type prevalence and fibre CSA was 
not significantly different in HIV+ and HIV- 
individuals 
• Frail PLWH had higher levels of type IIx 
fibres than prefrail and robust PLWH 
• CI deficiency appeared to predict 
increased type IIx prevalence and 
decreased type I prevalence, potentially 
attenuating frailty and sarcopenia onset 
• Proposed decrease in fibre type switching 
in response to  mitochondrial dysfunction 
Fibrosis • Greater fibrosis than in HIV- individuals  
• No difference between frail and robust, or 
sarcopenic and non-sarcopenic PLWH 
• Predicted by age-associated regenerated 
fibres and Pax+ SC prevalence 
• Not predicted by mitochondrial 
dysfunction 
• Significantly lower than in HIV+ 
individuals  
• HIV+ had higher skeletal muscle fibrosis 
• No difference between frail and robust, or 




Regenerated fibres • Lower prevalence than in HIV- individuals  
• No difference between frail and robust, or 
sarcopenic and non-sarcopenic PLWH 
• Predicted by months untreated HIV 
infection, Pax7+ SC prevalence, and 
fibrosis after age-adjustment 
• Predicted by Pax7+ SC prevalence and 
fibrosis after adjustment for age-related 
pathophysiological factors 
• Associated with higher fibre CSA 
• Not predicted by mitochondrial 
dysfunction 
• Significantly greater than in HIV+ 
individuals 
• HIV+ individuals had a lower prevalence 
of regenerated fibres 
• No difference between frail and robust, or 
sarcopenic and non-sarcopenic PLWH 
• Fibre regeneration induced by muscle 
damage in the form of fibrosis 
• Proposed compensatory upregulation in 
regenerative capacity 
Lipofuscin accumulation • Comparable to HIV- individuals 
• No difference between frail and robust, or 
sarcopenic and non-sarcopenic PLWH 
• Not predicted by mitochondrial 
dysfunction 
• Associated with decreased degenerative 
fibre prevalence 
• Comparable to HIV+ individuals • Lipofuscin accumulation was not 
significantly different in HIV+ and HIV- 
individuals. 
• No difference between frail and robust, or 
sarcopenic and non-sarcopenic PLWH 
• Lipofuscin accumulation did not appear to 
contribute to adverse ageing phenotypes 
Involvement of mitochondrial 
dysfunction 
• Predicted age-adjusted increase in type IIx 
and decrease in type I percentage  
• Predicted age-adjusted increase in Pax7+ 
prevalence  
• Not investigated  • Appeared to predict a decline in age-
related fibre type switching 
• Predicted compensatory upregulation in 
stem cell prevalence 
Potential pathophysiological 
mechanisms behind adverse ageing 
phenotypes in older PLWH 
Two distinct potential compensatory mechanisms: 
1. Mitochondrial dysfunction predicts a decline in age-related fibre type switching 
2. Upregulation in regenerative capacities in response to skeletal muscle damage, in which fibrosis and mitochondrial dysfunction are involved. 
However, this compensatory regenerative response may not be fully efficient.   
• Both mechanisms appear to be underpinned by age-related factors not investigated in the present study, such as chronic inflammation 
Table 7.23 – Summary of experimental findings.
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7.5.2 Limitations  
Whilst this study has several novel aspects, it is limited in the fact that it is not a longitudinal study. 
An important aspect of this study was the large data set and several parameters assessed, as no 
previous studies have been able to combine all these parameters. However, this limited the ability to 
recruit a large cohort. As a result of this, it is difficult to extrapolate whether several of the 
pathogenic skeletal muscle factors such as mitochondrial dysfunction or increased fibrosis are a 
consequence or causal factor of the increased prevalence of adverse ageing phenotypes in the HIV+ 
group. It is acknowledged though that due to the comprehensive nature of tissue acquisition 
outlined in the study manual, repeated study visits may be difficult to achieve. Additionally, 
variability in repeat muscle sections would restrict the validity of several muscle biopsies being 
taken.   
Whilst the HIV+ and HIV- groups are well matched for age, another limitation lies in the fact that the 
two groups are not perfectly matched in body composition. Notably, the HIV- individuals had a 
higher average BMI and mean percentage fat mass than the HIV+ group. It is not clear whether this 
was largely explained by differences in lifestyle factors between the groups or whether HIV-
associated changes in fat metabolism are implicated. BMI and malnutrition have been shown to 
affect the onset and progression of frailty in PLWH (Erlandson et al., 2017a; Onen et al., 2009), 
although BMI did not however seem to be predictive of any outcome measures in this study. In 
response, future studies should look to better match the body compositions of the experimental 
groups. As a low daily protein intake is associated with an increased susceptibility to developing 
frailty, another potential alteration to the study protocol could have been the addition of a food 
dairy (Bartali et al., 2006).   
Importantly, although our cohort size of 45 is large enough to allow us to get a reasonably firm 
understanding of the cellular and pathophysiological mechanisms underpinning frailty and 
sarcopenia in HIV+ individuals, a larger cohort size would increase the power afforded to us to make 
more detailed within-group observations. In addition, our cohort was solely made up of males, as 
older (≥ 50 years) males are less heterogeneic than older females (Kennedy et al., 2014), as well as 
the fact that there is a much larger population of older HIV-infected males as opposed to females in 
the UK, and especially in the North East (Public Health England, 2019). The fact that the MAGMA 
study recruited majority middle-aged individuals (50-65 years) also meant that the ability to 
potentially predict the age of onset of adverse ageing phenotypes was more restricted. Hence, 
future studies should look to study females. In addition, a wider range of age should be included, 
especially enriching for old (≥65 years) individuals.  
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7.5.3 Future work 
Whilst this study has many novel aspects, there is scope for additional work to be conducted in order 
to better answer the study’s experimental aims. As mentioned above, any future studies should aim 
to be longitudinal cohort studies. In addition, the sample size should increase and should ideally 
include younger and old (≥65 years) individuals, in addition to middle-aged (50-65 years) individuals. 
This would allow for the better understanding of the trajectories of adverse ageing conditions in 
PLWH, as well as allowing us to better test our compensatory mechanism hypotheses. In addition, 
HIV+ and HIV- females from various age ranges should be included. 
One of the most immediate areas of future work would be to perform proteomics or genomics on 
individual muscle fibres or homogenate tissue, with a keen interest in comparing the signatures of 
HIV+ vs HIV- individuals, frail vs robust HIV+ subjects, and individual fibres from HIV+ subjects with 
mitochondrial dysfunction vs fibres with normal mitochondrial function. This work would expand on 
several significant recent proteomic and genomic studies done in isolated muscle fibres (Murgia et 
al., 2019) and would completement the existing experimental work.  
An additional recent advance being pioneered by our lab is the use of multiplex imaging mass 
cytometry (IMC) (Warren et al., 2020). Here, instead of being limited to four or five channels in 
which to immunofluorescently stain muscle sections, IMC would allow the simultaneous staining and 
imaging of up to 40 channels. Any IMC work should be preceded by the proteomic or genomic work, 
as this will allow us to identify any additional proteins or genes of interest.  
One of the interesting findings of this study was that muscle damage in the form of mitochondrial 
dysfunction and fibrosis were predictive of an increased prevalence of Pax7+ SCs. However, whilst 
this led to increased fibre regeneration, it also predicted a further increase in the formation of tissue 
fibrosis – indicating a possible defect in Pax7+ SC functional efficiency (Sacco et al., 2010; Attia et al., 
2017; Dumont et al., 2015). As such, in order to further investigate this phenomenon, investigations 
should be undertaken into Pax7+ SC function in older PLWH. As it would be difficult to fully 
recapitulate the heterogeneity of older PLWH in mouse models such as the mdx mouse model or in 
in vitro studies (Lu et al., 2014; Sacco et al., 2010), other markers of muscle regeneration, such as 
MyoD and Myf5 should be investigated in muscle biopsies from older PLWH (Tedesco et al., 2010; 
Almada & Wagers, 2016).     
One of the primary research interests of this study was to better understand the role of 
mitochondrial dysfunction in adverse age-related complications such as frailty and sarcopenia in 
older PLWH. In this study I utilised a novel assay which allowed us to quantify protein levels of 
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OXPHOS complexes and mitochondrial mass in individual fibres (Rocha et al., 2015). There are 
however several other experimental methods that could be used to better understand the 
mitochondrial function in our patients (Hunt & Payne, 2020; Fraizer et al., 2020). These include 
quantifying mitochondrial OXHPOS capacity through physiological assessments such as 31P-MRS. 
Additionally, specific functions of mitochondria known to be adversely affected by ART and ageing 
itself such as fission and fusion dynamics, calcium handling, signalling pathway activity, or 
mitochondrial morphology can be assessed through a range of cellular assays and electron 
microscopy imaging. In particular, as mitochondrial biogenesis and particularly PGC-1α are involved 
in fibre type switching (Liu et al., 2016), it would be of interest to investigate this specifically. At the 
molecular level, whole exome sequencing (WES) could be used to screen for pathogenic mtDNA 
mutations (Taylor et al., 2014), or alternatively qPCR and long-range PCR can be used to better 
assess mtDNA mutations (Hunt & Payne, 2020). 
As chronic immunosenescence and other immune system alterations are significantly implicated in 
the pathology of adverse age-related complications (Dihn et al., 2019), future flow cytometry work, 
with the aim of assessing the cohorts’ immune profile, should be conducted. This would 
complement the existing experimental analyses and allow us to comprehensively assess its role in 
the majority of pathophysiological factors underpinning adverse age-related complications. In 
addition, it would be of interest to assess various mitochondrial parameters such as mitochondrial 
mass or OXPHOS capabilities in certain immune cell subsets of interest.  
Another important factor involved in the decline of muscle function with age is increased muscle 
denervation (Pannerec et al., 2016; Morat et al., 2016; Always et al., 2017). Indeed, as 
neuromuscular junction decline is associated with deregulated fibre type switching (Gonzalez-Freire 
et al., 2014), and the findings in this study demonstrated a potential alteration in fibre type 
switching in older PLWH, these investigations would be of interest. In addition, as alluded to 
previously, general interest in this area has increased over recent years and so it would be 
interesting to assess whether frail HIV+ individuals have greater levels of muscle denervation 
compared to robust HIV+ individuals or HIV- individuals. 
As both chronic inflammation and oxidative stress at both the systemic and skeletal muscle level 
have been associated with adverse ageing through a variety of mechanisms (Soysal et al., 2016; Leng 
et al., 2007), another interesting aspect of potential future work would be to investigate these 
factors. Unfortunately, both of these factors are difficult to experimentally investigate at the 




Finally, as a proxy for a larger cohort size, collaborators at University College London (UCL) possess a 
database and tissue resource for several thousand PLWH. Ideally, once the future work mentioned 
above is completed and pathologically defined ageing phenotypes are identified, it is hoped that I 




Chapter 8 – TDF-induced mitochondrial dysfunction in 
proximal convoluted tubules  
8.1 Introduction 
Prior to the advent of ART, HIV-associated kidney disease (HIVAN) was one of the most prevalent 
comorbidities associated with HIV infection itself (Phair & Palella, 2011; Choi et al., 2010; Swanepoel 
et al., 2018). However, ART drastically reduced the onset of HIVAN in PLWH (Ross & Klotman, 2002; 
Lucas et al., 2004; Swanepoel et al., 2018), reports of tissue-specific drug-induced toxicities surfaced.  
With regard to nephrotoxicities, acute kidney injury (AKI), nephrolithiasis, tubulopathies, and chronic 
kidney disease (CKD) were reported in virally supressed PLWH (Izzedine et al., 2004, Peyriere et al., 
2004; Izzedine et al., 2009, Wong et al., 2017; Guaraldi et al., 2011). Although the exact 
pathophysiological mechanisms underpinning these ART-induced nephrotoxicities are yet to be 
completely understood, it is well regarded that there are multiple potential mechanisms including 
direct and indirect tubular toxicity, and the precipitation of insoluble drug crystals, and that 
mitochondrial dysfunction is thought to play a significant role in these pathophysiological 
mechanisms (Kohler et al., 2009; Ramamoorthy et al., 2014; Hall, 2011; Zhao et al., 2017; 
Ramamoorthy et al., 2018; Samuels et al., 2017; Murphy et al., 2017).  
Although several ARVs of varying classes, including the PI atazanavir (ATV) (ritonavir-boosted) (Ryom 
et al., 2013), have been shown to contribute to the onset of some nephrotoxicities, the NRTI 
tenofovir has been consistently implicated in several nephrotoxicities occurring in PLWH (Thigpen et 
al., 2012; Gupta et al., 2014; Jotwani et al., 2016; Hertlitz et al., 2010; Samuels et al., 2017; Scherzer 
et al., 2012; Winston et al., 2006; Ryom et al., 2013; Poizot-Martin et al., 2013; Atta et al., 2006; Foy 
et al., 2013; Woodward et al., 2009; Hamzah et al., 2017; Mocroft et al., 2016).  
Therefore, in this pilot study I sought to better understand the role of mitochondrial dysfunction in 
nephrotoxicities in TDF-treated PLWH. 
8.1.1 Causes and pathology of tenofovir-induced nephrotoxicity   
Tenofovir (TFV) disoproxil fumarate (TDF) is a newer oral-prodrug NRTI produced in 2001 in order to 
overcome issues of earlier NRTIs such as difficult dosing schedules and several tissue-specific 
adverse effects (Gilead Sciences Inc, 2001). Clinical trials and early in vitro studies demonstrated the 
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advantages of TDF’s efficiency, tolerability, convenient dosing, and low toxicity compared to older 
NRTIs, and as a result TDF is now one of the most commonly used NRTIs in cART (Jimenez-Nacher et 
al., 2008, Izzedine et al., 2004; Nelson et al., 2007). In fact, a large cohort study of 10,343 TDF-
treated PLWH demonstrated that less than 1% of patients developed adverse renal effects after 4 
years of use (Nelson et al., 2007). Various other cohort studies have calculated that prior to 2008, 
the incidence of TDF-induced AKI ranged from 1.6 per 100 individuals to 1.5 per 1000 individuals 
(Antoniou et al., 2005; Madeddu et al., 2008). 
Initial concerns about the potential nephrotoxicity of TDF arose due to its structural similarity to the 
two acyclic nucleotide analogue drugs adefovir and cidofovir, which are used to treat hepatitis B and 
cytomegalovirus (CMV) infection (Gallant et al., 2004) (Figure 8.1). Both adefovir and cidofovir have 
been shown to cause acute tubular necrosis (ATN) and Fanconi’s syndrome, which lead to proximal 
tubulopathies (Tanji et al., 2001; Meier et al., 2002). Although the underlying mechanism is yet to be 
fully elucidated, it is widely believed that adefovir and cidofovir deplete mtDNA content by inhibiting 
PolG (Tanji et al., 2001; Zhao et al., 2017). This induces disruptions in proximal tubular mitochondrial 
function, similarly to how other NRTIs induce tissue-specific mitochondrial toxicities such as 
zidovudine (AZT)-induced myopathy or zalcitabine (ddC)-induced peripheral neuropathy (Dalkas et 
al., 1990; Dalakas et al., 2001). Notably, Fanconi’s syndrome and renal tubular acidosis are also 
reported in various mitochondrial disease patients (Gorman et al., 2016).  
Controversially, post-marketing studies supported the demonstration of TDF’s safe profile (Nelson et 
al., 2007), and early in vitro studies showed that TDF induced minimal changes in mtDNA content or 
cellular expression of the mitochondrial ETC protein cytochrome c oxidase in various human cell 
lines, including proximal renal tubules (Birkus et al., 2002; Biesecker et al., 2003). In vitro studies also 
demonstrated the significantly lower nephrotoxicity potential of TDF compared to both adefovir and 




Figure 8.1 – Chemical structures of acyclic nucleotide inhibitors tenofovir, adefovir and cidofovir.  
 
However, reports of AKIs such as ATN and Fanconi’s syndrome began to surface from case reports of 
TDF-treated PLWH following the widespread use of TDF in clinical practice (Rifkin & Perazella 2004; 
Coca & Perazella 2002, Peyriere et al., 2004, Zimmerman et al., 2006; Agarwala et al., 2010; Hall et 
al., 2011; Quinn, 2010). Proximal tubular injury baring a striking resemblance to adefovir and 
cidofovir-induced AKI, with characteristics such as loss of brush border, luminal ectasia, and 
hypereosinophilia, were noted in these renal histopathology investigations. Significantly, alterations 
in mitochondrial structure such as cristae remodelling, mitochondrial swelling, fragmentation, and 
reductions in mtDNA content were also observed in PLWH but not HIV- individuals with renal 
toxicities (Cote et al., 2006; Herlitz et al., 2010). Conversely however, the same retrospective studies 
failed to demonstrate a difference in mtDNA content in renal tissue from TDF-treated PLWH 
compared to TDF-unexposed PLWH (Cote et al., 2006; Herlitz et al., 2010).  
Other studies in rats, monkeys, woodchucks, and mice have supported the demonstration of TDF-
induced mtDNA depletion in proximal tubules (Kohler et al., 2009; Lebrecht et al., 2009; Biesecker et 
al., 2003) and a study on transgenic HIV+ mice showed, through electron microscopy (EM), that only 
mice exposed to TDF had ultrastructural changes to mitochondria in proximal tubule cells (Kohler et 
al., 2009). In both studies, the NRTI didanosine (ddI) was also given to the animals and induced 
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isolated hepatic alterations, but no abnormal renal changes. This further supports the hypothesis 
that ART-induced nephrotoxicities are caused by TDF-specific mechanisms. In support of this, recent 
studies demonstrated that chronic TDF exposure induced mitochondrial dysfunction which leads to 
kidney damage, primarily through ROS and RNS overproduction and oxidative stress (Ramamoorthy 
et al., 2012; Abraham et al., 2013; Ramamoorthy et al., 2014).  
Renal pathologies are complex and difficult to diagnose due to the undesirability of taking renal 
biopsies in most cases. Several validated biomarkers are therefore used for determining declining 
kidney function, including proteinuria, low eGFR and serum creatinine. A large cohort study of over 
10,000 PLWH demonstrated that TDF is significantly associated with increased proteinuria, rapid 
decline in eGFR, creatine doubling and incident CKD in PLWH, and that cumulative exposure to TDF 
increased these risks. The same study also found that these risk factors were not associated with 
concomitant use of PIs, NNRTIs, or ritonavir-boosted ART regimens (Scherzer et al., 2012). The 
association between TDF, eGFR decline, and serum creatine has also been demonstrated in other 
studies (Winston et al., 2006; Gallant et al., 2005; Ryom et al., 2013; Poizot-Martin et al., 2013; Rifkin 
& Perazella, 2004). 
Whilst the majority of the more recent studies on the effect of TDF on renal function have supported 
the notion of TDF exposure increasing the susceptibility of developing nephrotoxicities, several 
studies have argued against this theory (Antoniou et al., 2005; Gayet-Ageron et al., 2007; Padilla et 
al., 2005; Scott et al., 2006). A randomised study investigating the effect of exposure to 
TDF/emtricitabine (FTC) against abacavir (ABC)/lamivudine (3TC) found no significant differences in 
estimated glomerular filtration rate (eGFR) between the two groups (Martinez et al., 2009). 
Additionally, TDF was not found to be associated with worsening kidney function over 48 weeks in 
the multicentre FRAM study (Longenecker et al., 2009), whilst a 1 year prospective study of PLWH 
also failed to find an association between proximal tubular damage and exposure to TDF (Ando et 
al., 2011). These studies mainly determined kidney function through eGFR measurement, and unlike 
some of the studies mentioned above, did not use clinical observations of kidney damage, therefore 
limiting their clinical significance. These studies also used patients with short TDF follow-up times 
and so may not have allowed for the adverse effects of TDF exposure to sufficiently develop. For 
example, in another retrospective study PLWH who were exposed to TDF for 27 months on average 
had a significantly steeper decline in eGFR compared to age-matched PLWH who had never been 
exposed to TDF (Horberg et al., 2010). 
Although difficult to precisely pin down, the discrepancy between initial clinical trials and later 
clinical reports and experimental analysis of the potential of TDF to cause nephrotoxicities is partially 
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explained by the cohorts used in the early trials. These studies generally excluded subjects with pre-
existing renal impairments and those with a higher susceptibility to developing adverse renal 
pathologies (Squires et al., 2003; Gallant et al., 2004). The discrepancies may also be explained by 
the lack of consensus regarding the definition of what declining kidney function and kidney disease 
itself is.  
Although there is large heterogeneity in the HIV+ population, cohort studies have identified older 
age, lower CD4 count, lower BMI, higher serum creatinine levels, and the presence of other 
comorbidities as risk factors in the development of TDF-induced nephrotoxicities (Campbell et al., 
2009; Gallant et al., 2005; Wever et al., 2010; Nartey et al., 2019; Nelson et al., 2007; Madeddu et 
al., 2008; Guaraldi et al., 2011). In the normal population, kidney function, as measured by eGFR, 
declines 0.4ml/min with every year, and TDF treatment and HIV infection itself both significantly 
increase this rate (Wetzels et al., 2007; Scherezer et al., 2012). 
8.1.2 Mechanisms of TDF-induced nephrotoxicity  
Due to the vast heterogeneity in the HIV+ population, as well as the complexity in kidney biology and 
disease, the exact pathophysiological mechanism underpinning TDF-induced nephrotoxicity is not 
completely understood. From in vivo and in vitro studies of TDF and studies on other acyclic 
nucleoside inhibitors adefovir and cidofovir, the primary mechanism behind TDF-induced 
nephrotoxicities is believed to be driven by TDF-induced mitochondrial defects, which are caused by 
the accumulation of the metabolite TFV in proximal convoluted tubules (Kohler et al., 2009; 
Ramamoorthy et al., 2018; Murphy et al., 2017) (Figure 8.2). 
After oral administration, TDF undergoes rapid cleavage into TFV in plasma. TDF is then eliminated 
from circulation renally through a combination of glomerular filtration and active tubular secretion 
(Barditch-Crovo et al., 2001; Rodriguez-Novoa et al., 2009). Normally, active tubular secretion is 
tightly regulated by uptake transporters on the basolateral membrane and efflux transporters on the 
apical membrane of proximal convoluted tubules (PCTs) (Ray et al., 2006). These transporters 
mediate the active transport of small molecules from systemic circulation into urine. Initially, TFV is 
actively taken up by proximal tubular cells at the basolateral membrane through human organic 
anion transporter 1 (hOAT1) and hOAT3 (Cihlar et al., 2001). In vitro cell based studies have 
demonstrated that TFV has a >20 times higher affinity for hOAT1 than hOAT3, but that hOAT3 is 
significantly more highly expressed than hOAT1 (Cihlar et al., 2001). This study also showed that TFV 
is not a substrate for human organic cation transporter 1 (hOCT1) or hOCT2, and is therefore 
exclusively taken up by hOAT1 and hOAT3 at the basolateral membrane. After active uptake, TFV is 
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effluxed primarily by the ATP-binding cassette transporter subfamily member multidrug resistance-
associated protein type 4 (MRP4) and to a less potent degree MRP2, but not P glycoprotein (PgP) 
(Izzedine et al., 2004; Klokouzas et al., 2003; Reid et al., 2003; Schaub et al., 1997; van Aubel et al., 
2002; Ray et al., 2006).  
In the presence of increased TFV plasma concentration, or when apical efflux is inhibited, TFV 
accumulates in proximal renal cells. Here, the increased intracellular concentration of TFV becomes 
toxic and can lead to the partial inhibition of PolG (Lewis et al., 2003) and mtDNA depletion (Kohler 
et al., 2009; Cote et al., 2006), which subsequently causes defects in OXPHOS and other 
mitochondrially-mediated processes. Due to the resultant declines in ATP production, proximal 
tubular cells fail to perform active reabsorption of ions and small molecules such as phosphate, 
amino acids, and β2-microglobulin. These molecules are then secreted in abnormal quantities in 
urine, and thus are characteristic of Fanconi syndrome (Fanconi, 1936; Herlitz et al., 2010). Support 
for this theory was demonstrated through two studies which showed that significantly increased 
tubular toxicity was associated with polymorphisms in the MRP2 gene, which led to increased 
intracellular accumulation of TFV (Izzedine et al., 2006; Rodriquez-Novoa et al., 2009). A study from 
our group also provided evidence to support the theory of TDF-induced mitochondrial-dysfunction 
mediated nephrotoxicity by demonstrating the elevated presence of mtDNA deletions in urine from 
TDF-treated PLWH compared to PLWH who had not been exposed to TDF (Samuels et al., 2017).  
In more recent years, studies have suggested that the primary mechanism behind TDF-induced renal 
toxicities is increased ROS leading to cellular apoptosis and necrosis. This is mediated through 
mitochondrial abnormalities (Ramamoorthy et al., 2018; Murphy et al., 2017). Here, as the result of 
oxidative stress and increased inflammation, activation of apoptosis is upregulated. Neutrophil 
infiltration then further exacerbates the inflammatory response and oxidative stress, leading to 
tissue necrosis, hypoxia, kidney dysfunction, and failure (Fernandes Bertocchi et al., 2008; Schreiber 







Figure 8.2 – Transport pathway for TDF in proximal tubular cells. Tenofovir (TFV) is actively taken up into proximal tubular epithelial cells through the organic anion transporter 1 (OAT1) and 
OAT3 and is effluxed into urine through multidrug resistance protein 2 (MRP2) in individuals with normally functioning kidneys. When TFV accumulates intracellularly, possibly via increased 
uptake from plasma or decreased efflux into urine, it can cause mitochondrial defects. These defects can arise from mtDNA depletion, large-scale mtDNA deletions, and increased ROS and 
oxidative stress, leading to declines in energy production and an increased level of mitochondrially-mediated apoptosis.  
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8.1.3 Effect of concomitant use of PIs and NNRTIs on nephrotoxicity  
8.1.3.1 PIs and nephrotoxicity 
Between the roll-out of TDF in 2001 and 2006, the US FDA reported 164 cases of TDF-induced 
Fanconi syndrome (Gupta, 2014). 74% of those patients were co-exposed to a ritonavir-boosted PI - 
mainly ritonavir-boosted lopinavir (LPV). However, a more recent systematic review and meta-
analysis demonstrated that the risk of eGFR decline in PLWH treated with LPV or ATV was not 
substantial (Bagnis & Stellbrink, 2015).  
In a cohort study, declines in kidney function were more frequent and more pronounced in TDF-
treated PLWH who were co-administered with ddI or ritonavir-boosted PI than those TDF-treated 
PLWH without co-administration (Crane et al., 2007). Another study calculated that PLWH who are 
treated with TDF plus a ritonavir-boosted PI had a 3.7 times higher risk of developing 
nephrotoxicities than PLWH who were treated with TDF plus an NNRTI (Goicoechea et al., 2008). 
Other PIs such as saquinavir (SQV) and nelfinavir (NFV) have been reported to be associated with 
nephrotoxicities in both case reports and cohort studies (Rollot et al., 2003; Gutmann et al., 1999; 
Engeler et al., 2002; Mocroft et al., 2010; Ryom et al., 2013). Another large cohort study found that 
the PI atazanavir (ATV) was associated with an increased risk of the rapid decline in eGFR, but not 
CKD. In addition, another PI, NFV was associated with a decreased risk of both CKD and proteinuria 
(Scherzer et al., 2013).  
Unlike TDF, ARVs in the PI class are not eliminated renally. In fact, they are primarily eliminated 
through the hepatic cytochrome P450 system and so do not accumulate in proximal tubule cells like 
TDF (Balani et al., 1995). One proposed mechanism behind the adverse effects of ritonavir-boosted 
PIs is that both ARVs partially inhibit the apical efflux transporter MRP2, leading to decreased efflux 
and increased intracellular accumulation of TFV (Cihlar et al., 2007). 
8.1.3.2 Links between NNRTIs as well as other ARV classes and nephrotoxicity  
Like the majority of PIs, ARVs in the NNRTI class are also eliminated through the cytochrome P450 
system as opposed to renally. There have been no reports of NNRTIs interacting with any of the 
luminal proximal tubule transporters, and subsequently there have been no reports of an association 
between NNRTI use and nephrotoxicity (Gallant et al., 2005).  
Fusion inhibitors and integrase inhibitors are two of the most recently developed classes of ARV. 
Whilst the majority of ARVs in these two classes have demonstrated a good safety profile and do not 
induce toxicities like several other ARVs, there have been limited clinical and in vitro studies 
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undertaken in order to assess the nephrotoxicity potential of these drugs. A recent study into the 
metabolic, mitochondrial and renal impact of the fusion inhibitor enfuvirtide (T20) and the integrase 
inhibitor raltegravir (RAL) found that these two drugs produce no adverse effects on the factors 
mentioned above when given as either a monotherapy or in combination with other ARVs (Barroso 
et al., 2019). 
8.1.4 Potential treatment of TDF-induced nephrotoxicities 
Importantly, PLWH on stable ART should be monitored regularly for CKD in the form of urinalysis, 
GFR estimation, serum phosphate quantification, and quantification of proteinuria (Yombi et al., 
2015). If CKD is identified, patients should undergo risk stratification. Referral to nephrology should 
be conducted in patients with unexplained AKI or CKD, worsening proteinuria, and rapid kidney 
function decline. Here, a nephrologist will assess the degree of renal impairment and recommend 
treatments. In addition, patients with CKD stage G3b/G4 should have a biopsy taken and be 
recommended for kidney replacement therapy (Swanepoel et al., 2018). 
One of the most obvious treatments for TDF-induced nephrotoxicities is cessation of TDF treatment. 
Whilst treatment cessation appears to have at least some clinical benefit, the heterogeneity in renal 
disease type and severity dictates that this method will not always be successful. For example, only 
50% of PLWH who had discontinued TDF treatment following the onset of AKI had their renal 
function return to baseline (Herlitz et al. 2010). However, other cohort studies determined that the 
risk of renal events did not decrease after TDF cessation (Scherzer et al., 2012, Monteagudo-Chu et 
al., 2012).  
A meta-analysis demonstrated that there is a substantial statistical heterogeneity (I2 = 66%) between 
the cohort studies conducted prior and up to 2010 (Cooper et al., 2010). As such, due to the 
heterogeneity of the various studies, it is extremely difficult to reach a firm conclusion with regards 
to the potential beneficial effect of TDF cessation.  
Another viable option is lowering the toxicity of TDF itself (Jose et al., 2014; Post et al., 2017; Ryom 
et al., 2017; Waheed et al., 2015). Tenofovir alafenamide fumarate (TAF) is a recently developed 
prodrug form of TFV with a far lower plasma exposure than that of TDF (Podany et al., 2018). In vitro 
studies have also demonstrated the far lower pathogenic potential of TAF compared to TDF with 
regards to eGFR decline, general tubular function, as well as on bone mass (Venter et al., 2018), and 
switches from TDF to TAF have been associated with improved kidney function (Jose et al., 2014; 
Post et al., 2017; Ryom et al., 2017; Waheed et al., 2015). However, as TAF is newly administered 
antiretroviral, the long-term safety is not known.  
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A potential alternative previously considered was the administration of probenecid, which is 
commonly used to prevent cidofovir-induced nephrotoxicity. Probenecid is an effective inhibitor of 
the basolateral membrane transporter hOAT1 and so prevents the nephrotoxic build-up of cidofovir 
in proximal tubule cells (Izzedine et al., 2009; Perazella, 2010). Controversially though, use of 
probenecid has been associated with dose-limiting toxic side-effects (Lalezari et al., 1997). 
As the primary mechanism of TDF-induced renal toxicities is thought to be elevated oxidative stress, 
the potential therapeutic effect of the antioxidant melatonin is currently being investigated 
(Ramamoorthy et al., 2018). As melatonin has been shown to have several beneficial antioxidant 
effects, such as inhibiting apoptosis (Zhao et al., 2015; Perdomo et al., 2013), decreasing ROS and 
RNS levels (Rieter et al., 2002; Hardeland, 2005; Ding et al., 2014; Rodriguez et al., 2004), and 
improving mitochondrial function (Reiter et al., 2008; Kleszcynski et al., 2016), it is hoped it may 






8.2 Experimental aims  
In the years following the early clinical trials and in vitro studies which demonstrated the safe profile 
and low PolG-binding affinity of TDF, numerous clinical reports and cohort studies have 
demonstrated a link between TDF exposure and the development of various nephrotoxicities 
(Thigpen et al., 2012; Gupta et al., 2014; Jotwani et al., 2016; Hertlitz et al., 2010; Samuels et al., 
2017; Scherzer et al., 2012; Winston et al., 2006; Ryom et al., 2013; Poizot-Martin et al., 2013).  
Whilst the exact underlying pathogenic mechanisms behind this phenomenon are yet to be fully 
elucidated, various studies have suggested a causative role for TDF-induced mitochondrial 
dysfunction (Kohler et al., 2009; Ramamoorthy et al., 2014; Hall, 2013; Zhao et al., 2017; 
Ramamoorthy et al., 2018; Murphy et al., 2017). However, a comprehensive understanding of these 
mechanisms is limited due to the difficulty in acquiring renal biopsies, as well as extraction of genetic 
material from renal tubules and tubular cells. Hence, by using renal biopsies acquired from TDF-
treated PLWH and matched HIV- individuals in a pilot study, in this chapter I sought to: 
• Determine whether the novel immunofluorescence assay developed in our lab (Rocha et al., 
2015) can be applied to quantify mitochondrial ETC complexes CI, CIII, CIV, CV, and 
mitochondrial mass in renal tissue. 
• Determine whether mtDNA can be successfully extracted from proximal tubules and 
individual proximal tubule cells following laser capture microdissection. 
• Explore whether TDF-treated PLWH had higher levels of proximal tubule mitochondrial CI, 
CIII, CIV, and CV deficiency compared to HIV- individuals.  
• Explore whether TDF-treated PLWH had higher levels of CI, CIII, CIV, and CV deficiency 
compared to non-TDF-treated PLWH. 
• Determine if CI-deficient proximal tubules and tubule cells contained mtDNA deletions or 





8.3.1 Patient cohort  
This study was approved by the research ethics committee (Newcastle and North Tyneside 2; 17-NE-
0015), as described in Section 3.2.1 and Section 3.2.5. 
Percutaneous renal biopsies were taken from PLWH (n = 6) (supplied as residual diagnostic tissue 
from Royal Free London Hospital (RFH) Cellular Pathology Department) and open renal biopsies 
were taken from HIV- individuals (n = 5) (supplied by Dr Ashwin Sachdeva and Manchester University 
NHS Biobank), as described in Section 3.2.5. All biopsies were formalin-fixed and paraffin-
embedded. 
Of the PLWH, four were being treated with an ART regimen including TDF at the time of biopsy, 
while one had never been exposed to TDF, and clinical information was missing for one subject 
(Table 8.1). Of the four TDF-treated PLWH, only patient 3 had discontinued TDF treatment. 
8.3.2 Haematoxylin & Eosin histochemistry staining and imaging for renal tissue 
In order to visualise the renal biopsies, FFPE sections (4µm) were subjected to H&E histochemistry as 
described in Section 3.5.1. 
8.3.3 Multiplex immunofluorescence for OXPHOS complex I, III, IV and V activity in 
proximal convoluted tubules 
To objectively quantify mitochondrial dysfunction in renal tissue, serial FFPE renal sections (4µm) 
were subjected to both the CI + CIV as well as CIII + CV panels separately (Table 3.6/3.7), as 
described in Section 3.4.3. 
8.3.4 Image acquisition and determination of ETC complex activity in proximal tubules 
and proximal tubule epithelial cells  
Fluorescent images were acquired as described in Section 3.4.5. With regards to quantifying CI and 
CIV protein levels in individual proximal tubule epithelial cells, 37 putatively OXPHOS-deficient 
individual PCT cells were manually randomly identified from renal biopsies from PLWH (n = 3). No 
putatively deficient cells were identified from the HIV- individuals.  
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8.3.5 Laser microdissection of PCTs and individual PCT epithelial cells  
In order to isolate renal tissue for downstream molecular analysis, stained serial 4µm sections were 
removed from -20°C and left to air-dry for 1 hour at RT. Sections were then incubated in 1% PBS 
overnight at RT in order to remove cover slips. PCTs and individual PCT epithelial cells of interest 
were laser microdissected as described in Section 3.6.2 and captured into 15µm lysis buffer, as 
described in Section 3.6.1.  
8.3.6 Quantitative PCR for the detection and quantification of mtDNA mutations  
A duplex quantitative real-time PCR assay targeting the mitochondrial genes MT-ND1 and MT-ND4 
was used to detect and quantify deletions in the mitochondrial genome, as described in Section 
3.7.5. By assuming that MT-ND1 was not deleted through mutations I was also able to calculate 
mtDNA copy number. Details of all primers and standards used as well as their preparation are 
described in Section 3.7. 
8.3.7 Statistical analyses 
Normality was determined by Shapiro-Wilk tests.  
Individual PCTs were then classified into groups based on their z-scores for MTCO1, NDUFB8, 
UQCRFS1 and ATPB. Respective z-scores were calculated after normalisation to VDAC1 staining 
intensity: ‘positive’ (z > -3); ‘intermediate positive (+)’ (-3 > z > -4.5); ‘intermediate negative (-)’ (-4.5 
> z > -6) and ‘deficient’ (z < -6). Subsequently, the ‘deficient’, ‘intermediate -‘ and ‘intermediate +’ 
groups were pooled together to create the ‘deficient’ group (i.e. z < -3 = deficient). The log10-
transformed percentage of PCTs in either category for NDUFB8, UCQRFS1, MTCO1 and ATPB activity 
were compared between patient groups using unpaired t tests in Prism v5.04. Graphs were also 
made in Prism v5.04.  
The average mitochondrial mass (as indicated through VDAC1 staining intensity z-score) for each 
subject was also quantified, although not log-transformed. Individual PCTs were then classified into 
mitochondrial mass groups depending on their z-score: ‘very low’ (VDAC1_z < -3); ‘low’ (-3 < 
VDAC1_z < -2); ‘normal’ (-2 < VDAC1_z < +2); ‘high’ (+2 < VDAC1_z < +3) and ‘very high’ (3 < 
VDAC1_z). 
Unadjusted linear regression analysis (Pearson’s correlation) was undertaken in order to assess the 
relationship between mitochondrial complex deficiency and average mitochondrial mass.   




8.4.1 Cohort clinical characteristics 
The clinical characteristics of the HIV-infected subjects are described in Table 8.1. Clinical 
information was missing for patient 6. The mean age of the HIV+ subjects (n = 6) at biopsy was 55.6 
(range 47-79) years old and 100% of the subjects were male and white British. Of the HIV- subjects 
(n = 5), 80% were male and 100% were white British. The average age of the HIV- individuals was 32 
years old. Clinical information was missing from the HIV- individuals except for age, gender and 
ethnicity.  
Of the patients with available clinical information (n = 5), four of the five had an eGFR lower than 15 
ml/min/1.73m2, which is indicative of stage 5 kidney disease. The other individual, patient 5, had an 






















1  50 WB 294 294 50 5 
TDF, FTC, 
ATV/r 








Acute tubular injury + 
Diabetic neuropathy 
Cellulitis ACEi, cellulitis 
3  43 WB 510 - 40 6 
TDF, FTC, 
EFV, DRV/r 









nephritis + Diabetic 
neuropathy 
Diarrhoea LRTI 




Interstitial fibrosis and 
tubular atrophy 
None None 
6  - - - - - - - - - - - - 
Table 8.1 - Clinical characteristics of the PLWH. Clinical information was missing for patient 6. T2D = type 2 diabetes; TDF = tenofovir disoproxil fumarate; FTC = emtricitabine; ATV = 




8.4.2 Haematoxylin and Eosin (H&E) histochemistry 
Renal biopsies from PLWH (n = 6) and HIV- individuals (n = 5) were subjected to H&E histochemistry 
in order to determine the robustness of the tissue morphology prior to subjecting the sections to 
multiplex immunofluorescence and laser microdissection. H&E was also performed in order to 




Figure 8.3 – Representative example of a renal needle biopsy taken from a HIV+ and HIV- individual. (1) Proximal 
convoluted tubule (PCT). (2) Glomeruli. (3) Distal convoluted tubule (DCT). Proximal tubules exhibit partial loss of brush-

















8.4.3 PCT mitochondrial ETC CI and CV deficiency in PLWH  
Protein levels of the four mitochondrially-encoded ETC complexes - CI, CIII, CIV, and CV were 
quantified in 40 randomly selected PCTs from renal biopsies derived from a cohort of PLWH (n = 6) 
and HIV- individuals (n = 5) using novel multiplex immunofluorescence assays developed in our lab 
(Rocha et al., 2015) (Figure 8.4a). As there is a lack of literature describing immunofluorescence-
analysed mitochondrial activity in PCTs, I reported the findings using z < -3 as the cut-off for defining 
deficiency in the respective mitochondrial complexes. 
HIV+ patients (n = 6) had a significantly higher proportion of PCTs with CI deficiency (p = 0.021, 
unpaired t-test) compared to HIV uninfected individuals (n = 5) (Figure 8.4d). There was no 
significant difference in proportional PCT CIII and CIV deficiency. 
Proportional CV deficiency was high in both the HIV+ and HIV- groups. However, there was no 
statistically significant difference between the respective serostatus groups (unpaired t test) (Figure 
8.4d). 
Mitochondrial mass was quantified by background corrected VDAC1 staining intensity in individual 
PCTs from both groups. Although mean PCT mitochondrial mass was lower in the HIV+ compared to 
HIV-uninfected subjects, this did not reach statistical significance (p = 0.18, unpaired t test) (Figure 
8.4e).  
There was no significant correlation between mean PCT mitochondrial mass and proportional CI, CIII, 
CIV, or CV deficiency (Pearson’s correlation). 
Through immunofluorescence analysis of ETC activity in whole PCTs, it was observed that some 
individual epithelial cells had a staining pattern indicative of putative CI deficiency (i.e. 
hyperintensity in the mitochondrial mass channel with simultaneous downregulation of CI channel 
intensity). Therefore, further work was performed in order to investigate this perceived epithelial 




              
Figure 8.4 – Mitochondrial function in PCTs. (A) Example images of multiplex immunofluorescence stained renal biopsy 
sections stained for DAPI (nuclear marker), VDAC1 (mitochondrial mass), NDUFB8 (CI subunit), MTCO1 (CIV subunit), 
UQCRFS1 (CIII subunit), and ATPB (CV subunit). Scale bar = 50µm. (B-C) Example plot of (B) CI (x-axis) and CIV (y-axis) 
deficiency in 40 proximal tubules from each of the HIV+ (n = 6) and HIV- (n = 5) individuals; (C) CIII (x-axis) and CV (y-axis) 
deficiency in 40 proximal tubules from each of the HIV+ and HIV- individuals. Each dot represents an individual proximal 
tubule plotted by z-score. Red dots represent proximal tubules from HIV+ subjects and purple dots represent proximal 
tubules from HIV- individuals. (D) Proportional levels of CI, CIII, CIV and CV deficiency in proximal tubules from the HIV+ and 
HIV- groups. Each dot represents an individual subject and is plotted by the (log10) proportion of proximal tubules with the 
respective mitochondrial defects. (E) Dot plot (mean ± SEM) depicting mitochondrial mass as measured by normalised 
VDAC1 staining intensity. Each dot represents an individual subject and is plotted by the average VDAC1 z-score of the 40 






8.4.4 Differences in PCT CI and CV deficiency in PLWH 
Due to the large heterogeneity in the HIV+ individuals themselves, differences in PCT mitochondrial 
function between TDF-treated PLWH and non-TDF-treated PLWH, or PLWH with acute tubular injury 
(AKI) and those with other nephrotoxicities may be masked when solely comparing the HIV+ and 
HIV- groups. Therefore, by comparing the levels of PCT mitochondrial dysfunction (in the form of CI 
and CV deficiency) between the HIV+ individuals with available clinical information (n = 5), I 
attempted to qualitatively identify differences in the HIV+ group stratified by the above 
characteristics.  
Notably, the only patient not exposed to TDF (patient 5) had a similar level of PCT CI deficiency 
compared to the TDF-treated individuals (n = 4) (Figure 8.5a) as well as having the highest level of CV 
deficiency (Figure 8.5b). 
In addition, the two patients not diagnosed with AKI (patients 4 and 5) had comparable levels of PCT 
CI (Figure 8.5a) and CV (Figure 8.5b) deficiency compared to the AKI patients (patients 1, 2 and 3). 
 
Figure 8.5 – PCT CI and CV deficiency in PLWH. Bar charts depicting the differences in (A) log10(CI deficiency) and (B) 





8.4.5 PCT epithelial cell mitochondrial dysfunction  
Following the observation that there were individual PCT epithelial cells which putatively looked CI 
deficient within PCTs with ‘normal’ mitochondrial ETC activity (Figure 8.6), I manually identified a 
maximum of 33 individual cells (all from HIV+ subjects) and quantified their CI and CIV protein levels 
using methods described previously (Section 8.3.4). 
All single epithelial cells of interest were subsequently found to have z-scores < -3 for CI when 
compared to randomly identified epithelial cells with putatively ‘normal’ CI activity (n = 27) from 
both the HIV+ (n = 17) and HIV- group (n = 10), and so were classified as CI deficient.  
Notably, although proportional CV deficiency was the most prevalent ETC complex deficiency after CI 
deficiency at the whole PCT level, I was unable to identify any individual epithelial cells with putative 
CV deficiency.  
 
 
Figure 8.6 – Example image of a PCT epithelial cell with CI and CIV deficiency. Renal biopsies stained with markers for 
mitochondrial mass (VDAC1), CI (NDUFB8), and CIV (MTCO1). The arrow indicates a proximal tubule epithelial cell with 
putative CI and CIV deficiency, characterised by the weak staining intensity of CI and CIV markers in synergy with 





8.4.6 Molecular basis of CI deficiency in PCTs from PLWH 
I next wanted to explore the molecular basis of the observed CI deficiency in PCTs from PLWH. After 
isolating both CI deficient (n = 13), and CI normal (n = 33) PCTs, as well as glomeruli (n = 10) through 
laser microdissection (Figure 8.7a), I amplified genetic material from the lysate and subjected it to 
qPCR analysis (as described in Section 3.7.5) in order to detect and quantify mtDNA mutations.  
Initially, mtDNA depletion was excluded as a possible cause of CI deficiency in affected PCTs, as qPCR 
analysis demonstrated no reduction in mtDNA copy number when compared to CI normal PCTs 
(Figure 8.7b).  
Based on previous literature describing TDF-related renal mitochondrial defects, which suggests the 
predominant cause of mitochondrial dysfunction in TDF-treated PLWH are large-scale mtDNA 
deletions, I expected this to be the cause of CI deficiency in PCTs from PLWH (Samuels et al., 2017). 
By quantifying the copy number of two mtDNA-encoded genes (MT-ND1 and MT-ND4) I however 
observed mtDNA deletions in only 15% of CI-deficient PCTs and in 3% of CI-positive PCTs. No 
deletions were found in the isolated glomeruli (Figure 8.7c). These deletions occurred in both the 






      
Figure 8.7 – Molecular analysis of mtDNA mutations in laser microdissected proximal tubules. (A) Example image of a 
renal biopsy from a HIV+ individual with a proximal tubule isolated by laser capture microdissection. Scale bar = 500µm. (B) 
Dot plot (mean) depicting no significant differences in mtDNA content between CI-deficient and CI-normal proximal tubules 
as well as glomeruli isolated from HIV+ (n = 6) and HIV- (n = 5) individuals. Each dot represents an individual proximal 
tubule or glomeruli isolated by LCM. The thin dotted line represents 2 standard deviations below the mean MT-ND1 copy 
number for CI-positive proximal tubules and glomeruli. (C) Distribution (mean) of mtDNA deletion levels in CI-deficient (n = 
13) and CI-normal (n = 33) proximal tubules as well as glomeruli (n = 10). The dotted lines represent 2 standard deviations 
away from the mean Ct of positive PCTs and glomeruli. Dots that lie above the upper dotted line contained a deletion in 
the minor arc of the mtDNA genome, and dots that lie below the lower dotted line contained a deletion in the major arc of 







8.4.7 Molecular basis of CI deficiency in proximal tubule epithelial cells  
I next performed quantitative molecular analyses on individual PCT epithelial cells with either CI 
deficiency (n = 33) or normal CI activity (n = 27), after isolation by LCM (Figure 8.8a).  
qPCR analysis again demonstrated no reduction in mtDNA copy number and so mtDNA depletion 
was excluded as a potential cause of mitochondrial dysfunction (Figure 8.8b). In fact, MT-ND1 copy 
number was significantly higher in CI-deficient proximal tubular cells (n = 33) compared to CI-normal 
proximal tubular cells from HIV+ (n = 17; p = 0.047, unpaired t-test) and HIV- individuals (n = 10; p = 
0.017), as well as all CI-normal proximal tubular cells from both HIV+ and HIV- individuals (n = 27; p = 
0.013).  
I found that 18% of CI-deficient PCT epithelial cells contained an mtDNA deletion. These deletions 









Figure 8.8 – Molecular analysis of isolated individual proximal tubule epithelial cells. (A) Example image of an isolated 
proximal tubular epithelial cell from a HIV+ individual. Scale bar = 500µm. (B) Dot plot (mean) demonstrating significantly 
higher mtDNA content in CI-deficient proximal tubule cells compared to CI-normal proximal tubular cells overall (n = 27) (p = 
0.013), from HIV- individuals (n = 10) (p = 0.017) and HIV+ individuals (n = 17) (p = 0.047). Each dot represents an individual 
isolated proximal tubule epithelial cell and is plotted by its MT-ND1 copy number. (C) Distribution (mean) of mtDNA 
deletions in isolated CI-deficient (n = 33) and CI-normal (n = 27) proximal tubular epithelial cells. Dotted lines represent 2 
standard deviations away from the mean Ct of positive cells. Dots that lie above the upper dotted line contained a 
deletion in the minor arc of the mtDNA genome, and dots that lie below the lower dotted line contained a deletion in the 







In this chapter I assessed cellular and molecular mitochondrial function in whole proximal convoluted 
tubules and in individual proximal tubule epithelial cells derived from renal biopsies from TDF-treated 
PLWH who presented with varying clinically significant nephrotoxicities.  
8.5.1 Conclusions 
8.5.1.1 Successful application of novel immunofluorescence assay to quantify mitochondrial 
protein levels in renal tissue 
As there are limited experimental methods to assess renal mitochondrial function at the cellular level, 
an important aim of this study was to determine whether a novel multiplex immunofluorescence assay 
developed in our lab (Rocha et al., 2015) could be applied to renal tissue. As such, this 
immunofluorescence assay, with markers for mitochondrial mass as well as subunits of CI, CIII, CIV and 
CV of the mitochondrial ETC, was successfully applied to renal tissue from both HIV+ and HIV- 
individuals. Notably, this was the first study to demonstrate specific CI deficiency in proximal tubules of 
PLWH who had been treated with TDF at the cellular level, as opposed to in tissue homogenates. This 
assay also allowed for the quantification of lesser analysed subunits of the ETC - CIII and CV, as well as 
mitochondrial mass. Hence, I also demonstrated deficiency in CV protein levels in proximal tubules 
from PLWH. However, the proportional levels of CV deficiency appeared comparable with CV deficiency 
seen in PCTs in the HIV- group, suggesting CV deficiency could be a universal factor in renal toxicity.   
8.5.1.2 Assessment of proximal tubule mitochondrial dysfunction in PLWH 
Although the sample size was small and there was heterogeneity between the HIV+ individuals, another 
aim of this study was to explore whether there appeared to be differences in PCT mitochondrial 
dysfunction between TDF-treated PLWH and non-TDF-treated PLWH, as well as between PLWH 
diagnosed with AKI and those with other nephrotoxicities. Interestingly, the only non-TDF-treated 
patient had comparable levels of CI and CV deficiency compared to the TDF-treated patients, suggesting 
TDF exposure may not be the only pathogenic HIV-related factor. In addition, levels of PCT CI and CV 
deficiency were comparable between AKI patients and non-AKI patients, supporting previous 
observations that mitochondrial dysfunction is not restricted to AKI patients (Samuels et al., 2017). It 
should be stressed that due to the small size of the HIV+ group with available clinical information and 
the heterogeneity of the group, these observations are not heavily weighted.   
Importantly, this is also the first study to demonstrate CI and CIV protein deficiency at the individual 
proximal tubule epithelial cell level in TDF-induced nephrotoxicities. These results build on previous 
work which demonstrated the presence of punctate abnormal mitochondria, characterised by swelling 
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and irregular morphology, in TDF-exposed proximal tubules (Herlitz et al., 2010). Whilst highlighting the 
vast variability in how mitochondrial dysfunction may present in nephrotoxicities, these findings are 
suggestive of a mechanism by which individual proximal tubule epithelial cells develop mitochondrial 
dysfunction in a mosaic pattern. Nephrotoxicities then subsequently arise following the accumulation 
of abnormal epithelial cells, leading to defects in proximal tubule function (Biro et al., 2016; Zoja et al., 
2009).  
Importantly, mitochondrial mass was not significantly elevated in the HIV+ group at the proximal tubule 
level, indicating that there was no compensatory upregulation in mitochondrial content in response to 
ETC deficiencies. Notably though, there appeared to be hyperintense staining in the VDAC1 channel in 
individual proximal tubule epithelial cells with putative CI and CIV deficiency, indicative of a 
compensatory upregulation in mitochondrial mass in those cells. These results appear to indicate that 
punctate mitochondrial defects at the individual cellular level are compensated at the whole proximal 
tubule level, revealing unanswered questions regarding the contribution of individual epithelial cells or 
whole proximal tubules to the pathophysiology of various nephrotoxicities. This finding also argues 
against the mechanism of mtDNA depletion underpinning TDF-induced renal toxicities (Tanji et al., 
2001; Cote et al. 2006; Kohler et al., 2009). In addition, this finding highlights the need for further 
investigation into whether mitochondrial dysfunction in individual tubule cells expand to neighbouring 
epithelial cells and whether this leads to whole tubule dysfunction. 
8.5.1.3 Molecular basis of proximal tubule mitochondrial dysfunction  
Finally, this study is also the first to successfully isolate and amplify mtDNA from individual proximal 
tubule epithelial cells by LCM and qPCR techniques. Importantly, I found that 18% of CI-deficient 
proximal tubule epithelial cells harboured an mtDNA deletion in either the major or minor arc of the 
mtDNA genome, while simultaneously failing to detect evidence of mtDNA depletion in these cells. In 
fact, the results demonstrate an increase in mtDNA content, presumably as a result of upregulated 
mitochondrial biogenesis in response to ETC defects. However, a large proportion of CI-deficient tubule 
cells did not contain a detectable mtDNA deletion or mtDNA depletion and so the underlying 
mechanisms behind their CI deficiency remains unsolved (Samuels et al., 2017). One possibility may be 
mtDNA point mutations, which have been shown to eventually induce mitochondrial toxicities. mtDNA 
point mutations have been found in substantia nigra neurons as well as mitotic cells such as colonic 
crypt cells (Greaves et al., 2012; Reeve et al., 2009). These point mutations are most likely arising as the 
result of increased ROS production due to TFV accumulation (Ramamoorthy et al., 2012; Abraham et 
al., 2013; Ramamoorthy et al., 2014; Ramamoorthy et al., 20108). This theory is supported by the 
strong link between elevated ROS production and the generation of mtDNA point mutations (Taylor & 
Turnbull, 2005; Chung et al., 2014; Caldecott, 2008; Pinz et al., 1995; Baines et al., 2014). The increase 
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in ROS and subsequently mtDNA point mutations may be part of a vicious cycle, whereby mtDNA 
mutations further exacerbate ROS production, leading to further tubular damage through apoptosis 
and subsequently necrosis (Ramamoorthy et al., 2018, Murphy et al., 2017, Liu et al., 2014; Servais et 
al., 2008; Wang et al., 2013). These observations could be significant to future work in the field as they 
suggest more investigations are needed looking into the mitochondrial effects of TDF, in particular the 




8.5.2 Summary of results 




• High levels of CI and CV 
proximal tubule 
deficiency  
• Comparable levels of 
CV deficiency 
compared to HIV- 
individuals 
• Individual epithelial 
cells had CI deficiency 
inside whole tubules 
with normal CI levels 
• Comparably high levels 
of CV deficiency 
compared to HIV+ 
individuals 
• PLWH displayed high 
levels of CI and CV 
deficiency in whole 
proximal tubules 
• Punctate epithelial cells 




• Majority of CI-deficient 
whole tubules or 
epithelial cells did not 
contain mtDNA 
deletions 
• No evidence of mtDNA 
depletion 
• No tissue extracted for 
molecular analysis  
 
• CI deficiency at the 
whole tubule or 
epithelial cell level was 
not explained by 
mtDNA deletions 
• Most likely caused by 
mtDNA point mutations 
Disparities between 
TDF-treated PLWH and 
non-TDF treated PLWH 
• Comparable levels of CI 
and CV deficiency 
between groups 
• Not investigated • There appeared to be 
no difference in CI or 
CV proximal tubule 




PLWH with AKI and 
those with other renal 
pathology 
• Comparable levels of CI 
and CV deficiency 
between groups 
• Not investigated • No evidence of 
increased 
mitochondrial 
dysfunction in PLWH 
with AKI 





As this was a pilot study there are a few limitations which need to be noted. Most obviously, the 
greatest limitation lies in the small sample size of both the HIV+ and HIV- groups used in the study. This 
limitation significantly reduced the power to detect differences between the HIV+ and HIV- groups, as 
well as restricting the ability to include a HIV+/TDF- comparator group in order to determine how 
specific to TDF the mitochondrial defects were. Hence, I was unable to extrapolate pathophysiological 
information about the role chronic HIV-infection itself plays. Ideally, I would also have recruited a 
cohort with a wider variation in nephrotoxicity diagnoses, in order to better understand the role of 
mitochondrial defects in those specific pathologies.  
Another limitation was missing clinical information. With regards to the HIV+ group in our cohort, 
although I had information about whether the PLWH had ever been exposed to TDF, ATV/r, SQV, 3TC or 
FTC ARVs, information regarding current/previous exposure to NNRTIs or older, more mitochondrially-
toxic NRTIs such as AZT or ddI was missing. Missing clinical information from patient 6 also reduced our 
ability to understand potential mechanisms behind mitochondrial defects in their proximal tubules.  
Aside from their age, ethnicity and gender, little information was given to us about the HIV- control 
subjects. Biopsies came from ‘normal’ tissue adjacent to explanted renal masses, however, I did not 
know whether these individuals had been diagnosed with any renal pathologies and I had no 
information about potential co-morbidities or other adverse factors such as certain medications.  
Finally, another limitation lies in the fact that these biopsies were taken at one time point and I was 
therefore unable to extrapolate data directly to drug administration or disease progression. Ideally, 
biopsies should be taken when the patients eGFR began to decline and then at multiple follow up visits 
to the clinic. The biopsies used in this study were taken from PLWH who already had well developed 
nephrotoxicities, and so I was unable to determine whether mitochondrial dysfunction played a 
causative role in these nephrotoxicities or whether it was consequence of declining tissue homeostasis. 
However, due to the highly invasive nature of taking kidney biopsies, it is well acknowledged that taking 
several biopsies from the same individual is not entirely practical. 
8.5.4 Future work 
Due to the fact that this was a pilot study, there is significant scope for potential future work. The most 
significant addition to any future work would be to use a much larger cohort in order to increase our 
power to detect inter- and intragroup differences. As mentioned above, this would ideally include more 
patients in both the HIV+ and HIV- groups as well as a group of PLWH who had never been exposed to 
TDF. Ideally, this future cohort should also contain individuals with varying renal pathologies. This 
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would help extrapolate information about the specific role of mitochondrial dysfunction in the 
pathogenesis of various nephrotoxicities. In this regard, it would be hugely beneficial to conduct a 
longitudinal study in which renal biopsies are taken from patients at several time points, including 
when eGFR initially starts declining (or failing that, when symptoms first develop). As mentioned in the 
previous section (Section 8.5.2), this would help better the understanding of the pathogenesis of 
nephrotoxicities in TDF-treated PLWH. 
One of the most significant findings of this study was the presence of individual proximal tubule 
epithelial cells deficient in complex I of the ETC within a proximal tubule with normal mitochondrial 
protein levels. Future work should look to expand the understanding of the significance of punctate 
mitochondrial dysfunction in the pathogenesis of nephrotoxicities. As recent studies have suggested 
the potential causative factor of elevated ROS and inflammation in the pathophysiology of TDF-induced 
renal toxicities (Murphy et al., 2017; Ramamoorthy et al., 2018), investigations into these factors at the 
tubular and cellular level would also be of benefit.  
Conducting longitudinal studies is not always possible, especially when concerning the invasive nature 
of renal biopsies. With regards to this, research is steering away from human biopsy and toward non-
invasive fluid biomarkers and well-characterised animal models. Abraham et al. (2016) recently 
developed a mouse model with TDF-induced nephrotoxicity similar to that seen in humans. This mouse 
model has the potential to be hugely beneficial in studies investigating the pathogenic mechanisms 
behind TDF-induced nephrotoxicity. Additionally, a recent study by our lab investigated mtDNA 
mutations in the urine of TDF-treated PLWH (Samuels et al., 2017). Although urine contains a 
heterogenous mix of cell types, including non-proximal tubule tissue, it can still be used as a clinically 
relevant tissue to investigate renal pathology and mtDNA deletions, and may be useful in cases where 
renal biopsies are unavailable (Blackwood et al., 2010). 
EM studies should also be performed in any future work. It would be a significant benefit to analyse 
mitochondrial morphology, particularly in the CI-deficient proximal tubule cells. This would allow for 
comparisons to be made between these CI-deficient epithelial cells and adjacent cells which do not 
appear to have mitochondrial defects. This could be performed through super resolution microscopy, 
which allows for simultaneous detection of fluorescence (to identify CI-deficient tubules) and 
morphology, or immunofluorescence EM. Limitations lie in the fact that super resolution microscopy 
does not provide high enough resolution to analyse individual mitochondria to a high standard, and 




Finally, another future study with potential benefit would be one which performs detailed genetic 
assessment of pathologic proximal tubules through RNA sequencer analysis. Experiments such as this 
would be hugely informative regarding differences in gene expression between comparator groups and 





Chapter 9 – Conclusions 
In this chapter I discuss the main findings with relation to the thesis aims and objectives outlined in 
Chapter 2, as well as the potential impact these findings may have on the current and future work in 
the field of mitochondrial dysfunction and adverse ageing in the HIV setting. 
9.1 Physiological, cellular and molecular skeletal muscle mitochondrial 
dysfunction in the contemporary ART setting 
Several studies conducted over the course of the past three decades have established the link between 
older antiretrovirals (ARVs) and the development of mitochondrial toxicities such as myopathy or lactic 
acidosis (Dalakas et al., 1990; Arnaudo et al., 1991; Samuels et al., 2017; Domingo et al., 2014; Dragovic 
et al., 2014; Alikhani et al., 2019; Carr et al., 1999; Lewis, 2003; Brinkman & Kakuda, 2000). These 
mitochondrial toxicities are tissue-specific and heterogenous in presentation, and are induced by 
various ARVs of different classes. In particular, the NRTIs zidovudine (AZT), zalcitabine (ddC), didanosine 
(ddI), and stavudine (d4T) have been shown to induce mitochondrial dysfunction and subsequent 
toxicities (Dalakas et al., 1990; Arnaudo et al., 1991; Lim & Copeland, 2001; Lewis, 2003). However, no 
studies have assessed the impact of newer ARVs such as tenofovir disoproxil fumarate (TDF) and 
abacavir (ABC), which have been considered as being free from mitochondrial toxicity in vitro (Venhoff 
et al., 2007), on skeletal muscle mitochondrial function at the cellular level. This study was therefore 
the first to do so. In addition, previous studies such as those done by our group have suggested that 
previous exposure to early NRTIs such as AZT may predispose PLWH to an excess of skeletal muscle 
mitochondrial defects years after cessation of treatment with the NRTI (Payne et al., 2011). As such, I 
aimed to investigate whether there were differences in skeletal muscle mitochondrial dysfunction in 
PLWH stratified by the type of antiretrovirals they have been exposed to, in an effort to better 
understand skeletal muscle mitochondrial dysfunction in the contemporary ART era.  
Notably, this study was the first to demonstrate skeletal muscle mitochondrial defects in the form of CI 
deficiency in PLWH who have only been exposed to newer, supposedly non-mitochondrially toxic ARVs 
(Chapter 4). Here, using a novel immunofluorescence assay developed in our lab (Rocha et al., 2015) I 
demonstrated that PLWH who had been exposed to mitochondrially-toxic NRTIs had a significantly 
higher proportion of myofibres with CI deficiency than treatment-naïve PLWH. In addition, PLWH who 
had only been exposed to newer NRTIs also had a significantly higher proportion of CI and CIV deficient 
fibres than ART-naïve PLWH, and a comparable level to historical NRTI-treated PLWH. Finally, results 
presented in Chapter 6 using age-matched older HIV+ and HIV- individuals supported the notion that 
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skeletal muscle mitochondrial dysfunction in PLWH in the contemporary ART era is not primarily age 
related, and there are therefore other pathogenic mechanisms driving this mitochondrial dysfunction.  
Through qPCR analysis I then demonstrated that the majority of CI-deficient myofibres contained 
mtDNA deletions, supporting previous work (Payne et al,. 2011). As CI is the largest mtDNA-encoded 
complex of the electron transport chain, it is more likely to be affected by large-scale mtDNA deletions. 
The cellular and molecular work was also supported by in vivo functional evidence from previously 
obtained 31P-MRS data (Payne et al., 2014). 
The final aim of the study conducted in Chapter 4 was to determine whether there was the presence of 
a ‘legacy effect’ in PLWH who have previously been exposed to older NRTIs such as AZT, ddC, ddI, d4T 
(Hunt & Payne, 2020). Surprisingly, data presented in Chapter 4 seemingly argues against the existence 
of this phenomenon, at least in skeletal muscle. Support for this observation centres around the fact 
that PLWH who had been exposed to these older NRTIs had comparable levels of skeletal muscle 
mitochondrial defects compared to age-matched PLWH who had never been exposed to the older 
NRTIs. Importantly, the majority of these cellular mitochondrial defects were underpinned by mtDNA 
deletions in both sets of ART-treated PLWH. Indeed, as PLWH treated only with newer NRTIs over a 
long duration had comparable levels of skeletal muscle mitochondrial defects compared to those 
treated with the older NRTIs, the mechanisms behind this mitochondrial dysfunction could therefore be 
underpinned by other factors seen in long-term ART-treated PLWH, such as chronic inflammation or 
oxidative stress (Melov et al., 1999; Zorov et al., 2014; Rao et al., 2014; Massaad & Klann, 2011; Deeks, 
2011).  
9.2 Older PLWH have a higher prevalence of frailty and sarcopenia 
compared to age-matched HIV- individuals 
The advent of cART has greatly reduced the mortality rate of PLWH as well as considerably extending 
their lifespan. As a result, the average age of the HIV+ population is now ~50 years old, with this 
number still increasing (Public Health England, 2019; Smit et al., 2015). Consequently, whilst the 
mortality rate and prevalence of HIV-associated comorbidities has decreased, the prevalence of age-
associated conditions such as frailty or cardiovascular diseases in PLWH has increased (Desquilbet et al., 
2007; Nou et al., 2016; Leng et al., 2015; Guaraldi et al., 2011; Smit et al., 2015; Chow et al., 2012; 
Althoff et al., 2014; Drummond et al., 2014; Kirk et al., 2013; Shiels et al., 2009; Sico et al., 2015; 
Silverberg et al., 2015). 
Work in Chapter 5 using data obtained from the MAGMA study supported observations from previous 
studies which demonstrated the increased prevalence of both frailty and sarcopenia in PLWH compared 
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to age-matched HIV- individuals (Desquilbet et al., 2007; 2009; Hanlon et al., 2018; Brothers et al., 
2017; Erlandson et al., 2015; Echeverria et al., 2018; Pinto Neto et al., 2016; Oliveria et al., 2020).  
Interestingly, metabolic expenditure (MET) score was significantly lower in frail/prefrail PLWH 
compared to robust PLWH. As this was a cross-sectional study I cannot be certain whether low MET 
score was a cause or consequence of frailty in older PLWH. However, as lower MET score was also seen 
in prefrailty this may suggest that decreased metabolic expenditure predates the onset of frailty. In 
addition, whilst none of the clinical or lifestyle parameters were associated with either frailty or 
sarcopenia in older PLWH themselves, a longer duration of untreated HIV infection, adjusted for age, 
significantly predicted weaker grip strength, which is well-recognised to be a very important measure of 
declining physical function. In addition, a poorer immune function in the form of CD4 count significantly 
predicted poorer muscle mass adjusted for height (ASMI). The link between these factors may well be 
mediated through increased inflammation and immune senescence (Deeks, 2011; Baylis et al., 2013; 
Shaw et al., 2010), however further work is required. 
Altogether, these findings suggest that poorer immune function, possibly as the result of delayed 
initiation of ART after initial HIV infection, may contribute to reduced muscle strength in older PLWH. 
This, among potentially other untested factors, is responsible for the greater prevalence of adverse 
ageing phenotypes in older PLWH compared to the age-matched general population. Importantly, 
these findings suggest that physical activity interventions aimed at improving muscle strength would 
likely to be beneficial to older PLWH who are more susceptible to developing adverse ageing 
phenotypes, supporting previous data from the general population (Landi et al., 2014; Zubala et al., 
2017; Lo et al., 2020). 
9.3 Skeletal muscle mitochondrial dysfunction in frail and sarcopenic 
PLWH 
One of the important aims of this thesis was to determine whether older PLWH had greater levels of 
skeletal muscle mitochondrial dysfunction compared to age-matched HIV- individuals.  
Hence, a major finding from the study in Chapter 6 was the demonstration of significantly higher 
skeletal muscle mitochondrial dysfunction in older PLWH compared to age-matched HIV- individuals. 
Specifically, individuals in the HIV+ group had a significantly higher proportion of myofibres with CI and 
CIV deficiency compared to the HIV- individuals, although there was no difference in mean skeletal 
muscle mitochondrial mass. This mitochondrial dysfunction did not seem to be explained by exposure 
to particular ARVs including NRTIs such as AZT and ddC, or protease inhibitors (PIs), supporting work 
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from Chapter 4. Neither could this mitochondrial dysfunction be explained by other HIV-related factors 
such as duration on ART in adjusted linear regression models.  
Whilst average myofibre mitochondrial mass was not significantly different between the HIV+ and HIV- 
individuals, it was notable that increased myofibre mitochondrial mass was significantly associated with 
a decline in fat mass in the older PLWH. This observation may suggest that obesity adversely impacts 
mitochondrial content, reducing skeletal muscle quality, and resulting in physical decline (Shetty et al., 
2009; Winalawansa, 2019; Li et al.,2017; Slawik & Vidal-Puig, 2006). In addition, this finding supports 
the idea that increased physical exercise, in this instance particularly aerobic exercise resulting in a 
reduction in fat mass, may be beneficial in improving mitochondrial function in older PLWH (Marzetti et 
al., 2008; Rowe et al., 2014).  
Following the demonstration of a greater prevalence of adverse ageing phenotypes in older PLWH 
compared to the HIV- individuals in Chapter 5, and owing to the link between mitochondrial 
dysfunction and these phenotypes in both frailty and sarcopenia (Chistiakov et al. 2014; Andreux et al., 
2018; Sayeed et al., 2018), I also sought to assess whether increased mitochondrial dysfunction 
contributed to frailty and sarcopenia in PLWH.  
Somewhat surprisingly, it was demonstrated that frail and sarcopenic PLWH did not have a significantly 
higher level of skeletal muscle mitochondrial dysfunction compared to robust and non-sarcopenic 
PLWH – suggesting that mitochondrial dysfunction alone is not driving these adverse ageing 
phenotypes in older PLWH. However, this finding should be treated with caution, owing to the 
relatively small numbers of frail and sarcopenic individuals. Furthermore, mitochondrial dysfunction 
can be measured through different parameters (Hunt & Payne, 2020; Fraizer et al., 2020). In addition, 
other pathophysiological factors that were not analysed in this study, such as chronic inflammation or 
immunosenescence, may also be driving adverse ageing phenotypes in PLWH (Deeks, 2011; Baylis et al., 
2013; Shaw et al., 2010; Soysal et al., 2016). 
9.4 Analysis of age-associated cellular skeletal muscle 
pathophysiological decline and its associations with adverse ageing 
phenotypes  
Due to the fact that the pathophysiology of declining muscle function in frailty and sarcopenia is 
extremely heterogenic in the general population (Fried et al., 2009; Cruz-Jentoft et al., 2019), and the 
fact that skeletal muscle pathology is little studied in PLWH, I sought to better understand these 
pathophysiological mechanisms in the context of ageing with HIV. As such, one aim of the work 
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conducted in Chapter 7 was to compare the levels of several skeletal muscle pathophysiologic factors in 
older HIV+ and HIV- individuals.  
The most notable aspect of the study conducted in Chapter 7 using data and tissue collected as part of 
the MAGMA study is the fact that it is the first study to assess a range of pathophysiological factors 
such as satellite (stem) cell availability and fibrosis in the skeletal muscle of older PLWH. The 
comprehensive nature of this study allowed for a wider understanding of the factors that are at play in 
age-related physiological decline in older PLWH. 
Notably, I failed to find any significant difference in several of these factors between the HIV+ and HIV- 
groups, including, intramyocellular lipid accumulation, Pax7+ satellite cell (muscle stem cell) prevalence, 
fibre type proportions, average fibre size, lipofuscin accumulation, or proportion of degenerated fibres. 
I did however demonstrate that older PLWH had a significantly greater level of skeletal muscle fibrosis 
and significantly lower percentage of regenerated fibres compared to age-matched HIV- individuals.  
In addition, it was demonstrated that except for an increased prevalence of type IIx fibres, none of 
these pathophysiological factors were significantly altered in frail PLWH compared to robust and 
prefrail PLWH. Interestingly, no skeletal muscle pathophysiological factor appeared to be altered in 
sarcopenic PLWH compared to non-sarcopenic PLWH. Importantly, these were novel findings in the 
context of skeletal muscle function in older PLWH. 
9.5 Role of skeletal muscle mitochondrial dysfunction in muscle 
pathophysiological factors, and the combined role in adverse ageing 
phenotypes in older PLWH – potential compensatory mechanisms? 
After investigating whether there were differences in several skeletal muscle pathophysiological factors 
between the age-matched HIV+ and HIV- groups, I next sought to determine whether there was any 
association between mitochondrial dysfunction and these other factors in the skeletal muscle of older 
PLWH.  
Importantly, the only factors that appeared to be predicted by skeletal muscle mitochondrial 
dysfunction was the relative fibre type proportions, and an increased Pax7+ satellite cell (SC) 
prevalence.  
In particular, greater proportional CI deficiency was significantly predictive of a lower proportion of 
oxidative type I fibres, and therefore a greater proportion of glycolytic type IIx fibres, both after 
adjustment for age. These novel findings suggest that skeletal muscle mitochondrial dysfunction may 
be compensated in older PLWH by a reduction in the usual pattern of age-associated fibre type 
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switching (from type II to type I). This preservation of glycolytic fibres might partially compensate for a 
loss of oxidative metabolism, and therefore diminish the onset of adverse ageing phenotypes (Wang et 
al., 2013; Maughan et al., 1983; Anderson, 2003; Phillips & Leeuwenburgh, 2005). Conversely though, 
mitochondrial dysfunction may be leading to selective atrophy of type I fibres. As it was not possible to 
fully elucidate which mechanisms were occurring, future studies should investigate neuromuscular 
junction efficiency and fibre apoptosis.  
Furthermore, mitochondrial dysfunction (in the form of proportional CIV deficiency) predicted a higher 
prevalence of Pax7+ SCs in the older PLWH. This may again suggest the presence of a compensatory 
mechanism whereby an intact stem cell population allows skeletal muscle to respond to the adverse 
effects of mitochondrial dysfunction. However, a greater prevalence of Pax7+ SCs predicted not only a 
greater level of regenerated fibres, but also increased fibrosis. This may suggest an impairment in the 
regenerative function of quiescent satellite cells in older PLWH, with some muscle damage being 
resolved by scarring (fibrosis) rather than regeneration.   
With regard to potential clinical or therapeutic implications of these findings, they support previous 
work in the general population which has suggested that increased exercise is the most effective 
mechanism in preventing the onset of adverse ageing conditions (Walston et al., 2018; Cameron et al., 
2013; Silva et al., 2017). For example, resistance and aerobic exercise is known to improve muscle 
function (Cesari et al., 2015; Suetta et al., 2008; Binder et al., 2005; Campbell et al., 2002; Benito et al., 
2020), muscle mitochondrial function (Zampieri et al., 2015; Marzetti et al., 2008; Rowe et al., 2014), 
improve stem cell function (Yang et al., 2017; Berberoglu et al., 2017), metabolic function (Kang & 
Krauss, 2010), and a greater proportion of type I fibres is known to be associated with poorer physical 
performance (Kitada et al., 2015). Future studies should therefore investigate the role of exercise in 
preventing or treating declining muscle function in older PLWH. 
9.6 Novel investigations of mitochondrial function at the cellular and 
molecular level in renal tissue 
Chronic kidney disease (CKD) remains an important comorbidity in older PLWH. In recent years, there 
has been particular concern about the renal toxicities of tenofovir disoproxil fumarate (TDF) (Atta et al., 
2006; Foy et al., 2013; Woodward et al., 2009; Hamzah et al., 2017; Mocroft et al., 2016; Guaraldi et al., 
2011). Although TDF has been shown to have a low binding affinity to the mitochondrial polymerase – 
PolG – it is nevertheless considered that the most likely pathological mechanism underpinning these 
renal-specific toxicities is TDF-induced mitochondrial dysfunction (Kohler et al., 2009; Samuels et al., 
2017; Murphy et al., 2017; Ramamoorthy et al., 2018).  
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However, due to limitations around the ability to firstly acquire renal tissue in TDF-treated PLWH, and 
secondly investigate mitochondrial function at the individual cellular level (as opposed to homogenate 
studies), the underlying mechanisms remain poorly understood. In addition, whilst in vitro models allow 
for the assessment of these factors in specific renal cells, they fail to fully recapitulate the real effects of 
TDF in human renal toxicity in PLWH.  
Hence, after acquiring renal biopsies from TDF and non-TDF-treated PLWH, as well as HIV- individuals 
who all presented with varying renal pathologies, I sought to determine whether renal mitochondrial 
function can be better assessed using novel validated cellular and molecular techniques pioneered in 
our lab (Rocha et al., 2015).   
Indeed, the novel immunofluorescence assay which quantifies protein levels of CI, CIII, CIV, CV and 
mitochondrial mass, previously used on skeletal muscle (Rocha et al., 2015; Ahmed et al., 2017; Warren 
et al., 2020; Lehmann et al., 2019; Chapter 4; Chapter 6), brain (Hatton et al., 2020), and 
colon/intestinal tissue (Smith et al., 2020) was successfully applied to renal tissue, as discussed in 
Chapter 8.  
In addition, individual proximal tubules and proximal tubule epithelial cells were successfully isolated by 
laser capture microdissection (LCM). Finally, using a quantitative real-time PCR assay with mtDNA gene 
targets, mtDNA deletions were investigated in isolated renal proximal tubules and single renal tubular 
epithelial cells for the first time. Hence, the work conducted as part of Chapter 8 contained several 
novel experimental protocols which could have beneficial implications for future work aiming to better 
understand the pathophysiological mechanisms behind TDF-induced mitochondrial dysfunction and 
renal pathology.  
9.7 Potential underlying mechanisms of mitochondrial dysfunction in 
older PLWH 
A clear finding throughout this thesis was that mitochondrial dysfunction is implicated in age-related 
pathophysiology in older PLWH. Although specific CI dysfunction was demonstrated in both renal tissue 
(in Chapter 8) and skeletal muscle tissue (Chapter 4, Chapter 6), the mechanisms underpinning these 
phenomena are most likely different.  
Whilst it is heavily suspected that the cause of skeletal muscle CI (and to a lesser extent CIV) deficiency 
in the HIV+ individuals was somatic large-scale mtDNA deletions that have clonally expanded and 
subsequently accumulated to a point exceeding the threshold for biochemical function (Payne et al., 
2011), this was likely not the case for the CI and CV renal dysfunction. Instead, although this was not 
proven through the data collected as part of Chapter 8, the most likely genetic mechanisms 
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underpinning this CI and CV deficiency are somatic mtDNA point mutations. These de novo mtDNA 
point mutations could be the result of increased ROS production and subsequent oxidative stress, 
which is known to induce mtDNA point mutations (Taylor & Turnbull, 2005; Chung et al., 2014; 
Caldecott, 2008; Pinz et al., 1995; Baines et al., 2014). Indeed, more recent work in the field has 
suggested the role of enhanced oxidative stress in renal tubules leading to higher levels of 
mitochondrially-mediated apoptosis (Murphy et al., 2017; Ramamoorthy et al., 2018). Although CV is 
not a commonly affected ETC complex in age-associated mitochondrial dysfunction, preliminary work 
from our collaborators has suggested through genomic analyses of in vitro nephrotoxicity cell models 
that there is an upregulation in cristae remodelling genes and a downregulation of CV genes in TDF-
exposed renal cells. They/we suggest that TDF proximal tubule accumulation induces enhanced ROS 
production, which would lead to mitochondrial stress and cristae remodelling (Cole et al., 2011; Cogliati 
et al., 2016), ultimately leading to a dysregulation in CV activity (Geromel et al., 2001; Ide et al., 1999). 
This model would also explain the formation of mtDNA point mutations, which subsequently could be 
affecting CI activity (Taylor & Turnbull, 2005). 
9.8 Final conclusions 
In this thesis, I have presented the first comprehensive analysis of skeletal muscle function in older 
PLWH, combining histopathological data with physical function, body composition and clinical 
parameters. This approach has allowed several novel observations to be made. Many of which provide 
a basis for future work, and some of which could have potential future clinical and therapeutic 
implications.  
Firstly, I have shown that older PLWH in the contemporary ART era have an excess of skeletal muscle 
mitochondrial dysfunction. However, in contrast to the historical literature (Dalakas et al., 1990; 
Arnaudo et al., 1991; Lim & Copeland, 2001), this skeletal muscle mitochondrial dysfunction in PLWH 
was not solely predicted by ART exposure. In fact, the findings suggest that other potential factors such 
as chronic inflammation, oxidative stress, or immunosenescence are driving skeletal muscle 
mitochondrial dysfunction in older PLWH in the contemporary ART era.  
Importantly, skeletal muscle function in older PLWH, including frail and sarcopenic PLWH, was 
comprehensively studied. Overall, these studies have significantly advanced our understanding of the 
potential pathophysiological mechanisms contributing to adverse ageing phenotypes in older PLWH. Of 
note, it was demonstrated that older PLWH experience dysregulated fibre type switching, in which 
mitochondrial dysfunction is playing a significant role. In addition, I demonstrated that older PLWH 
have an excess of skeletal muscle fibrosis. Both mitochondrial dysfunction and fibrosis were correlated 
with myofibre regeneration, suggesting an adaptive response to muscle damage. 
 
377  
However, neither mitochondrial dysfunction nor fibrosis appeared to directly explain the greater 
prevalence of frailty and sarcopenia in PLWH compared to age-matched HIV- individuals. This suggests 
that other HIV-related factors such as chronic inflammation are likely to also be playing a causative role 
in these adverse ageing phenotypes.  
With regard to potential clinical impacts, these findings suggest that targeted exercise regimes may be 
beneficial in attenuating age-related physiological decline in older PLWH.  
In conclusion, the work described in this thesis has demonstrated the importance of several aspects of 
skeletal muscle function in older people living with HIV, including mitochondrial function. Future work 
should attempt to link muscle and mitochondrial dysfunction with chronic inflammation in PLWH, and 
explore therapeutic strategies to improve these factors.  
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Short title: MAGMA 
Protocol version: 1.21 
Protocol date: 22.5.2017 
Chief Investigator: Dr Brendan Payne 
Sponsor: Newcastle-upon-Tyne Hospitals NHS Foundation Trust 
Funder: Wellcome Trust 
Study design: Observational, cross-sectional 
Primary objective: To determine whether anti-retroviral treated HIV-infected older 
people have an excess of mitochondrial defects in skeletal muscle 
compared with age-matched uninfected people. 
Secondary objectives: To determine whether mitochondrial defects in HIV-infected older 
people are in keeping with accelerated clonal expansion of 
mitochondrial DNA mutations. 
To determine whether mitochondrial defects in older HIV-infected 
people correlate with clinical parameters, anti-retroviral treatment, 
or markers of systemic inflammation. 
To determine whether muscle mitochondrial defects in HIV-infected 
people correlate with reduced physical function. 
Number of study sites: 2 
Study population/size: 45 




Anti-retroviral treated HIV-infected persons achieve good immune reconstitution, but nevertheless 
experience an increase in many of the common diseases and physiological changes of older age (1-3). 
Given the known links between mitochondria and ageing (4-8), and mitochondria and HIV infection 
(9-12), it is plausible that increased mitochondrial damage may be a biological mediator of ageing in 
HIV. 
 
We have previously demonstrated that younger (aged <50) anti-retroviral treated persons have an 
excess of cells containing mtDNA mutations, but the mechanism remains to be determined (13). Our 
modelling suggests that the increase may be consistent with an acceleration of clonal expansion of 
mtDNA mutations within cells, particularly in the setting of exposure to certain NRTI anti-retroviral 
drugs. Conversely, other authors have suggested that HIV infection or therapy may be mutagenic for 






1) Anti-retroviral treated HIV-infected older men will have an excess of mitochondrial defects in 
skeletal muscle compared with age-matched HIV-uninfected men. 
2) The pattern of mitochondrial defects found in HIV-infected men will be consistent with a 
mechanism of accelerated clonal expansion of mtDNA mutations. 
3) Correlates of mitochondrial damage will include: increased age (>60 years), longer history of 
treated HIV infection (>15 years), increased systemic inflammation. 





Primary objective: To determine whether anti-retroviral treated HIV-infected older men 
have an excess of mitochondrial defects in skeletal muscle compared 
with age-matched uninfected men. 
 
Secondary objectives: To determine whether mitochondrial defects in HIV-infected older 
men are in keeping with accelerated clonal expansion of 
mitochondrial DNA mutations. 
To determine whether mitochondrial defects in HIV-infected men 
correlate with clinical parameters, anti-retroviral treatment, or 
markers of systemic inflammation. 
To determine whether muscle mitochondrial defects in HIV-infected 




This is an observational cross-sectional study. 
 
 
Primary outcome measures: 
The proportion of skeletal muscle fibres with functional mitochondrial COX (cytochrome c oxidase) 
defects. 
The level of mtDNA mutations in skeletal muscle. 
 
 
Secondary outcome measures: 
The plasma levels of inflammatory cytokines. 
Physical performance as measured by a testing battery. 
 
 
Definition of end of study: 
For the purposes of recruitment, the end of study will be the last participant’s final study contact. 
Recruitment is expected to take approximately 12 months. 





Study of archived tissue: 
The ethical and HRA permission for this study also allows for similar mitochondrial analyses to be 
performed on anonymised archival tissue samples obtained from research tissue banks and residual 
tissue from NHS histopathology departments. 
Study of these tissues will allow cellular and molecular findings from the muscle biopsies to be 
extended to other tissues. 
Tissues studied may include (but are not limited to): brain, bowel, cardiac, renal, plasma/serum, 
urine. 
Samples requested may be from HIV positive subjects or healthy controls. 
Samples will be supplied in anonymised form. 
 Tissue may be supplied as blocks or as slides (10μm sections, 2 sections per slide, 10 slides per case) 




A total of 45 subjects will be recruited: 
 
HIV-infected n = 30. 
HIV-uninfected n = 15. 
 
Inclusion criteria 
• Patient has provided written informed consent for participation in the study prior to any study 
specific procedures 
• Age ≥50 years at time of study visit. 
• Male 
• Willing to travel to one of the study sites 
• Willing to have muscle biopsy 
HIV-infected group only: 
• Documented positive HIV status at study entry 
HIV-uninfected group only: 





• Inability to give informed consent 
• In the opinion of the investigator, those unable or unwilling to comply with the requirements 
of the study 
• Life expectancy <6 months 
• Known coagulation disorder or taking anti-coagulant medication 
• Known or suspected neuromuscular disorder of a genetic basis 
• Unable to walk 4 metres (use of a stick or walking frame is permitted) 
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Screening, Recruitment and Consent 
Identification and screening of participants 
Different processes will apply at the two study sites (Newcastle-upon-Tyne Hospitals, Imperial 
College Healthcare NHS Trust as follows): 
 
Imperial College 
• All subjects recruited will already be part of an existing longitudinal study of ageing in HIV 
(‘POPPY’). 
• Potential subjects will be identified by a member of the POPPY study team, or the normal 
clinical team at site. 
• This mechanism applies to both HIV-infected and uninfected subjects. 
 
Newcastle 
• Potential HIV-infected participants will be identified through screening of clinical records by a 
member of the study team who is also a member of the usual clinical team (the PI, or a 
colleague with documented, delegated responsibility). 
• Potential HIV-infected participants will also be eligible if they receive their usual HIV care at 
other clinics within the Northeast HIV Network. In these cases those sites will serve as PIC 
sites. At these sites potential participants will be identified by a member of the usual clinical 
team at site. 
• Potential HIV-uninfected subjects will be identified through genitourinary medicine clinics 
within the Northeast HIV Network (operating as PIC sites, as described above). 





Potential participants from POPPY can be approached at the time of their routine clinic appointment, 
or a planned POPPY study visit. They may also be contacted by email or letter. A study Participant 
Information Sheet will be provided at this time and the patient allowed time to read it. At least 24 
hours later this will be followed up by a telephone call to allow the patient to ask further questions, 
and if they are then agreeable, to book the study visit. 





Eligible participants will be invited to participate by a member of the study team, who is also a 
member of the clinical team, during their routine consultation. A study Participant Information Sheet 
will be provided at this time and the patient allowed time to read it. Where prior consent exists to 
contact the patient by email or by letter a PIS may also be sent out in this manner. At least 24 hours 
later this will be followed up by a telephone call to allow the patient to ask further questions, and if 
they are then agreeable, to book the study visit. 
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Whilst (for practical reasons) there is no specific stratification of recruitment target by age bands, 
sites will be specifically encouraged to identify older subjects, aged over 60, in addition to those aged 
50-60 years. 
In the case of HIV-uninfected subjects, these will be specifically age (by 5 year bands: 50-54, 55-59, 
60-64, 65+) and sex matched with HIV-infected cases. This will be facilitated by identification of 




Informed consent discussions will be untaken only by the investigator who is to perform the study 
procedures. Opportunity will be given for participants to ask any questions. Those wishing to take 
part will provide written informed consent by signing and dating the study consent form, which will 
be witnessed and dated by a member of the research team with documented, delegated 
responsibility to do so. Written informed consent should always be obtained prior to study specific 
investigations. The original signed consent form will be retained in the Investigator Site File, with a 
copy in the clinical notes and a copy provided to the participant. The participant will specifically 
consent to their GP being informed of their participation in the study. The right to refuse to 
participate without giving reasons must be respected. 
Due to the small subject population, the information sheet and consent form for the study will be 
available only in English. Interpreters will be arranged for all visits of patients who require them via 
local NHS arrangements. Qualified interpreters will be used to explain the consent form and 
information sheet, and great priority will be placed on finding the most direct communication. 
Consent will be taken at the time of the study visit, which in all cases will be at least 24 hours after 





There will be some differences in the number of study procedures performed at the two study sites 
as those subjects attending the Imperial site will have already had some procedures performed as 
part of the POPPY study (procedures not required for these participants indicated *) and those data 
will be available for this study. HIV-specific data is not required for HIV uninfected participants 
(indicated †). 
Subjects will attend for a single study visit, where the following will be performed: 
- Written informed consent 
- Completion of health and treatment questionnaires: 
o Demographics (age, self-reported ethnicity, country of birth, sexual orientation)* 
o Lifestyle factors (smoking, alcohol, drug use history), past medical history, current 
(non-HIV) medications* 
o General health and wellbeing (frailty assessment questions) 
o Current HIV treatment† 
o Past HIV treatment*† 
o HIV history (duration of infection, nadir CD4)† 
- Completion of physical activity questionnaire 
- Anthropometric measurements: height, weight, BMI, waist circumference 
- Collection of serum, whole blood and urine samples, for immune / inflammatory cytokine 
profiling, mitochondrial DNA analyses, and storage for possible future metabolic profiling. 
- Lean muscle mass assessment by whole body DXA* 
- Short physical performance battery (17) 
- Percutaneous skeletal muscle biopsy (from leg muscle) for mitochondrial analyses and gene 
expression profiling. 
See study appendix for details of procedures. 
 
Timings 
All procedures will be performed in a single study visit, approximately as follows: 
- Consent, collection of clinical data and blood samples: 30 mins 
- Completion of questionnaires: 20 mins 
- DXA scan: 20 mins 
- Physical performance assessments: 20 mins 
- Muscle biopsy: 20 mins 
- Rest / observation after biopsy: 120 mins 
All procedures should be completed within ~4hr. 
Clinical laboratory data 
Clinical and past treatment data for subjects in POPPY will be obtained by a data download. Only 
those parameters marked (†) will need verifying at the time of study visit. 
In addition to those data collected by questionnaire (as above), clinical disease and treatment data 
will be collected by case-note review by a member of the study team who is also a member of the 
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clinical team. The following will be recorded: 
- Current CD4 lymphocyte count† 
- Current HIV RNA plasma viral load† 
- Most recent laboratory tests will be recorded (in the HIV-infected cohort): renal, liver, lipid 
and bone profiles, glucose, full blood count. These tests should have been performed within 
a year of the clinic visit. 
 
Data Handling & Record Keeping 
A Study File will be maintained at each of the two study sites by the PI / Co-I in a locked office. Only 
members of the study team will have access to this file. This will contain a copy of the screening log 
and copies of the consent forms for enrolled subjects. This file will also contain a key of patient 
identifiers linked to anonymised study code for each subject. 
All patient-identifiable data will be handled at the two clinical study sites and all samples and data 
handled at the University site will use anonymised codes only. 




The primary analysis is the between-group comparison (HIV-infected vs. uninfected) of mtDNA 
mutation burden. The chosen sample sizes are well-powered to detect a mean difference of 0.33 
log10 between groups (α 0.05, 1-β 0.92), based on past experience of SD for this measure. 
Secondary analyses will include within group (HIV-infected) correlation between treatment 
parameters and mtDNA defect. The selected sample size will allow detection of a moderate (r 0.5) 




Participants have the right to withdraw from the study at any time for any reason, and without giving 
a reason. Should a patient decide to withdraw from the study, all efforts will be made to report the 
reason for withdrawal as thoroughly as possible. 
As the study is a single visit, a request to withdrawal from the study will mean that no data is used 




All blood results on HIV-infected subjects will already have been performed as part of routine clinical 
care and will have been actioned already if required. 
Although not the primary purpose of performing the test, DXA scans may produce clinically 
actionable results regarding bone mineral density. This will be communicated to the patient’s usual 
physician and GP. 
The molecular analyses performed on mtDNA are such that no genetic information of potential 




Adverse event reporting for this study will be as follows: 
All Adverse Events (AE) that are related to any of the study procedures outlined in the protocol (e.g. 
during muscle biopsy, physical function testing, DXA scanning) will be reported to the sponsor. 
(Discomfort and bruising in line with that expected for the muscle biopsy or venepuncture does not 
count as an AE.) 
As such AEs may present up to a few days after the study procedures, if the patient reports any AE 
with reference to the study visit then this will be recorded. 
All Serious Adverse Events (SAE) will be reported to the sponsor (both those related to study 
procedures and those which may not be related to study procedures). 
All study-related adverse events, however minor, will be documented. An adverse event is any 
untoward medical occurrence in a subject administered a pharmaceutical product or, in the case of 
this study, in a subject undergoing a study procedure (including events that do not necessarily have a 
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causal relationship with the study procedure). Adverse events observed by the Investigator, or 
reported by the subject, and any remedial action taken, will be recorded in the subject’s CRF and 
should be verifiable in the subject’s notes throughout the study. The nature of each event, time of 
onset (if known), after undergoing a study procedure will be documented together with in the 
Investigator’s opinion of the causal relationship to the study procedure (unrelated, unlikely, possible, 
probable, definite and not assessable). All subjects experiencing adverse events, whether considered 
associated with study procedures or not, must be monitored until the symptoms subside. 
Severity should be recorded and graded according to the AIDS Clinical Trial Group (ACTG) Grading 
Scale. Moreover, adverse events should be assessed in relation to their intensity, defined as follows: 
MILD: the adverse event does not interfere with subject’s usual function 
MODERATE: the adverse event interferes to some extent with subject’s usual function 
SEVERE: the adverse event interferes significantly with subject’s usual function 
 
Serious Adverse Events (SAE) 
A SAE is any untoward medical occurrence or effect that: 
• Results in death 
• Is life-threatening – refers to an event in which the subject was at risk of death at the time of the 
event; it does not refer to an event which hypothetically might have caused death if it were more 
severe 
• Requires hospitalisation, or prolongation of existing inpatients’ hospitalisation 
• Results in persistent or significant disability or incapacity – there is a substantial disruption of a 
person’s ability to carry out normal life functions 
• Is a congenital abnormality or birth defect 
 
 
An SAE form should be completed and faxed to for all SAEs within 24 hours of notification about the 
event. The ICTU / CRF will inform the following individuals within 24 hours of receiving notice of 
them: 
- The Sponsor (Newcastle-upon-Tyne Hospitals) 
- The Chief Investigator (Dr Brendan Payne) 
 
 
Given the observational and nature of this study, no additional information on SAEs will be captured. 
All SAEs and AEs will be recorded on the annual study reports that are sent to the REC. 
Also, given the observational and non-interventional nature of this study, no serious, unexpected 
adverse drug reactions (SUSARs) reporting will be undertaken. As all subjects continue with their 
general clinical care, which is unaltered during the course of this study, the ‘yellow card’ reporting 
will be unaffected. 
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Ethics & Regulatory Issues 
The conduct of this study will be in accordance with the recommendations for physicians involved in 
research on human subjects adopted by the 18th World Medical Assembly, Helsinki 1964 and later 
revisions. 
Favourable ethical opinion from an appropriate REC and NHS R&D approval will be obtained prior to 
commencement of the study. 
Information sheets will be provided to all eligible subjects and written informed consent obtained 




A study management group will be convened which will meet quarterly or as required (in person or 
by teleconference). This will include the CI, Co-I, research nurses involved in the study. 
 
Confidentiality 
Personal data will be regarded as strictly confidential. To preserve anonymity, any data leaving the 
site will identify participants by a unique study identification code only. The study will comply with 
the Data Protection Act, 1998. All study records and Investigator Site Files will be kept at site in a 




The Newcastle-upon-Tyne Hospitals NHS Foundation Trust has liability for clinical negligence that 
harms individuals toward whom they have a duty of care. NHS Indemnity covers NHS staff and 
medical academic staff with honorary contracts conducting the trial for potential liability in respect 
of negligent harm arising from the conduct of the study. The Trust is Sponsor and through the 
Sponsor, NHS indemnity is provided in respect of potential liability and negligent harm arising from 
study management. Indemnity in respect of potential liability arising from negligent harm related to 
study design is provided by NHS schemes for those protocol authors who have their substantive 
contracts of employment with the NHS and by Newcastle University Insurance schemes for those 
protocol authors who have their substantive contract of employment with the University. This is a 
non-commercial study and there are no arrangements for non-negligent compensation. 
 
 
Study Report / Publications 
The data will be the property of the Chief Investigator and Co-Investigators. Publication will be the 
responsibility of the Chief Investigator. 
It is planned to publish this study in peer review articles and to present data at national and 
international meetings. Results of the study will also be reported to the Sponsor and Funder. All 
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manuscripts, abstracts or other modes of presentation will be reviewed by the Trial Steering 
Committee and Funder prior to submission. Individuals will not be identified from any study report. 
Participants will be informed about their treatment and their contribution to the study at the end of 
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Appendix 2 – Health Questionnaire 
 
Instructions to Clinical Research Nurse: 
Please ask the participant to complete the following forms. 
 
This questionnaire is in 5 sections. Not all participants need to complete all sections. Please check 
the top of each section before giving it to the participant. 
 
Please write the participant code number on the top of each sheet before giving them to the 
participant. 
 
The table below shows which forms are required for each group of participants: 
 












HIV negative participant at Newcastle site 
Section 1 
Section 2 





Section 1 – questions about your medical history 
Note to research nurse: this section is for participants at Newcastle site only. 
 
Please complete this questionnaire as best as you can. Please ask the research nurse / doctor if you are 
uncertain. This section contains 3 sides of questions. 
 
General questions: 
What is your age in years?    
What country were you born in?    
How would you describe your ethnic group (e.g. black African, white British etc.)? 
(leave blank if prefer not to say)    
How would you describe your sexual orientation? 
Gay Bisexual 
Straight Other / prefer not to say 
 
Lifestyle questions: 
Have you ever smoked? (Please tick one answer): I 
am a current smoker 
I am a social smoker I 
am an ex-smoker 
I have never smoked 
 
Do you drink alcohol? 
Yes currently 
Previously but not currently 
Never / almost never 
 
If you drink alcohol currently, how much do you drink in an average week? (Please write the number 
of each drink per week in the box): 
Beer or cider (pints) 
Wine (glasses) 
Spirits (single measures) 
 




If yes, please list which    
Please turn over for the next set of questions 
Medical history: 
Below is a list of common types of medical conditions, with examples of each type. Please tick any that you 
have ever suffered from. Please give any further details in the right hand column where indicated. 
 
Medical condition Tick if here you 
have been affected 
Further details 
Heart disease 
Includes: myocardial infarction (‘heart 
attack’), angina, acute coronary 
syndrome, coronary artery bypass, 
coronary artery stenting, cardiac 
arrhythmias (abnormal heart 
rhythms), cardiac arrest, heart failure 
(congestive cardiac failure) 
 Please state type of cardiovascular 
disease: 
Peripheral vascular disease 
Includes: claudication, bypass grafts 
of legs, stents to legs, aortic 
aneurysm 
 Please state type of peripheral 
vascular disease: 
Stroke 
Includes: ‘mini stroke’, TIA 
 Please state type: 
Renal (kidney) disease  Please state type: 
Liver disease 
Includes: hepatitis, hep B, hep C 
 Please state type: 
Diabetes   
Cancer  Please state type: 
Joint disease (arthritis) or joint 
replacements 
 Please state type of arthritis and 
any joints that have been replaced: 
Fractures (broken bones)  Please state which bones: 
Osteoporosis   
Falls  Please state number of falls that 





Please list below all the medications that you currently take. Please list both prescribed 
medications and ones that you buy over-the-counter. 
 































Thank you for completing this form. Please hand it back to the research nurse / doctor. 
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Section 2 – questions about your general health and wellbeing 
Note to research nurse: this section is for all participants 
 
Please complete the following questions. It is not a test! Please just choose the answer that you think 
fits best for you. If you are not sure, please ask the research nurse / doctor. 
1. In the last 12 months has your weight decreased, increased or has it stayed about the same? 
(Please tick one answer): 
1-Decreased 2-Increased 3-Stayed about the same 
 
If you chose answer 1, go to question 2. 
If you chose answer 2 or 3, go straight to question 3. 
 
2. Was your weight loss intentional, for example, you were dieting? (Please tick): 
1-Yes 2-No 
 
If you answered ‘Yes’, go to question 3. 
If you answered ‘No’, continue with this question. 
a. Approximately how much weight did you lose over the last 12 months? (You can give 
your answer in either kg or lbs): 
 
...... kg ...................... lbs 
 
3. Does your health limit you in vigorous activities, such as running, lifting heavy objects, or 
participating in strenuous sports? (Please tick one answer): 
1- Yes, limited a lot 2-Yes, limited a little 3-No, not limited at all 
 
For the following statement, tick the answer that best describes how often you felt or behaved this way 
during the past week: 
4. Everything I did was an effort: 1-Rarely or none of the time (<1 day) 
 
2- Some or a little of the time (1-2 days) 
 
3- Occasionally or a moderate amount of time (3-4 days) 
4-Most or all of the time (5-7 days) 
For the following statement, tick the answer that best describes how often you felt or behaved this way 
during the past week: 
5. I could not get going: 1-Rarely or none of the time (<1 day) 
 
2- Some or a little of the time (1-2 days) 
 
3- Occasionally or a moderate amount of time (3-4 days) 
4-Most or all of the time (5-7 days) 
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Section 3 – questions about your current HIV treatment 
Note for research nurse: this section is for HIV positive participants only 
 
Please write the names of all the HIV drugs that you are currently taking in the table below. We just need 
drug names, not doses or how many times per day. 
If you cannot remember the date that you started a drug please just put a ? in the relevant box (e.g. 
??/12 for sometime in 2012, or ??/?? if you have no idea). If you are not sure about how to complete 








   
   
   





Thank you for completing this form. Please hand it back to the research nurse / doctor. 
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Section 4 – questions about your previous HIV treatment 
Note for research nurse: this section is for HIV positive participants at the Newcastle site only. 
 
We would like you to try and remember the details of any HIV treatment that you may have had in the past. 
Please include all previous HIV treatments but do not include the treatment you are on now. We just need 
drug names, not doses or how many times per day. 
If you cannot remember the dates please just put a ? in the relevant box (e.g. ??/12 for sometime in 2012, 
or ??/?? if you have no idea). If you are not sure about how to complete this form, please ask the research 
nurse or doctor. Thank you. 
If your current HIV treatment is your first ever regimen then please tick this box (you do not need to 
complete the rest of this page). 
If you have had other HIV treatment regimens in the past but cannot remember any of them please tick this 








   
   
   
   
   
   
   
   
   
 
 




Thank you for completing this form. Please hand it back to the research nurse / doctor. 
 
 
Section 5 – questions about your HIV 
Note for research nurse: this section is for HIV positive participants only 
 
Please try and complete the three questions below. 
 
If you cannot remember the dates please just put a ? in the relevant box (e.g. ??/12 for sometime in 2012, or ??/?? if 












What is the lowest CD4 count that you can ever remember having (please tick the relevant box)? 
 
Between 0 and 100 
 
Between 100 and 200 
 








Thank you for completing this form. Please hand it back to the research nurse / doctor. 
  
More than 350 








Single Chair Rise, Repeated Chair Rise 
1) "This is a test of strength in your legs in which you stand up without using your arms." 
2) "Fold your arms across your chest, like this, and stand when I say GO, keeping your arms in this position. OK? 
Ready, go!” 
 
Able to rise 1 time? 
 
3) If able to rise… “This time, I want you to stand up ten times as quickly as you can, keeping your arms folded 
across your chest. When you stand up, come to a full standing position each time, and when you sit down, sit 
all the way down each time. I’ll demonstrate two chair stands to show you how it is done.” Rise two times as 
quickly as you can, counting as you sit down each time. Cross your arms over your chest and emphasize full 
standing position, all the way down. 
 
4) "When I say ‘Go’ stand ten times in a row, as quickly as you can, without stopping. Stand up all the way, and 
sit all the way down each time. Ready? Go!" Start timing as soon as you say “Go.” Count aloud: "1, 2, 3, 4, 5, 6, 
7, 8, 9, 10" when the participant sits down each time. After the participant sits down for the fifth time, 
depress the split button on the stopwatch. When the participant stops for the tenth time, then “stop” the 
stopwatch. 
10x chair rise  :  seconds 
 
  Unable to complete 5 chair stands 
 
  Complete > 5 but < 10 stands 
 
  # completed  :  sec 
 
  :  seconds 5 x chair rise 





  Side-by-side x 10 sec 
   Side-by-side x 30 sec 
Time (if other than 30 sec) 
  :    
 
   Not attempted 
Balance Test 
 
1. “I’m going to ask you to stand in several different positions that test your balance. I’ll demonstrate each position and 
then ask you to try to stand in each position for up to 30 seconds. I’ll be near you to provide support, and the wall is 
close enough to prevent you from falling if you lose your balance. Do you have any questions?” 
 
2. “First I would like you to try to stand with your feet together, side-by side, for 30 seconds. Please watch while I 
demonstrate.” Demonstrate while you say: “You may use your arms, 
bend your knees, or move your body to maintain your balance, but try not 
to move your feet. Try to hold your feet in this position until I say stop.” 
 
3. Begin the test.  Allow the participant to hold onto your arm to get 
balanced. “Hold onto the chair while you get in position. When you are 
ready, let go and I’ll start timing. Ready? Go!” Start timing when the 
participant lets go. (If the participant does not hold onto your arm, start 
timing when he/she is in position. Stop the stopwatch if he/she takes a step 
or grabs for support. Record to 0.01 second the time the participant could 
hold this position. Say, “STOP” after 30 seconds. 
 
If side-by-side test is 10 seconds or longer, proceed with the next test: 
 
4. “Now I would like you to try to stand with the side of the heel of one foot 
touching the big toe of the other foot for 30 seconds. Please watch while I 
demonstrate.” Demonstrate and say: “You may put either foot in front, 
whichever is more comfortable. You can use your arms and body to 
maintain your balance. Try to hold your feet in position until I say stop. If 
you lose your balance, take a step like this. Hold onto the chair while you 
get in position. When you are ready, let go and I’ll start timing. Ready? 
Go!” Start timing when the participant lets go. (If the participant does not 
hold onto your arm, start timing when he/she is in position. Stop the 
stopwatch if he/she takes a step or grabs for support. Record to 0.01 




If able to hold semi-tandem for 10 seconds or longer, proceed with next test: 
 
 
5.  “Now I would like you to try to stand with the heel of one foot in front of 
and touching the toes of the other foot. I’ll demonstrate.” Demonstrate, 
and say: “Again, you may use your arms and body to maintain your 
balance. Try to hold your feet in position until I say stop. If you lose your 
balance, take a step, like this. Hold onto the chair while you get in 
position. When you are ready, let go and I’ll start timing. Ready? Go!” 
Start timing when the participant lets go. Stop the stopwatch if he/she 
takes a step or grabs for support. Record to 0.01 second how long the 
participant is able to hold this position. Say, “STOP” after 30 seconds. 
 
   Tandem x 10 sec 
 
    Tandem x 30 sec 
Time (if other than 30 sec) 
  :    
 
    
Not attempted 
 
  Semi-tandem x 10 sec 
Semi-tandem x 30 sec 
Time (if other than 30 sec) 
  :    
 





6. If the participant holds the position for at least 10 seconds, go to the Single Leg Stand. If the participant 
attempts the Tandem Stand and is unable or cannot hold it for at least one second, perform a second trial of the 
Tandem Stand. “Now, let’s try that again. Hold onto my arm while you get into position. When you are ready, 
let go and I’ll start timing.” 
 
 
If able to hold tandem stand for 10 seconds or longer, proceed with the next test: 
 
7.  “For the last position, I would like you to try to stand on one leg for 30 seconds. You may 
stand on either leg, whichever is more comfortable. I’ll demonstrate.” Demonstrate the 
single leg stand by lifting the heel of one leg so that the toes are about 2 inches off the floor. 
The knee should be flexed and hip should remain straight (so that the foot goes behind the 
participant rather than in front). Demonstrate and say: “Try to stand on one leg until I say 
stop. If you lose your balance, then put your foot down.  Hold onto my arm while you get 
in position. When you are ready, let go, and I’ll start timing. Ready? Go!” Start timing 
when the participant lets go. Stop the stopwatch if he/she takes a step or grabs for support. 
Record to 0.01 second how long participant is able to hold this position. Say, “STOP” after 
30 seconds. 
 
8. If the position is held for less than 30 seconds, for this test only, perform a second trial of the Single Leg Stand. 
“Now, let’s try the same thing one more time.” 
 
   One-leg x 30 sec on 1st try 
 
   One-leg x 30 sec on 2nd try 
 
Time (if not 30 sec) on 1st try  :    
Time (if not 30 sec) on 2nd  try   :     






Assess whether the participant can complete the Grip Strength Test. 
 
Script: “In this exercise, I am going to use this instrument to measure the strength in your dominant hand.” 
 
1) “Are you right handed or left handed?” 
2) “Have you had any recent pain in your wrist or hand, or any acute 
flare-up in your wrist or hand from conditions like arthritis, tendonitis or carpel tunnel syndrome? Do you 
think that squeezing this instrument would cause you to have pain”? 
3) “Have you had any surgery on your hands or arms during the last 3 months?” 
4) “Do you think you can safely squeeze this instrument as hard as you can with your [right/left] hand?” 
 
 
Instructions and Demonstration 
 
While the examiner is demonstrating the procedure, read the following script: “I’d like you to take your dominant arm, 
press your arm against your side and grab the two pieces of metal together like this.” (Examiner should be holding the 
dynamometer in the correct position). 
 
“When I say ‘squeeze,’ squeeze as hard as you can (examiner demonstrates). The two pieces of metal do not move, but I will 
be able to read the force of your grip on the dial (examiner points to the dial). I will ask you to do this three times. If you feel 
any pain or discomfort, tell me. Do you have any questions?” 
 
Performance and Scoring 
 
1. Hand the dynamometer to the participant and place the wrist strap around his/her wrist. 
 
2. Script: “Press your arm against your side and grip the two pieces of metal with your dominant hand. Your 
wrist should be straight. “Ready? Go! Squeeze, squeeze, squeeze!! When the needle starts to go down, tell the 
subject to stop. 
 
3. Record the strength in kilograms (round DOWN to the nearest line). Reset the 
dynamometer to zero. 
 
4. “Now we will test your strength a second time. When I say ‘squeeze,’ squeeze as 
hard as you can. Ready? Go! Squeeze, squeeze, squeeze! When the needle starts 
to go down, tell the subject to stop. 
 
5. Record the strength in kilograms (round DOWN to the nearest line). Reset the dynamometer to zero. 
 
6. “Now we will test your strength a third and final time. When I say ‘squeeze,’ squeeze as hard as you can. 
Ready? Go! Squeeze, squeeze, squeeze! When the needle starts to go down, tell the subject to stop. 
 
If unable, indicate why he/she was unable to complete the grip strength test and STOP TESTING. If attempted, but 
unable physically, STOP TESTING. 
 
Attempt #1  kg 
 
Attempt #2  kg 
 
Attempt #3  kg 










Script: “In this test, I would like you to 
walk at your usual pace from this red 
line to the other red line. Do you think 
you could do that? Good. Can you see 
the tape? Good. Let me demonstrate 
what I want you to do.” Read the 
following script while demonstrating the 
procedure for the participant: “To do 
this test, place your toes behind the 
tape. I will time you. When I say ‘Go!’ 
walk at your usual pace past the line 
(examiner walks the 4 meters past the 
other piece of tape). Do you have any 
questions?” 
 
Performance and Scoring 
 
1. The tester will stay at the finish line to time the test. When you are in position, say: “Now 
we will begin the test. Please start with your toes behind the piece of tape.” 
 
2. When the participant is properly at the starting tape, say “Ready? Go!” and start the 
stopwatch when you say go (even if the participant has a pause before he/she begins). 
Stop the stopwatch when the participant’s first foot is completely across the finish line. 
 
3. Record the time and reset the stopwatch to 0. Ask the participant to return to the starting line. 
 
4. Script: “Now, I’d like you to try this test a second time. Start with your toes behind the piece of 
tape. 
When I say “Go!” walk at your usual pace to the line.” 
 
4. When the participant is properly at the cone, say “Ready, go!” and start the stopwatch 
when you say go. Stop the stopwatch when the participant’s first foot is completely 




Record if participant regularly uses an 
assistive device (cane/walking stick, 
walker, wheelchair, scooter, or other) 
when walking? Y / N 
 









“Thank you. This is the end of this test.” 
  
Walk attempted?   Y / N If no, record reason(s) 
 
 
Walk #1  ▪  seconds 
 




Appendix 4 – Physical activity questionnaire  
We are interested in finding out about the kinds of physical activities that people do as part of their 
everyday lives. The questions will ask you about the time you spent being physically active in the last 7 
days. Please answer each question even if you do not consider yourself to be an active person. Please 
think about the activities you do at work, as part of your house and garden work, to get from place to 
place, and in your spare time for recreation, exercise or sport. 
 
Think about all the vigorous activities that you did in the last 7 days. Vigorous physical activities refer to 
activities that take hard physical effort and make you breathe much harder than normal. Think only 
about those physical activities that you did for at least 10 minutes at a time. 
 
1. During the last 7 days, on how many days did you do vigorous physical 
activities like heavy lifting, digging, aerobics, or fast bicycling? 
 
  days per week 
 
No vigorous physical activities Skip to question 3 
 
2. How much time did you usually spend doing vigorous physical activities on one of 
those days? 
 
  hours per day 
  minutes per day 
 
Don’t know/Not sure 
 
Think about all the moderate activities that you did in the last 7 days. Moderate activities refer to 
activities that take moderate physical effort and make you breathe somewhat harder than normal. 
Think only about those physical activities that you did for at least 10 minutes at a time. 
 
 
3. During the last 7 days, on how many days did you do moderate physical activities like 
carrying light loads, bicycling at a regular pace, or doubles tennis? Do not include 
walking. 
 
  days per week 
 
No moderate physical activities Skip to question 5 
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4. How much time did you usually spend doing moderate physical activities on one of those days? 
 
  hours per day 
  minutes per day 
 
Don’t know/Not sure 
 
 
Think about the time you spent walking in the last 7 days. This includes at work and at home, walking to travel from 
place to place, and any other walking that you have done solely for recreation, sport, exercise, or leisure. 
 
5. During the last 7 days, on how many days did you walk for at least 10 minutes at a time? 
 
  days per week 
 
No walking                   Skip to question 7 
 
 
6. How much time did you usually spend walking on one of those days? 
 
  hours per day 
  minutes per day 
 
Don’t know/Not sure 
 
The last question is about the time you spent sitting on weekdays during the last 7 days. Include time spent at 
work, at home, while doing course work and during leisure time. This may include time spent sitting at a desk, 
visiting friends, reading, or sitting or lying down to watch television. 
 
7. During the last 7 days, how much time did you spend sitting on a week day? 
 
  hours per day 
  minutes per day 
 
Don’t know/Not sure 
 











Appendix 5 – IRAS approval 
 
17 March 2017 
Dear Dr Payne 
 
 
Study title: Muscle Ageing and Anti-retroviral study 
IRAS project ID: 212276 
REC reference: 17/NE/0015 
Sponsor Newcastle-upon-Tyne Hospitals NHS Foundation Trust 
 
 
I am pleased to confirm that HRA Approval has been given for the above referenced study, on the basis 
described in the application form, protocol, supporting documentation and any clarifications noted in this 
letter. 
 
Participation of NHS Organisations in England 
The sponsor should now provide a copy of this letter to all participating NHS organisations in England. 
 
Appendix B provides important information for sponsors and participating NHS organisations in England for 
arranging and confirming capacity and capability. Please read Appendix B carefully, in particular the 
following sections: 
• Participating NHS organisations in England – this clarifies the types of participating organisations in 
the study and whether or not all organisations will be undertaking the same activities 
• Confirmation of capacity and capability - this confirms whether or not each type of participating NHS 
organisation in England is expected to give formal confirmation of capacity and capability. Where 
formal confirmation is not expected, the section also provides details on the time limit given to 
participating organisations to opt out of the study, or request additional time, before their 
participation is assumed. 
• Allocation of responsibilities and rights are agreed and documented (4.1 of HRA assessment criteria) - 
this provides detail on the form of agreement to be used in the study to confirm capacity and 
capability, where applicable. 









It is critical that you involve both the research management function (e.g. R&D office) supporting each 
Letter of HRA Approval 
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organisation and the local research team (where there is one) in setting up your study. Contact details and 
further information about working with the research management function for each organisation can be 
accessed from www.hra.nhs.uk/hra-approval. 
 
Appendices 
The HRA Approval letter contains the following appendices: 
• A – List of documents reviewed during HRA assessment 
• B – Summary of HRA assessment 
 
After HRA Approval 
The document “After Ethical Review – guidance for sponsors and investigators”, issued with your REC 
favourable opinion, gives detailed guidance on reporting expectations for studies, including: 
• Registration of research 
• Notifying amendments 
• Notifying the end of the study 
The HRA website also provides guidance on these topics, and is updated in the light of changes in reporting 
expectations or procedures. 
 
In addition to the guidance in the above, please note the following: 
• HRA Approval applies for the duration of your REC favourable opinion, unless otherwise 
notified in writing by the HRA. 
• Substantial amendments should be submitted directly to the Research Ethics Committee, as detailed 
in the After Ethical Review document. Non-substantial amendments should be submitted for review 
by the HRA using the form provided on the HRA website, and emailed to hra.amendments@nhs.net. 
• The HRA will categorise amendments (substantial and non-substantial) and issue confirmation of 
continued HRA Approval. Further details can be found on the HRA website. 
 
Scope 
HRA Approval provides an approval for research involving patients or staff in NHS organisations in England. 
 
If your study involves NHS organisations in other countries in the UK, please contact the relevant national 
coordinating functions for support and advice. Further information can be found at 
http://www.hra.nhs.uk/resources/applying-for-reviews/nhs-hsc-rd-review/. 
 
If there are participating non-NHS organisations, local agreement should be obtained in accordance with the 
procedures of the local participating non-NHS organisation. 
 
User Feedback 
The Health Research Authority is continually striving to provide a high quality service to all applicants and 








We are pleased to welcome researchers and research management staff at our training days – see details at 
http://www.hra.nhs.uk/hra-training/ 
 















Appendix A - List of Documents 
 
The final document set assessed and approved by HRA Approval is listed below. 
 
 
Document Version Date 
Contract/Study Agreement [Template Agreement]  24 December 2016 
Copies of advertisement materials for research participants [Poster] 1.0 06 December 2016 
Covering letter on headed paper  12 December 2016 
Covering letter on headed paper  10 February 2017 
Evidence of Sponsor insurance or indemnity (non NHS Sponsors only) 
[Indemnity for study design - Newcastle University] 
 19 July 2016 
GP/consultant information sheets or letters 1.0 06 December 2016 
IRAS Application Form [IRAS_Form_21122016]  21 December 2016 
IRAS Application Form XML file [IRAS_Form_21122016]  21 December 2016 
Laboratory Manual [Skeletal muscle biopsy] 1.1 10 February 2017 
Laboratory Manual [Physical performance assessment - 
instructions] 
1.0 06 December 2016 
Laboratory Manual [Physical performance assessment - record] 1.0 06 December 2016 
Letter from funder [Fellowship award letter - Wellcome Trust]  18 December 2015 
Letters of invitation to participant [Letter of invitation] 1.1 10 February 2017 
Non-validated questionnaire [Health questionnaire] 1.0 06 December 2016 
Other [SoA PIC Sites] 1.0 10 February 2017 
Other [SoA Study Sites] 1.1 10 February 2017 
Other [SoE PIC Sites] 1.0 10 February 2017 
Other [SoE Study Sites] 1.0 10 February 2017 
Participant consent form 1.0 06 December 2016 
Participant information sheet (PIS) [Newcastle site] 1.3 08 March 2017 
Participant information sheet (PIS) [St Mary's Site] 1.3 08 March 2017 
Referee's report or other scientific critique report [Reviewer's comments - 
Wellcome Trust] 
  
Research protocol or project proposal 1.2 10 February 2017 
Summary CV for Chief Investigator (CI)  06 December 2016 




Appendix B - Summary of HRA Assessment 
 
This appendix provides assurance to you, the sponsor and the NHS in England that the study, as reviewed 
for HRA Approval, is compliant with relevant standards. It also provides information and clarification, where 
appropriate, to participating NHS organisations in England to assist in assessing and arranging capacity and 
capability. 
For information on how the sponsor should be working with participating NHS organisations in England, 
please refer to the, participating NHS organisations, capacity and capability and Allocation of responsibilities 
and rights are agreed and documented (4.1 of HRA assessment criteria) sections in this appendix. 
The following person is the sponsor contact for the purpose of addressing participating organisation 
questions relating to the study: 
 
 
Name: Andrew Johnston 
Tel: 0191 282 5969 
Email: andrew.johnston@nuth.nhs.uk 
 
HRA assessment criteria 
 
Section HRA Assessment Criteria Compliant with 
Standards 
Comments 
1.1 IRAS application completed 
correctly 
Yes No comments 
    
2.1 Participant information/consent 
documents and consent process 
Yes No comments 
    
3.1 Protocol assessment Yes No comments 
    
4.1 Allocation of responsibilities 
and rights are agreed and 
documented 
Yes The sponsor intends that an unmodified 
mNCA acts as the agreement between the 
sponsor and the research site. 
The statement of activities will act as the 
agreement for participant identification 
centres (PICs), there will be no funding 
provided by the sponsor to the PICs. 





Section HRA Assessment Criteria Compliant with 
Standards 
Comments 
 arrangements assessed  contractors (e.g. General Practitioners) 
should ensure that the professional 
indemnity provided by their medical 
defence organisation covers the activities 
expected of them for this research study 
4.3 Financial arrangements 
assessed 
Yes Financial arrangements for research 
sites are detailed in the mNCA. 
There is no funding available from the 
sponsor for the PICs. 
    
5.1 Compliance with the Data 
Protection Act and data 
security issues assessed 
Yes No comments 
5.2 CTIMPS – Arrangements for 
compliance with the Clinical 
Trials Regulations assessed 
Not Applicable No comments 
5.3 Compliance with any applicable 
laws or regulations 
Yes Human Tissue Act – the applicant 
confirmed that any samples imported 
for the study would have the 
appropriate consent in place taken in 
the country of origin. 
    
6.1 NHS Research Ethics Committee 
favourable opinion received for 
applicable studies 
Yes No comments 
6.2 CTIMPS – Clinical Trials 
Authorisation (CTA) letter 
received 
Not Applicable No comments 
6.3 Devices – MHRA notice of no 
objection received 
Not Applicable No comments 
6.4 Other regulatory approvals 
and authorisations received 




Participating NHS Organisations in England 
 
This provides detail on the types of participating NHS organisations in the study and a statement as to whether the 
activities at all organisations are the same or different. 
There are two types of participating NHS organisations. 
1) Research sites will identify, recruit and consent participants and conduct the study 
interventions including blood and urine samples, muscle biopsies and DXA scans. 
2) PICs will identify and approach potential participants regarding their participation in the study. 
 
The Chief Investigator or sponsor should share relevant study documents with participating NHS organisations 
in England in order to put arrangements in place to deliver the study. The documents should be sent to both 
the local study team, where applicable, and the office providing the research management function at the 
participating organisation. For NIHR CRN Portfolio studies, the Local LCRN contact should also be copied into 
this correspondence. For further guidance on working with participating NHS organisations please see the HRA 
website. 
 
If chief investigators, sponsors or principal investigators are asked to complete site level forms for 
participating NHS organisations in England which are not provided in IRAS or on the HRA website, the chief 
investigator, sponsor or principal investigator should notify the HRA immediately at hra.approval@nhs.net. 
The HRA will work with these organisations to achieve a consistent approach to information provision. 
Confirmation of Capacity and Capability 
 
This describes whether formal confirmation of capacity and capability is expected from participating NHS organisations in 
England. 
Participating NHS organisations in England will be expected to formally confirm their capacity and 
capability to host this research. 
• Following issue of this letter, participating NHS organisations in England may now confirm to the 
sponsor their capacity and capability to host this research, when ready to do so. How capacity and 
capacity will be confirmed is detailed in the Allocation of responsibilities and rights are agreed and 
documented (4.1 of HRA assessment criteria) section of this appendix. 
• The Assessing, Arranging, and Confirming document on the HRA website provides further 
information for the sponsor and NHS organisations on assessing, arranging and confirming 
capacity and capability. 
Principal Investigator Suitability 
 
This confirms whether the sponsor position on whether a PI, LC or neither should be in place is correct for each type of 
participating NHS organisation in England and the minimum expectations for education, training and 
experience that PIs should meet (where applicable). 
PIs have been identified at the research sites, neither local collaborators nor PIs are expected at the PICs. 
 








HR Good Practice Resource Pack Expectations 
 
This confirms the HR Good Practice Resource Pack expectations for the study and the pre-engagement 
checks that should and should not be undertaken 
Where arrangements are not already in place, network staff (or similar) undertaking any 
research activities that may impact on the quality of care of the participant (such as blood 
sampling, informed consent procedures), would be expected to obtain an honorary research 
contract from one NHS organisation (if university employed), followed by Letters of Access 
for subsequent organisations. 
This would be on the basis of a Research Passport (if university employed) or an NHS to 
NHS confirmation of pre-engagement checks letter (if NHS employed). These should 
confirm enhanced DBS checks, including appropriate barred list checks, and occupational 
health clearance. 
 
For research team members undertaking activities that do not impact on the quality of 
care of the participant (for example, administering questionnaires) a Letter of Access 
based on standard DBS checks and occupational health clearance would be appropriate. 
 
Other Information to Aid Study Set-up 
 
This details any other information that may be helpful to sponsors and participating NHS organisations 
in England to aid study set-up. 
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